




CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Proposed Grant Awards

February 19, 2025





CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: MICHELLE LE BEAU, PH.D., CHIEF SCIENTIFIC OFFICER
SUBJECT: ACADEMIC RESEARCH FY2024 CYCLE 2, FY2025 CYCLE 1, AND RECRUITMENT AWARD RECOMMENDATIONS FY2025, CYCLE 25.2 AND 25.3
DATE: FEBRUARY 19, 2025

The Program Intergration Committee (PIC) has completed its review of the recommendations forwarded by the Scientific Review Council (SRC) and recommends awarding 53 applications for Fiscal Year 2024 Cycle 2, Fiscal Year 2025 Cycle 1, and Recruitment Fiscal Year 2025, Cycle 2 and Cycle 3 totaling \$67,753,626. The grant recommendations are presented in nine slates, as displayed in Table 1.

Table 1.

Grant Mechanism	SRC Recommendations	
	Awards	Funding
Individual Investigator Research Awards	28	\$25,183,459
Individual Investigator Research Awards for Childhood and Adolescent Cancers	6	\$ 7,162,997
Individual Investigator Research Awards for Computational Systems Biology of Cancer	3	\$ 2,862,063
Individual Investigator Research Awards for Clinical Trials	3	\$ 4,588,613
Individual Investigator Research Awards for Prevention and Early Detection	5	\$ 5,956,505
Collaborative Action Program (CAP) to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center	1	\$3,000,000
Core Facility Support Awards (CFSA)	1	\$2,999,989
Recruitment of Established Investigators	1	\$6,000,000
Recruitment of First-Time, Tenure-Track Faculty Members	5	\$10,000,000
Total	53	\$67,753,626

Program Priorities Addressed:

The applications proposed to the Program Integration Committee for funding address the following Academic Research Program Priorities: recruitment of outstanding cancer researchers

to Texas, a broad range of innovative, investigator-initiated research projects, childhood and adolescent cancers, implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions, hepatocellular cancer, expanding access to clinical trials, investment in core facilities, drug discovery, and computational oncology and analytic methods. Priorities addressed by the proposed slate of awards are displayed in Table 2 and Attachment 1.

Table 2.

Program Priorities Addressed by Grant Recommendations		
# Awards*	Program Priorities	Funding*
6	Recruitment of outstanding cancer researchers to Texas	\$16,000,000
46	A broad range of innovative, investigator-initiated research projects	\$48,753,637
3	Expand access to innovative clinical trials	\$4,588,613
5	Hepatocellular cancer	\$6,589,799
7	Childhood and adolescent cancers	\$9,162,997
2	Implementation research to accelerate adoption and deployment of evidence-based prevention, early detection, risk assessment and interventions	\$4,187,187
1	Investment in core facilities	\$2,999,989
4	Computational oncology and analytical methods	\$4,862,063
1	Drug Discovery	\$2,999,989
*Some grant awards address more than one program priority and are double counted.		

1. INDIVIDUAL INVESTIGATOR RESEARCH AWARDS (RFA R-25.1. IIRA) SLATE

Peer Review Recommendations:

The Scientific Review Council recommended 28 Individual Investigator Research Awards (IIRA) totaling \$25,183,459.

Purpose of Individual Investigator Research Awards:

Supports applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer. Areas of interest include laboratory research, translational studies, and/or clinical investigations. Competitive renewal applications are accepted.

Individual Investigator Research Awards Funding Levels:

Up to \$300,000 per year. Exceptions permitted if extremely well justified; maximum duration: 3 years.

Table 3:

FY2025 Cycle 1: Recommended IIRA Applications

Rank	ID	Award RFA	Score	Application Title	PI	PI Organization	Rec. Budget
1	RP250118	IIRA	1.0	Ribosome Localization at Mitochondria-ER Contacts in Obesity-Associated Liver Cancer	Morita, Masahiro	The University of Texas Health Science Center at San Antonio	\$900,000
2	RP250061	IIRA	1.0	Imaging of cranial radiotherapy neuroinflammatory sequelae by Positron Emission Tomography	Pisaneschi, Federica	The University of Texas Health Science Center at Houston	\$900,000
3	RP250208	IIRA	1.4	RPS23 is a new drug target to activate the integrated stress response and treat leukemia	Ready, Joseph	The University of Texas Southwestern Medical Center	\$900,000
4	RP250201	IIRA	1.4	Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in oral cavity squamous cell carcinoma	Gillison, Maura	The University of Texas M. D. Anderson Cancer Center	\$899,998
5	RP250028	IIRA	1.5	MALAT1 protects against osteoporosis and bone metastasis	Ma, Li	The University of Texas M. D. Anderson Cancer Center	\$900,000
6	RP250247	IIRA	1.5	Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETs	Yao, James	The University of Texas M. D. Anderson Cancer Center	\$900,000
7	RP250220	IIRA	1.8	Decellularized tissue matrices to study the “bad soil” in cancer metastasis	Wang, Andrew	The University of Texas Southwestern Medical Center	\$900,000
8	RP250222	IIRA	1.9	KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC	Gibbons, Don	The University of Texas M. D. Anderson Cancer Center	\$899,997
9	RP250043	IIRA	1.9	An integrated imaging informatics platform for HCC surveillance	Zhou, Xiaobo	The University of Texas Health Science Center at Houston	\$899,991

10	RP250213	IIRA	2.0	KRAS spatiotemporal dynamics: lipid glycosylation as a novel therapeutic target	Hancock, John	The University of Texas Health Science Center at Houston	\$900,000
11	RP250428	IIRA	2.0	Studying Hematopoietic Stem Cells to Predict and Understand Mechanisms of Post-transplant Relapse in the Myelodysplastic Syndromes	Chung, Stephen	The University of Texas Southwestern Medical Center	\$899,025
12	RP250143	IIRA	2.0	Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy	Lissanu, Yonathan	The University of Texas M. D. Anderson Cancer Center	\$899,991
13	RP250398	IIRA	2.1	Synthetic lethality of TRIP13 and Aurora A in Rb-deficient cancer	Johnson, Faye	The University of Texas M. D. Anderson Cancer Center	\$899,994
14	RP250402	IIRA	2.1	Exploiting Tryptophan Metabolite Addiction to identify and Inhibit HCC	Conacci Sorrell, Maralice	The University of Texas Southwestern Medical Center	\$900,000
15	RP250282	IIRA	2.2	Harnessing BACH2 to enhance anti-tumor T cell immunity	Yao, Chen	The University of Texas Southwestern Medical Center	\$900,000
16	RP250280	IIRA	2.2	The role of glutathione in leukemia development	Agathocleous, Michalis	The University of Texas Southwestern Medical Center	\$900,000
17	RP250062	IIRA	2.3	Clonal hematopoiesis and toxicity from radiation therapy	Nead, Kevin	The University of Texas M. D. Anderson Cancer Center	\$899,885
18	RP250407	IIRA	2.3	Protecting the GI tract with a C60 fullerene derivative to facilitate dose-escalated abdominopelvic radiotherapy	Mackeyev, Yuri	The University of Texas Health Science Center at Houston	\$900,000
19	RP250055	IIRA	2.4	TET2 mutations promote myeloid malignancies by dysregulating m5C oxidation of chromatin-associated RNAs	Xu, Mingjiang	The University of Texas Health Science Center at San Antonio	\$900,000

20	RP250391	IIRA	2.5	Novel PCDH7 monoclonal antibodies that direct immune surveillance and combat drug resistance in lung cancer	O'Donnell, Kathryn	The University of Texas Southwestern Medical Center	\$900,000
21	RP250069	IIRA	2.6	HSP90 Capacitance: Discovery of a New Mechanism Driving Evolution of Drug Resistance in Head and Neck Squamous Cell Carcinoma	Karras, Georgios	The University of Texas M. D. Anderson Cancer Center	\$890,201
22	RP250305	IIRA	2.6	Exploiting synthetic lethalties between HNRNPK loss and ribosomal dysfunction in del9q AML	Post, Sean	The University of Texas M. D. Anderson Cancer Center	\$896,322
23	RP250091	IIRA	2.6	Dissecting the Survival Mechanisms of Latent Brain-Tropic Cancer Cells for Therapeutic Interventions	Malladi, Srinivas	The University of Texas Southwestern Medical Center	\$900,000
24	RP250322	IIRA	2.6	Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2-mutant non-small cell lung cancer (NSCLC)	Heymach, John	The University of Texas M. D. Anderson Cancer Center	\$900,000
25	RP250154	IIRA	2.6	Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients	Fuentes, David	The University of Texas M. D. Anderson Cancer Center	\$899,808
26	RP250097	IIRA	2.9	Deciphering and targeting age-related metastatic competence of the omentum	Naora, Honami	The University of Texas M. D. Anderson Cancer Center	\$899,984
27	RP250099	IIRA	2.9	Targeting lethal prostate cancers with a clinical-stage inverse agonist for G protein-coupled receptor 6	Li, Wenliang	The University of Texas Health Science Center at Houston	\$900,000
28	RP250191	IIRA	3.1	Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$898,263

2. Individual Investigator Research Awards for Cancer in Children and Adolescents (RFA R-25.1 IIRACCA) Slate

Peer Review Recommendations:

The Scientific Review Council recommended 6 Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA), totaling \$ 7,162,997.

Purpose of Individual Investigator Research Awards for Cancer in Children and Adolescents:

Supports applications for innovative research projects addressing questions that will advance knowledge of the causes, prevention, progression, detection, or treatment of cancer in children and adolescents. Laboratory, clinical, or population-based studies are all acceptable. CPRIT expects the outcome of the research to reduce the incidence, morbidity, or mortality from cancer in children and/or adolescents in the near or long term. Competitive renewal applications accepted.

Individual Investigator Research Awards for Cancer in Children and Adolescents Funding Levels:

Up to \$300,000 per year. Exceptions permitted if extremely well justified; maximum duration: 4 years.

Table 4:

FY2025 Cycle 1: Recommended IIRACCA Applications

Rank	ID	Award RFA	Score	Application Title	PI	PI Organization	Rec. Budget
1	RP250278	IIRACCA	1.2	Developmental origins of IDH-mutant glioma in adolescents	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,198,416
2	RP250144	IIRACCA	1.5	Decoding how neuronal activity remodels the epigenome in ependymoma	Deneen, Benjamin	Baylor College of Medicine	\$1,200,000
3	RP250374	IIRACCA	1.9	Dissecting TFE3 Mediated tRCC Tumorigenesis	Brugarolas, James	The University of Texas Southwestern Medical Center	\$1,196,812
4	RP250119	IIRACCA	2.8	Comparison of Symptom Burden, Neurocognitive Change, and Functional Outcomes in Pediatric	Kahalley, Lisa	Baylor College of Medicine	\$1,200,000

				Brain Tumor Patients treated with Surgery vs. Surgery and Chemotherapy			
5	RP250190	IIRACCA	2.8	Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-Exercise Intervention	Swartz, Maria	The University of Texas M. D. Anderson Cancer Center	\$1,199,756
6	RP250164	IIRACCA	3.1	Prediction of CAR-T Cell Immunotherapy Outcomes in Neuroblastoma using FE-MRI Nano-radiomics	Ghaghada, Ketan	Baylor College of Medicine	\$1,168,013

3. Individual Investigator Research Awards for Computational Systems Biology of Cancer (RFA R-25.1 IIRACSBC) Slate

Peer Review Recommendations:

The Scientific Review Council recommended 3 Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC), totaling \$ 2,862,063.

Purpose of Individual Investigator Research Awards for Computational Systems Biology of Cancer:

Supports applications for innovative mathematical and/or computational research projects addressing questions that will advance current knowledge in the (a) mechanisms that tie altered gene expression and downstream molecular mechanisms to functional cancer phenotypes and/or (b) mechanisms that tie tumor morphology to functional cancer phenotypes and/or mechanisms that tie treatment sequence and combination to evolving functional cancer phenotypes (that emerge as a result of treatment selection).

Individual Investigator Research Awards for Computational Systems Biology of Cancer Funding Levels:

Up to a maximum of \$350,000 per year. Exceptions permitted if extremely well justified; maximum duration: 3 years.

Table 5:**FY2025 Cycle 1: Recommended IIRACSBC Applications**

Rank	ID	Award RFA	Score	Application Title	PI	PI Organization	Rec. Budget
1	RP250044	IIRACSBC	2.0	Heterogeneity of resistance to endocrine therapy and Cdk inhibition: An integrated systems biology approach to biologically informed treatment regimens	Brock, Amy	The University of Texas at Austin	\$763,596
2	RP250399	IIRACSBC	2.9	Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture	Vokes, Natalie	The University of Texas M. D. Anderson Cancer Center	\$1,049,033
3	RP250090	IIRACSBC	2.9	Artificial Intelligence for Early Identification of Androgen-Indifferent, Lethal Prostate Cancer and Therapy Selection	Merényi, Erzsébet	Rice University	\$1,049,434

**4. Individual Investigator Research Awards for Clinical Trials
(RFA R-25.1 IIRACT) SLATE**

Peer Review Recommendations:

The Scientific Review Council recommended 3 Individual Investigator Research Awards for Clinical Trials (IIRACT) totaling \$ 4,588,613.

Purpose of Individual Investigator Research Awards for Clinical Translation:

Supports applications that propose innovative cancer clinical studies that are hypothesis driven and involve patients enrolled prospectively on a clinical trial. Areas of interest include clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices. Clinical trial must be planned to begin when contract is awarded.

Individual Investigator Research Awards for Clinical Translation Funding Levels:

Up to \$400,000 per year. Maximum duration: 4 years. Exceptions permitted if extremely well justified.

Table 6:**FY2025 Cycle 1: Recommended IIRACT Applications**

Rank	ID	Award RFA	Score	Application Title	PI	PI Organization	Rec. Budget
1	RP250131	IIRACT	2.1	Randomized Clinical Trial Evaluating Fecal Microbiota Transplant in Chimeric Antigen Receptor Therapy for Reversing Antimicrobial-Associated Dysbiosis	Saini, Neeraj	The University of Texas M. D. Anderson Cancer Center	\$1,598,410
2	RP250321	IIRACT	2.5	Leveraging synthetic and collateral lethality in MTAP loss tumors	Rodon Ahnert, Jordi	The University of Texas M. D. Anderson Cancer Center	\$1,599,783
3	RP250094	IIRACT	2.7	A phase 2 clinical trial with Avasopasem, with anti-estrogen therapy (ET) and a CDK4/6 inhibitor in metastatic breast cancer progressing on ET/CDK4/6 therapy.	Gius, David	The University of Texas Health Science Center at San Antonio	\$1,390,420

***5. Individual Investigator Research Awards for Prevention and Early Detection
(RFA R-25.1 IIRAP) SLATE***

Peer Review Recommendations:

The Scientific Review Council recommended five Individual Investigator Research Award for Prevention and Early Detection, totaling \$ 5,956,505.

Purpose of Individual Investigator Research Awards for Prevention and Early Detection:

Supports applications which propose clinical and population-based projects designed to develop effective prevention and early detection interventions to reduce cancer risk, mortality, and morbidity among Texans. Projects that propose such research collaborations with existing CPRIT Prevention Program awardees including the CPRIT funded *Texas Collaborative Center for Hepatocellular Cancer* are strongly encouraged.

Individual Investigator Research Awards for Prevention and Early Detection Funding

Levels:

Up to \$300,000 per year. Exceptions permitted if extremely well justified; maximum duration: 4 years.

Table 7:

FY2025 Cycle 1: Recommended IIRAP Application

Rank	ID	Award RFA	Score	Application Title	PI	PI Organization	Rec. Budget
1	RP250293	IIRAP	1.2	Development of a shared decision tool to facilitate uptake of the levonorgestrel-releasing intrauterine system for the primary prevention of endometrial cancer	Meyer, Larissa	The University of Texas M. D. Anderson Cancer Center	\$1,199,542
2	RP250269	IIRAP	1.8	Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules.	Ostrin, Edwin	The University of Texas M. D. Anderson Cancer Center	\$1,169,776
3	RP250156	IIRAP	2.6	Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer	Wu, Jia	The University of Texas M. D. Anderson Cancer Center	\$1,200,000
4	RP250418	IIRAP	2.7	Approach Bias Retraining to Augment Long-Term Smoking Cessation Among a Diverse Sample	Garey, Lorra	University of Houston	\$1,200,000
5	RP250182	IIRAP	2.8	Implementing Newborn Screening for Pediatric Cancer Predisposition Syndromes in Texas: The INSPECT Study	Parsons, Donald	Baylor College of Medicine	\$1,187,187

6. Collaborative Action Program (CAP) to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center (RFA R-25.1 CAP: CAC) SLATE

Peer Review Recommendations:

The Scientific Review Council recommended one Collaborative Action Program (CAP) to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center award, totaling \$3,000,000.

Purpose of Collaborative Action Program (CAP) to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center:

Supports a competitive renewal of one single Collaborative Action Center whose function will be to innovatively expand the administrative services, resources, and support to CPRIT funded hepatocellular cancer research projects.

Collaborative Action Program (CAP) to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center Funding Levels:

Up to \$600,000 per year. Exceptions permitted if extremely well justified; maximum duration: 5 years.

Table 8:

FY2025 Cycle 1: Recommended CAP:CAC Application

Rank	ID	Award RFA	Score	Application Title	PI	PI Organization	Rec. Budget
1	RP250355	CAP-CAC-CR	2.8	The Texas Collaborative Center for Hepatocellular Cancer (TeCH)	El-Serag, Hashem	Baylor College of Medicine	\$3,000,000

7. CORE FACILITY SUPPORT AWARDS (RFA R-24.2 CFSA) SLATE

Scientific Review Council Recommendations:

The Scientific Review Council recommended one Core Facility Support (CFSA), totaling \$2,999,989.

Purpose of Core Facility Support Awards:

Supports applications that facilitate the development or improvement of core facilities that will provide valuable services to support and enhance scientifically meritorious cancer research projects.

Core Facility Support Award Funding Levels:

Award: Up to \$3M (total costs) for a new application and up to \$2M for renewals; Maximum duration: 5 years.

Recommended CFSA Institutions (1):

Baylor Research Institute

RP240537

PI: Erxi Wu, Ph.D.

Title: Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core

Applicant Organization: Baylor Research Institute

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.0

Recommended Total Budget Award and Duration: \$2,999,989

CPRIT Priorities Addressed: Investment in core facilities; Drug Discovery

Description:

This is a new award to establish the Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core. This core will serve researchers across Texas in drug target identification and therapeutic aptamer development and is driven by the demonstrated interest of numerous Texas-based researchers focused on developing effective anticancer drugs. Their services aim to create a robust foundation for pioneering drug development and application in oncology. They aim to offer this resource for identifying critical drug binding partners, expediting their research in cancer drug discovery.

8. RECRUITMENT OF ESTABLISHED INVESTIGATORS SLATE
(FY25 - Cycles 25.2 and 25.3) Slate

Peer Review Recommendations

The applications were evaluated and scored by the Scientific Review Council (SRC) to determine the candidates' potential to make a significant contribution to the cancer research program of the nominating institution. Review criteria focused on the overall impression of the candidate and his/her potential for continued superb performance as a cancer researcher, scientific merit of the proposed research program, his/her long-term impact on the field of cancer research, and strength of the institutional commitment to the candidate.

Purpose of Recruitment of Established Investigators Awards:

The aim is to recruit outstanding senior research faculty with distinguished professional careers and established cancer research programs to academic institutions in Texas.

Funding levels for Recruitment of Established Investigators Awards:

Up to \$6 million over a period of 5 years.

Recommended Awards:

Two Recruitment of Established Investigators grant applications were submitted and one was recommended by the Scientific Review Council for an Established Investigators Award.

RR250072

Candidate: Pernilla Wittung Stafshede, Ph.D.

Funding Mechanism: Recruitment of Established Investigator

Applicant Organization: Rice University

Original Organization of Nominee: Chalmers University of Technology

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.0

Recommended Total Budget Award and Duration: \$6,000,000

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

Pernilla Wittung-Stafshede, Ph.D., has been nominated for a CPRIT Established Investigators Award, by Rice University, and appointment as a professor in the Department of Chemistry in the Wiess School of Natural Sciences. Dr. Wittung-Stafshede is an accomplished and highly gifted biophysical scientist, whose combination of expertise in bioinorganic chemistry, biophysical chemistry and biochemistry gives her a superior ability to tackle complicated biological questions on the role of metals and metal dysregulation in various diseases. She pioneered a new research field around the role of metal ions in folding and function of metalloproteins.

Metal ions, especially copper, often act as cofactors in essential enzymes, providing them with chemical reactivity important for their biological functions. Notably, in addition to basic functions, copper seems to play an important role in many cancer processes. Several hallmarks of cancer, such as cell migration and metastasis, demand high levels of copper. As free copper ions can damage cellular components, copper ions are strictly controlled by dedicated copper-transport proteins. Dr. Wittung-Stafshede's recent fundamental work on mechanisms of copper transport led to her discovery of new copper binding proteins, most notably Memo1 and Atox1, that interact with copper chaperones and play previously unknown roles in cancer cell migration, research that forms the basis for this CPRIT application. Specifically, she found that the Atox1 copper-transport protein stimulates breast cancer cell migration, and that breast cancer patients with high levels of Atox1 in their tumors, had poorer overall survival.

Dr. Wittung-Stafshede's overarching goal is to identify novel pathways that can act as starting points for new approaches to prevent cancer metastasis. In Aim 1, she will investigate whether Memo1 – a Cu-binding protein that is known to be a cancer oncoprotein - protects against Cu-mediated reactive oxygen species (ROS) in cancer cells (ROS are highly reactive chemicals that damage cellular components, such as DNA, resulting in mutations). In Aim 2, she will determine whether Memo1 delivers Cu to Atox1 for cell export via the secretory pathway. In Aim 3, she will examine whether there is a Cu-dependent interplay between another Cu-binding

protein - LOX - and Memo1 in cancer cells. Overall, these studies will pinpoint Atox1 binding partner proteins, and identify the relevant copper-dependent pathways that promote breast cancer cell migration and metastasis.

Given that metastatic cancer is the main cause of mortality in patients with solid tumors, the outcome of this project has a high potential to provide a unique scientific platform identifying novel therapeutic targets, predicted to extend to many types of cancer, as well as new prognostic and predictive biomarkers.

9. RECRUITMENT OF FIRST-TIME TENURE-TRACK FACULTY MEMBERS (FY25 – Cycles 25.2 and 25.3) Slate

Peer Review Recommendations

The applications were evaluated and scored by the Scientific Review Council to determine the candidates' potential to make a significant contribution to the cancer research program of the nominating institution. Review criteria focused on the overall impression of the candidate and his/her potential for continued superb performance as a cancer researcher, his/her scientific merit of the proposed research program, his/her long-term contribution to and impact on the field of cancer research, and strength of the institutional commitment to the candidate.

Purpose of First-Time Tenure-Track Faculty Recruitment

The aim is to recruit and support very promising emerging investigators, pursuing their first faculty appointment in Texas, who can make outstanding contributions to the field of cancer research.

Funding levels for First-Time Tenure-Track Faculty Members Recruitment

Up to \$2 million over a period of up to 5 years.

Recommended Projects:

Six Recruitment of First-Time, Tenure-Track Faculty Member grant applications were submitted and five were recommended by the Scientific Review Council for an award.

Below is a listing of the candidates with their associated expertise:

RR250077

Candidate: Daniel (Xin) Gao, Ph.D.

Funding Mechanism: Recruitment of First-Time, Tenure-Track Faculty Member

Applicant Organization: Baylor College of Medicine

Original Organization of Nominee: Broad Institute of MIT and Harvard University

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.0

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas; research on childhood and adolescent cancers.

Description:

Baylor College of Medicine (BCM) is recruiting Daniel Gao as a First-Time, Tenure-Track Faculty Member in the Department of Biochemistry and Molecular Pharmacology. Upon recruitment, he will be appointed as a tenure-track Assistant Professor with the title “CPRIT Scholar in Cancer Research”. Dr. Gao is currently a Postdoctoral Fellow in the laboratory of Dr. David Liu at Harvard University. Dr. Gao will bring an outstanding record of productivity in the areas of protein engineering, genome biology, and genome engineering to BCM and the state of Texas.

As a postdoctoral fellow, Dr. Gao built on his expertise to apply protein engineering and evolution to uncover biological mechanisms and enable novel therapeutics to treat genetic diseases. He developed a prime-editing-assisted, site-specific integrase gene editing method, achieving large gene integration in the human genome with good efficiency. He also developed a therapeutic base editing approach to treat Zellweger spectrum disorder – a rare, genetic, multi-organ congenital disorder. Dr. Gao’s long-term goals are to leverage his expertise in engineering biomolecules to edit the human genome to create new methods for studying genetic variants of uncertain significance in cancer genomes, to develop effective targeted therapies, and to engineer immunotherapies with enhanced precision and efficiency.

In Aim 1, Dr. Gao will develop a recombinase-based screening platform to flexibly and comprehensively annotate the functions of variants of uncertain significance in tumor suppressor genes and regulatory regions that affect breast and thyroid cancers. Successful development of this recombinase-based screening system will revolutionize current pipelines by enabling a more comprehensive understanding of unannotated variants with reduced costs and increased flexibility. This advancement will enhance cancer prognosis and the selection of precision cancer treatments.

In Aim 2, he will develop an optimized non-viral, site-specific gene integration tool for immune cells, using molecular engineering to improve product purity, increase DNA donor capacity, and evade cellular immune surveillance of donor DNA. Dr. Gao proposes to extend this work to enhance cargo-size capacity and eliminate dsDNA immunogenicity to enable effective multi-CAR-T cell therapy targeting osteosarcoma, and will assess its efficacy in both cellular (in vitro) and animal (in vivo) models of osteosarcoma. These advancements may enhance cancer prognosis and precision cancer treatments in clinical settings and hold promise for advancing novel immunotherapies to effectively target solid tumors with enhanced precision and efficacy without requiring viral donors.

RR250070

Candidate: Rosalie Griffin, Ph.D.

Funding Mechanism: Recruitment of First-Time, Tenure-Track Faculty Member

Applicant Organization: The University of Texas M.D. Anderson Cancer Center

Original Organization of Nominee: Mayo Clinic

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:1.0

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas; Computational oncology and analytic methods

Description:

Rosalie Griffin, Ph.D., is a human computational geneticist, with training in biomedical engineering and epidemiology. Dr. Griffin is being nominated for a CPRIT First-Time, Tenure-Track Faculty Member Award and appointment as an assistant professor on the Tenure Track in the Department of Epidemiology with a joint appointment in the department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center.

Her research combines state-of-the-art genomics, computational techniques and lymphoma biology to inform strategies for risk stratification, early detection and interception of lymphoid malignancies. She will be mentored by the Division head of Cancer Medicine - Dr. Christopher Flowers – A CPRIT Scholar and internationally renowned translational scientist in the biology and treatment of lymphoma and multiple myeloma. Dr. Griffin has made transformative contributions to cancer science and prevention, pioneering insights into clonal hematopoiesis of indeterminate potential (CHIP), inherited genomics and tumor genomics. Her research has established CHIP in the form of mosaic chromosomal alterations (mCAs) in blood cells as early markers of disease risk and progression in lymphoid malignancies, with implications for cancer health disparities. Her work on families at high risk for multiple myeloma has uncovered key roles for chromatin remodeling and DNA repair pathways.

In her laboratory in Texas, Dr. Griffin will leverage a remarkable resource developed by Dr. Flowers - the largest and most diverse prospective cohort of lymphoma survivors in the world to decipher the role of mCAs in lymphoid malignancy risk, clonal expansion, and prognosis. In Aim 1, she will determine the association between mCAs and lymphoid malignancy subtype risk by assessing mCAs in 34,000 cases and 63,000 controls, with validation studies in 5,000 incident lymphoma cases. In Aim 2, Dr. Griffin will evaluate the prognostic role of mCAs in lymphoid malignancies. In Aim 3, she will elucidate the lineage of blood cells with mCAs in lymphoid malignancies, in that some mCA events may occur outside the lymphoid tumor lineage. Finally in Aim 4, Dr. Griffin will decipher the relationship between mCAs and inherited genetics. Inherited risk may predispose individuals to mCAs that drive lymphomagenesis. This integrative research approach holds the potential to unlock new strategies to anticipate and intercept lymphoid malignancies in high-risk individuals.

RR250071**Candidate: Nipun Verma, M.D., Ph.D.****Funding Mechanism:** Recruitment of First-Time, Tenure-Track Faculty Member**Applicant Organization:** Baylor College of Medicine**Original Organization of Nominee:** Yale University School of Medicine**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.1**Recommended Total Budget Award and Duration:** \$2,000,000.**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas**Description:**

Baylor College of Medicine has nominated Nipun Verma, M.D., Ph.D., for a CPRIT First-Time, Tenure-Track Faculty Member Award. Dr. Verma is being jointly recruited as a tenure-track assistant professor by the Department of Radiation Oncology and the Dan L Duncan

Comprehensive Cancer Center. Dr. Verma has a unique multi-disciplinary background and extensive experience in molecular and cell biology, and cancer immunology, and has distinguished herself with impactful clinical, basic, and translational research. She has received a number of prestigious awards during her training, including an HHMI Medical Scholars Fellowship, a Yale Cancer Center Physician Scientist T32 Research Fellowship, and the ASTRO Residents/Fellows in Radiation Oncology Seed Grant Award.

During her radiation oncology residency program at Yale School of Medicine, she conducted research using a CRISPR screen to look for targets that impact the killing of cancer cells by CD8+ T cells following radiation treatment. She identified a number of different genes which when altered impacted the response to radiation and immune therapy via cooperative interaction through the c-GAS/STING pathway (a pathway that acts to trigger an immune response).

In her independent laboratory, she will take advantage of these earlier findings to evaluate several different interacting proteins that are involved in the c-GAS/STING pathway. One such protein is expressed on the cell membrane of cancer cells following radiation treatment and induction of the c-GAS/STING pathway and acts to suppresses the immune response. In Aim 1, she will investigate whether blocking this immunosuppressive ligand in combination with radiation treatment will stimulate an immune response, and lead to reduced tumor growth in a variety of in vivo mouse cancer models (pancreatic, breast, ovarian, and prostate cancer). In Aim 2, she will use CRISPR screens to modify parts of a pancreatic cancer cell genome to see if these modifications lead to greater tumor cell death following radiation, either due to increased DNA damage in the cancer cells or the cancer cells releasing signals that stimulate the immune system. The goal of these CRISPR screens would be to identify additional targets that can be used to augment the immune activating effects of radiation treatment. These targets can then be used to develop novel therapeutics that can be used clinically in combination with radiation.

Over half of cancer patients receive radiation during their cancer treatment. Although radiation is very effective in controlling the primary targeted tumor, it cannot treat areas of microscopic metastases that are not seen on imaging, or target all sites of widespread metastatic disease. Although Dr. Verma's studies will be done on a few initial cancer types, this paradigm can be extended to investigate additional cancers, and could have a transformative impact for cancer patients.

RR250063**Candidate: Tao Zou, M.D., Ph.D.****Funding Mechanism:** Recruitment of First-Time, Tenure-Track Faculty Member**Applicant Organization:** The University of Texas Southwestern Medical Center**Original Organization of Nominee:** Dana-Farber Cancer Institute, Harvard Medical School**Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:** 1.1**Recommended Total Budget Award and Duration:** \$2,000,000.**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas,**Description:**

The University of Texas Southwestern Medical Center has nominated Tao Zou, M.D., Ph.D. for a CPRIT First-Time, Tenure-Track Scholar Award. Dr. Zou is being recruited to join the Division of Hematology and Oncology in the Department of Internal Medicine as Assistant Professor on the tenure track, with a secondary appointment in the Simmons Comprehensive Cancer Center. Dr. Zou, a superbly trained physician scientist with a strong background in tumor immunology and lung cancer will establish a translational research program focused on developing strategies to therapeutically target cellular RNA processing and modification pathways in lung cancer. His work has been funded by a Conquer Cancer Young Investigator Award from the American Society of Clinical Oncology, and a prestigious K08 Mentored Career Development Award from the National Cancer Institute.

Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in the United States. The discovery of targeted tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has improved outcomes in NSCLC. However, most patients with NSCLCs treated with ICIs or TKIs develop resistance to these drugs. Thus, there is a critical need to develop new strategies to treat NSCLC in these contexts. In his prior work, Dr. Zou showed that blocking the metabolism of cellular RNA can cause activation of the cells' "innate immune sensors", which initially evolved to detect foreign, infectious viral RNA structures. Dr. Zou also showed that stimulation of these RNA sensing pathways in specific subsets of NSCLC cells can cause a robust antiviral immune response, leading to death of the cancer cells, leading him to hypothesize that antiviral innate immune pathways may represent novel therapeutic targets in specific subsets of NSCLC.

Dr. Zou will now focus on developing new approaches to target innate immune pathways in NSCLC, i.e., effectively tricking them into mounting an antiviral immune response that blocks cancer cell growth. First, he will use both human and mouse models of lung cancer that have developed resistance to cancer immunotherapy to identify new therapeutic targets that activate the antiviral immune machinery in lung cancers, to highlight novel strategies for overcoming resistance to cancer immunotherapy. In the second Aim, he will design an innovative RNA-based therapeutic strategy to activate this antiviral immune machinery in lung cancers driven by DNA mutations that promote tumor growth. This approach will engage the antiviral immune responses, and block tumor growth while recruiting immune cells to attack the tumor. Overall, this innovative approach of targeting the antiviral immune machinery has the potential to produce impactful discoveries in lung cancer research, and to stimulate the development of new treatments for clinically relevant types of lung cancer.

RR250061

Candidate: Ziwen Jiang, Ph.D.

Funding Mechanism: Recruitment of First-Time, Tenure-Track Faculty Member

Applicant Organization: University of Texas at Dallas

Original Organization of Nominee: University of California San Francisco

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]:2.0

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:


Ziwen Jiang, Ph.D. has been nominated by the University of Texas at Dallas for a CPRIT First-Time, Tenure-Track Faculty Member Scholar Award, and appointment as an Assistant Professor in the Department of Chemistry and Biochemistry. Dr. Jiang is an outstanding chemical biology researcher with an extremely strong publication record that includes more than 40 peer-reviewed publications in prestigious journals, 17 of which are first-author papers. During his postdoctoral studies, Dr. Jiang received world-class training in chemical biology and drug discovery and developed a novel methodology with engineered antibody tools to reprogram the cellular process of “autophagy”.

Autophagy is a process that helps break down and recycle harmful contents within a cell, such as unwanted proteins and damaged cell components. As such, autophagy has an important role in maintaining the viability of cells and tissues, as well as in conferring protection against diseases by working in concert with the immune system. Autophagy has long been considered a target for cancer therapies; however, currently available drugs targeting this pathway modulate the overall level of autophagy, resulting in undesired off-target side effects on essential cellular components.

In his independent laboratory, Dr. Jiang will further the development of a novel approach he discovered to control the degradative process of autophagy by depleting its intracellular targets. Specifically, he will focus on the development of engineered protein tools - specifically functional antibodies - to precisely target and control specific compartments during the autophagy signaling process. The initial goals are to regulate the dynamics of hard-to-degrade cancer-relevant targets such as protein aggregates (Aim 1) and dysfunctional organelles (Aim 2). The technology developed by Dr. Jiang will provide new tools to facilitate studies to understand how these autophagy targets relate to cancer development. Additionally, these antibodies could also be explored in translational applications for the development of new therapeutic agents and strategies for cancer prevention and treatment.

Attachment #1

		*Academic Research Program Priorities Addressed by Recommended Awards (*Some grant awards address more than one program priority and are double counted.)						
Scale	Recruitment of outstanding cancer researchers to Texas	Expand access to innovative clinical trials	A broad range of innovative, investigator-initiated research projects.	Childhood and Adolescent Cancers	Implementation Research	Computational oncology and analytic methods	Investment in Core Facilities	Hepatocellular Cancer



Attachment #2
RFA Descriptions



- **Individual Investigator Research Awards (IIRA)**
Supports applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer. Areas of interest include laboratory research, translational studies, and/or clinical investigations. Competitive renewal applications accepted.
Award: Up to \$300,000 per year. Exceptions permitted if extremely well justified; maximum duration: 3 years.
- **Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)**
Supports applications for innovative mathematical and/or computational research projects addressing questions that will advance current knowledge in the (a) mechanisms that tie altered gene expression and downstream molecular mechanisms to functional cancer phenotypes and/or (b) mechanisms that tie tumor morphology to functional cancer phenotypes and/or mechanisms that tie treatment sequence and combination to evolving functional cancer phenotypes (that emerge as a result of treatment selection).
Award: Up to \$350,000 in total costs per year for up to 3 years. Exceptions permitted if extremely well justified.
- **Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)**
Supports applications for innovative research projects addressing questions that will advance knowledge of the causes, prevention, progression, detection, or treatment of cancer in children and adolescents. Laboratory, clinical, or population-based studies are all acceptable. CPRIT expects the outcome of the research to reduce the incidence, morbidity, or mortality from cancer in children and/or adolescents in the near or long term. Competitive renewal applications accepted.
Award: Up to \$300,000 per year. Exceptions permitted if extremely well justified; maximum duration: 4 years.
- **Individual Investigator Research Awards for Prevention and Early Detection (IIRAP)**
Supports applications which propose clinical and population-based projects designed to develop effective prevention and early detection interventions to reduce cancer risk, mortality, and morbidity among Texans. Projects that propose such research collaborations with existing CPRIT Prevention Program awardees including the CPRIT funded *Texas Collaborative Center for Hepatocellular Cancer*

<https://www.bcm.edu/research/labs-and-centers/research-centers/texas-collaborative-center-for-hepatocellular-cancer>) are strongly encouraged.

Award: Up to \$300,000 per year. Exceptions permitted if extremely well justified; maximum duration: 4 years.

- **Individual Investigator Research Awards for Clinical Trials (IIRACT)**
Supports applications that propose innovative cancer clinical studies that are hypothesis driven and involve patients enrolled prospectively on a clinical trial. Areas of interest include clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices. Clinical trial must be planned to begin when contract is awarded
Award: Up to \$400,000 per year. Maximum duration: 4 years. Exceptions permitted if extremely well justified.
- **Core Facility Support Awards (RFA R-24-2. CFSA):**
Supports applications that facilitate the development or improvement of core facilities that will provide valuable services to support and enhance scientifically meritorious cancer research projects.
Award: Up to \$3 million over a period of five years.
- **Collaborative Action Program (CAP) to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center (Competitive Renewal)**
Supports a competitive renewal of one single Collaborative Action Center whose function will be to innovatively expand the administrative services, resources, and support to CPRIT funded hepatocellular cancer research projects.
Award: Up to \$3 million over a period of five years.
- **Recruitment of Established Investigators (RFA R-25-1 REI):**
Recruits outstanding senior research faculty with distinguished professional careers and established cancer research programs to academic institutions in Texas.
Award: Up to \$6 million over a period of five years.
- **Recruitment of First-Time, Tenure-Track Faculty Members (RFA R-25-1. RFT):**
Supports very promising emerging investigators, pursuing their first faculty appointment in Texas, who have the ability to make outstanding contributions to the field of cancer research.
Award: Up to \$2 million over a period of up to five years.

UC San Diego

SCHOOL OF MEDICINE

January 5, 2025

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Ms. Kristen Doyle
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to kdoyle@cprit.texas.gov

Dear Dr. Cummings and Ms. Doyle,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for the Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal); Core Facility Support Award (FY2024); Individual Investigator Research Awards; Individual Investigator Research Awards for Childhood and Adolescent Cancers; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; Investigator Research Awards for Early-Onset Cancers; Individual Investigator Research Awards for Prevention and Early Detection; Recruitment of Established Investigators; Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 12, 2024 to consider the FY25.1 applications recommended by the peer review panels following their meetings held October 16, 2024 to October 24, 2024 and one FY24.2 Core Facility application recommended by a peer review panel on April 24, 2024. The SRC met on November 14, 2024 to review recruitment applications submitted for Cycle FY25.2 and then on December 12, 2024 to review recruitment applications submitted for Cycle FY25.3.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the 53 recommended applications is \$67,753,626.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Chair, CPRIT Scientific Review Council

Rank	Grant ID	RFA	Score	Title	PI	Institution	Recommended Budget
1	RP250118	IIRA	1.0	Ribosome Localization at Mitochondria-ER Contacts in Obesity-Associated Liver Cancer	Morita, Masahiro	The University of Texas Health Science Center at San Antonio	\$900,000
2	RP250061	IIRA	1.0	Imaging of cranial radiotherapy neuroinflammatory sequelae by Positron Emission Tomography	Pisaneschi, Federica	The University of Texas Health Science Center at Houston	\$900,000
3	RR250077	RFTFM	1.0	Developing next generation of genome editing tools to study and engineer genetic variants for effective precision cancer treatment	Gao, Xin "Daniel"	Baylor College of Medicine	\$2,000,000
4	RR250070	RFTFM	1.0	Unlocking the Potential of Clonal Hematopoiesis in Early Detection and Interception of Lymphoid Malignancies	Griffin, Rosalie	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
5	RR250063	RFTFM	1.1	Co-opting antiviral innate immune pathways to target non-small cell lung cancer	Zou, Tao	The University of Texas Southwestern Medical Center	\$2,000,000
6	RR250071	RFTFM	1.1	CRISPR screening to uncover tumor intrinsic modulators of DNA repair and immune effects of radiation therapy	Verma, Nipun	Baylor College of Medicine	\$2,000,000
7	RP250278	IIRACCA	1.2	Developmental origins of IDH-mutant glioma in adolescents	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,198,416
8	RP250293	IIRAP	1.2	Development of a shared decision tool to facilitate uptake of the levonorgestrel-releasing intrauterine system for the primary prevention of endometrial cancer	Meyer, Larissa	The University of Texas M. D. Anderson Cancer Center	\$1,199,542
9	RP250208	IIRA	1.4	RPS23 is a new drug target to activate the integrated stress response and treat leukemia	Ready, Joseph	The University of Texas Southwestern Medical Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

10	RP250201	IIRA	1.4	Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in oral cavity squamous cell carcinoma	Gillison, Maura	The University of Texas M. D. Anderson Cancer Center	\$899,998
11	RP250028	IIRA	1.5	MALAT1 protects against osteoporosis and bone metastasis	Ma, Li	The University of Texas M. D. Anderson Cancer Center	\$900,000
12	RP250247	IIRA	1.5	Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETS	Yao, James	The University of Texas M. D. Anderson Cancer Center	\$900,000
13	RP250144	IIRACCA	1.5	Decoding how neuronal activity remodels the epigenome in ependymoma	Deneen, Benjamin	Baylor College of Medicine	\$1,200,000
14	RP250220	IIRA	1.8	Decellularized tissue matrices to study the “bad soil” in cancer metastasis	Wang, Andrew	The University of Texas Southwestern Medical Center	\$900,000
15	RP250269	IIRAP	1.8	Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules.	Ostrin, Edwin	The University of Texas M. D. Anderson Cancer Center	\$1,169,776
16	RP250222	IIRA	1.9	KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC	Gibbons, Don	The University of Texas M. D. Anderson Cancer Center	\$899,997
17	RP250043	IIRA	1.9	An integrated imaging informatics platform for HCC surveillance	Zhou, Xiaobo	The University of Texas Health Science Center at Houston	\$899,991
18	RP250374	IIRACCA	1.9	Dissecting TFE3 Mediated tRCC Tumorigenesis	Brugarolas, James	The University of Texas Southwestern Medical Center	\$1,196,812
19	RP240537	CFSA	2.0	Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core	Wu, Erxi	Baylor Research Institute	\$2,999,989
20	RP250213	IIRA	2.0	KRAS spatiotemporal dynamics: lipid glycosylation as a novel therapeutic target	Hancock, John	The University of Texas Health Science Center at Houston	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

21	RP250428	IIRA	2.0	Studying Hematopoietic Stem Cells to Predict and Understand Mechanisms of Post-transplant Relapse in the Myelodysplastic Syndromes	Chung, Stephen	The University of Texas Southwestern Medical Center	\$899,025
22	RP250143	IIRA	2.0	Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy	Lissanu, Yonathan	The University of Texas M. D. Anderson Cancer Center	\$899,991
23	RP250044	IIRACSBC	2.0	Heterogeneity of resistance to endocrine therapy and Cdk inhibition: An integrated systems biology approach to biologically informed treatment regimens	Brock, Amy	The University of Texas at Austin	\$763,596
24	RR250072	REI	2.0	Mechanisms behind copper dependence of cancer cells	Wittung Stafshede, Pernilla	Rice University	\$6,000,000
25	RR250061	RFTFM	2.0	Engineered antibody tools for targeted regulation of cancer-associated proteins and organelles through redirected autophagy process	Jiang, Ziwen	The University of Texas at Dallas	\$2,000,000
26	RP250398	IIRA	2.1	Synthetic lethality of TRIP13 and Aurora A in Rb-deficient cancer	Johnson, Faye	The University of Texas M. D. Anderson Cancer Center	\$899,994
27	RP250402	IIRA	2.1	Exploiting Tryptophan Metabolite Addiction to identify and Inhibit HCC	Conacci Sorrell, Maralice	The University of Texas Southwestern Medical Center	\$900,000
28	RP250131	IIRACT2	2.1	Randomized Clinical Trial Evaluating Fecal Microbiota Transplant in Chimeric Antigen Receptor Therapy for Reversing Antimicrobial-Associated Dysbiosis	Saini, Neeraj	The University of Texas M. D. Anderson Cancer Center	\$1,598,410
29	RP250282	IIRA	2.2	Harnessing BACH2 to enhance anti-tumor T cell immunity	Yao, Chen	The University of Texas Southwestern Medical Center	\$900,000
30	RP250280	IIRA	2.2	The role of glutathione in leukemia development	Agathocleous, Michalis	The University of Texas	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

						Southwestern Medical Center	
31	RP250062	IIRA	2.3	Clonal hematopoiesis and toxicity from radiation therapy	Nead, Kevin	The University of Texas M. D. Anderson Cancer Center	\$899,885
32	RP250407	IIRA	2.3	Protecting the GI tract with a C60 fullerene derivative to facilitate dose-escalated abdominopelvic radiotherapy	Mackeyev, Yuri	The University of Texas Health Science Center at Houston	\$900,000
33	RP250055	IIRA	2.4	TET2 mutations promote myeloid malignancies by dysregulating m5C oxidation of chromatin-associated RNAs	Xu, Mingjiang	The University of Texas Health Science Center at San Antonio	\$900,000
34	RP250391	IIRA	2.5	Novel PCDH7 monoclonal antibodies that direct immune surveillance and combat drug resistance in lung cancer	O'Donnell, Kathryn	The University of Texas Southwestern Medical Center	\$900,000
35	RP250321	IIRACT2	2.5	Leveraging synthetic and collateral lethality in MTAP loss tumors	Rodon Ahnert, Jordi	The University of Texas M. D. Anderson Cancer Center	\$1,599,783
36	RP250069	IIRA	2.6	HSP90 Capacitance: Discovery of a New Mechanism Driving Evolution of Drug Resistance in Head and Neck Squamous Cell Carcinoma	Karras, Georgios	The University of Texas M. D. Anderson Cancer Center	\$890,201
37	RP250305	IIRA	2.6	Exploiting synthetic lethality between HNRNPK loss and ribosomal dysfunction in del9q AML	Post, Sean	The University of Texas M. D. Anderson Cancer Center	\$896,322
38	RP250091	IIRA	2.6	Dissecting the Survival Mechanisms of Latent Brain-Tropic Cancer Cells for Therapeutic Interventions	Malladi, Srinivas	The University of Texas Southwestern Medical Center	\$900,000
39	RP250322	IIRA	2.6	Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2-mutant non-small cell lung cancer (NSCLC)	Heymach, John	The University of Texas M. D. Anderson Cancer Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

40	RP250154	IIRA	2.6	Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients	Fuentes, David	The University of Texas M. D. Anderson Cancer Center	\$899,808
41	RP250156	IIRAP	2.6	Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer	Wu, Jia	The University of Texas M. D. Anderson Cancer Center	\$1,200,000
42	RP250094	IIRACT2	2.7	A phase 2 clinical trial with Avasopasem, with anti-estrogen therapy (ET) and a CDK4/6 inhibitor in metastatic breast cancer progressing on ET/CDK4/6 therapy.	Gius, David	The University of Texas Health Science Center at San Antonio	\$1,390,420
43	RP250418	IIRAP	2.7	Approach Bias Retraining to Augment Long-Term Smoking Cessation Among a Diverse Sample	Garey, Lorra	University of Houston	\$1,200,000
44	RP250355	CAP-CAC-CR	2.8	The Texas Collaborative Center for Hepatocellular Cancer (TeCH)	El-Serag, Hashem	Baylor College of Medicine	\$3,000,000
45	RP250119	IIRACCA	2.8	Comparison of Symptom Burden, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients treated with Surgery vs. Surgery and Chemotherapy	Kahalley, Lisa	Baylor College of Medicine	\$1,200,000
46	RP250190	IIRACCA	2.8	Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-Exercise Intervention	Swartz, Maria	The University of Texas M. D. Anderson Cancer Center	\$1,199,756
47	RP250182	IIRAP	2.8	Implementing Newborn Screening for Pediatric Cancer Predisposition Syndromes in Texas: The INSPECT Study	Parsons, Donald	Baylor College of Medicine	\$1,187,187
48	RP250097	IIRA	2.9	Deciphering and targeting age-related metastatic	Naora, Honami	The University of Texas M. D.	\$899,984

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				competence of the omentum		Anderson Cancer Center	
49	RP250099	IIRA	2.9	Targeting lethal prostate cancers with a clinical-stage inverse agonist for G protein-coupled receptor 6	Li, Wenliang	The University of Texas Health Science Center at Houston	\$900,000
50	RP250399	IIRACSBC	2.9	Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture	Vokes, Natalie	The University of Texas M. D. Anderson Cancer Center	\$1,049,033
51	RP250090	IIRACSBC	2.9	Artificial Intelligence for Early Identification of Androgen-Indifferent, Lethal Prostate Cancer and Therapy Selection	Merényi, Erzsébet	Rice University	\$1,049,434
52	RP250191	IIRA	3.1	Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$898,263
53	RP250164	IIRACCA	3.1	Prediction of CAR-T Cell Immunotherapy Outcomes in Neuroblastoma using FE-MRI Nano-radiomics	Ghaghada, Ketan	Baylor College of Medicine	\$1,168,013

Core Facility Support Award (CFSA)

Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal)

Individual Investigator Research Awards (IIRA)

Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)

Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)

Individual Investigator Research Awards for Clinical Trials (IIRACT)

Individual Investigator Research Awards for Early Onset Cancers (IIRAEOC)

Individual Investigator Research Awards for Prevention and Early Detection (IIRAP)

Recruitment of Established Investigators (REI)

Recruitment of Rising Stars (RRS)

Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

February 7, 2025

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendation for funding 53 grant applications totaling \$67,753,626. I have attached the PIC's recommendations for the 53 academic research grant awards.

Chief Scientific Officer Dr. Michelle Le Beau has prepared an overview of the proposed grant slates to assist your evaluation of the recommended awards. The overview provides a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overview, all the information considered by each review council is available by clicking on the appropriate link in the Govenda app. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The statutory process governing the approval of these grant recommendations requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations are not final until the Oversight Committee approves the awards at the meeting on February 19, 2025. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, please keep the recommendations confidential and do not disclose information to anyone until CPRIT announces the award list publicly at the Oversight Committee meeting. I request that Oversight Committee members not print, email, or save to your computer's hard drive any grant material on the Govenda app. I appreciate your assistance in taking all necessary precautions to protect this information.

These projects recommended for awards are a major step in our efforts to mitigate the effects of cancer in Texas. If you have any questions or would like more information on the review process or any of the proposed projects, CPRIT's staff, including myself and Dr. Le Beau, are always available. Please feel free to contact us directly should you have any questions.

Thank you for being part of this endeavor.

Sincerely,
Kristen P. Doyle
Chief Executive Officer

ACADEMIC RESEARCH GRANT AWARD RECOMMENDATIONS

The PIC unanimously recommends approval of 53 academic research grant proposals totaling \$67,753,626. Applicants submitted the recommended grant proposals in response to the following grant mechanisms:

- *Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center*
- *Core Facilities Support Awards*
- *Individual Investigator Research Awards*
- *Individual Investigator Research Awards for Cancer in Children and Adolescents*
- *Individual Investigator Research Awards for Computational and Systems Biology of Cancer*
- *Individual Investigator Research Awards for Clinical Trials*
- *Individual Investigator Research Awards for Prevention and Early Detection*
- *Recruitment of Established Investigators (REI)*
- *Recruitment of First-Time, Tenure-Track Faculty Members*

The Scientific Review Council (SRC) provided a prioritized list of 53 grant award recommendations to the presiding officers of the PIC and Oversight Committee on January 10, 2025. The PIC approved the awards as presented by the SRC.

The PIC must give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that the recommended academic research proposals met one or more of the following CPRIT funding priorities:

- Could lead to immediate or long-term medical and scientific breakthroughs in the area of Cancer Prevention or cures for cancer;
- Strengthen and enhance fundamental science in Cancer Research;
- Ensure a comprehensive coordinated approach to Cancer Research and Cancer Prevention;
- Are interdisciplinary or interinstitutional;
- Address federal or other major research sponsors' priorities in emerging scientific or Technology fields in the area of Cancer Prevention, or cures for cancer;
- Are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- Are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state
- Have a demonstrable economic development benefit to this state;

- Enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not located in this state and other research entities, or enhancing existing research superiority by attracting from outside this state additional researchers and resources; and
 - This priority is met by all applications except for the *Core Facility Support Award*
- Address the goals of the Texas Cancer Plan.

Academic Research and Recruitment Award Recommendations							
<i>CAC: Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center</i>							
<i>CFSA: Core Facilities Support Awards</i>							
<i>IIRA: Individual Investigator Research Awards</i>							
<i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i>							
<i>IIRACSBC: Individual Investigator Research Awards for Computational and Systems Biology of Cancer</i>							
<i>IIRACT: Individual Investigator Research Awards for Clinical Trials</i>							
<i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i>							
<i>REI: Recruitment of Established Investigators</i>							
<i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
1.	RP250118	IIRA	Ribosome Localization at Mitochondria-ER Contacts in Obesity-Associated Liver Cancer	Morita, Masahiro	The University of Texas Health Science Center at San Antonio	\$900,000	1.0
2.	RP250061	IIRA	Imaging of cranial radiotherapy neuroinflammatory sequelae by Positron Emission Tomography	Pisaneschi, Federica	The University of Texas Health Science Center at Houston	\$900,000	1.0
3.	RR250077	RFTFM	Developing next generation of genome editing tools to study and engineer genetic variants for effective precision cancer treatment	Gao, Xin “Daniel”	Baylor College of Medicine	\$2,000,000	1.0
4.	RR250070	RFTFM	Unlocking the Potential of Clonal Hematopoiesis in Early Detection and Interception of Lymphoid Malignancies	Griffin, Rosalie	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
5.	RR250063	RFTFM	Co-opting antiviral innate immune pathways to target non-small cell lung cancer	Zou, Tao	The University of Texas Southwestern Medical Center	\$2,000,000	1.1
6.	RR250071	RFTFM	CRISPR screening to uncover tumor intrinsic modulators of DNA repair	Verma, Nipun	Baylor College of Medicine	\$2,000,000	1.1

Academic Research and Recruitment Award Recommendations							
<i>CAC: Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center</i>							
<i>CFSA: Core Facilities Support Awards</i>							
<i>IIRA: Individual Investigator Research Awards</i>							
<i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i>							
<i>IIRACSBC: Individual Investigator Research Awards for Computational and Systems Biology of Cancer</i>							
<i>IIRACT: Individual Investigator Research Awards for Clinical Trials</i>							
<i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i>							
<i>REI: Recruitment of Established Investigators</i>							
<i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
			and immune effects of radiation therapy				
7.	RP250278	IIRACCA	Developmental origins of IDH-mutant glioma in adolescents	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,198,416	1.2
8.	RP250293	IIRAP	Development of a shared decision tool to facilitate uptake of the levonorgestrel-releasing intrauterine system for the primary prevention of endometrial cancer	Meyer, Larissa	The University of Texas M. D. Anderson Cancer Center	\$1,199,542	1.2
9.	RP250208	IIRA	RPS23 is a new drug target to activate the integrated stress response and treat leukemia	Ready, Joseph	The University of Texas Southwestern Medical Center	\$900,000	1.4
10.	RP250201	IIRA	Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in oral cavity squamous cell carcinoma	Gillison, Maura	The University of Texas M. D. Anderson Cancer Center	\$899,998	1.4
11.	RP250028	IIRA	MALAT1 protects against osteoporosis and bone metastasis	Ma, Li	The University of Texas M. D. Anderson Cancer Center	\$900,000	1.5
12.	RP250247	IIRA	Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETs	Yao, James	The University of Texas M. D. Anderson Cancer Center	\$900,000	1.5
13.	RP250144	IIRACCA	Decoding how neuronal activity remodels the epigenome in ependymoma	Deneen, Benjamin	Baylor College of Medicine	\$1,200,000	1.5

Academic Research and Recruitment Award Recommendations							
<i>CAC: Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center</i>							
<i>CFSA: Core Facilities Support Awards</i>							
<i>IIRA: Individual Investigator Research Awards</i>							
<i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i>							
<i>IIRACSBC: Individual Investigator Research Awards for Computational and Systems Biology of Cancer</i>							
<i>IIRACT: Individual Investigator Research Awards for Clinical Trials</i>							
<i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i>							
<i>REI: Recruitment of Established Investigators</i>							
<i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
14.	RP250220	IIRA	Decellularized tissue matrices to study the “bad soil” in cancer metastasis	Wang, Andrew	The University of Texas Southwestern Medical Center	\$900,000	1.8
15.	RP250269	IIRAP	Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules.	Ostrin, Edwin	The University of Texas M. D. Anderson Cancer Center	\$1,169,776	1.8
16.	RP250222	IIRA	KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC	Gibbons, Don	The University of Texas M. D. Anderson Cancer Center	\$899,997	1.9
17.	RP250043	IIRA	An integrated imaging informatics platform for HCC surveillance	Zhou, Xiaobo	The University of Texas Health Science Center at Houston	\$899,991	1.9
18.	RP250374	IIRACCA	Dissecting TFE3 Mediated tRCC Tumorigenesis	Brugarolas, James	The University of Texas Southwestern Medical Center	\$1,196,812	1.9
19.	RP240537	CFSA	Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core	Wu, Erxi	Baylor Research Institute	\$2,999,989	2.0
20.	RP250213	IIRA	KRAS spatiotemporal dynamics: lipid glycosylation as a novel therapeutic target	Hancock, John	The University of Texas Health Science Center at Houston	\$900,000	2.0
21.	RP250428	IIRA	Studying Hematopoietic Stem Cells to Predict and Understand Mechanisms of Post-transplant Relapse in the Myelodysplastic Syndromes	Chung, Stephen	The University of Texas Southwestern Medical Center	\$899,025	2.0

Academic Research and Recruitment Award Recommendations							
<i>CAC: Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center</i>							
<i>CFSA: Core Facilities Support Awards</i>							
<i>IIRA: Individual Investigator Research Awards</i>							
<i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i>							
<i>IIRACSBC: Individual Investigator Research Awards for Computational and Systems Biology of Cancer</i>							
<i>IIRACT: Individual Investigator Research Awards for Clinical Trials</i>							
<i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i>							
<i>REI: Recruitment of Established Investigators</i>							
<i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
22.	RP250143	IIRA	Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy	Lissanu, Yonathan	The University of Texas M. D. Anderson Cancer Center	\$899,991	2.0
23.	RP250044	IIRACSBC	Heterogeneity of resistance to endocrine therapy and Cdk inhibition: An integrated systems biology approach to biologically informed treatment regimens	Brock, Amy	The University of Texas at Austin	\$763,596	2.0
24.	RR250072	REI	Mechanisms behind copper dependence of cancer cells	Wittung Stafshede, Pernilla	Rice University	\$6,000,000	2.0
25.	RR250061	RFTFM	Engineered antibody tools for targeted regulation of cancer-associated proteins and organelles through redirected autophagy process	Jiang, Ziwen	The University of Texas at Dallas	\$2,000,000	2.0
26.	RP250398	IIRA	Synthetic lethality of TRIP13 and Aurora A in Rb- deficient cancer	Johnson, Faye	The University of Texas M. D. Anderson Cancer Center	\$899,994	2.1
27.	RP250402	IIRA	Exploiting Tryptophan Metabolite Addiction to identify and Inhibit HCC	Conacci Sorrell, Maralice	The University of Texas Southwestern Medical Center	\$900,000	2.1
28.	RP250131	IIRACT	Randomized Clinical Trial Evaluating Fecal Microbiota Transplant in Chimeric Antigen Receptor Therapy for Reversing	Saini, Neeraj	The University of Texas M. D. Anderson Cancer Center	\$1,598,410	2.0

Academic Research and Recruitment Award Recommendations							
<i>CAC: Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center</i>							
<i>CFSA: Core Facilities Support Awards</i>							
<i>IIRA: Individual Investigator Research Awards</i>							
<i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i>							
<i>IIRACSBC: Individual Investigator Research Awards for Computational and Systems Biology of Cancer</i>							
<i>IIRACT: Individual Investigator Research Awards for Clinical Trials</i>							
<i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i>							
<i>REI: Recruitment of Established Investigators</i>							
<i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
			Antimicrobial-Associated Dysbiosis				
29.	RP250282	IIRA	Harnessing BACH2 to enhance anti-tumor T cell immunity	Yao, Chen	The University of Texas Southwestern Medical Center	\$900,000	2.2
30.	RP250280	IIRA	The role of glutathione in leukemia development	Agathocleous, Michalis	The University of Texas Southwestern Medical Center	\$900,000	2.2
31.	RP250062	IIRA	Clonal hematopoiesis and toxicity from radiation therapy	Nead, Kevin	The University of Texas M. D. Anderson Cancer Center	\$899,885	2.3
32.	RP250407	IIRA	Protecting the GI tract with a C60 fullerene derivative to facilitate dose-escalated abdominopelvic radiotherapy	Mackeyev, Yuri	The University of Texas Health Science Center at Houston	\$900,000	2.3
33.	RP250055	IIRA	TET2 mutations promote myeloid malignancies by dysregulating m5C oxidation of chromatin-associated RNAs	Xu, Mingjiang	The University of Texas Health Science Center at San Antonio	\$900,000	2.4
34.	RP250391	IIRA	Novel PCDH7 monoclonal antibodies that direct immune surveillance and combat drug resistance in lung cancer	O'Donnell, Kathryn	The University of Texas Southwestern Medical Center	\$900,000	2.5
35.	RP250321	IIRACT	Leveraging synthetic and collateral lethality in MTAP loss tumors	Rodon Ahnert, Jordi	The University of Texas M. D. Anderson Cancer Center	\$1,599,783	2.5

Academic Research and Recruitment Award Recommendations							
<i>CAC: Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center</i>							
<i>CFSA: Core Facilities Support Awards</i>							
<i>IIRA: Individual Investigator Research Awards</i>							
<i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i>							
<i>IIRACSBC: Individual Investigator Research Awards for Computational and Systems Biology of Cancer</i>							
<i>IIRACT: Individual Investigator Research Awards for Clinical Trials</i>							
<i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i>							
<i>REI: Recruitment of Established Investigators</i>							
<i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
36.	RP250069	IIRA	HSP90 Capacitance: Discovery of a New Mechanism Driving Evolution of Drug Resistance in Head and Neck Squamous Cell Carcinoma	Karras, Georgios	The University of Texas M. D. Anderson Cancer Center	\$890,201	2.6
37.	RP250305	IIRA	Exploiting synthetic lethalties between HNRNPK loss and ribosomal dysfunction in del9q AML	Post, Sean	The University of Texas M. D. Anderson Cancer Center	\$896,322	2.6
38.	RP250091	IIRA	Dissecting the Survival Mechanisms of Latent Brain-Tropic Cancer Cells for Therapeutic Interventions	Malladi, Srinivas	The University of Texas Southwestern Medical Center	\$900,000	2.6
39.	RP250322	IIRA	Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2- mutant non-small cell lung cancer (NSCLC)	Heymach, John	The University of Texas M. D. Anderson Cancer Center	\$900,000	2.6
40.	RP250154	IIRA	Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients	Fuentes, David	The University of Texas M. D. Anderson Cancer Center	\$899,808	2.6
41.	RP250156	IIRAP	Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in	Wu, Jia	The University of Texas M. D. Anderson Cancer Center	\$1,200,000	2.6

Academic Research and Recruitment Award Recommendations							
<i>CAC: Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center</i>							
<i>CFSA: Core Facilities Support Awards</i>							
<i>IIRA: Individual Investigator Research Awards</i>							
<i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i>							
<i>IIRACSBC: Individual Investigator Research Awards for Computational and Systems Biology of Cancer</i>							
<i>IIRACT: Individual Investigator Research Awards for Clinical Trials</i>							
<i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i>							
<i>REI: Recruitment of Established Investigators</i>							
<i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
			HPV-associated oropharyngeal cancer				
42.	RP250094	IIRACT	A phase 2 clinical trial with Avasopasem, with anti-estrogen therapy (ET) and a CDK4/6 inhibitor in metastatic breast cancer progressing on ET/CDK4/6 therapy.	Gius, David	The University of Texas Health Science Center at San Antonio	\$1,390,420	2.7
43.	RP250418	IIRAP	Approach Bias Retraining to Augment Long-Term Smoking Cessation Among a Diverse Sample	Garey, Lorra	University of Houston	\$1,200,000	2.7
44.	RP250355	CAC	The Texas Collaborative Center for Hepatocellular Cancer (TeCH)	El-Serag, Hashem	Baylor College of Medicine	\$3,000,000	2.8
45.	RP250119	IIRACCA	Comparison of Symptom Burden, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients treated with Surgery vs. Surgery and Chemotherapy	Kahalley, Lisa	Baylor College of Medicine	\$1,200,000	2.8
46.	RP250190	IIRACCA	Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele- Exercise Intervention	Swartz, Maria	The University of Texas M. D. Anderson Cancer Center	\$1,199,756	2.8
47.	RP250182	IIRAP	Implementing Newborn Screening for Pediatric Cancer Predisposition Syndromes in Texas: The INSPECT Study	Parsons, Donald	Baylor College of Medicine	\$1,187,187	2.8

Academic Research and Recruitment Award Recommendations							
<i>CAC: Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center</i>							
<i>CFSA: Core Facilities Support Awards</i>							
<i>IIRA: Individual Investigator Research Awards</i>							
<i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i>							
<i>IIRACSBC: Individual Investigator Research Awards for Computational and Systems Biology of Cancer</i>							
<i>IIRACT: Individual Investigator Research Awards for Clinical Trials</i>							
<i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i>							
<i>REI: Recruitment of Established Investigators</i>							
<i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
48.	RP250097	IIRA	Deciphering and targeting age-related metastatic competence of the omentum	Naora, Honami	The University of Texas M. D. Anderson Cancer Center	\$899,984	2.9
49.	RP250099	IIRA	Targeting lethal prostate cancers with a clinical-stage inverse agonist for G protein-coupled receptor 6	Li, Wenliang	The University of Texas Health Science Center at Houston	\$900,000	2.9
50.	RP250399	IIRACSBC	Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture	Vokes, Natalie	The University of Texas M. D. Anderson Cancer Center	\$1,049,033	2.9
51.	RP250090	IIRACSBC	Artificial Intelligence for Early Identification of Androgen-Indifferent, Lethal Prostate Cancer and Therapy Selection	Merényi, Erzsébet	Rice University	\$1,049,434	2.9
52.	RP250191	IIRA	Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$898,263	3.1
53.	RP250164	IIRACCA	Prediction of CAR-T Cell Immunotherapy Outcomes in Neuroblastoma using FE- MRI Nano-radiomics	Ghaghada, Ketan	Baylor College of Medicine	\$1,168,013	3.1



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: VINCE BURGESS, CHIEF COMPLIANCE OFFICER
SUBJECT: COMPLIANCE CERTIFICATION – FEBRUARY 2025 AWARDS
DATE: FEBRUARY 7, 2025

Summary and Recommendation:

As CPRIT’s Chief Compliance Officer, I am responsible for reporting to the Oversight Committee regarding the agency’s compliance with applicable statutory and administrative rule requirements during the grant review process. I have reviewed the compliance pedigrees for the grant applications submitted to CPRIT for the:

- Recruitment of Established Investigators
- Recruitment of First-Time, Tenure-Track Faculty Members
- Individual Investigator Research Awards
- Individual Investigator Research Awards for Childhood and Adolescent Cancers
- Individual Investigator Research Awards for Computational Systems Biology of Cancer
- Individual Investigator Research Awards for Clinical Trials
- Individual Investigator Research Awards for Prevention and Early Detection
- Collaborative Action Program (CAP) to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center
- Core Facility Support Awards (CFSA)

I note the following grant mechanisms received applications but did not result in any award recommendations: Individual Investigator Research Awards for Early-Onset Cancers, and Recruitment of Rising Stars. I have conferred with staff at CPRIT and General Dynamics Information Technology (GDIT), CPRIT’s contracted third-party grants administrator, regarding the academic research awards, and studied the supporting grant review documentation, including third-party observer reports for the peer review meetings. I am satisfied that the application review process that resulted in the above mechanisms recommended by the Program Integration Committee (PIC) followed applicable laws and agency administrative rules. I certify the academic research award recommendations for the Oversight Committee’s consideration.

One Core Facility Support Award (CFSA) application recommended by the Program Integration Committee (PIC) to the Oversight Committee for February 19, 2025, meeting was initially reviewed by peer reviewers during academic research cycle 24.2. The Scientific Review Council (SRC) recommended cycle 24.2 applications to the PIC and Oversight Committee at their July 11, 2024, meeting. However, at that time, the SRC took no action on the 24.2 application that is part of the recommended awards for the February 2025 meeting. The SRC recommended the cycle 24.2 application with the cycle 25.1 awards at their December 12, 2024, meeting. I certified the cycle 24.2 CFSA mechanism for the August 21, 2024, Oversight Committee meeting; therefore, I will not repeat the certification here but instead will make available copies of that certification.

Background:

CPRIT's Chief Compliance Officer must report to the Oversight Committee regarding compliance with the statute and the agency's administrative rules. Among the Chief Compliance Officer's responsibilities is the obligation "to ensure that all grant proposals comply with this chapter and rules adopted under this chapter before the proposals are submitted to the oversight committee for approval." Texas Health & Safety Code § 102.051(c) and (d).

CPRIT uses a compliance pedigree process to formally document compliance for the grant award process. The compliance pedigree tracks the grant application as it moves through the review process and documents compliance with applicable laws and administrative rules. A compliance pedigree is created for each application; the information related to the procedural steps listed on the pedigree is entered and attested to by GDIT employees and CPRIT employees. CPRIT relies on GDIT to accurately record a majority of the information on the pedigree from the pre-receipt stage to final Review Council recommendation. To the greatest extent possible, information reported in the compliance pedigree is imported directly from data contained in CPRIT's Application Receipt System (CARS), the grant application database managed by GDIT. This is done to minimize the opportunity for error caused by manual data entry.

No Prohibited Donations:

Although CPRIT is statutorily authorized to accept gifts and grants pursuant to Texas Health & Safety Code § 102.054, the statute prohibits CPRIT from awarding a grant to an applicant who has made a gift or grant to CPRIT, or a nonprofit organization established to provide support to CPRIT. I note that Texas Health & Safety Code § 102.251(a)(3) specifically addresses "donors from any nonprofit organization established to provide support to the institute compiled from information made available under § 102.262(c)." To the best of my knowledge, there are no nonprofit organizations that have been established to provide support to CPRIT on or after June 14, 2013, the effective date of this statutory change. The only nonprofit organization established to provide support to the Institute was the CPRIT Foundation; however, the CPRIT Foundation

ceased operations and changed its name and its purpose prior to June 14, 2013. The institute has received no donations from the CPRIT Foundation made on or after June 14, 2013.

I have reviewed the list of donors to CPRIT maintained by CPRIT (and listed on CPRIT's website) and compared the donors to the list of applicants. No donors to CPRIT have submitted applications for grant awards during the award cycles that are the subject of this report.

Pre-Receipt Compliance:

The activities listed on a compliance pedigree in the pre-receipt stage cover the period beginning with CPRIT's approval and issuance of the Request for Applications (RFA) through the submission of grant applications. For the period covering these RFAs, CPRIT published the RFAs on the Texas.gov eGrants website. The RFA specifies a deadline and mandates that only those applications submitted electronically through CPRIT's Application Receipt System (CARS) are eligible for consideration. CARS blocks an application from being submitted once the deadline passes. Occasionally, an applicant may have technical difficulties that prevent the applicant from completing the application submission. When this occurs, the applicant may appeal to CPRIT (through the CPRIT Helpdesk that is managed by GDIT) to allow for a submission after the deadline. The program officer considers any requests for extension and may approve an extension for good cause. When a late filing request is approved, the applicant is notified, and CARS is reopened for a brief period – usually two to three hours – the next business day.

Academic Research:

For recruitment cycles 25.2 and 25.3, two applications were received for the Recruitment of Established Investigators RFA, four applications were received for the Recruitment of Rising Stars RFA, and six applications were received in response to the Recruitment of First-Time, Tenure Track Faculty Members RFA.

In response to the academic, non-recruitment RFAs for cycle 25.1, CPRIT received 346 applications. Four applications were administratively withdrawn, and three applications were voluntarily withdrawn by the applicant.

All academic research RFAs were posted on the Texas.gov eGrants website and all applications were submitted through CARS. Three applicants requested an extension to submit an application after the deadline. The program officer determined that there was good cause for the requests and the deadline was extended.

Receipt, Referral, and Assignment Compliance:

Once applications have been submitted through CARS, GDIT staff reviews the applications for compliance with RFA directions. If an applicant does not comply with the directions, GDIT notifies the program officer, and the program officer makes the final decision whether to administratively withdraw the application. Recruitment grant applications are assigned to the Scientific Review Council members for peer review. All other academic research, product development research, and prevention applications are assigned by the peer review panel chair to their respective peer review panels. Prior to distribution of the applications, reviewers are given summary information about the applicant, including the Project Director and collaborators. Reviewers must sign a conflict of interest agreement and confirm that they do not have a conflict of interest with the application before they are provided with the full application.

The pedigrees attest that a conflict of interest statement was signed by each primary reviewer for each Grant Application.

Academic Research:

Seven academic research applications were withdrawn during this cycle: four non-recruitment applications were administratively withdrawn prior to peer review and three non-recruitment applications were voluntarily withdrawn by the applicant.

Peer Review:

Primary reviewers (typically three) must submit written critiques for each of their assigned applications prior to the peer review meeting. Sign out sheets are used to document when a reviewer with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application.

Following the peer review meeting, each participating peer reviewer must sign a post-review peer review statement certifying that the reviewer knew of and understood CPRIT's conflict of interest policy and followed the policy for this review process. After the peer review meetings, a final score report from the review committee is delivered to the Review Council for additional review.

Academic Research:

For the recruitment awards, the applications are reviewed by the Scientific Review Council (SRC), which assigns two members of the SRC to be primary reviewers. I reviewed the supporting documentation, such as the sign-out sheets, third-party observer reports, and post-review peer reviewer statements. Sign out sheets are used to document when a reviewer with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application. One conflict of interest was declared by

the SRC for recruitment cycle 25.3. The reviewer was not present during the meeting on December 12, 2024.

I reviewed and confirmed that the post review conflict of interest statements were signed by the 9 SRC members that attended the 25.2 Recruitment Review Panel meeting on November 14, 2024 and the 9 SRC members that attended the 25.3 Recruitment Review Panel on December 12, 2024.

Academic research applications (non-recruitment) are reviewed by peer review panels and recommended to the SRC. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in the Individual Investigator mechanisms in this cycle. This process allows the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments. A total of 176 applications across the six Individual Investigator mechanisms were recommended for full review and of those, 94 applications were discussed during the peer review panel meetings. As documented by GDIT, reviewers with conflicts of interest did not participate in review of those applications. I reviewed supporting documentation, such as conflict of interest statements (COIs), third-party observer reports, and sign out sheets. All declared COIs left the room or disengaged from the conference call and did not participate in the discussion of relevant applications.

I also reviewed and confirmed that the post review conflict of interest statements were signed by peer review members for each review panel as well as the seven SRC members that attended the Review Council meeting on December 12, 2024.

Programmatic Review:

Programmatic review is conducted by the Scientific Review Council, Prevention Review Council, and Product Development Review Council for their respective awards. Each review council creates a final list of grant applications it will recommend to the PIC for grant award slates.

The Oversight Committee approved a fiscal year 2025 conflict of interest waiver for review council members pursuant to Health & Safety Code §102.1062. To the extent that any Review Council member identified a conflict of interest not covered by the approved FY 2025 waiver, I reviewed documentation confirming that the review council member did not participate in the discussion or vote on the application(s).

I also reviewed the third-party observer reports for the Review Council meeting. The third-party observer reports document that the Review Council discussions were limited to the merits of the applications and established evaluation criteria and that conflicted reviewers, if applicable, exited the room or the conference call when the application was discussed.

For the Academic Research awards, I reviewed and confirmed that the Review Council recommendations corresponded to RFAs that had been released. I also confirmed that the pedigrees reflect the date of the Review Council meeting and that the applications were recommended by the Review Council.

Academic Research:

The SRC met on December 12, 2024, to consider 46 applications recommended by the peer review panels following their meetings held on October 16-18 and 22-25, 2024 and one Core Facility Support Award (CFSA) application recommended by a peer review panel on April 24, 2024. I note that CPRIT temporarily withdrew this CFSA application to undergo additional compliance verifications. After confirming that the application met compliance requirements, CPRIT allowed the application to resume peer review.

After review of these applications, the SRC recommended 47 applications to the Program Integration Committee (PIC) for consideration. In addition, six academic recruitment applications were recommended to the PIC by the SRC at their meetings on November 14, 2024, and December 12, 2024.

Dr. Jason Lewis, an SRC member, declared two conflicts of interest with RP250069 and RP250428 for the SRC meeting on December 12, 2024. Pursuant to the approved Texas Health & Safety Code § 102.1062 conflict of interest waiver applicable to review councils in FY2025, Dr. Lewis' two conflicts were waived.

I note that some non-recruitment grant applications are not recommended for funding with scores that are the same as or more favorable than some applications that were recommended within the Individual Investigator Research Award mechanism. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. This means that each peer review panel independently sets a cut-off score that determines which applications move forward to the SRC. A panel's cut off score may be different than other the cut off score of other panels. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

Program Integration Committee (PIC) Review:

Texas Health & Safety Code § 102.051(d) requires the Chief Compliance Officer to attend and observe the PIC meetings to ensure compliance with CPRIT's statute and administrative rules. CPRIT's statute requires that, at the time the PIC's final Grant Award recommendations are formally submitted to the Oversight Committee, the Chief Executive Officer shall prepare a written affidavit for each Grant Application recommended by the PIC containing relevant information related to the Grant Application recommendations.

I attended the February 5, 2025, PIC meeting as an observer and confirm that the PIC review process complied with CPRIT's statute and administrative rules. All five PIC members were present at the meeting.

The PIC considered 53 applications that were recommended by the Scientific Review Council and voted to recommend all 53 applications to move forward to the Oversight Committee.

A review of the CEO affidavits confirms that such affidavits were executed and provided for each grant application recommendation.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: VINCE BURGESS, CHIEF COMPLIANCE OFFICER
SUBJECT: COMPLIANCE CERTIFICATION – AUGUST 2024 AWARDS
DATE: AUGUST 8, 2024

Summary and Recommendation:

As CPRIT’s Chief Compliance Officer, I am responsible for reporting to the Oversight Committee regarding the agency’s compliance with applicable statutory and administrative rule requirements during the grant review process. I have reviewed the compliance pedigrees for the grant applications submitted to CPRIT for the:

- Recruitment of First-Time, Tenure-Track Faculty Members
- Clinical Investigator Awards
- Core Facility Support Awards
- High-Impact/High-Risk Research Awards
- Multi-Investigator Research Awards

I have conferred with staff at CPRIT and General Dynamics Information Technology (GDIT), CPRIT’s contracted third-party grants administrator, regarding the academic research awards and studied the supporting grant review documentation, including third-party observer reports for the peer review meetings. I am satisfied that the application review process that resulted in the above mechanisms recommended by the Program Integration Committee (PIC) followed applicable laws and agency administrative rules. I certify the academic research award recommendations for the Oversight Committee’s consideration.

Background:

CPRIT’s Chief Compliance Officer must report to the Oversight Committee regarding compliance with the statute and the agency’s administrative rules. Among the Chief Compliance Officer’s responsibilities is the obligation “to ensure that all grant proposals comply with this chapter and rules adopted under this chapter before the proposals are submitted to the oversight committee for approval.” Texas Health & Safety Code § 102.051(c) and (d).

CPRIT uses a compliance pedigree process to formally document compliance for the grant award process. The compliance pedigree tracks the grant application as it moves through the review process and documents compliance with applicable laws and administrative rules. A compliance pedigree is created for each application; the information related to the procedural steps listed on the pedigree is entered and attested to by GDIT employees and CPRIT employees. CPRIT relies on GDIT to accurately record a majority of the information on the pedigree from the pre-receipt stage to final Review Council recommendation. To the greatest extent possible, information reported in the compliance pedigree is imported directly from data contained in CPRIT's Application Receipt System (CARS), the grant application database managed by GDIT. This is done to minimize the opportunity for error caused by manual data entry.

No Prohibited Donations:

Although CPRIT is statutorily authorized to accept gifts and grants pursuant to Texas Health & Safety Code § 102.054, the statute prohibits CPRIT from awarding a grant to an applicant who has made a gift or grant to CPRIT, or a nonprofit organization established to provide support to CPRIT. I note that Texas Health & Safety Code § 102.251(a)(3) specifically addresses “donors from any nonprofit organization established to provide support to the institute compiled from information made available under § 102.262(c).” To the best of my knowledge, there are no nonprofit organizations that have been established to provide support to CPRIT on or after June 14, 2013, the effective date of this statutory change. The only nonprofit organization established to provide support to the Institute was the CPRIT Foundation; however, the CPRIT Foundation ceased operations and changed its name and its purpose prior to June 14, 2013. The institute has received no donations from the CPRIT Foundation made on or after June 14, 2013.

I have reviewed the list of donors to CPRIT maintained by CPRIT (and listed on CPRIT's website) and compared the donors to the list of applicants. No donors to CPRIT have submitted applications for grant awards during the award cycles that are the subject of this report.

Pre-Receipt Compliance:

The activities listed on a compliance pedigree in the pre-receipt stage cover the period beginning with CPRIT's approval and issuance of the Request for Applications (RFA) through the submission of grant applications. The RFA specifies a deadline and mandates that only those applications submitted electronically through CPRIT's Application Receipt System (CARS) are eligible for consideration. CARS blocks an application from being submitted once the deadline passes. Occasionally, an applicant may have technical difficulties that prevent the applicant from completing the application submission. When this occurs, the applicant may appeal to CPRIT (through the CPRIT Helpdesk that is managed by GDIT) to allow for a submission after the deadline. The program officer considers any requests for extension and may approve an

extension for good cause. When a late filing request is approved, the applicant is notified, and CARS is reopened for a brief period – usually two to three hours – the next business day.

Academic Research:

For recruitment cycle 24.12, nine applications were received in response to the Recruitment of First-Time, Tenure Track Faculty Members RFA.

In response to the academic, non-recruitment RFAs for cycle 24.2, CPRIT received 147 applications.

All applications were submitted through CARS. One applicant requested an extension to submit an application after the deadline. The program officer determined that there was good cause for the request and the deadline was extended.

Receipt, Referral, and Assignment Compliance:

Once applications have been submitted through CARS, GDIT staff reviews the applications for compliance with RFA directions. If an applicant does not comply with the directions, GDIT notifies the program officer, and the program officer makes the final decision whether to administratively withdraw the application. Recruitment grant applications are assigned to the Scientific Review Council members for peer review. All other academic research, product development research, and prevention applications are assigned by the peer review panel chair to their respective peer review panels. Prior to distribution of the applications, reviewers are given summary information about the applicant, including the Project Director and collaborators. Reviewers must sign a conflict of interest agreement and confirm that they do not have a conflict of interest with the application before they are provided with the full application.

The pedigrees attest that a conflict of interest statement was signed by each primary reviewer for each Grant Application.

Academic Research:

One academic research, recruitment application was administratively withdrawn for cycle 24.12. Ten academic research, non-recruitment applications were withdrawn during cycle 24.2: nine applications were administratively withdrawn prior to peer review, and one application was withdrawn by the applicant after peer review but prior to the Scientific Review Council (SRC) meeting.

Peer Review:

Primary reviewers (typically three) must submit written critiques for each of their assigned applications prior to the peer review meeting. Sign out sheets are used to document when a reviewer

with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application.

Following the peer review meeting, each participating peer reviewer must sign a post-review peer review statement certifying that the reviewer knew of and understood CPRIT's conflict of interest policy and followed the policy for this review process. After the peer review meetings, a final score report from the review committee is delivered to the Review Council for additional review.

Academic Research:

For the recruitment awards, the applications are reviewed by the SRC, which assigns two members of the SRC to be primary reviewers. I reviewed the supporting documentation, such as the sign-out sheets, third-party observer reports, and post-review peer reviewer statements. Sign out sheets are used to document when a reviewer with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application. One conflict of interest was declared by an SRC member for recruitment cycle 24.12.

I reviewed and confirmed that the post review conflict of interest statements were signed by the seven SRC members that attended the 24.12 Recruitment Review Panel meeting on July 11, 2024.

Academic research applications (non-recruitment) are reviewed by peer review panels and recommended to the SRC. As documented by GDIT, reviewers with conflicts of interest did not participate in review of those applications. I reviewed supporting documentation, such as conflict of interest statements (COIs), third-party observer reports, and sign out sheets. All declared COIs left the room or disengaged from the conference call and did not participate in the discussion of relevant applications.

I also reviewed and confirmed that the post review conflict of interest statements were signed by peer review members for each review panel as well as the six SRC members that attended the Scientific Review Council meeting on July 11, 2024, and the six SRC members that attended the SRC meeting on July 29, 2024.

Programmatic Review:

Programmatic review is conducted by the Scientific Review Council, Prevention Review Council, and Product Development Review Council for their respective awards. Each review council creates a final list of grant applications it will recommend to the PIC for grant award slates.

To the extent that any Review Council member identified a conflict of interest, I reviewed documentation confirming that the review council member did not participate in the discussion or vote on the application(s).

I also reviewed the third-party observer reports for each Review Council meeting. The third-party observer reports document that the Review Council discussion was limited to the merits of the applications and established evaluation criteria and that conflicted reviewers, if applicable, exited the room or the conference call when the application was discussed.

For the academic research awards, I reviewed and confirmed that the Review Council recommendations corresponded to RFAs that had been released. I also confirmed that the pedigrees reflect the date of the Review Council meeting and that the applications were recommended by the Review Council.

Academic Research:

I note that within the Multi-Investigator Research Award and High-Impact/High-Risk Research Award mechanisms some grant applications are not recommended for funding with scores that are the same as or more favorable than some applications that were recommended within each mechanism. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be discussed or recommended for funding by a peer review panel.

Within the Core Facility Support Award grant mechanism, one, not recommended application has a score that is more favorable than some recommended applications. The application was withdrawn after peer review but prior to the SRC meeting so the members did not consider it.

The SRC met twice to consider and recommend 32 academic non-recruitment applications from cycle 24.2 to the PIC. After its first meeting on July 11, 2024, the SRC met on July 29, 2024, to recommend an additional application after it became clear to the SRC that grant funds were available to fund the additional application. The SRC also recommended four academic recruitment applications at their meeting on July 11, 2024, for cycle 24.12. The SRC recommended a total of 36 applications to the Program Integration Committee (PIC) for consideration.

Program Integration Committee (PIC) Review:

Texas Health & Safety Code § 102.051(d) requires the Chief Compliance Officer to attend and observe the PIC meetings to ensure compliance with CPRIT's statute and administrative rules. CPRIT's statute requires that, at the time the PIC's final Grant Award recommendations are formally submitted to the Oversight Committee, the Chief Executive Officer shall prepare a written affidavit for each Grant Application recommended by the PIC containing relevant information related to the Grant Application recommendations.

I attended the August 7, 2024, PIC meeting as an observer and confirm that the PIC review process complied with CPRIT's statute and administrative rules. Three PIC members were present for the meeting.

The PIC considered 36 applications and voted to recommend all 36 applications to move forward to the Oversight Committee.

A review of the CEO affidavits confirms that such affidavits were executed and provided for each grant application recommendation.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2025—Cycle 1**

***Collaborative Action Program to Reduce
Liver Cancer Mortality in Texas:
Collaborative Action Center***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS

RFA R-25.1-CAP:CAC

**Collaborative Action Program to Reduce
Liver Cancer Mortality in Texas:
Collaborative Action Center**

Competitive Renewal

**Please also refer to the Instructions for Applicants document,
which will be posted on February 22, 2024.**

Application Receipt Opening Date: March 19, 2024

Application Receipt Closing Date: June 11, 2024

FY2025

Fiscal Year Award Period

September 1, 2024-August 31, 2025

TABLE OF CONTENTS

1. BRIEF DESCRIPTION OF RFA.....	4
2. ABOUT CPRIT.....	4
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	5
3. PROGRAM DESCRIPTION.....	5
4. COLLABORATIVE ACTION CENTER DESCRIPTION- CONTINUATION	7
5. FUNDING INFORMATION	8
6. ELIGIBILITY.....	9
7. RESPONDING TO THIS RFA	11
7.1. APPLICATION SUBMISSION GUIDELINES	11
7.1.1. <i>Submission Deadline Extension</i>	11
7.2. APPLICATION COMPONENTS	11
7.2.1. <i>Abstract and Significance (5,000 characters)</i>	12
7.2.2. <i>Layperson’s Summary (2,000 characters)</i>	12
7.2.3. <i>Specific Aims and Subaims</i>	12
7.2.4. <i>Timeline (1 page)</i>	12
7.2.5. <i>Renewal Summary (3 pages)</i>	13
7.2.6. <i>Center Description (10 pages)</i>	14
7.2.7. <i>Human Subjects (2 pages)</i>	15
7.2.8. <i>Publications/References</i>	16
7.2.9. <i>Budget and Justification</i>	16
7.2.10. <i>Biographical Sketches for Key Personnel (5 pages each)</i>	17
7.2.11. <i>Current and Pending Support</i>	17
7.2.12. <i>Institutional/Collaborator Support and/or Other Certification (10 pages)</i>	17
7.3. FORMATTING INSTRUCTIONS	17
8. APPLICATION REVIEW.....	18
8.1. PRELIMINARY EVALUATION.....	18
8.2. CONFIDENTIALITY OF REVIEW	19
8.3. REVIEW CRITERIA.....	20
8.3.1. <i>Primary Criteria</i>	20
8.3.2. <i>Secondary Criteria</i>	21
9. KEY DATES	21
10. AWARD ADMINISTRATION.....	22
11. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS.....	23
12. CONTACT INFORMATION.....	23
12.1. HELPDESK.....	23
12.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	23

RFA VERSION HISTORY

2/22/24 RFA Released

1. BRIEF DESCRIPTION OF RFA

- This is a competitive renewal, supporting a single Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center (CAP:CAC).
- A competitive renewal application will address the expansion of administrative services, resources, and support to funded hepatocellular carcinoma research projects along with strong justification for the continuation of the FY19.2 CAP:CAC award.
- Applicants may request a maximum of \$3,000,000 in total costs for a period of 5 years.
- Multi-Principal Investigators (MIs) are allowed under this Request for Applications (RFA). See the Information for Applicants (IFA) document for definition and eligibility of MIs.
- See application limitations for Principal Investigators (PIs)/MIs, regardless of whether the MI is from the prime institution or a subcontracted institution.
- **Note that CPRIT does not allow the use of the term Co-PI.**
- Minimum effort for the PI and/or MIs throughout the project period is required.
- FY25 salary cap is \$225,000 per year.
- Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

Established Principles:

- Scientific excellence and impact on cancer

- Increasing the life sciences infrastructure in all regions of the state
- Reducing disparities in cancer incidence and mortality

2.1. Academic Research Program Priorities

The program priorities for Academic Research adopted by the Oversight Committee include the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention, early detection, risk assessment and interventions.
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer (HCC)
- Expanding access to innovative clinical trials

3. PROGRAM DESCRIPTION

The goal of the **Collaborative Action Program to Reduce Liver Cancer Mortality in Texas** is to position Texas as a national leader in reversing the trajectory of liver cancer incidence and mortality.

Liver cancer, also known as HCC, is the fastest increasing lethal cancer in the United States, with an annual incidence that has tripled during the past 2 decades. The incidence of HCC is 3 times higher in men than women, and there are significant racial and ethnic differences in liver cancer occurrence and mortality.

Risk factors for liver cancer include viral hepatitis (hepatitis B virus and hepatitis C virus), nonalcoholic steatohepatitis (NASH), and alcoholic liver disease. Approximately 80% to 90% of HCCs occur in patients with underlying cirrhosis, making individuals with advanced cirrhosis at particularly high risk for developing HCC.

Texas has the highest incidence of HCC in the US, with an annual incidence that is nearly double the national average. The rise is particularly virulent among Texans of Hispanic ethnicity living along the US-Mexican border where HCC incidence and mortality is the highest in the nation.

While the reasons for the increase in HCC in this population are not fully understood, HCC development has been linked to multiple risk factors including genetic predisposition and socioeconomic factors, but significant gaps remain in knowledge about the relationship between HCC in high-risk populations compared to non-Hispanic whites.

To address this challenge, CPRIT invested in the **Collaborative Action Program (CAP) to reduce liver cancer mortality in Texas** and the CAP Research awards, which are now integrated into Individual Investigator Research Awards (IIRA).

The CAP-related IIRA Research Awards RFA (RFA 25.1 IIRAP and IIRA) support investigator-initiated research projects designed to do the following:

1. Identify risk factors for cirrhosis and HCC in Texas populations and predictors of high risk for progression of cirrhosis to HCC, including environmental and behavioral factors, genetic markers, and health disparities;
2. Identify and validate biomarkers and/or imaging methods that will enhance the surveillance and better stratify patients with cirrhosis leading to detection of HCC at an early stage;
3. Increase implementation of evidence-based interventions for the prevention and/or early detection of HCC among populations at high risk; and
4. Conduct health services research in populations at highest risk for developing cirrhosis and HCC designed to identify the most effective ways to address the disparities (eg, through systems change, outreach, access) and delivery of early detection and preventive care.

The CAP Collaborative Action Center Competitive Renewal RFA seeks to support a single Collaborative Action Center (Center) that will continue to catalyze interactions and enable data sharing among the awardees of the CAP IIRA Awards and forge innovative relationships among academic content experts, health providers, and policymakers in Texas to promote awareness and implementation of best practices for HCC prevention and early detection.

4. COLLABORATIVE ACTION CENTER DESCRIPTION- CONTINUATION

Applicants are invited to propose a competitive renewal Center whose functions will be to continue to (1) promote interactions and collaboration across the hepatocellular cancer IIRA Research Awards; (2) provide opportunities for academic content experts, health care providers, and community stakeholders to exchange ideas and to explore new opportunities to impact the rise of HCC in Texas; (3) educate health care providers and the public on best practices to alter the trajectory of HCC in Texas; and (4) inform public health officials and influence, where possible, public health care policy to improve prevention, detection, and treatment of HCC.

To accomplish these goals, the Center will be expected to do the following:

- Demonstrate a compelling justification for continued CPRIT support of the Collaborative Action Center, based upon the scientific impact of current and continued CPRIT support.
- Quality and cost efficiency of the services alone are not sufficient justifications for continued CPRIT support. Renewal applications will be expected to demonstrate an exceptional record of impact on HCC research as measured by the following:
 - Utilization (number of PIs utilizing the Center; number of institutions served);
 - Publications that cite CPRIT support;
 - New peer-reviewed grant awards supported;
 - Clinical trials supported;
 - Patents supported;
 - Other metrics, such as practice-changing, or policy-influencing initiatives.
- Strong plan delineating how the Collaborative Action Center services provided will be developed further to advance HCC research.
- Provide current updates on the following FY2019 RFA deliverables and provide program expansion plans for the following:
 - Use of a steering committee consisting of the PIs and MIs of the funded HCC Research Awards to facilitate communications and interactions across these CPRIT-funded research projects;
 - Support collaborations across the HCC Research Projects by providing access to services that will facilitate data sharing among the HCC-funded research projects;

- Engage private and public entities across the state, (eg, representatives of health practices and health care systems, health insurers, pharmaceutical and biotech industry leaders, government agencies, etc), in policy considerations addressing issues critical to the reduction of HCC mortality in the state;
- Convene an annual scientific forum that will promote awareness of the burden of HCC, highlight CAP-supported research, and foster interactions with others whose research is relevant to HCC;
- Collect, synthesize, and disseminate findings and lessons learned from the CAP Research Awards and conduct an evaluation of the impact of the CAP program.

Applicants for this Center RFA are encouraged to identify additional assets that would leverage unique resources—such as established cohorts, biobanks, and annotated clinical data—that will provide additional opportunities and increase the impact of the *Collaborative Action Program to Reduce Liver Cancer Mortality in Texas*.

5. FUNDING INFORMATION

CPRIT plans to make 1 award to a single applicant in response to this RFA.

Applicants may request a maximum of \$3,000,000 in total costs for a period of 5 years.

Applicants may request salary support and fringe benefits for a Center Contact PI, MIs, data analysts, and additional programmatic and support staff required to carry out the Center functions.

Funds may be used for research supplies, data management support, website development, production of educational materials (promotional marketing products such as pens, etc, are not allowable costs), and allowable costs associated with hosting annual symposiums.

CPRIT awards cannot be used to pay for food and beverages related to holding meetings/annual conferences.

Travel to attend scientific or technical meetings, to attend onsite meetings with CAP-supported research programs, and to meet health providers and policymakers is also an allowable expense for the PI and the Center’s senior-level staff. Travel expenses related to the Center’s mission and to support travel expenses of steering committee members to attend Center meetings and annual symposium are appropriate expenses.

Up to 10% of the Center's annual direct budget may be used to fund special projects recommended by the CAP steering committee to extend the impact of the individual CAP Research Awards to additional geographic areas and/or populations.

Requests for funds to support major equipment, construction, and/or renovation will not be approved under this funding mechanism.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

6. ELIGIBILITY

- The application must come from a Texas-based entity. Any not-for-profit institution or organization is eligible to apply for funding under this award mechanism;
- Only institutions with an active CAP:CAC award may submit an application under this RFA.
- The PI must be the director of the proposed Center, must have requisite management experience, and must reside in Texas during the time the research that is the subject of the grant is conducted;
- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent. The PI should also hold a faculty position, preferably at the level of associate or full professor or the equivalent.
- The contact PI is required to maintain a minimum of **15%** level of effort through the duration of the entire award period. For applications that include MIs, **each** MI is required to maintain a minimum of **10%** effort through the entire duration of the award period.
- A PI may **not** submit applications to this RFA and to RFA R-25.1-IIRA, RFA R-25.1-IIRACSBC, RFA R-25.1-IIRACCA, RFA R-25.1-IIRACT, RFA R-2.1-IIRAP, or RFA R-25.1-IIRAEOC.
- A PI may **not** submit more than 1 application, either a new, resubmission, **or** renewal application under this RFA during this funding cycle.
- A PI may **not** be a part of more than 1 application, whether as a single applicant or as an MI on an application, under this RFA and RFA R-25.1-IIRA, RFA R-25.1-IIRACSBC,

RFA R-25.1-IIRACCA, RFA R-25.1-IIRACT, RFA R-25.1-IIRAP, or RFA R-25.2-IIRAEOC.

- **An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants.** Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project MIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2025).
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member, or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member ([Texas Administrative Code, Title 25, Rule 703.3](#));
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants are awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESPONDING TO THIS RFA

7.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. The non-contact PI does not have to create a user account in CARS; the PI will be added to the application by the Center Contact PI. Please refer to the *Instructions for Applicants (IFA)* document for the instructions on adding Multi PIs to an application. The *IFA* document will be available when the application receipt system opens. Applications will be accepted beginning at 7 AM central time on March 19, 2024, and must be submitted by 4 PM central time on June 11, 2024. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

7.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

7.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details. The IFA will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

7.2.1. Abstract and Significance (5,000 characters)

Clearly present the organizational structure, content expertise, and unique qualifications that will enable the applicant to meet the requirements described in [section 4](#) for the Center. Discuss special assets that the proposed Center will bring to the overall mission of the CAP program. State the added value that the Center will contribute to the projects supported by CAP Research Awards and discuss how the Center will (1) support collaborations across these CAP Research Awards, (2) engage private and public entities across the state in policy considerations that address issues critical to the reduction of HCC mortality in the state, and (3) educate health care providers and the public on best practices and new opportunities that will impact the trajectory of HCC in Texas.

7.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed Center. Describe, in simple, nontechnical terms, the overall goals of the Center, how the Center will accomplish the requirements identified in [section 4](#), and discuss any unique assets and/or experience that the Center will bring to the CAP program. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. Do not include any proprietary information in the layperson's summary. The layperson's summary will also be used by advocate reviewers ([section 8](#)) in evaluating the significance and impact of the proposed work.

7.2.3. Specific Aims and Subaims

Provide a list of specific aims and subaims for each year of the award. These aims will also be used in the initial assessment of the Center and in the evaluation of annual progress reports if the award is made.

7.2.4. Timeline (1 page)

Provide an outline (chart) of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

7.2.5. Renewal Summary (3 pages)

Renewal applications must demonstrate a compelling justification for continued CPRIT support of the Center that is based upon the scientific impact of current and continued CPRIT support, as well as a strong plan delineating how the services provided will be developed further to advance HCC research. Renewal applications will be expected to demonstrate an exceptional record of impact on HCC research as measured overall and by administrative duties of the CAP:CAC as described in the FY19.2 CAP:CAC RFA. Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 8](#).

Overall Summary

Provide a summary of the Center's progress and accomplishments related to:

1. The identification of risk factors for cirrhosis and HCC in Texas populations and predictors of high risk for progression of cirrhosis to HCC, including environmental and behavioral factors, genetic markers, and health disparities;
2. The identification and validation of biomarkers and/or imaging methods that enhanced the surveillance and better stratification of patients with cirrhosis leading to detection of HCC at an early stage;
3. Details regarding the implementation of evidence-based interventions for the prevention and/or early detection of HCC among populations at high risk; and
4. Health services research projects in populations at highest risk for developing cirrhosis and HCC designed to identify the most effective ways to address the disparities (eg, through systems change, outreach, access) and delivery of early detection and preventive care.

Administrative Collaborative Action Center Summary:

1. Provide a roster of steering committee members, number of meetings, and actions executed;
2. Summarize the support provided to the CAP and IIRA-related research projects including, but not limited to, tissue collections and the facilitation of data sharing among the CAP-funded research projects;

3. Describe the engagement with private and public entities across the state in policy considerations addressing issues critical to the reduction of HCC mortality in the state;
4. Summarize annual scientific forums by number of participants, speakers, and forum outcomes; and
5. Discuss the responses to the Center's external evaluations conducted and summarize the lessons learned.

7.2.6. Center Description (10 pages)

Overview and Capabilities

Provide an overview of the continuation award Center proposal in the context of the overall CPRIT Collaborative Action Program to Reduce Liver Cancer Mortality in Texas indicating how the Center will continue to facilitate, enhance, and support the research of the CAP Research Awards and **promote collaborations among the CAP program participants and others in Texas such that the whole is greater than the sum of the parts.**

Highlight any unique approaches or special assets the Center will bring to the overall CAP program.

Expertise and capabilities

Summarize the collective capabilities of the Center personnel, recent accomplishments, etc, in areas vital to the role of Center, including expertise relevant to liver cancer, including early detection and surveillance, development and validation of biomarkers including imaging approaches, dissemination and implementation research, health services research, and outreach and education.

Plans and Approaches to required Collaborative Action Center Functions

Describe a plan for continued evolution and operation of the Center that addresses all the functions of the Center identified in [section 4](#). The plan should address (but is not limited to) the following aspects:

- *Program Coordination.* Describe how the Center will (1) Provide organizational and logistical support for CAP Steering Committee meetings and additional program meetings as needed; (2) maintain or expand the Center's role in promoting collaborations

by identifying synergistic research opportunities among the funded CAP Research Awards, especially collaborations that involve different regions of the state; (3) plan activities that will facilitate collaborations between the CAP Research Awards and other Texas research programs (eg, CPRIT-, NIH-, DOD-funded research) addressing HCC prevention and early detection; and (4) convene representatives of private and public entities across the state to address policy issues critical to reduction of HCC mortality in the state.

- *Research Support.* The Center should plan to develop uniform protocols for specimen and data collection; coordinate, when feasible, the sharing of biospecimens (blood, other body fluids and, when feasible, liver tissue) across the CAP Research Awards; and support the Steering Committee’s selection of special projects designed to extend the impact of the CAP Research Awards.
- *Outreach and education.* Describe a plan to enhance initiatives to build awareness among health care providers and the public of cirrhosis and HCC risk factors and best practices for preventive measures and treatment; describe a plan to engage private and public entities across the state, (eg, representatives of health practices and health care systems, health insurers, pharmaceutical and biotech industry leaders, government agencies, etc), in public policy considerations addressing issues critical to the reduction of HCC in the state.
- *Evaluation and dissemination of new findings.* Describe how the Center will evaluate the impact of the *Collaborative Action Program to Reduce Liver Cancer Mortality in Texas* and how the Center will disseminate new findings from the individual CAP Research Awards as well as policy recommendations from the CAP-sponsored statewide policy considerations.

Applicants are encouraged to describe any additional assets that would leverage unique resources—such as established cohorts, biobanks, and annotated clinical data—for the benefit of the CAP program.

7.2.7. Human Subjects (2 pages)

If human subjects or human biological samples will be used, please use this section to provide any additional details that may have not been covered in the description of the Center.

7.2.8. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

7.2.9. Budget and Justification

Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.

The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2025 is \$225,000; CPRIT FY 2025 is from September 1, 2024, through August 31, 2025. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

Applicants may request salary support and fringe benefits for a Center contact PI, MIs, data analysts, and additional programmatic and support staff required to carry out the Center functions.

Funds may be used for research supplies, data management support, website development, production of educational materials (promotional marketing products such as pens, etc, are not allowable costs), and allowable costs associated with hosting annual symposiums.

CPRIT awards cannot be used to pay for food and beverages related to holding meetings/annual conferences.

Travel to attend scientific or technical meetings, to attend onsite meetings with CAP-supported research programs, and to meet health providers and policymakers is also an allowable expense for the PI and the Center's senior level staff. Travel expenses related to the Center's mission and

to support travel expenses of steering committee members to attend Center meetings and annual symposium are appropriate expenses.

Up to 10% of the Center’s annual direct budget may be used to support special projects recommended by the CAP steering committee to extend the impact of the individual CAP Research Awards to additional geographic areas and/or populations.

7.2.10. Biographical Sketches for Key Personnel (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. A biographical sketch must be provided for the PI and, if applicable, any additional MIs (for an MI application), as required by the online application receipt system. Up to 5 **additional** biographical sketches for key personnel may be provided; these should be concatenated into a single PDF with a 25-page limit. **Each biographical sketch must not exceed 5 pages.** The NIH biosketch format is appropriate.

7.2.11. Current and Pending Support

State the funding source and duration of all current and pending support for the PI, MIs, and all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and key personnel must be provided.

7.2.12. Institutional/Collaborator Support and/or Other Certification (10 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed Center. A maximum of 10 pages may be provided.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively withdrawn without review.

7.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English.

- **Document Format:** PDF only.
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point).
- **Line Spacing:** Single.
- **Page Size:** 8.5 x 11 inches.
- **Margins:** 0.75 inch, all directions.
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations may be submitted as part of the submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable if the journal information is stated. URLs of publications referenced in the application may be included.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.
- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

8. APPLICATION REVIEW

8.1. Preliminary Evaluation

Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. All eligible applications submitted in response to the CAP

Collaborative Action Center RFA will be evaluated using a 2-stage peer review process: (1) Full peer review and (2) prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 8.3](#). Applicants will be notified of peer review panel assignments prior to the peer review meeting dates. Peer review panel membership can be found on the CPRIT website. In the second stage, applications judged to be most meritorious by the peer review panel will be evaluated and recommended for funding by the CPRIT Scientific Review Council (SRC) who will take into consideration how well the Center's expertise and attributes complement the top-ranked HCC individual investigator research awards.

The SRC recommendations will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the CPRIT Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

8.2. Confidentiality of Review

Each stage of the application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, SRC members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and SRC members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#). Communication

regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: An Oversight Committee member, a PIC member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period prior to the opening of CARS. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

8.3. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Peer review committees will evaluate and score each primary criterion and subsequently assign an overall score that reflects a complete assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the merit of each application is within the sole discretion of the peer reviewers.**

8.3.1. Primary Criteria

The primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed project. Primary criteria include the following:

Significance and Impact: Has the Center achieved the goals outlined in the initial FY19 RFA? Has the Center been impactful in advancing collaborations and research on HCC? Has the Center developed resources that advance HCC research or care? How well does the proposed Center address the responsibilities described in the RFA? Will the Center effectively engage the CAP Research Awardees and create new opportunities for collaboration? Will the Center bring unique advantages or capabilities to the CAP? Will the Center provide statewide leadership and engage appropriate stakeholders in advancing policies and practices that will impact HCC in Texas? Does the Center include plans for developing outreach to health care providers, policymakers, and

others whose participation will increase the likelihood of success, and has the Center been effective in their current effort?

Will the overall impact of the Center lead to a program whose whole is greater than the sum of the individual components?

Technical Expertise: Is there sufficient technical expertise to carry out the duties of the Center?

Institutional Commitment: Is there clear institutional commitment for support of the Center? Has the host institution provided appropriate space and infrastructure support?

Center Personnel: Are the PI and other key personnel well suited to their roles in the Center? Do they have appropriate experience and training, and have they demonstrated significant experience with coordinating collaborative clinical research and implementation science? Is the leadership approach, governance, plan for conflict resolution, and organizational structure appropriate for the Center?

8.3.2. Secondary Criteria

Secondary criteria contribute to the overall score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed project.

Secondary criteria include the following:

Research Environment: Does the team have the needed facilities and access to resources to accomplish all aspects of the Center? Are the levels of effort of the key personnel appropriate?

Human Subjects: If human biological samples are included in the proposed research, is the human subjects plan adequate and sufficiently detailed? Note that certification of approval by the institutional IRB will be required before funding can occur.

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

9. KEY DATES

RFA

RFA release February 22, 2024

Application

Online application opens March 19, 2024, 7 AM central time

Application due June 11, 2024, 4 PM central time

Application review June 2024-February 2025

Award

Award notification February 2025

Anticipated start date March 1, 2025

10. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals documented in the grant award contract and address plans for the upcoming year. In addition, fiscal reporting and human studies reporting will be required as appropriate.

CPRIT will review annual progress reports and continuation of funding is contingent upon the timely receipt of these reports and documentation of sufficient progress toward completing

project goals. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of award contract. Forms and instructions will be made available at www.cprit.texas.gov.

11. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding.

12. CONTACT INFORMATION

12.1. Helpdesk

The Helpdesk will answer queries submitted via email within 1 business day. Helpdesk support is available for questions regarding user registration, online submission of applications as well as page limitations, formatting and how to upload application components/subsections in the appropriate tabs of the CPRIT Application Receipt System. Helpdesk staff cannot answer scientific questions and/or Academic Research programs aspects of an application. Before contacting the Helpdesk, please refer to the *Instructions for Applicants* document, which provides a step-by-step guide on using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

12.2. Scientific and Programmatic Questions

Scientific and Programmatic Questions-should be directed to the CPRIT Director of Academic Research. **Before contacting CPRIT, please refer to the *Instructions for Applicants* document and contact the Helpdesk for any items related to the Application Receipt System (CARS), page limitations, formatting, etc.**

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports

Cancer Prevention and Research Institute of Texas (CPRIT)**25.1 Academic Research Peer Review C/TCR-2****(25.1 ACR C/TCR-2)****Observation Report**

Report No. 2024-10-16 25.1_ACR_C/TCR-2
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Peer Review_C/TCR-2 (25.1_ACR_C/TCR-2)
Panel Date: October 16, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Peer Review_C/TCR-2 (25.1_ACR_C/TCR-2) meeting. The meeting was chaired by Richard O'Reilly and conducted via videoconference on October 16, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and seven (7) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Peer Review CB (25.1 ACR CB)
Observation Report

Report No. 2024-10-17 25.1_ACR_CB
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Peer Review_CB (25.1 _ACR_CB)
Panel Date: October 17, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Peer Review_CB (25.1_ACR_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on October 17, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, seventeen (17) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Research Imaging Technology and Informatics (ITI) (25.1 ACR-ITI)

Observation Report

Report No. 2024-10-18 25.1_ACR-ITI
Program Name: Academic Research
Panel Name: 25.1 Academic Research- Imaging Technology and Informatics (ITI) (25.1_ACR-ITI)
Panel Date: October 18, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research- Imaging Technology and Informatics (ITI) (25.1_ACR-ITI) meeting. The meeting was chaired by Jason Lewis and conducted via videoconference on October 18, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed and five (5) applications were not discussed
- Panelists: One (1) panel chair, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Seven (7)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Research Cancer Prevention Research

(25.1 ACR CPR)

Observation Report

Report No. 2024-10-22 25.1_ACR_CPR
Program Name: Academic Research
Panel Name: 25.1 Academic Research Cancer Prevention Research
(25.1_ACR_CPR)
Panel Date: October 22, 2024
Report Date: October 23, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Cancer Prevention Research (25.1_ACR_CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 22, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and eight (8) applications were not discussed
- Panelists: One (1) panel chair, ten (10) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict(s) of Interest (COIs) identified prior to and/or during the meeting. The COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Basic Cancer Research-1 (BCR-1)
Observation Report

Report No. 2024-10-23 25.1_ACR_BCR-1
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Basic Cancer Research-1 (BCR-1)
Panel Date: October 23, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Basic Cancer Research-1 (BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on October 23, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: One (15) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewer
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Basic Cancer Research-2 (BCR-2)
Observation Report

Report No. 2024-10-24 25.1_ACR_BCR-2
Program Name: Academic Research
Panel Name: 25.1 Academic Research Basic Cancer Research-2 (BCR-2)
Panel Date: October 24, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Basic Cancer Research-2 (BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 24, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Ten (10) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Clinical and Translational Cancer
Research-1 (CTCR-1) Observation Report

Report No. 2024-10-25 25.1_ACR_CTCR-1
Program Name: Academic Research
Panel Name: 25.1 Academic Research Clinical and Translational Cancer
Research-1 (CTCR-1)
Panel Date: October 25, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Clinical and Translational Cancer Research-1 (CTCR-1) meeting. The meeting was chaired by Margaret Tempero and conducted via videoconference on October 25, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed and twenty-nine (29) applications were not discussed
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Scientific Review Council (25.1 SRC)

Observation Report

Report No. 2024-12-12 25.1_SRC
Program Name: Academic Research
Panel Name: 25.1 Academic Scientific Review Council (25.1_SRC)
Panel Date: December 12, 2024
Report Date: December 18, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Scientific Review Council (25.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 12, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Forty-seven (47) applications were discussed
- Panelists: One (1) panel chair, six (6) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting; however, they are waived pursuant to the Section 102.1062 Conflict of Interest Waiver for FY 2025 approved by the CPRIT Oversight Committee.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a horizontal line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 25.1

Awards Announced at the February 19, 2025, Oversight Committee Meeting

The following table lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research cycle 25.1 include *Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center; Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual; Investigator Research Awards for Computational and Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; and Individual Investigator Research Awards for Prevention and Early Detection.*

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP250156	Jia Wu	The University of Texas M.D. Anderson Cancer Center	Issam El Naqa
RP250247	James Yao	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250118	Masahiro Morita	The University of Texas Health Science Center at San Antonio	Sanja Vicković
RP250399	Natalie Vokes	The University of Texas M.D. Anderson Cancer Center	Walter Stadler
RP250355	Hashem El-Serag	Baylor College of Medicine	Christopher Haiman

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250069	Georgios Karras	The University of Texas M.D. Anderson Cancer Center	Jason Lewis ¹
RP250438	Stephen Chung	The University of Texas M.D. Anderson Cancer Center	Jason Lewis ²
RP250278	Samuel McBrayer	The University of Texas Southwestern Medical Center	Craig Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP250124	Payal Kapur	The University of Texas Southwestern Medical Center	Anna Wu
RP250007	Debananda Pati	Baylor College of Medicine	Steffi Oesterreich
RP250230	Anirban Maitra	The University of Texas M.D. Anderson Cancer Center	Michael Hollingsworth
RP250014	Alexander Pertsemlidis	The University of Texas Health Science Center at San Antonio	Jose Conejo-Garcia
RP250088	Christopher Rylander	The University of Texas at Austin	Jose Conejo-Garcia
RP250187	Fredrik Thege	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250216	Khalid Mohamedali	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250265	Nabil Ahmed	Baylor College of Medicine	Ying Lu
RP250173	Katsumi Kitagawa	The University of Texas Health Science Center at San Antonio	Alan Tomkinson
RP250229	Kunal Rai	The University of Texas M.D. Anderson Cancer Center	Vijaya B. Kolachalama

¹ This conflict was waived pursuant to an approved Texas Health and Safety Code § 102.1062 waiver applicable to CPRIT review councils. A copy of the FY2025 waiver is available on [CPRIT's website](#).

² Same as footnote 1.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250153	Ronald DePinho	The University of Texas M.D. Anderson Cancer Center	Kornelia Polyak
RP250307	Sandeep Burma	The University of Texas Health Science Center at San Antonio	Bart Williams
RP250046	Surendranath Shastri	The University of Texas M.D. Anderson Cancer Center	Karen Emmons
RP250063	Aaron Thrift	Baylor College of Medicine	Christopher Haiman
RP250163	Robert Bast	The University of Texas M.D. Anderson Cancer Center	Karen Emmons
RP250231	Weiva Sieh	The University of Texas M.D. Anderson Cancer Center	Christopher Haiman; Lawrence Kushi; Melissa Troester
RP250053	Dae Kim	The University of Texas Rio Grande Valley	Alan Tomkinson
RP250334	Linghua Wang	The University of Texas M.D. Anderson Cancer Center	Benjamin Greenbaum
RP250371	John Tainer	The University of Texas M.D. Anderson Cancer Center	Alan Tomkinson; John Petrini; Walter Chazin
RP250411	Salma Kaochar	Baylor College of Medicine	John Petrini
RP250121	Dan Nguyen	The University of Texas Southwestern Medical Center	Jun Deng
RP250219	Marites Melancon	The University of Texas M.D. Anderson Cancer Center	David Mankoff; James Babilion
RP250251	Hao Peng	The University of Texas Southwestern Medical Center	Jun Deng
RP250375	Alexander Bishop	The University of Texas Health Science Center at San Antonio	Patrick Grohar
RP250026	Eduardo Vilar-Sanchez	The University of Texas M.D. Anderson Cancer Center	Gregory Lesinski

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250135	Bouthaina Dabaja	The University of Texas M.D. Anderson Cancer Center	Charles Mullighan
RP250217	Ehsan Irajizad	The University of Texas M.D. Anderson Cancer Center	Lawrence Kushi

De-Identified Overall Evaluation Scores

Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center

Academic Research Cycle 25.1

Application ID	Final Overall Evaluation Score
RP250355*	2.8

* Recommended for funding.

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 5, 2025

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Ms. Kristen Doyle
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to kdoyle@cprit.texas.gov

Dear Dr. Cummings and Ms. Doyle,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for the Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal); Core Facility Support Award (FY2024); Individual Investigator Research Awards; Individual Investigator Research Awards for Childhood and Adolescent Cancers; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; Investigator Research Awards for Early-Onset Cancers; Individual Investigator Research Awards for Prevention and Early Detection; Recruitment of Established Investigators; Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 12, 2024 to consider the FY25.1 applications recommended by the peer review panels following their meetings held October 16, 2024 to October 24, 2024 and one FY24.2 Core Facility application recommended by a peer review panel on April 24, 2024. The SRC met on November 14, 2024 to review recruitment applications submitted for Cycle FY25.2 and then on December 12, 2024 to review recruitment applications submitted for Cycle FY25.3.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the 53 recommended applications is \$67,753,626.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Chair, CPRIT Scientific Review Council

Rank	Grant ID	RFA	Score	Title	PI	Institution	Recommended Budget
1	RP250118	IIRA	1.0	Ribosome Localization at Mitochondria-ER Contacts in Obesity-Associated Liver Cancer	Morita, Masahiro	The University of Texas Health Science Center at San Antonio	\$900,000
2	RP250061	IIRA	1.0	Imaging of cranial radiotherapy neuroinflammatory sequelae by Positron Emission Tomography	Pisaneschi, Federica	The University of Texas Health Science Center at Houston	\$900,000
3	RR250077	RFTFM	1.0	Developing next generation of genome editing tools to study and engineer genetic variants for effective precision cancer treatment	Gao, Xin "Daniel"	Baylor College of Medicine	\$2,000,000
4	RR250070	RFTFM	1.0	Unlocking the Potential of Clonal Hematopoiesis in Early Detection and Interception of Lymphoid Malignancies	Griffin, Rosalie	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
5	RR250063	RFTFM	1.1	Co-opting antiviral innate immune pathways to target non-small cell lung cancer	Zou, Tao	The University of Texas Southwestern Medical Center	\$2,000,000
6	RR250071	RFTFM	1.1	CRISPR screening to uncover tumor intrinsic modulators of DNA repair and immune effects of radiation therapy	Verma, Nipun	Baylor College of Medicine	\$2,000,000
7	RP250278	IIRACCA	1.2	Developmental origins of IDH-mutant glioma in adolescents	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,198,416
8	RP250293	IIRAP	1.2	Development of a shared decision tool to facilitate uptake of the levonorgestrel-releasing intrauterine system for the primary prevention of endometrial cancer	Meyer, Larissa	The University of Texas M. D. Anderson Cancer Center	\$1,199,542
9	RP250208	IIRA	1.4	RPS23 is a new drug target to activate the integrated stress response and treat leukemia	Ready, Joseph	The University of Texas Southwestern Medical Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

10	RP250201	IIRA	1.4	Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in oral cavity squamous cell carcinoma	Gillison, Maura	The University of Texas M. D. Anderson Cancer Center	\$899,998
11	RP250028	IIRA	1.5	MALAT1 protects against osteoporosis and bone metastasis	Ma, Li	The University of Texas M. D. Anderson Cancer Center	\$900,000
12	RP250247	IIRA	1.5	Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETs	Yao, James	The University of Texas M. D. Anderson Cancer Center	\$900,000
13	RP250144	IIRACCA	1.5	Decoding how neuronal activity remodels the epigenome in ependymoma	Deneen, Benjamin	Baylor College of Medicine	\$1,200,000
14	RP250220	IIRA	1.8	Decellularized tissue matrices to study the “bad soil” in cancer metastasis	Wang, Andrew	The University of Texas Southwestern Medical Center	\$900,000
15	RP250269	IIRAP	1.8	Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules.	Ostrin, Edwin	The University of Texas M. D. Anderson Cancer Center	\$1,169,776
16	RP250222	IIRA	1.9	KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC	Gibbons, Don	The University of Texas M. D. Anderson Cancer Center	\$899,997
17	RP250043	IIRA	1.9	An integrated imaging informatics platform for HCC surveillance	Zhou, Xiaobo	The University of Texas Health Science Center at Houston	\$899,991
18	RP250374	IIRACCA	1.9	Dissecting TFE3 Mediated tRCC Tumorigenesis	Brugarolas, James	The University of Texas Southwestern Medical Center	\$1,196,812
19	RP240537	CFSA	2.0	Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core	Wu, Erxi	Baylor Research Institute	\$2,999,989
20	RP250213	IIRA	2.0	KRAS spatiotemporal dynamics: lipid glycosylation as a novel therapeutic target	Hancock, John	The University of Texas Health Science Center at Houston	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

21	RP250428	IIRA	2.0	Studying Hematopoietic Stem Cells to Predict and Understand Mechanisms of Post-transplant Relapse in the Myelodysplastic Syndromes	Chung, Stephen	The University of Texas Southwestern Medical Center	\$899,025
22	RP250143	IIRA	2.0	Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy	Lissanu, Yonathan	The University of Texas M. D. Anderson Cancer Center	\$899,991
23	RP250044	IIRACSBC	2.0	Heterogeneity of resistance to endocrine therapy and Cdk inhibition: An integrated systems biology approach to biologically informed treatment regimens	Brock, Amy	The University of Texas at Austin	\$763,596
24	RR250072	REI	2.0	Mechanisms behind copper dependence of cancer cells	Wittung Stafshede, Pernilla	Rice University	\$6,000,000
25	RR250061	RFTFM	2.0	Engineered antibody tools for targeted regulation of cancer-associated proteins and organelles through redirected autophagy process	Jiang, Ziwen	The University of Texas at Dallas	\$2,000,000
26	RP250398	IIRA	2.1	Synthetic lethality of TRIP13 and Aurora A in Rb-deficient cancer	Johnson, Faye	The University of Texas M. D. Anderson Cancer Center	\$899,994
27	RP250402	IIRA	2.1	Exploiting Tryptophan Metabolite Addiction to identify and Inhibit HCC	Conacci Sorrell, Maralice	The University of Texas Southwestern Medical Center	\$900,000
28	RP250131	IIRACT2	2.1	Randomized Clinical Trial Evaluating Fecal Microbiota Transplant in Chimeric Antigen Receptor Therapy for Reversing Antimicrobial-Associated Dysbiosis	Saini, Neeraj	The University of Texas M. D. Anderson Cancer Center	\$1,598,410
29	RP250282	IIRA	2.2	Harnessing BACH2 to enhance anti-tumor T cell immunity	Yao, Chen	The University of Texas Southwestern Medical Center	\$900,000
30	RP250280	IIRA	2.2	The role of glutathione in leukemia development	Agathocleous, Michalis	The University of Texas	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

						Southwestern Medical Center	
31	RP250062	IIRA	2.3	Clonal hematopoiesis and toxicity from radiation therapy	Nead, Kevin	The University of Texas M. D. Anderson Cancer Center	\$899,885
32	RP250407	IIRA	2.3	Protecting the GI tract with a C60 fullerene derivative to facilitate dose-escalated abdominopelvic radiotherapy	Mackeyev, Yuri	The University of Texas Health Science Center at Houston	\$900,000
33	RP250055	IIRA	2.4	TET2 mutations promote myeloid malignancies by dysregulating m5C oxidation of chromatin-associated RNAs	Xu, Mingjiang	The University of Texas Health Science Center at San Antonio	\$900,000
34	RP250391	IIRA	2.5	Novel PCDH7 monoclonal antibodies that direct immune surveillance and combat drug resistance in lung cancer	O'Donnell, Kathryn	The University of Texas Southwestern Medical Center	\$900,000
35	RP250321	IIRACT2	2.5	Leveraging synthetic and collateral lethality in MTAP loss tumors	Rodon Ahnert, Jordi	The University of Texas M. D. Anderson Cancer Center	\$1,599,783
36	RP250069	IIRA	2.6	HSP90 Capacitance: Discovery of a New Mechanism Driving Evolution of Drug Resistance in Head and Neck Squamous Cell Carcinoma	Karras, Georgios	The University of Texas M. D. Anderson Cancer Center	\$890,201
37	RP250305	IIRA	2.6	Exploiting synthetic lethality between HNRNPK loss and ribosomal dysfunction in del9q AML	Post, Sean	The University of Texas M. D. Anderson Cancer Center	\$896,322
38	RP250091	IIRA	2.6	Dissecting the Survival Mechanisms of Latent Brain-Tropic Cancer Cells for Therapeutic Interventions	Malladi, Srinivas	The University of Texas Southwestern Medical Center	\$900,000
39	RP250322	IIRA	2.6	Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2-mutant non-small cell lung cancer (NSCLC)	Heymach, John	The University of Texas M. D. Anderson Cancer Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

40	RP250154	IIRA	2.6	Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients	Fuentes, David	The University of Texas M. D. Anderson Cancer Center	\$899,808
41	RP250156	IIRAP	2.6	Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer	Wu, Jia	The University of Texas M. D. Anderson Cancer Center	\$1,200,000
42	RP250094	IIRACT2	2.7	A phase 2 clinical trial with Avasopasem, with anti-estrogen therapy (ET) and a CDK4/6 inhibitor in metastatic breast cancer progressing on ET/CDK4/6 therapy.	Gius, David	The University of Texas Health Science Center at San Antonio	\$1,390,420
43	RP250418	IIRAP	2.7	Approach Bias Retraining to Augment Long-Term Smoking Cessation Among a Diverse Sample	Garey, Lorra	University of Houston	\$1,200,000
44	RP250355	CAP-CAC-CR	2.8	The Texas Collaborative Center for Hepatocellular Cancer (TeCH)	El-Serag, Hashem	Baylor College of Medicine	\$3,000,000
45	RP250119	IIRACCA	2.8	Comparison of Symptom Burden, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients treated with Surgery vs. Surgery and Chemotherapy	Kahalley, Lisa	Baylor College of Medicine	\$1,200,000
46	RP250190	IIRACCA	2.8	Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-Exercise Intervention	Swartz, Maria	The University of Texas M. D. Anderson Cancer Center	\$1,199,756
47	RP250182	IIRAP	2.8	Implementing Newborn Screening for Pediatric Cancer Predisposition Syndromes in Texas: The INSPECT Study	Parsons, Donald	Baylor College of Medicine	\$1,187,187
48	RP250097	IIRA	2.9	Deciphering and targeting age-related metastatic	Naora, Honami	The University of Texas M. D.	\$899,984

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				competence of the omentum		Anderson Cancer Center	
49	RP250099	IIRA	2.9	Targeting lethal prostate cancers with a clinical-stage inverse agonist for G protein-coupled receptor 6	Li, Wenliang	The University of Texas Health Science Center at Houston	\$900,000
50	RP250399	IIRACSBC	2.9	Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture	Vokes, Natalie	The University of Texas M. D. Anderson Cancer Center	\$1,049,033
51	RP250090	IIRACSBC	2.9	Artificial Intelligence for Early Identification of Androgen-Indifferent, Lethal Prostate Cancer and Therapy Selection	Merényi, Erzsébet	Rice University	\$1,049,434
52	RP250191	IIRA	3.1	Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$898,263
53	RP250164	IIRACCA	3.1	Prediction of CAR-T Cell Immunotherapy Outcomes in Neuroblastoma using FE-MRI Nano-radiomics	Ghaghada, Ketan	Baylor College of Medicine	\$1,168,013

Core Facility Support Award (CFSA)

Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal)

Individual Investigator Research Awards (IIRA)

Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)

Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)

Individual Investigator Research Awards for Clinical Trials (IIRACT)

Individual Investigator Research Awards for Early Onset Cancers (IIRAEOC)

Individual Investigator Research Awards for Prevention and Early Detection (IIRAP)

Recruitment of Established Investigators (REI)

Recruitment of Rising Stars (RRS)

Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2025—Cycle 1**

Individual Investigator Research Awards

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS

RFA R-25.1-IIRA

Individual Investigator Research Awards

**Please also refer to the Instructions for Applicants document, which will be posted
on February 22, 2024.**

**Due to the highly competitive nature of this RFA mechanism and available funds for
FY25, CPRIT projects that only 10% of submitted applications will be funded.**

Application Receipt Opening Date: March 19, 2024

Application Receipt Closing Date: June 11, 2024

FY2025

Fiscal Year Award Period

September 1, 2024-August 31, 2022

TABLE OF CONTENTS

1. BRIEF DESCRIPTION OF RFA	4
2. ABOUT CPRIT	4
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES.....	5
3. RATIONALE	5
4. RESEARCH OBJECTIVES	6
5. FUNDING INFORMATION	7
6. ELIGIBILITY	7
7. RESUBMISSION POLICY	9
8. RENEWAL POLICY	9
9. RESPONDING TO THIS RFA	9
9.1. APPLICATION SUBMISSION GUIDELINES.....	9
9.1.1. <i>Submission Deadline Extension</i>	10
9.2. APPLICATION COMPONENTS.....	10
9.2.1. <i>Abstract and Significance (5,000 characters)</i>	10
9.2.2. <i>Layperson’s Summary (2,000 characters)</i>	11
9.2.3. <i>Specific Aims and Subaims</i>	11
9.2.4. <i>Timeline (1 page)</i>	11
9.2.5. <i>Specific Aims (1 Page)</i>	12
9.2.6. <i>Resubmission Summary (2 pages)</i>	12
9.2.7. <i>Renewal Summary (2 pages)</i>	12
9.2.8. <i>Research Plan (10 pages)</i>	12
9.2.9. <i>Vertebrate Animals (1 page)</i>	13
9.2.10. <i>Human Subjects (2 pages)</i>	13
9.2.11. <i>Publications/References</i>	13
9.2.12. <i>Budget and Justification</i>	13
9.2.13. <i>Biographical Sketches (5 pages each)</i>	14
9.2.14. <i>Current and Pending Support</i>	15
9.2.15. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i>	15
9.2.16. <i>Previous Summary Statement</i>	15
9.3. FORMATTING INSTRUCTIONS.....	15
10. APPLICATION REVIEW	16
10.1. PRELIMINARY EVALUATION.....	16
10.2. FULL PEER REVIEW.....	17
10.3. CONFIDENTIALITY OF REVIEW.....	17
10.4. REVIEW CRITERIA.....	18
10.4.1. <i>Primary Criteria</i>	19
10.4.2. <i>Secondary Criteria</i>	19
11. KEY DATES	20
12. AWARD ADMINISTRATION	20
13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	21
14. CONTACT INFORMATION	22
14.1. HELPDESK.....	22
14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS.....	22

RFA VERSION HISTORY

2/22/24 RFA released

1. BRIEF DESCRIPTION OF RFA

- Supports applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer.
- Applicants may request a maximum of \$300,000 per year for a 3-year period.
- **Multi-Principal Investigators (MIs)** are allowed under this Request for Applications (RFA). See the Information for Applicants (IFA) document for definition and eligibility of MIs. See application limitations for **Principal Investigators (PIs)/MIs**, regardless of whether the MI is from the prime institution or a subcontracted institution.
- **Note that CPRIT does not allow the use of the term Co-PI.**
- Minimum effort for the PI and/or MIs throughout the project period is required.
- A PI and/or MI may not submit more than **one application** for this RFA (defined as either a new application, resubmission application, or *competitive renewal application).
- *Renewal applications are limited to one competitive renewal under this RFA, regardless of the year of the funded parent IIRA award.
- The FY25 salary cap is \$225,000 per year.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state
- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

3. RATIONALE

The goals of the CPRIT Academic Research Grants Program are to support the discovery of new information about cancer that can lead to prevention, early detection, and cures and to translate new and existing discoveries into practical advances in cancer diagnosis and treatment. CPRIT encourages applications that seek new fundamental knowledge about cancer and cancer development as well as those attempting to develop state-of-the-art technologies, tools, computational models, and/or resources for cancer research, including those with potential commercialization opportunities. This award allows experienced or early-career-stage cancer researchers the opportunity to explore new methods and approaches for investigating a question

of importance that has been inadequately addressed or for which there may be an absence of an established paradigm or technical framework. CPRIT will look with special favor on new approaches to be taken or new areas of investigation to be explored by established investigators and on supporting the research programs of the most promising investigators at the beginning of their research careers. Applicants do not need to be trained specifically in cancer research. CPRIT strongly encourages investigators from other fields, including mathematical and computational modeling, physical, chemical, and engineering sciences, to address challenging problems posed by cancer. CPRIT expects outcomes of funded studies to directly and indirectly benefit subsequent cancer research efforts, cancer public health policy, and efforts to reduce cancer disparities on the continuum of cancer care—from prevention to early detection, treatment, and survivorship.

To fulfill this vision, applications may address any topic or issue related to cancer, including cancer biology, computational modeling, and systems biology, causation, prevention, detection or screening, treatment, or survivorship. Successful applicants should be working in a research environment capable of supporting potentially high-impact studies. Access to a clinical environment and interaction with translational cancer physician-scientists are highly desirable.

4. RESEARCH OBJECTIVES

CPRIT will foster cancer research in Texas by providing financial support for a wide variety of projects relevant to cancer research. This RFA solicits applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer. The intent of this RFA is to fund exceptionally innovative research projects with great potential impact that are directed by a single or multiple investigators. Areas of interest include laboratory research, translational studies, and/or clinical investigations. In that cancers arise from a large number of derangements of basic molecular and cellular functions and, in turn, cause many alterations in basic biological processes, almost any aspect of biology may be relevant to cancer research, more or less directly. The *degree of relevance* to cancer research is a critical criterion for evaluation of projects for funding by CPRIT ([section 10.4.1](#)). For example, are alterations in the process in question *primarily* responsible for oncogenesis or secondary manifestations of malignant transformation? Will understanding the process or interfering with it offer selective and useful insight into

prevention, diagnosis, or treatment of cancer? *Successful applicants for funding from CPRIT will have addressed these questions satisfactorily.*

5. FUNDING INFORMATION

Applicants may request a maximum of \$300,000 in total costs per year for up to 3 years for research. Exceptions to these limits may be requested if extremely well justified (see [section 9.2.12](#)). Funds may be used for salary and fringe benefits, research supplies, equipment, subject participation costs, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of indirect costs to no more than 5% of the total award amount.

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.
- This award mechanism allows MIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for MI awards).
- For applications that include 1 PI, the PI is required to maintain a minimum of 15% level of effort through the duration of the entire award period. For applications that include MIs, **each** PI is required to maintain a minimum of 10% effort through the entire duration of the award period.
- A PI may not submit applications to this RFA and to RFA R-25.1-IIRACSBC, RFA R-25.1-IIRACCA, RFA R-25.1-IIRACT, RFA R-25.1-IIRAP, or RFA R-25.1-IIRAEOC.

- A PI may not submit more than 1 application, either a new, resubmission, **or** renewal application under this RFA during this funding cycle.
- A PI may not be a part of more than 1 application, whether as a single applicant or as an MI on an application, under this RFA and RFA R-25.1-IIRACSBC, RFA R-25.1-IIRACCA, RFA R-25.1-IIRACT, RFA R-25.1-IIRAP, or RFA R-25.1 -IIRAEOC
- **An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants.** Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project MIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2025).
- Applications that address prevention and early detection population-based studies, cancers in children and adolescents, computational systems biology of cancer, or innovative clinical trials should be submitted under the appropriate targeted RFA.
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity) has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, regardless of whether these individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant

funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 12](#) and [section 13](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** and must follow all resubmission guidelines. **More than 1 resubmission is not permitted.** An application is considered a resubmission if the proposed project is the same project presented in the original submission. A change in the identity of the PI for a project, a change in the project title that was previously submitted to CPRIT, or omission or modification of an aim does not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 9.2.6](#).

8. RENEWAL POLICY

An application funded by CPRIT under this mechanism may be submitted for one competitive renewal. This policy is in effect for all awards submitted to date. See [section 9.2.7](#). Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 10.2](#).

9. RESPONDING TO THIS RFA

9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism

specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 19, 2024, and must be submitted by 4 PM central time on June 11, 2024. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details. The IFA will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

9.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and significance of the research alone. Therefore, applicants are advised to prepare this section wisely. Based on the Abstract and Significance statement (and the Specific Aims, Budget and Justification, and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from peer review (see [section 10.1](#)). Applicants should not waste this

valuable space by stating obvious facts (e.g., that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. Provide the hypothesis to be tested, the specific aims, and the overall experimental approaches.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Indicate whether this research will address cancers associated with disparities. Summarize how the proposed research creates new paradigms or challenges existing ones. Indicate whether this research plan represents a new direction for the PI.

9.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary will also be used by advocate reviewers ([section 10.2](#)) to evaluate the significance and impact of the proposed work.

9.2.3. Specific Aims and Subaims

Please provide a description of the aims and subaims and milestones to be achieved for each year of the project. Provide 2 to 3 sentences describing activities to be performed and anticipated milestones. These aims will also be used during the submission and evaluation of progress reports and assessment of project success.

9.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

9.2.5. Specific Aims (1 Page)

Please provide a 1-page summary of the aims of the proposal. The Specific Aims page should identify the problem or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches. Address the proposal's innovation, novel approaches, and significance and impact on the field and cancer research. Please also refer to the template located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.6. Resubmission Summary (2 pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a new research plan or modify the original research plan and mark the changes. However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with only editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

9.2.7. Renewal Summary (2 pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

9.2.8. Research Plan (10 pages)

Background: Provide the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed.

Hypothesis and Specific Aims: Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application. Describe the significance, innovation, and potential impact of the research.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required.

9.2.9. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

9.2.10. Human Subjects (2 pages)

If human subjects or human biological samples will be used, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional review board (IRB) will be required before funding.

9.2.11. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

9.2.12. Budget and Justification

Provide a detailed justification of the budget for the entire proposed period of support, including salaries and fringe benefits, supplies, equipment, patient care costs, animal care costs, subject participation costs, travel to scientific/technical meetings or collaborating institutions, and other expenses. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. Applicants are advised not to interpret the maximum allowable request under this award as a suggestion that they should expand their anticipated budget to this level. Reasonable budgets clearly work in favor of the applicant.

However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the

budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cpritis.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2025 is \$225,000; CPRIT FY 2025 is from September 1, 2024, through August 31, 2025. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

9.2.13. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. A biographical sketch must be provided for the PI and, if applicable, any additional MIs (for an MI application), as required by the online application receipt system. Up to **5 additional** biographical sketches for key personnel may be provided; these should be concatenated into a single PDF with a 25-page limit. **Each biographical sketch must not exceed 5 pages.** The NIH biosketch format is appropriate.

9.2.14. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, any additional MIs (for an MI application) must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.15. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. **A maximum of 4 pages may be provided.**

9.2.16. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively rejected without review.

9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions

- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations may be submitted as part of the submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. URLs of publications referenced in the application may be included.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants must not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see **Page Numbering section** below).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be printed, signed, scanned, and then uploaded in PDF format.

10. APPLICATION REVIEW

10.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may undergo a preliminary evaluation by CPRIT Scientific Research Program panel members for scientific merit and potential impact.

The preliminary evaluation is based on a subset of material presented in the application—namely, the Abstract and Significance, Specific Aims page, Budget and Justification, and Biographical Sketches. Applications that do not sufficiently capture the reviewers' interest at this stage will not be considered for further peer review. Such applications will have been judged to offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

10.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 10.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

10.3. Confidentiality of Review

Each stage of the application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and

scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules ([Texas Administrative Code RULE §703.9](#)).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

10.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Peer review committees will evaluate and score each primary criterion and subsequently assign an overall score that reflects a complete assessment of the application. **The overall score will not be an average of the individual criteria scores; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

10.4.1. Primary Criteria

The primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention, diagnosis, or treatment for patients? Is the application innovative? Does the applicant propose new paradigms or challenge existing ones? Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required creativity and expertise to make a significant contribution to the research? Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant(s) devoted a sufficient amount of their time (percent effort) to this project?

Relevance: Does the proposed research have a high degree of relevance to cancer research? This is a critical criterion for evaluation of applications for CPRIT support.

10.4.2. Secondary Criteria

Secondary criteria contribute to the overall score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

11. KEY DATES

RFA

RFA release February 22, 2024

Application

Online application opens March 19, 2024, 7 AM central time

Application due June 11, 2024, 4 PM central time

Application review June 2024-February 2025

Award

Award notification February 2025

Anticipated start date March 1, 2025

12. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports.

Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The

demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

14. CONTACT INFORMATION

14.1. Helpdesk

The Helpdesk will answer queries submitted via email within 1 business day. Helpdesk support is available for questions regarding user registration, online submission of applications as well as page limitations, formatting, and how to upload application components/subsections in the appropriate tabs of the CPRIT Application Receipt System. Helpdesk staff cannot answer scientific questions and/or Academic Research programs aspects of an application. Before contacting the Helpdesk, please refer to the *Instructions for Applicants* document, which provides a step-by-step guide on using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

14.2. Scientific and Programmatic Questions

Scientific and Programmatic Questions should be directed to the CPRIT Director of Academic Research. **Before contacting CPRIT, please refer to the *Instructions for Applicants* document and contact the Helpdesk for any items related to the Application Receipt System (CARS), page limitations, formatting, etc.**

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports

Cancer Prevention and Research Institute of Texas (CPRIT)**25.1 Academic Research Peer Review C/TCR-2****(25.1 ACR C/TCR-2)****Observation Report**

Report No. 2024-10-16 25.1_ACR_C/TCR-2
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Peer Review_C/TCR-2 (25.1_ACR_C/TCR-2)
Panel Date: October 16, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Peer Review_C/TCR-2 (25.1_ACR_C/TCR-2) meeting. The meeting was chaired by Richard O'Reilly and conducted via videoconference on October 16, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and seven (7) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Peer Review CB (25.1 ACR CB)
Observation Report

Report No. 2024-10-17 25.1_ACR_CB
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Peer Review_CB (25.1 _ACR_CB)
Panel Date: October 17, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Peer Review_CB (25.1_ACR_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on October 17, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, seventeen (17) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Research Imaging Technology and Informatics (ITI) (25.1 ACR-ITI)

Observation Report

Report No. 2024-10-18 25.1_ACR-ITI
Program Name: Academic Research
Panel Name: 25.1 Academic Research- Imaging Technology and Informatics (ITI) (25.1_ACR-ITI)
Panel Date: October 18, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research- Imaging Technology and Informatics (ITI) (25.1_ACR-ITI) meeting. The meeting was chaired by Jason Lewis and conducted via videoconference on October 18, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed and five (5) applications were not discussed
- Panelists: One (1) panel chair, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Seven (7)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)**25.1 Academic Research Cancer Prevention Research****(25.1 ACR CPR)****Observation Report**

Report No. 2024-10-22 25.1_ACR_CPR
Program Name: Academic Research
Panel Name: 25.1 Academic Research Cancer Prevention Research
(25.1_ACR_CPR)
Panel Date: October 22, 2024
Report Date: October 23, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Cancer Prevention Research (25.1_ACR_CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 22, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and eight (8) applications were not discussed
- Panelists: One (1) panel chair, ten (10) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict(s) of Interest (COIs) identified prior to and/or during the meeting. The COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Basic Cancer Research-1 (BCR-1)
Observation Report

Report No. 2024-10-23 25.1_ACR_BCR-1
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Basic Cancer Research-1 (BCR-1)
Panel Date: October 23, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Basic Cancer Research-1 (BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on October 23, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: One (15) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewer
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Basic Cancer Research-2 (BCR-2)
Observation Report

Report No. 2024-10-24 25.1_ACR_BCR-2
Program Name: Academic Research
Panel Name: 25.1 Academic Research Basic Cancer Research-2 (BCR-2)
Panel Date: October 24, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Basic Cancer Research-2 (BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 24, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Ten (10) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Clinical and Translational Cancer
Research-1 (CTCR-1) Observation Report

Report No. 2024-10-25 25.1_ACR_CTCTCR-1
Program Name: Academic Research
Panel Name: 25.1 Academic Research Clinical and Translational Cancer
Research-1 (CTCR-1)
Panel Date: October 25, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Clinical and Translational Cancer Research-1 (CTCR-1) meeting. The meeting was chaired by Margaret Tempero and conducted via videoconference on October 25, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed and twenty-nine (29) applications were not discussed
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Scientific Review Council (25.1 SRC)

Observation Report

Report No. 2024-12-12 25.1_SRC
Program Name: Academic Research
Panel Name: 25.1 Academic Scientific Review Council (25.1_SRC)
Panel Date: December 12, 2024
Report Date: December 18, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Scientific Review Council (25.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 12, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Forty-seven (47) applications were discussed
- Panelists: One (1) panel chair, six (6) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting; however, they are waived pursuant to the Section 102.1062 Conflict of Interest Waiver for FY 2025 approved by the CPRIT Oversight Committee.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 25.1

Awards Announced at the February 19, 2025, Oversight Committee Meeting

The following table lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research cycle 25.1 include *Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center; Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual; Investigator Research Awards for Computational and Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; and Individual Investigator Research Awards for Prevention and Early Detection.*

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP250156	Jia Wu	The University of Texas M.D. Anderson Cancer Center	Issam El Naqa
RP250247	James Yao	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250118	Masahiro Morita	The University of Texas Health Science Center at San Antonio	Sanja Vicković
RP250399	Natalie Vokes	The University of Texas M.D. Anderson Cancer Center	Walter Stadler
RP250355	Hashem El-Serag	Baylor College of Medicine	Christopher Haiman

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250069	Georgios Karras	The University of Texas M.D. Anderson Cancer Center	Jason Lewis ¹
RP250438	Stephen Chung	The University of Texas M.D. Anderson Cancer Center	Jason Lewis ²
RP250278	Samuel McBrayer	The University of Texas Southwestern Medical Center	Craig Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP250124	Payal Kapur	The University of Texas Southwestern Medical Center	Anna Wu
RP250007	Debananda Pati	Baylor College of Medicine	Steffi Oesterreich
RP250230	Anirban Maitra	The University of Texas M.D. Anderson Cancer Center	Michael Hollingsworth
RP250014	Alexander Pertsemlidis	The University of Texas Health Science Center at San Antonio	Jose Conejo-Garcia
RP250088	Christopher Rylander	The University of Texas at Austin	Jose Conejo-Garcia
RP250187	Fredrik Thege	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250216	Khalid Mohamedali	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250265	Nabil Ahmed	Baylor College of Medicine	Ying Lu
RP250173	Katsumi Kitagawa	The University of Texas Health Science Center at San Antonio	Alan Tomkinson
RP250229	Kunal Rai	The University of Texas M.D. Anderson Cancer Center	Vijaya B. Kolachalama

¹ This conflict was waived pursuant to an approved Texas Health and Safety Code § 102.1062 waiver applicable to CPRIT review councils. A copy of the FY2025 waiver is available on [CPRIT's website](#).

² Same as footnote 1.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250153	Ronald DePinho	The University of Texas M.D. Anderson Cancer Center	Kornelia Polyak
RP250307	Sandeep Burma	The University of Texas Health Science Center at San Antonio	Bart Williams
RP250046	Surendranath Shastri	The University of Texas M.D. Anderson Cancer Center	Karen Emmons
RP250063	Aaron Thrift	Baylor College of Medicine	Christopher Haiman
RP250163	Robert Bast	The University of Texas M.D. Anderson Cancer Center	Karen Emmons
RP250231	Weiva Sieh	The University of Texas M.D. Anderson Cancer Center	Christopher Haiman; Lawrence Kushi; Melissa Troester
RP250053	Dae Kim	The University of Texas Rio Grande Valley	Alan Tomkinson
RP250334	Linghua Wang	The University of Texas M.D. Anderson Cancer Center	Benjamin Greenbaum
RP250371	John Tainer	The University of Texas M.D. Anderson Cancer Center	Alan Tomkinson; John Petrini; Walter Chazin
RP250411	Salma Kaochar	Baylor College of Medicine	John Petrini
RP250121	Dan Nguyen	The University of Texas Southwestern Medical Center	Jun Deng
RP250219	Marites Melancon	The University of Texas M.D. Anderson Cancer Center	David Mankoff; James Babilion
RP250251	Hao Peng	The University of Texas Southwestern Medical Center	Jun Deng
RP250375	Alexander Bishop	The University of Texas Health Science Center at San Antonio	Patrick Grohar
RP250026	Eduardo Vilar-Sanchez	The University of Texas M.D. Anderson Cancer Center	Gregory Lesinski

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250135	Bouthaina Dabaja	The University of Texas M.D. Anderson Cancer Center	Charles Mullighan
RP250217	Ehsan Irajizad	The University of Texas M.D. Anderson Cancer Center	Lawrence Kushi

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards

Academic Research Cycle 25.1

Final Scores for Fully Reviewed Applications

Some Individual Investigator Research Awards grant applications are not recommended for funding with scores that are the same as or more favorable than applications that were recommended. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

This comprehensive list of Individual Investigator Research Awards de-identified application scores created for the purpose of this CEO affidavit packet combines the information for all Academic Research review panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not. Within each panel, no application with a less favorable score was recommended ahead of an application with a more favorable score.

Application ID	Final Overall Evaluation Score
RP250118*	1.0
RP250061*	1.0
RP250208*	1.4
RP250201*	1.4
RP250028*	1.5
RP250247*	1.5
RP250220*	1.8
RP250222*	1.9
RP250043*	1.9
RP250213*	2.0
RP250428*	2.0
RP250143*	2.0
RP250398*	2.1
RP250402*	2.1
RP250282*	2.2
RP250280*	2.2
RP250062*	2.3
RP250407*	2.3
RP250055*	2.4
RP250391*	2.5
RP250069*	2.6
RP250305*	2.6
RP250091*	2.6

* Recommended for funding.

Application ID	Final Overall Evaluation Score
RP250322*	2.6
RP250154*	2.6
C	2.8
D	2.8
RP250097*	2.9
RP250099*	2.9
E	2.9
F	3.0
G	3.0
H	3.0
I	3.0
J	3.0
K	3.0
RP250191*	3.1
L	3.1
M	3.1
N	3.3
O	3.3
P	3.3
Q	3.3
R	3.3
S	3.3
T	3.3
U	3.3
V	3.3
W	3.3
X	3.3
Y	3.3
Z	3.3
Aa	3.3
Ab	3.4
Ac	3.4
Ad	3.4
Ae	3.5
Af	3.5
Ag	3.5
Ah	3.5
Ai	3.5
Aj	3.5
Ak	3.6
Al	3.7
Am	3.7
An	3.7

* Recommended for funding.

Application ID	Final Overall Evaluation Score
Ao	3.7
Ap	3.7
Aq	3.7
Ar	3.7
As	3.7
At	3.7
Au	3.7
Av	3.7
Aw	3.7
Ax	3.7
Ay	3.8
Az	3.8
Ba	3.8
Bb	3.8
Bc	3.8
Bd	3.8
Be	3.9
Bf	3.9
Bg	3.9
Bh	3.9
Bi	4.0
Bj	4.0
Bk	4.0
Bl	4.0
Bm	4.0
Bn	4.0
Bo	4.0
Bp	4.0
Bq	4.0
Br	4.0
Bs	4.0
Bt	4.0
Bu	4.2
Bv	4.3
Bw	4.3
Bx	4.3
By	4.3
Bz	4.3
Ca	4.3
Cb	4.3
Cc	4.3
Cd	4.3
Ce	4.3

* Recommended for funding.

Application ID	Final Overall Evaluation Score
Cf	4.3
Cg	4.3
Ch	4.3
Ci	4.4
Cj	4.6
Ck	4.7
Cl	4.7

* Recommended for funding.

Individual Investigator Research Awards

Academic Research Cycle 25.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

Application ID	Final Overall Evaluation Score
Ha	3.7
Hb	3.7
Hc	3.7
Hd	3.7
He	3.7
Hf	3.7
Hg	3.7
Hh	3.7
Hi	3.7
Hj	3.7
Hk	3.7
Hl	3.7
Hm	3.7
Hn	3.7
Ho	4.0
Hp	4.0
Hq	4.0
Hr	4.0
Hs	4.0
Ht	4.0
Hu	4.0
Hv	4.0
Hw	4.0
Hx	4.0
Hy	4.0
Hz	4.0
Ia	4.0
Ib	4.0
Ic	4.0
Id	4.0
Ie	4.0
If	4.3

Application ID	Final Overall Evaluation Score
Ig	4.3
Ih	4.3
Ii	4.3
Ig	4.3
Ik	4.3
Il	4.3
Im	4.3
In	4.3
Io	4.3
Ip	4.3
Iq	4.3
Ir	4.3
Is	4.3
It	4.3
Iu	4.3
Iv	4.3
Iw	4.3
Ix	4.3
Iy	4.3
Iz	4.3
Ja	4.7
Jb	4.7
Jc	4.7
Jd	4.7
Je	4.7
Jf	4.7
Jg	4.7
Jh	4.7
Ji	4.7
Jj	4.7
Jk	5.0
Jl	5.0
Jm	5.0
Jn	5.0
Jo	5.0
Jp	5.0
Jq	5.0
Jr	5.0
Js	5.0
Jt	5.0
Ju	5.0

25.1 IIRA
Final Scores for Preliminary Evaluation

Application ID	Final Overall Evaluation Score
Jv	5.0
Jw	5.0
Jx	5.3
Jy	5.3
Jz	5.3
Ka	5.3
Kb	5.3
Kc	5.3
Kd	5.3
Ke	5.3
Kf	5.7
Kg	5.7
Kh	5.7
Ki	5.7
Kj	5.7
Kk	5.7
Kl	6.0
Km	6.0
Kn	6.0
Ko	6.0
Kp	6.0
Kq	6.3
Kr	6.3
Ks	6.7
Kt	7.3
Ku	7.7

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 5, 2025

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Ms. Kristen Doyle
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to kdoyle@cprit.texas.gov

Dear Dr. Cummings and Ms. Doyle,


The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for the Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal); Core Facility Support Award (FY2024); Individual Investigator Research Awards; Individual Investigator Research Awards for Childhood and Adolescent Cancers; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; Investigator Research Awards for Early-Onset Cancers; Individual Investigator Research Awards for Prevention and Early Detection; Recruitment of Established Investigators; Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 12, 2024 to consider the FY25.1 applications recommended by the peer review panels following their meetings held October 16, 2024 to October 24, 2024 and one FY24.2 Core Facility application recommended by a peer review panel on April 24, 2024. The SRC met on November 14, 2024 to review recruitment applications submitted for Cycle FY25.2 and then on December 12, 2024 to review recruitment applications submitted for Cycle FY25.3.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the 53 recommended applications is \$67,753,626.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Chair, CPRIT Scientific Review Council

Rank	Grant ID	RFA	Score	Title	PI	Institution	Recommended Budget
1	RP250118	IIRA	1.0	Ribosome Localization at Mitochondria-ER Contacts in Obesity-Associated Liver Cancer	Morita, Masahiro	The University of Texas Health Science Center at San Antonio	\$900,000
2	RP250061	IIRA	1.0	Imaging of cranial radiotherapy neuroinflammatory sequelae by Positron Emission Tomography	Pisaneschi, Federica	The University of Texas Health Science Center at Houston	\$900,000
3	RR250077	RFTFM	1.0	Developing next generation of genome editing tools to study and engineer genetic variants for effective precision cancer treatment	Gao, Xin "Daniel"	Baylor College of Medicine	\$2,000,000
4	RR250070	RFTFM	1.0	Unlocking the Potential of Clonal Hematopoiesis in Early Detection and Interception of Lymphoid Malignancies	Griffin, Rosalie	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
5	RR250063	RFTFM	1.1	Co-opting antiviral innate immune pathways to target non-small cell lung cancer	Zou, Tao	The University of Texas Southwestern Medical Center	\$2,000,000
6	RR250071	RFTFM	1.1	CRISPR screening to uncover tumor intrinsic modulators of DNA repair and immune effects of radiation therapy	Verma, Nipun	Baylor College of Medicine	\$2,000,000
7	RP250278	IIRACCA	1.2	Developmental origins of IDH-mutant glioma in adolescents	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,198,416
8	RP250293	IIRAP	1.2	Development of a shared decision tool to facilitate uptake of the levonorgestrel-releasing intrauterine system for the primary prevention of endometrial cancer	Meyer, Larissa	The University of Texas M. D. Anderson Cancer Center	\$1,199,542
9	RP250208	IIRA	1.4	RPS23 is a new drug target to activate the integrated stress response and treat leukemia	Ready, Joseph	The University of Texas Southwestern Medical Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

10	RP250201	IIRA	1.4	Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in oral cavity squamous cell carcinoma	Gillison, Maura	The University of Texas M. D. Anderson Cancer Center	\$899,998
11	RP250028	IIRA	1.5	MALAT1 protects against osteoporosis and bone metastasis	Ma, Li	The University of Texas M. D. Anderson Cancer Center	\$900,000
12	RP250247	IIRA	1.5	Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETs	Yao, James	The University of Texas M. D. Anderson Cancer Center	\$900,000
13	RP250144	IIRACCA	1.5	Decoding how neuronal activity remodels the epigenome in ependymoma	Deneen, Benjamin	Baylor College of Medicine	\$1,200,000
14	RP250220	IIRA	1.8	Decellularized tissue matrices to study the “bad soil” in cancer metastasis	Wang, Andrew	The University of Texas Southwestern Medical Center	\$900,000
15	RP250269	IIRAP	1.8	Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules.	Ostrin, Edwin	The University of Texas M. D. Anderson Cancer Center	\$1,169,776
16	RP250222	IIRA	1.9	KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC	Gibbons, Don	The University of Texas M. D. Anderson Cancer Center	\$899,997
17	RP250043	IIRA	1.9	An integrated imaging informatics platform for HCC surveillance	Zhou, Xiaobo	The University of Texas Health Science Center at Houston	\$899,991
18	RP250374	IIRACCA	1.9	Dissecting TFE3 Mediated tRCC Tumorigenesis	Brugarolas, James	The University of Texas Southwestern Medical Center	\$1,196,812
19	RP240537	CFSA	2.0	Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core	Wu, Erxi	Baylor Research Institute	\$2,999,989
20	RP250213	IIRA	2.0	KRAS spatiotemporal dynamics: lipid glycosylation as a novel therapeutic target	Hancock, John	The University of Texas Health Science Center at Houston	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

21	RP250428	IIRA	2.0	Studying Hematopoietic Stem Cells to Predict and Understand Mechanisms of Post-transplant Relapse in the Myelodysplastic Syndromes	Chung, Stephen	The University of Texas Southwestern Medical Center	\$899,025
22	RP250143	IIRA	2.0	Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy	Lissanu, Yonathan	The University of Texas M. D. Anderson Cancer Center	\$899,991
23	RP250044	IIRACSBC	2.0	Heterogeneity of resistance to endocrine therapy and Cdk inhibition: An integrated systems biology approach to biologically informed treatment regimens	Brock, Amy	The University of Texas at Austin	\$763,596
24	RR250072	REI	2.0	Mechanisms behind copper dependence of cancer cells	Wittung Stafshede, Pernilla	Rice University	\$6,000,000
25	RR250061	RFTFM	2.0	Engineered antibody tools for targeted regulation of cancer-associated proteins and organelles through redirected autophagy process	Jiang, Ziwen	The University of Texas at Dallas	\$2,000,000
26	RP250398	IIRA	2.1	Synthetic lethality of TRIP13 and Aurora A in Rb-deficient cancer	Johnson, Faye	The University of Texas M. D. Anderson Cancer Center	\$899,994
27	RP250402	IIRA	2.1	Exploiting Tryptophan Metabolite Addiction to identify and Inhibit HCC	Conacci Sorrell, Maralice	The University of Texas Southwestern Medical Center	\$900,000
28	RP250131	IIRACT2	2.1	Randomized Clinical Trial Evaluating Fecal Microbiota Transplant in Chimeric Antigen Receptor Therapy for Reversing Antimicrobial-Associated Dysbiosis	Saini, Neeraj	The University of Texas M. D. Anderson Cancer Center	\$1,598,410
29	RP250282	IIRA	2.2	Harnessing BACH2 to enhance anti-tumor T cell immunity	Yao, Chen	The University of Texas Southwestern Medical Center	\$900,000
30	RP250280	IIRA	2.2	The role of glutathione in leukemia development	Agathocleous, Michalis	The University of Texas	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

						Southwestern Medical Center	
31	RP250062	IIRA	2.3	Clonal hematopoiesis and toxicity from radiation therapy	Nead, Kevin	The University of Texas M. D. Anderson Cancer Center	\$899,885
32	RP250407	IIRA	2.3	Protecting the GI tract with a C60 fullerene derivative to facilitate dose-escalated abdominopelvic radiotherapy	Mackeyev, Yuri	The University of Texas Health Science Center at Houston	\$900,000
33	RP250055	IIRA	2.4	TET2 mutations promote myeloid malignancies by dysregulating m5C oxidation of chromatin-associated RNAs	Xu, Mingjiang	The University of Texas Health Science Center at San Antonio	\$900,000
34	RP250391	IIRA	2.5	Novel PCDH7 monoclonal antibodies that direct immune surveillance and combat drug resistance in lung cancer	O'Donnell, Kathryn	The University of Texas Southwestern Medical Center	\$900,000
35	RP250321	IIRACT2	2.5	Leveraging synthetic and collateral lethality in MTAP loss tumors	Rodon Ahnert, Jordi	The University of Texas M. D. Anderson Cancer Center	\$1,599,783
36	RP250069	IIRA	2.6	HSP90 Capacitance: Discovery of a New Mechanism Driving Evolution of Drug Resistance in Head and Neck Squamous Cell Carcinoma	Karras, Georgios	The University of Texas M. D. Anderson Cancer Center	\$890,201
37	RP250305	IIRA	2.6	Exploiting synthetic lethality between HNRNPK loss and ribosomal dysfunction in del9q AML	Post, Sean	The University of Texas M. D. Anderson Cancer Center	\$896,322
38	RP250091	IIRA	2.6	Dissecting the Survival Mechanisms of Latent Brain-Tropic Cancer Cells for Therapeutic Interventions	Malladi, Srinivas	The University of Texas Southwestern Medical Center	\$900,000
39	RP250322	IIRA	2.6	Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2-mutant non-small cell lung cancer (NSCLC)	Heymach, John	The University of Texas M. D. Anderson Cancer Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

40	RP250154	IIRA	2.6	Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients	Fuentes, David	The University of Texas M. D. Anderson Cancer Center	\$899,808
41	RP250156	IIRAP	2.6	Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer	Wu, Jia	The University of Texas M. D. Anderson Cancer Center	\$1,200,000
42	RP250094	IIRACT2	2.7	A phase 2 clinical trial with Avasopasem, with anti-estrogen therapy (ET) and a CDK4/6 inhibitor in metastatic breast cancer progressing on ET/CDK4/6 therapy.	Gius, David	The University of Texas Health Science Center at San Antonio	\$1,390,420
43	RP250418	IIRAP	2.7	Approach Bias Retraining to Augment Long-Term Smoking Cessation Among a Diverse Sample	Garey, Lorra	University of Houston	\$1,200,000
44	RP250355	CAP-CAC-CR	2.8	The Texas Collaborative Center for Hepatocellular Cancer (TeCH)	El-Serag, Hashem	Baylor College of Medicine	\$3,000,000
45	RP250119	IIRACCA	2.8	Comparison of Symptom Burden, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients treated with Surgery vs. Surgery and Chemotherapy	Kahalley, Lisa	Baylor College of Medicine	\$1,200,000
46	RP250190	IIRACCA	2.8	Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-Exercise Intervention	Swartz, Maria	The University of Texas M. D. Anderson Cancer Center	\$1,199,756
47	RP250182	IIRAP	2.8	Implementing Newborn Screening for Pediatric Cancer Predisposition Syndromes in Texas: The INSPECT Study	Parsons, Donald	Baylor College of Medicine	\$1,187,187
48	RP250097	IIRA	2.9	Deciphering and targeting age-related metastatic	Naora, Honami	The University of Texas M. D.	\$899,984

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				competence of the omentum		Anderson Cancer Center	
49	RP250099	IIRA	2.9	Targeting lethal prostate cancers with a clinical-stage inverse agonist for G protein-coupled receptor 6	Li, Wenliang	The University of Texas Health Science Center at Houston	\$900,000
50	RP250399	IIRACSBC	2.9	Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture	Vokes, Natalie	The University of Texas M. D. Anderson Cancer Center	\$1,049,033
51	RP250090	IIRACSBC	2.9	Artificial Intelligence for Early Identification of Androgen-Indifferent, Lethal Prostate Cancer and Therapy Selection	Merényi, Erzsébet	Rice University	\$1,049,434
52	RP250191	IIRA	3.1	Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$898,263
53	RP250164	IIRACCA	3.1	Prediction of CAR-T Cell Immunotherapy Outcomes in Neuroblastoma using FE-MRI Nano-radiomics	Ghaghada, Ketan	Baylor College of Medicine	\$1,168,013

Core Facility Support Award (CFSA)

Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal)

Individual Investigator Research Awards (IIRA)

Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)

Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)

Individual Investigator Research Awards for Clinical Trials (IIRACT)

Individual Investigator Research Awards for Early Onset Cancers (IIRAEOC)

Individual Investigator Research Awards for Prevention and Early Detection (IIRAP)

Recruitment of Established Investigators (REI)

Recruitment of Rising Stars (RRS)

Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2025—Cycle 1**

***Individual Investigator Research Awards for
Cancer in Children and Adolescents***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS

RFA R-25.1-IIRACCA

**Individual Investigator Research Awards
for Cancer in Children and Adolescents**

Please also refer to the Instructions for Applicants document, which will be posted on February 22, 2024.

Due to the highly competitive nature of this RFA mechanism and available funds for FY25, CPRIT projects that only 10% of submitted applications will be funded.

Application Receipt Opening Date: March 19, 2024

Application Receipt Closing Date: June 11, 2024

FY2025

Fiscal Year Award Period
September 1, 2024-August 31, 2025

TABLE OF CONTENTS

1. BRIEF DESCRIPTION OF RFA.....	4
2. ABOUT CPRIT.....	4
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES.....	5
3. RATIONALE.....	5
4. RESEARCH OBJECTIVES.....	6
5. FUNDING INFORMATION.....	7
6. ELIGIBILITY.....	7
7. RESUBMISSION POLICY.....	9
8. RENEWAL POLICY.....	9
9. RESPONDING TO THIS RFA.....	10
9.1. APPLICATION SUBMISSION GUIDELINES.....	10
9.1.1. <i>Submission Deadline Extension</i>	10
9.2. APPLICATION COMPONENTS.....	10
9.2.1. <i>Abstract and Significance (5,000 characters)</i>	11
9.2.2. <i>Layperson’s Summary (2,000 characters)</i>	11
9.2.3. <i>Specific Aims and Sub-aims</i>	12
9.2.4. <i>Timeline (1 page)</i>	12
9.2.5. <i>Specific Aims (1 Page)</i>	12
9.2.6. <i>Resubmission Summary (2 Pages)</i>	12
9.2.7. <i>Renewal Summary (2 pages)</i>	13
9.2.8. <i>Research Plan (10 pages)</i>	13
9.2.9. <i>Vertebrate Animals (1 page)</i>	13
9.2.10. <i>Human Subjects (2 pages)</i>	13
9.2.11. <i>Publications/References</i>	14
9.2.12. <i>Budget and Justification</i>	14
9.2.13. <i>Biographical Sketches (5 pages each)</i>	15
9.2.14. <i>Current and Pending Support</i>	15
9.2.15. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i>	16
9.2.16. <i>Previous Summary Statement</i>	16
9.3. FORMATTING INSTRUCTIONS.....	16
10. APPLICATION REVIEW.....	17
10.1. PRELIMINARY EVALUATION.....	17
10.2. FULL PEER REVIEW.....	18
10.3. CONFIDENTIALITY OF REVIEW.....	18
10.4. REVIEW CRITERIA.....	19
10.4.1. <i>Primary Criteria</i>	19
10.4.2. <i>Secondary Criteria</i>	20
11. KEY DATES.....	21
12. AWARD ADMINISTRATION.....	21
13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS.....	22
14. CONTACT INFORMATION.....	23
14.1. HELPDESK.....	23
14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS.....	23

RFA VERSION HISTORY

2/22/24 RFA released

1. BRIEF DESCRIPTION OF RFA

- Supports applications for innovative research projects addressing questions that will advance knowledge of the etiology, prevention, progression, detection, treatment, or survivorship of cancer in children and adolescents.
- Applicants may request a maximum of \$300,000 per year for a period of up to 4 years.
- **Multi-Principal Investigators (MIs)** are allowed under this Request for Applications (RFA). See the Information for Applicants (IFA) document for definition and eligibility of MIs.
- See application limitations for **Principal Investigators (PI)s/MIs**, regardless of whether the MI is from the prime institution or a subcontracted institution.
- **Note that CPRIT does not allow the use of the term Co-PI.**
- Minimum effort for the PI and/or MIs throughout the project period is required.
- A PI and/or MI may not submit more than **one application** for this RFA (defined as either a new application, resubmission application, or *competitive renewal application).
- *Renewal applications are limited to one competitive renewal under this RFA, regardless of the year of the funded parent IIRACCA award.
- The FY25 salary cap is \$225,000 per year.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state
- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

3. RATIONALE

In recent decades, great strides have been made in reducing mortality from childhood cancers. Most of these gains have been realized in childhood leukemia and lymphoma. However, improvements in survival have been less robust in other types of childhood cancers, which make up more than 40% of total cancer cases in children and adolescents aged 0 to 19 years.

Furthermore, the overall incidence of pediatric cancer has increased at an annual rate of 0.6% since 1975, with most of the increases being seen in acute lymphoblastic leukemia, brain and central nervous system tumors, non-Hodgkin lymphoma, and testicular germ cell tumors.

Reasons for increases in these tumor types are unknown, indicating that information on the

etiology of these cancers is urgently needed. Because of the high rates of survival for certain childhood and adolescent cancers, there are increasing numbers of survivors of such cancers living today. These individuals have a high rate of late effects from the cancer or its treatment, including the occurrence of additional cancers. Clearly, more effective, less-toxic treatments are needed for these diseases. However, few new therapies have been developed in recent years. Several reasons account for the paucity of new treatments, including the lack of interest on the part of pharmaceutical companies in developing treatments for cancers that account for only 1% of all cancer cases and the difficulty of collecting sufficient numbers of tumors for laboratory studies.

Because cancers in children and adolescents differ from those in adults with regard to genetic alterations and biological behavior, application of adult therapies to these cancers may not be successful. Therefore, this area of investigation represents an opportunity for CPRIT to deploy funding in an area of critical need that is not heavily represented in other funding portfolios.

4. RESEARCH OBJECTIVES

This RFA solicits applications for innovative research projects addressing questions that will advance current knowledge of the causes, prevention, progression, detection, treatment, or survivorship of cancer in children and adolescents. Applications may address any topic related to these areas as well as projects dealing with the causes or amelioration of the late effects of cancer treatment. Laboratory, clinical, or population-based studies are all acceptable. CPRIT expects the outcome of the research to reduce the incidence, morbidity, or mortality from cancer in children and/or adolescents in the near or long term. Applications that seek to apply or develop state-of-the-art approaches, technologies, tools, treatments, and/or resources are encouraged, particularly those with potential for commercialization. Applications that address cancer disparities will be looked on with special favor. Successful applicants should be working in a research environment capable of supporting potentially high-impact studies.

The subject of applications may include, but is not limited to, the following:

- Causes of cancer in children and adolescents, including genetic factors or prenatal or early life exposure to environmental agents;
- Identification of risk factors for cancer development;

- New methods for diagnosing cancers in children and/or adolescents;
- Preclinical studies or development of new therapies, including targeted therapies, immunotherapies, and new drugs (excludes clinical trials);
- Identification of patients at risk of developing late effects of cancer treatment;
- Improvements in quality of life for survivors of childhood and adolescent cancers; and
- Identification of the determinants for cancer outcomes and mitigation to reduce cancer disparities.

The *degree of relevance* to reducing the burden of cancer in these populations is a critical criterion for evaluation of projects for funding by CPRIT ([section 10.4.1](#)).

5. FUNDING INFORMATION

Applicants may request a maximum of \$300,000 per year for a period of up to 4 years. Exceptions to these limits may be requested if extremely well justified. Funds may be used for salary and fringe benefits, research supplies, equipment, subject participation costs, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of indirect costs to no more than 5% of the total award amount.

Please see [section 9.2.12](#) and the IFA for additional information.

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.
- This award mechanism allows MIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for MI awards).

- For applications that include 1 PI, the PI is required to maintain a minimum of 15% level of effort through the duration of the entire award period. For applications that include MIs, **each** PI is required to maintain a minimum of 10% effort through the entire duration of the award period.
- A PI may not submit applications to this RFA and to RFA R-25.1-IIRA, RFA 25.1-IIRACCSBC, RFA R-25.1-IIRACT, RFA R-25.1-IIRAP, or RFA R-25.1-IIRAEOC.
- A PI may not submit more than 1 application, either a new, resubmission **or** renewal application under this RFA during this funding cycle.
- A PI may not be a part of more than 1 application, whether as a single applicant or as an MI on an application, under this RFA and RFA R-25.1-IIRA, RFA R-25.1-IIRACCSBC, RFA R-25.1-IIRACT, RFA R-25.1-IIRAP, or RFA R25.1-IIRAEOC.
- **An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants.** Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project MIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2025).
- Applications that address prevention, early detection, or population-based studies, computational oncology studies of cancer, or are focused solely on innovative clinical trials should be submitted under the appropriate targeted RFA.
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.

- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, regardless of whether those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 12](#) and [section 13](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** and must follow all resubmission guidelines. **More than 1 resubmission is not permitted.** An application is considered a resubmission if the proposed project is the same project presented in the original submission. A change in the identity of the PI for a project, a change in the project title that was previously submitted to CPRIT, or omission or modification of an aim do not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 9.2.6](#).

8. RENEWAL POLICY

An application funded by CPRIT under this mechanism may be submitted for one competitive renewal. An application originally funded by CPRIT as an IIRA that is appropriate for the IIRACCA mechanism may be submitted under this RFA for a competitive renewal. See [section](#)

[9.2.7](#). Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 10.2](#).

9. RESPONDING TO THIS RFA

9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 19, 2024, and must be submitted by 4 PM central time on June 11, 2024. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#), within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details. The IFA will be available when the application receipt system opens. Submissions that are missing 1 or more components

or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

9.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the abstract and significance of the research alone. Therefore, applicants are advised to prepare this section wisely. Based on the Abstract and Significance statement (and the Specific Aims, Budget and Justification and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from peer review (see [section 10.1](#)). Applicants should not waste this valuable space by stating obvious facts (e.g., that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. Provide the hypothesis to be tested, the specific aims, and the overall experimental approaches.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Indicate whether this research will address cancers associated with disparities. Summarize how the proposed research creates new paradigms or challenges existing ones. Indicate whether this research plan represents a new direction for the PI.

9.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary will also be used by advocate reviewers ([section 10.2](#)) to evaluate the significance and impact of the proposed work.

9.2.3. Specific Aims and Sub-aims

Please provide a description of the aims and sub-aims and milestones to be achieved for each year of the project. Provide 2 to 3 sentences describing activities to be performed and anticipated milestones. These aims will also be used during the submission and evaluation of progress reports and assessment of project success.

9.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

9.2.5. Specific Aims (1 Page)

Please provide a 1-page summary of the aims of the proposal. The Specific Aims page should identify the problem, or gap in our current knowledge. It should present a hypothesis and briefly describe the aims, sub-aims, and approaches. Address the proposal's innovation, novel approaches and significance and impact on the field and cancer research. Please also refer to the template located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.6. Resubmission Summary (2 Pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a new research plan or modify the original research plan and mark the changes.

However, **all resubmitted applications should be carefully reconstructed**; a simple revision of

the prior application with only editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

9.2.7. Renewal Summary (2 pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

9.2.8. Research Plan (10 pages)

Background: Provide the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed.

Hypothesis and Specific Aims: Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application. Describe the significance, innovation, and potential impact of the research.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required.

9.2.9. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

9.2.10. Human Subjects (2 pages)

If human subjects or human biological samples will be used, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional review board (IRB) will be required before funding.

9.2.11. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

9.2.12. Budget and Justification

Provide a detailed justification of the budget for the entire proposed period of support, including salaries and fringe benefits, supplies, equipment, costs associated with the conduct of a clinical trial, animal care costs, subject participation costs, travel to scientific/technical meetings or collaborating institutions, and other expenses. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. Do not exceed \$300,000 per year for a period of up to 4 years. Applicants are advised not to interpret the maximum allowable time and funding under this award as a suggestion that they should expand their anticipated work and budget to this level. Reasonable budgets clearly work in favor of the applicant.

However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2025 is \$225,000; CPRIT FY 2025 is from September 1, 2024, through August 31, 2025. Salary does not include

fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

- Funds can be used to pay for costs that a cancer clinical trial participant may have associated with their participation in a clinical trial, including (1) transportation, including car mileage, parking, bus fare, taxi or ride hailing fare exclusive of tips, and commercial economy class airfare within the borders of the State of Texas and (2) lodging.

9.2.13. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. A biographical sketch must be provided for the PI and, if applicable, any additional MIs (if an MI application), as required by the online application receipt system. Up to **5 additional** biographical sketches for key personnel may be provided; these should be concatenated into a single PDF with a 25-page limit. **Each biographical sketch must not exceed 5 pages.** The NIH biosketch format is appropriate.

9.2.14. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, any additional MIs (for an MI application), must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.15. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

9.2.16. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components, exceed the specified page, word, or budget limits, or that do not meet the eligibility requirements listed above will be administratively rejected without review.

9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations may be submitted as part of the submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters

are also acceptable as long as the journal information is stated. URLs of publications referenced in the application may be included.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants must not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see **Page Numbering section below**).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be printed, signed, scanned, and then uploaded in PDF format.

10. APPLICATION REVIEW

10.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may undergo preliminary evaluation by CPRIT Scientific Research Program panel members for scientific merit and potential impact.

The preliminary evaluation based on a subset of material presented in the application—namely, the Abstract and Significance, Specific Aims page, Budget and Justification, and Biographical Sketches. Applications that do not sufficiently capture the reviewers' interest at this stage will not be considered for further peer review. Such applications will have been judged to offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

10.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 10.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC.

The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

10.3. Confidentiality of Review

Each stage of the application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, ([Texas Administrative Code RULE §703.9](#)).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

10.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Peer Review committees will evaluate and score each primary criterion and subsequently assign an overall_score that reflects a complete assessment of the application. **The overall score will not be an average of the individual criteria scores; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

10.4.1. Primary Criteria

The primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention, diagnosis, or treatment for patients? Is the application innovative? Does the applicant propose new paradigms or challenge

existing ones? Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required creativity and expertise to make a significant contribution to the research? Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant(s) devoted a sufficient amount of their time (percent effort) to this project?

Relevance: Does the proposed research address cancer in children or adolescents? Is it likely to make an impact on these diseases? This is a critical criterion for evaluation of applications for CPRIT support.

10.4.2. Secondary Criteria

Secondary criteria contribute to the overall score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

11. KEY DATES

RFA

RFA release February 22, 2024

Application

Online application opens March 19, 2024, 7 AM central time

Application due June 11, 2024, 4 PM central time

Application review June 2024-February 2025

Award

Award notification February 2025

Anticipated start date March 1, 2025

12. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cpr.it.texas.gov. Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

14. CONTACT INFORMATION

14.1. Helpdesk

The Helpdesk will answer queries submitted via email within 1 business day. Helpdesk support is available for questions regarding user registration, online submission of applications as well as page limitations, formatting, and how to upload application components/subsections in the appropriate tabs of the CPRIT Application Receipt System. Helpdesk staff cannot answer scientific questions and/or Academic Research programs aspects of an application. Before contacting the Helpdesk, please refer to the *Instructions for Applicants* document, which provides a step-by-step guide on using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

14.2. Scientific and Programmatic Questions

Scientific and Programmatic Questions-should be directed to the CPRIT Director of Academic Research. **Before contacting CPRIT, please refer to the *Instructions for Applicants* document and contact the Helpdesk for any items related to the Application Receipt System (CARS), page limitations, formatting, etc.**

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports

Cancer Prevention and Research Institute of Texas (CPRIT)**25.1 Academic Research Peer Review C/TCR-2****(25.1 ACR C/TCR-2)****Observation Report**

Report No. 2024-10-16 25.1_ACR_C/TCR-2
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Peer Review_C/TCR-2 (25.1_ACR_C/TCR-2)
Panel Date: October 16, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Peer Review_C/TCR-2 (25.1_ACR_C/TCR-2) meeting. The meeting was chaired by Richard O'Reilly and conducted via videoconference on October 16, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and seven (7) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Peer Review CB (25.1 ACR CB)
Observation Report

Report No. 2024-10-17 25.1_ACR_CB
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Peer Review_CB (25.1 _ACR_CB)
Panel Date: October 17, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Peer Review_CB (25.1_ACR_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on October 17, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, seventeen (17) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a series of connected loops and a long horizontal tail.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Research Imaging Technology and Informatics (ITI) (25.1 ACR-ITI)

Observation Report

Report No. 2024-10-18 25.1_ACR-ITI
Program Name: Academic Research
Panel Name: 25.1 Academic Research- Imaging Technology and Informatics (ITI) (25.1_ACR-ITI)
Panel Date: October 18, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research- Imaging Technology and Informatics (ITI) (25.1_ACR-ITI) meeting. The meeting was chaired by Jason Lewis and conducted via videoconference on October 18, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed and five (5) applications were not discussed
- Panelists: One (1) panel chair, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Seven (7)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)**25.1 Academic Research Cancer Prevention Research****(25.1 ACR CPR)****Observation Report**

Report No. 2024-10-22 25.1_ACR_CPR
Program Name: Academic Research
Panel Name: 25.1 Academic Research Cancer Prevention Research
(25.1_ACR_CPR)
Panel Date: October 22, 2024
Report Date: October 23, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Cancer Prevention Research (25.1_ACR_CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 22, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and eight (8) applications were not discussed
- Panelists: One (1) panel chair, ten (10) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict(s) of Interest (COIs) identified prior to and/or during the meeting. The COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Basic Cancer Research-1 (BCR-1)
Observation Report

Report No. 2024-10-23 25.1_ACR_BCR-1
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Basic Cancer Research-1 (BCR-1)
Panel Date: October 23, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Basic Cancer Research-1 (BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on October 23, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: One (15) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewer
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Basic Cancer Research-2 (BCR-2)
Observation Report

Report No. 2024-10-24 25.1_ACR_BCR-2
Program Name: Academic Research
Panel Name: 25.1 Academic Research Basic Cancer Research-2 (BCR-2)
Panel Date: October 24, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Basic Cancer Research-2 (BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 24, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Ten (10) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Clinical and Translational Cancer
Research-1 (CTCR-1) Observation Report

Report No. 2024-10-25 25.1_ACR_CTCR-1
Program Name: Academic Research
Panel Name: 25.1 Academic Research Clinical and Translational Cancer
Research-1 (CTCR-1)
Panel Date: October 25, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Clinical and Translational Cancer Research-1 (CTCR-1) meeting. The meeting was chaired by Margaret Tempero and conducted via videoconference on October 25, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed and twenty-nine (29) applications were not discussed
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Scientific Review Council (25.1 SRC)

Observation Report

Report No. 2024-12-12 25.1_SRC
Program Name: Academic Research
Panel Name: 25.1 Academic Scientific Review Council (25.1_SRC)
Panel Date: December 12, 2024
Report Date: December 18, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Scientific Review Council (25.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 12, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Forty-seven (47) applications were discussed
- Panelists: One (1) panel chair, six (6) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting; however, they are waived pursuant to the Section 102.1062 Conflict of Interest Waiver for FY 2025 approved by the CPRIT Oversight Committee.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 25.1

Awards Announced at the February 19, 2025, Oversight Committee Meeting

The following table lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research cycle 25.1 include *Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center; Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual; Investigator Research Awards for Computational and Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; and Individual Investigator Research Awards for Prevention and Early Detection.*

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP250156	Jia Wu	The University of Texas M.D. Anderson Cancer Center	Issam El Naqa
RP250247	James Yao	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250118	Masahiro Morita	The University of Texas Health Science Center at San Antonio	Sanja Vicković
RP250399	Natalie Vokes	The University of Texas M.D. Anderson Cancer Center	Walter Stadler
RP250355	Hashem El-Serag	Baylor College of Medicine	Christopher Haiman

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250069	Georgios Karras	The University of Texas M.D. Anderson Cancer Center	Jason Lewis ¹
RP250438	Stephen Chung	The University of Texas M.D. Anderson Cancer Center	Jason Lewis ²
RP250278	Samuel McBrayer	The University of Texas Southwestern Medical Center	Craig Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP250124	Payal Kapur	The University of Texas Southwestern Medical Center	Anna Wu
RP250007	Debananda Pati	Baylor College of Medicine	Steffi Oesterreich
RP250230	Anirban Maitra	The University of Texas M.D. Anderson Cancer Center	Michael Hollingsworth
RP250014	Alexander Pertsemlidis	The University of Texas Health Science Center at San Antonio	Jose Conejo-Garcia
RP250088	Christopher Rylander	The University of Texas at Austin	Jose Conejo-Garcia
RP250187	Fredrik Thege	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250216	Khalid Mohamedali	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250265	Nabil Ahmed	Baylor College of Medicine	Ying Lu
RP250173	Katsumi Kitagawa	The University of Texas Health Science Center at San Antonio	Alan Tomkinson
RP250229	Kunal Rai	The University of Texas M.D. Anderson Cancer Center	Vijaya B. Kolachalama

¹ This conflict was waived pursuant to an approved Texas Health and Safety Code § 102.1062 waiver applicable to CPRIT review councils. A copy of the FY2025 waiver is available on [CPRIT's website](#).

² Same as footnote 1.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250153	Ronald DePinho	The University of Texas M.D. Anderson Cancer Center	Kornelia Polyak
RP250307	Sandeep Burma	The University of Texas Health Science Center at San Antonio	Bart Williams
RP250046	Surendranath Shastri	The University of Texas M.D. Anderson Cancer Center	Karen Emmons
RP250063	Aaron Thrift	Baylor College of Medicine	Christopher Haiman
RP250163	Robert Bast	The University of Texas M.D. Anderson Cancer Center	Karen Emmons
RP250231	Weiva Sieh	The University of Texas M.D. Anderson Cancer Center	Christopher Haiman; Lawrence Kushi; Melissa Troester
RP250053	Dae Kim	The University of Texas Rio Grande Valley	Alan Tomkinson
RP250334	Linghua Wang	The University of Texas M.D. Anderson Cancer Center	Benjamin Greenbaum
RP250371	John Tainer	The University of Texas M.D. Anderson Cancer Center	Alan Tomkinson; John Petrini; Walter Chazin
RP250411	Salma Kaochar	Baylor College of Medicine	John Petrini
RP250121	Dan Nguyen	The University of Texas Southwestern Medical Center	Jun Deng
RP250219	Marites Melancon	The University of Texas M.D. Anderson Cancer Center	David Mankoff; James Babilion
RP250251	Hao Peng	The University of Texas Southwestern Medical Center	Jun Deng
RP250375	Alexander Bishop	The University of Texas Health Science Center at San Antonio	Patrick Grohar
RP250026	Eduardo Vilar-Sanchez	The University of Texas M.D. Anderson Cancer Center	Gregory Lesinski

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250135	Bouthaina Dabaja	The University of Texas M.D. Anderson Cancer Center	Charles Mullighan
RP250217	Ehsan Irajizad	The University of Texas M.D. Anderson Cancer Center	Lawrence Kushi

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards for Cancer in Children and Adolescents

Academic Research Cycle 25.1

Final Scores for Fully Reviewed Applications

Application ID	Final Overall Evaluation Score
RP250278*	1.2
RP250144*	1.5
RP250374*	1.9
RP250119*	2.8
RP250190*	2.8
RP250164*	3.1
Da	3.3
Db	3.3
Dc	3.7
Dd	3.7
De	3.7
Df	3.7
Dg	3.7
Dh	3.7
Di	3.8
Dj	4.0
Dk	4.0
Dl	4.3
Dm	4.3
Dn	4.7

* Recommended for funding.

Individual Investigator Research Awards for Cancer in Children and Adolescents

Academic Research Cycle 25.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

Application ID	Final Overall Evaluation Score
La	3.7
Lb	3.7
Lc	4.0
Ld	4.3
Le	4.3
Lf	4.3
Lg	4.3
Lh	4.3
Li	4.7
Lj	4.7
Lk	4.7
Ll	5.3
Lm	5.7
Ln	6.3
Lo	6.7

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 5, 2025

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Ms. Kristen Doyle
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to kdoyle@cprit.texas.gov

Dear Dr. Cummings and Ms. Doyle,


The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for the Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal); Core Facility Support Award (FY2024); Individual Investigator Research Awards; Individual Investigator Research Awards for Childhood and Adolescent Cancers; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; Investigator Research Awards for Early-Onset Cancers; Individual Investigator Research Awards for Prevention and Early Detection; Recruitment of Established Investigators; Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 12, 2024 to consider the FY25.1 applications recommended by the peer review panels following their meetings held October 16, 2024 to October 24, 2024 and one FY24.2 Core Facility application recommended by a peer review panel on April 24, 2024. The SRC met on November 14, 2024 to review recruitment applications submitted for Cycle FY25.2 and then on December 12, 2024 to review recruitment applications submitted for Cycle FY25.3.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the 53 recommended applications is \$67,753,626.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Chair, CPRIT Scientific Review Council

Rank	Grant ID	RFA	Score	Title	PI	Institution	Recommended Budget
1	RP250118	IIRA	1.0	Ribosome Localization at Mitochondria-ER Contacts in Obesity-Associated Liver Cancer	Morita, Masahiro	The University of Texas Health Science Center at San Antonio	\$900,000
2	RP250061	IIRA	1.0	Imaging of cranial radiotherapy neuroinflammatory sequelae by Positron Emission Tomography	Pisaneschi, Federica	The University of Texas Health Science Center at Houston	\$900,000
3	RR250077	RFTFM	1.0	Developing next generation of genome editing tools to study and engineer genetic variants for effective precision cancer treatment	Gao, Xin "Daniel"	Baylor College of Medicine	\$2,000,000
4	RR250070	RFTFM	1.0	Unlocking the Potential of Clonal Hematopoiesis in Early Detection and Interception of Lymphoid Malignancies	Griffin, Rosalie	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
5	RR250063	RFTFM	1.1	Co-opting antiviral innate immune pathways to target non-small cell lung cancer	Zou, Tao	The University of Texas Southwestern Medical Center	\$2,000,000
6	RR250071	RFTFM	1.1	CRISPR screening to uncover tumor intrinsic modulators of DNA repair and immune effects of radiation therapy	Verma, Nipun	Baylor College of Medicine	\$2,000,000
7	RP250278	IIRACCA	1.2	Developmental origins of IDH-mutant glioma in adolescents	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,198,416
8	RP250293	IIRAP	1.2	Development of a shared decision tool to facilitate uptake of the levonorgestrel-releasing intrauterine system for the primary prevention of endometrial cancer	Meyer, Larissa	The University of Texas M. D. Anderson Cancer Center	\$1,199,542
9	RP250208	IIRA	1.4	RPS23 is a new drug target to activate the integrated stress response and treat leukemia	Ready, Joseph	The University of Texas Southwestern Medical Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

10	RP250201	IIRA	1.4	Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in oral cavity squamous cell carcinoma	Gillison, Maura	The University of Texas M. D. Anderson Cancer Center	\$899,998
11	RP250028	IIRA	1.5	MALAT1 protects against osteoporosis and bone metastasis	Ma, Li	The University of Texas M. D. Anderson Cancer Center	\$900,000
12	RP250247	IIRA	1.5	Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETS	Yao, James	The University of Texas M. D. Anderson Cancer Center	\$900,000
13	RP250144	IIRACCA	1.5	Decoding how neuronal activity remodels the epigenome in ependymoma	Deneen, Benjamin	Baylor College of Medicine	\$1,200,000
14	RP250220	IIRA	1.8	Decellularized tissue matrices to study the “bad soil” in cancer metastasis	Wang, Andrew	The University of Texas Southwestern Medical Center	\$900,000
15	RP250269	IIRAP	1.8	Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules.	Ostrin, Edwin	The University of Texas M. D. Anderson Cancer Center	\$1,169,776
16	RP250222	IIRA	1.9	KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC	Gibbons, Don	The University of Texas M. D. Anderson Cancer Center	\$899,997
17	RP250043	IIRA	1.9	An integrated imaging informatics platform for HCC surveillance	Zhou, Xiaobo	The University of Texas Health Science Center at Houston	\$899,991
18	RP250374	IIRACCA	1.9	Dissecting TFE3 Mediated tRCC Tumorigenesis	Brugarolas, James	The University of Texas Southwestern Medical Center	\$1,196,812
19	RP240537	CFSA	2.0	Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core	Wu, Erxi	Baylor Research Institute	\$2,999,989
20	RP250213	IIRA	2.0	KRAS spatiotemporal dynamics: lipid glycosylation as a novel therapeutic target	Hancock, John	The University of Texas Health Science Center at Houston	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

21	RP250428	IIRA	2.0	Studying Hematopoietic Stem Cells to Predict and Understand Mechanisms of Post-transplant Relapse in the Myelodysplastic Syndromes	Chung, Stephen	The University of Texas Southwestern Medical Center	\$899,025
22	RP250143	IIRA	2.0	Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy	Lissanu, Yonathan	The University of Texas M. D. Anderson Cancer Center	\$899,991
23	RP250044	IIRACSBC	2.0	Heterogeneity of resistance to endocrine therapy and Cdk inhibition: An integrated systems biology approach to biologically informed treatment regimens	Brock, Amy	The University of Texas at Austin	\$763,596
24	RR250072	REI	2.0	Mechanisms behind copper dependence of cancer cells	Wittung Stafshede, Pernilla	Rice University	\$6,000,000
25	RR250061	RFTFM	2.0	Engineered antibody tools for targeted regulation of cancer-associated proteins and organelles through redirected autophagy process	Jiang, Ziwen	The University of Texas at Dallas	\$2,000,000
26	RP250398	IIRA	2.1	Synthetic lethality of TRIP13 and Aurora A in Rb-deficient cancer	Johnson, Faye	The University of Texas M. D. Anderson Cancer Center	\$899,994
27	RP250402	IIRA	2.1	Exploiting Tryptophan Metabolite Addiction to identify and Inhibit HCC	Conacci Sorrell, Maralice	The University of Texas Southwestern Medical Center	\$900,000
28	RP250131	IIRACT2	2.1	Randomized Clinical Trial Evaluating Fecal Microbiota Transplant in Chimeric Antigen Receptor Therapy for Reversing Antimicrobial-Associated Dysbiosis	Saini, Neeraj	The University of Texas M. D. Anderson Cancer Center	\$1,598,410
29	RP250282	IIRA	2.2	Harnessing BACH2 to enhance anti-tumor T cell immunity	Yao, Chen	The University of Texas Southwestern Medical Center	\$900,000
30	RP250280	IIRA	2.2	The role of glutathione in leukemia development	Agathocleous, Michalis	The University of Texas	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

						Southwestern Medical Center	
31	RP250062	IIRA	2.3	Clonal hematopoiesis and toxicity from radiation therapy	Nead, Kevin	The University of Texas M. D. Anderson Cancer Center	\$899,885
32	RP250407	IIRA	2.3	Protecting the GI tract with a C60 fullerene derivative to facilitate dose-escalated abdominopelvic radiotherapy	Mackeyev, Yuri	The University of Texas Health Science Center at Houston	\$900,000
33	RP250055	IIRA	2.4	TET2 mutations promote myeloid malignancies by dysregulating m5C oxidation of chromatin-associated RNAs	Xu, Mingjiang	The University of Texas Health Science Center at San Antonio	\$900,000
34	RP250391	IIRA	2.5	Novel PCDH7 monoclonal antibodies that direct immune surveillance and combat drug resistance in lung cancer	O'Donnell, Kathryn	The University of Texas Southwestern Medical Center	\$900,000
35	RP250321	IIRACT2	2.5	Leveraging synthetic and collateral lethality in MTAP loss tumors	Rodon Ahnert, Jordi	The University of Texas M. D. Anderson Cancer Center	\$1,599,783
36	RP250069	IIRA	2.6	HSP90 Capacitance: Discovery of a New Mechanism Driving Evolution of Drug Resistance in Head and Neck Squamous Cell Carcinoma	Karras, Georgios	The University of Texas M. D. Anderson Cancer Center	\$890,201
37	RP250305	IIRA	2.6	Exploiting synthetic lethality between HNRNPK loss and ribosomal dysfunction in del9q AML	Post, Sean	The University of Texas M. D. Anderson Cancer Center	\$896,322
38	RP250091	IIRA	2.6	Dissecting the Survival Mechanisms of Latent Brain-Tropic Cancer Cells for Therapeutic Interventions	Malladi, Srinivas	The University of Texas Southwestern Medical Center	\$900,000
39	RP250322	IIRA	2.6	Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2-mutant non-small cell lung cancer (NSCLC)	Heymach, John	The University of Texas M. D. Anderson Cancer Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

40	RP250154	IIRA	2.6	Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients	Fuentes, David	The University of Texas M. D. Anderson Cancer Center	\$899,808
41	RP250156	IIRAP	2.6	Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer	Wu, Jia	The University of Texas M. D. Anderson Cancer Center	\$1,200,000
42	RP250094	IIRACT2	2.7	A phase 2 clinical trial with Avasopasem, with anti-estrogen therapy (ET) and a CDK4/6 inhibitor in metastatic breast cancer progressing on ET/CDK4/6 therapy.	Gius, David	The University of Texas Health Science Center at San Antonio	\$1,390,420
43	RP250418	IIRAP	2.7	Approach Bias Retraining to Augment Long-Term Smoking Cessation Among a Diverse Sample	Garey, Lorra	University of Houston	\$1,200,000
44	RP250355	CAP-CAC-CR	2.8	The Texas Collaborative Center for Hepatocellular Cancer (TeCH)	El-Serag, Hashem	Baylor College of Medicine	\$3,000,000
45	RP250119	IIRACCA	2.8	Comparison of Symptom Burden, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients treated with Surgery vs. Surgery and Chemotherapy	Kahalley, Lisa	Baylor College of Medicine	\$1,200,000
46	RP250190	IIRACCA	2.8	Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-Exercise Intervention	Swartz, Maria	The University of Texas M. D. Anderson Cancer Center	\$1,199,756
47	RP250182	IIRAP	2.8	Implementing Newborn Screening for Pediatric Cancer Predisposition Syndromes in Texas: The INSPECT Study	Parsons, Donald	Baylor College of Medicine	\$1,187,187
48	RP250097	IIRA	2.9	Deciphering and targeting age-related metastatic	Naora, Honami	The University of Texas M. D.	\$899,984

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				competence of the omentum		Anderson Cancer Center	
49	RP250099	IIRA	2.9	Targeting lethal prostate cancers with a clinical-stage inverse agonist for G protein-coupled receptor 6	Li, Wenliang	The University of Texas Health Science Center at Houston	\$900,000
50	RP250399	IIRACSBC	2.9	Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture	Vokes, Natalie	The University of Texas M. D. Anderson Cancer Center	\$1,049,033
51	RP250090	IIRACSBC	2.9	Artificial Intelligence for Early Identification of Androgen-Indifferent, Lethal Prostate Cancer and Therapy Selection	Merényi, Erzsébet	Rice University	\$1,049,434
52	RP250191	IIRA	3.1	Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$898,263
53	RP250164	IIRACCA	3.1	Prediction of CAR-T Cell Immunotherapy Outcomes in Neuroblastoma using FE-MRI Nano-radiomics	Ghaghada, Ketan	Baylor College of Medicine	\$1,168,013

Core Facility Support Award (CFSA)

Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal)

Individual Investigator Research Awards (IIRA)

Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)

Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)

Individual Investigator Research Awards for Clinical Trials (IIRACT)

Individual Investigator Research Awards for Early Onset Cancers (IIRAEOC)

Individual Investigator Research Awards for Prevention and Early Detection (IIRAP)

Recruitment of Established Investigators (REI)

Recruitment of Rising Stars (RRS)

Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit

Supporting Information

Academic Research
FY 2025—Cycle 1

***Individual Investigator Research Awards for
Computational and Systems Biology of Cancer***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-25.1-IIRACSB

**Individual Investigator Research Awards for
Computational and Systems Biology of Cancer**

**Please also refer to the Instructions for Applicants document,
which will be posted on February 22, 2024.**

**Due to the highly competitive nature of this RFA mechanism and available
funds for FY25, CPRIT projects that only 10% of submitted applications will
be funded.**

Application Receipt Opening Date: March 19, 2024

Application Receipt Closing Date: June 11, 2024

FY 2025

Fiscal Year Award Period
September 1, 2024-August 31, 2025

TABLE OF CONTENTS

1. BRIEF DESCRIPTION OF RFA	4
2. ABOUT CPRIT	4
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES.....	5
3. RATIONALE	5
4. RESEARCH OBJECTIVES	6
5. FUNDING INFORMATION	8
6. ELIGIBILITY	8
7. RESUBMISSION POLICY	10
8. RENEWAL POLICY	10
9. RESPONDING TO THIS RFA	11
9.1. APPLICATION SUBMISSION GUIDELINES.....	11
9.1.1. <i>Submission Deadline Extension</i>	11
9.2. APPLICATION COMPONENTS.....	11
9.2.1. <i>Abstract and Significance (5,000 characters)</i>	12
9.2.2. <i>Layperson’s Summary (2,000 characters)</i>	12
9.2.3. <i>Aims and Subaims</i>	12
9.2.4. <i>Timeline (1 page)</i>	13
9.2.5. <i>Specific Aims (1 page)</i>	13
9.2.6. <i>Resubmission Summary (2 pages)</i>	13
9.2.7. <i>Renewal Summary (2 pages)</i>	13
9.2.8. <i>Research Plan (10 pages)</i>	14
9.2.9. <i>Vertebrate Animals (1 page)</i>	14
9.2.10. <i>Human Subjects (2 pages)</i>	14
9.2.11. <i>Publications/References</i>	14
9.2.12. <i>Budget and Justification</i>	14
9.2.13. <i>Biographical Sketches (5 pages each)</i>	16
9.2.14. <i>Current and Pending Support</i>	16
9.2.15. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i>	16
9.2.16. <i>Previous Summary Statement</i>	16
9.3. FORMATTING INSTRUCTIONS.....	17
10. APPLICATION REVIEW	18
10.1. PRELIMINARY EVALUATION.....	18
10.2. FULL PEER REVIEW.....	18
10.3. CONFIDENTIALITY OF REVIEW.....	19
10.4. REVIEW CRITERIA.....	20
10.4.1. <i>Primary Criteria</i>	20
10.4.2. <i>Secondary Criteria</i>	21
11. KEY DATES	21
12. AWARD ADMINISTRATION	22
13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	22
14. CONTACT INFORMATION	23
14.1. HELPDESK.....	23
14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS.....	23

RFA VERSION HISTORY

2/22/24 RFA released

1. BRIEF DESCRIPTION OF RFA

- Supports applications for projects that integrate innovative computational and mathematical approaches with experimental cancer biology to address challenging questions that will advance current knowledge in the etiology, biology, progression, treatment, metastasis, and immunology of cancer.
- Applicants may request a maximum of \$350,000 per year for a period of up to 3 years.
- Multi-Principal Investigators (MIs) are allowed under this Request for Applications (RFA). See Information for Applicants for definition and eligibility of MIs.
- See application limitations for Principal Investigators (PIs)/MIs, regardless of whether the MI is from the primary institution or a subcontracted institution.
- **Note that CPRIT does not allow the use of the term Co-PI.**
- Minimum effort for the PI and/or MIs throughout the project period is required.
- A PI and/or MI may only submit **one application** for this RFA (defined as either a new application, resubmission application or *competitive renewal application).
- *Renewal applications are limited to one competitive renewal under this RFA, regardless of the year of the funded parent IIRACSBC award.
- FY25 salary cap has been set at \$225,000 per year.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state
- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

3. RATIONALE

Cancer is a complex multiscale disease involving the interaction of dynamic processes at the molecular, cellular, and multicellular levels. These interactive processes adapt and evolve in response to both intracellular and extracellular cues, and across temporal and spatial scales, making cancer difficult to prevent and treat as well as to predict the effects of therapy. Cancer systems biology has emerged as a powerful field that employs multidimensional data as well as mathematical and computational modeling to address these complexities in cancer biology and to predict integrated mechanisms underlying cancer initiation, progression, metastasis, prognosis, and treatment response. The historic focus on single genetic alterations has now expanded to embrace a broader view of the changing cancer ecosystem and evolving patterns of genotypes

and phenotypes associated with progression and therapeutic intervention, facilitated by an explosion in the quantity of experimental data available from high-throughput technologies, such as genomics/epigenomics, transcriptomics, metabolomics, and proteomics. Systems analyses and predictive modeling are proving to be valuable tools to convert these large data sets, spanning different length and time scales, into predictions that can then be experimentally tested or validated in a disease-relevant context, thereby enabling cancer biologists and oncologists to understand and predict how one alteration effects an entire tumor system, increasing our understanding of tumor biology, treatment options, and patient outcomes.

In the past decade, substantial increases in computational power and memory have enabled the development and implementation of artificial intelligence (AI) techniques for handling and analyzing large data sets, as well as radiological and histological images. Computer vision has enabled some of the most striking studies predicting molecular and pathological cues from digitalized images. In pathology, AI for data-driven cancer diagnosis involves clinical diagnosis, tumor detection and grading, and outcomes prediction from tissue stained with hematoxylin and eosin, as well as predicting the presence of gene mutations or genomic alterations, to inform the selection of targeted therapies. Computer vision and digital pathology are only the beginning, and AI systems are being explored in multiple additional settings, eg, computer vision is being used to generate accurate, customized molecular predictions and spatiotemporal modeling based on complex live-cell imaging data.

The remarkable advancements in systems biology and convergence of big data and AI in oncology provides a unique interface to explore the full capabilities of these approaches for the benefit of patients and create an opportunity for CPRIT to deploy funding in an area of critical need that remains underrepresented in other funding portfolios.

4. RESEARCH OBJECTIVES

CPRIT will foster cancer research in Texas by providing financial support for a wide variety of projects relevant to cancer research. This RFA solicits applications for innovative research projects in computational oncology and/or systems biology. CPRIT has adopted the National Cancer Institute's (NCI's) definition of cancer systems biology as "a holistic approach to the study of the complexities of cancer through the explicit integration of experimental biology and computational and mathematical methods to build predictive models of cancer that are tested and

validated in a disease-relevant context” (<https://www.cancer.gov/about-nci/organization/dcb/research-programs/csbc>). Examples of projects responsive to this RFA include, but are not limited to, scientific proposals addressing the following:

- Developing integrated models of genetic/epigenetic, chemical, cytoplasmic/network, microenvironment, and structural features across space and time scales to understand the mechanisms of cancer initiation, progression, metastasis, and therapeutic response;
- Characterization of cellular interactions and their impact on local, systemic, and evolving cellular behaviors that underlie cancer processes, such as initiation, progression, and metastasis;
- Delineation of the interactions between tumor and nontumor components, eg, tumor-immune cell interactions and involvement in mediating the response or resistance to therapy;
- Integration of the biology underlying normal physiological processes, such as development, aging, metabolism, immunity, or chronic inflammation, to inform cancer development, progression, metastasis, or treatment response;
- Elucidation of the mechanism(s) by which external factors, such as the microbiome, affect tumor biology, including therapeutic response;
- Application of systems biology approaches, eg, network and multiscale modeling, to discover targetable molecular or cellular mechanisms and to test biologically informed therapies, sequences of therapies, and combinations of therapies that incorporate variables such as toxicities, dose, and timing;
- Integration of molecular and cellular oncogenic processes with population-level risk factors, such as obesity or chronic inflammation, or environmental factors that may differentially impact patient populations and influence cancer disparities;
- Development of diagnostic, prognostic, and prognostic systems using computational oncology approaches;
- Integration of spatiotemporal and cell behavior data (dynamic imaging data) with omics data, such as epigenomics, proteomics, or genomics profiles;
- The application of computational modeling and artificial intelligence for radiotherapy treatment planning and monitoring; and
- New therapy development aided by the analysis of large data sets.

Partnering of mathematical or computational scientists with cancer biologists or oncologists is highly recommended to form a truly interdisciplinary team that can both develop and validate models leading to a deeper integrated understanding of cancer progression and treatment.

NCI established the Cancer Systems Biology Consortium ([CSBC](#)) to support computational systems biology approaches to cancer research in recognition of the potential for the integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research. The CSBC website includes descriptions of the CSBC portfolio of NCI-funded projects that are examples of the type of applications this RFA seeks to attract. Applications that propose projects focused on purely bioinformatic analyses of omics data or propose correlative studies without a mathematical or computational model are not responsive to this RFA. CPRIT expects the outcomes of activities supported by this RFA to lead to new insights into cancer biology or clinical outcomes in the long term. The degree of relevance to reducing the burden of cancer is a critical criterion for evaluation of projects for funding by CPRIT ([section 10.4.1](#)).

5. FUNDING INFORMATION

Applicants may request a maximum of \$350,000 in total costs per year for up to 3 years. Exceptions to these limits may be requested if extremely well justified (see [section 9.2.12](#)). Funds may be used for salary and fringe benefits, research supplies, equipment, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.

- This award mechanism allows MIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for MI awards).
- For applications that include 1 PI, the PI is required to maintain a minimum of 15% level of effort through the duration of the entire award period. For applications that include MIs, **each** PI is required to maintain a minimum of 10% effort through the entire duration of the award period.
- A PI may not submit applications to this RFA and to RFA R-25.1-IIRA, RFA R-25.1-IIRACCA, RFA R-25.1-IIRACT, RFA R-2.1-IIRAP, or RFA R-25.1-IIRAEOC.
- A PI may not submit more than 1 application, either a new, resubmission, **or** renewal application under this RFA during this funding cycle.
- A PI may not be a part of more than 1 application, whether as a single applicant or as an MI on an application, under this RFA and RFA R-25.1-IIRA, RFA R-25.1-IIRACCA, RFA R-25.1-IIRACT, RFA R-25.1-IIRAP, or RFA R-25.2-IIRAEOC.
- **An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants.** Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project MIs s equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2025).
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the

grant applicant's organization or institution is related to a CPRIT Oversight Committee member.

- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, regardless of whether those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 12](#) and [section 13](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** if the proposed project meets the IIRACSBC research objectives (see [section 4](#)) and follows all resubmission guidelines. More than 1 resubmission is not permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PI for a project or a change of title of the project that was previously submitted to CPRIT does not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 9.2.6](#).

8. RENEWAL POLICY

An application funded by CPRIT under this mechanism may be submitted for one competitive renewal. An application originally funded by CPRIT as an IIRA or IIRACSBC mechanism may be submitted under this RFA for a competitive renewal if the proposed project meets the IIRACSBC research objectives. See [section 4](#) and [section 9.2.7](#). Competitive renewals are not

subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 10.2](#).

9. RESPONDING TO THIS RFA

9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 19, 2024, and must be submitted by 4 PM central time on June 11 2024. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grant applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

9.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section wisely. **Based on the Abstract and Significance statement (and the Specific Aims page, Budget and Justification and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from further peer review (see [section 10.1](#)).**

Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. Provide the hypothesis to be tested, the specific aims of the application, and the overall experimental approaches.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Indicate whether this research will address cancers associated with disparities. Summarize how the proposed research creates new paradigms or challenges existing ones. Indicate whether this research plan represents a new direction for the PI.

9.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary will also be used by advocate reviewers ([section 10.2](#)) in evaluating the significance and impact of the proposed work.

9.2.3. Aims and Subaims

Please provide a description of the aims and subaims and milestones to be achieved for each year of the project. Provide 2 to 3 sentences describing activities to be performed and anticipated

milestones. These aims will also be used during the submission and evaluation of progress reports and assessment of project success.

9.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

9.2.5. Specific Aims (1 page)

Please provide a 1-page summary of the aims of the proposal. The Specific Aims page should identify the problem, or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches. Address the proposal's innovation, novel approaches and significance and impact on the field and cancer research. Please also refer to the template located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.6. Resubmission Summary (2 pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a new research plan or modify the original research plan and mark the changes. However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

9.2.7. Renewal Summary (2 pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and

manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

9.2.8. Research Plan (10 pages)

Background: Provide the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed.

Hypothesis and Specific Aims: Concisely state the hypothesis to be tested, and specific aims to be addressed by the research described in the application. Describe the significance, innovation, and potential impact of the research.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required.

9.2.9. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

9.2.10. Human Subjects (2 pages)

If human subjects or human biological samples will be used, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional review board (IRB) will be required before funding can occur.

9.2.11. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

9.2.12. Budget and Justification

Provide a detailed justification of the budget for the entire proposed period of support, including salaries and fringe benefits, supplies, equipment, patient care costs, animal care costs, travel to scientific/technical meetings or collaborating institutions, and other expenses. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism.

Applicants may request a maximum of \$350,000 in total costs per year for up to 3 years. Applicants are advised not to interpret the maximum allowable time and funding under this award as a suggestion that they should expand their anticipated work and budget to this level. Reasonable budgets clearly work in favor of the applicant.

However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2025 is \$225,000; CPRIT FY 2025 is from September 1, 2024, through August 31, 2025. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

9.2.13. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. A biographical sketch must be provided for the PI and, if applicable, any additional MIs (for an MI application), as required by the online application receipt system. Up to 5 additional biographical sketches for key personnel may be provided, these should be concatenated into a single PDF with a 25-page limit. **Each biographical sketch must not exceed 5 pages.** The NIH biosketch format is appropriate.

9.2.14. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, any additional MIs (for an MI application), must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.15. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

9.2.16. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components, exceed the specified page, word, or budget limits, or that do not meet the eligibility requirements listed above will be administratively rejected without review.

9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations may be submitted as part of the submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. URLs of publications referenced in the application may be included.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants must not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see **Page Numbering section** below).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be printed, signed, scanned, and then uploaded in PDF format.

10. APPLICATION REVIEW

10.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may undergo a preliminary evaluation by CPRIT Scientific Research Program panel members for scientific merit and potential impact.

The preliminary evaluation is based on a subset of material presented in the application—namely, the Abstract and Significance, Specific Aims page, Budget and Justification, and Biographical Sketches. Applications that do not sufficiently capture the reviewers' interest at this stage will not be considered for further peer review. Such applications will have been judged to offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

10.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 10.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of

the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

10.3. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, (Texas Administrative Code RULE §703.9).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

10.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Peer review committees will evaluate and score each primary criterion and subsequently assign an overall score that reflects a complete assessment of the application. **The overall score will not be an average of the individual criteria scores; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

10.4.1. Primary Criteria

The primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention, diagnosis, or treatment for patients? Is the application innovative? Does the applicant propose new paradigms or challenge existing ones? Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required experience and creativity to make a significant contribution to the research? Does the applicant investigator(s) demonstrate the required expertise to make a significant contribution in both mathematical or computational sciences and oncology, or are there appropriate collaborators or consultants with expertise in oncology or cancer biology? It is highly encouraged that applicant investigators engage such collaborators. Applicants' credentials will be evaluated in a career stage-specific

fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant(s) devoted a sufficient amount of their time (percent effort) to this project?

Relevance: Does the proposed research have a high degree of relevance to cancer research? This is a critical criterion for evaluation of applications for CPRIT support.

10.4.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

11. KEY DATES

RFA

RFA release February 22, 2024

Application

Online application opens March 19, 2024, 7 AM central time

Application due June 11, 2024, 4 PM central time

Application review June 2024-February 2025

Award

Award notification February 2025

Anticipated start date March 1, 2025

12. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in chapter [703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private

institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

14. CONTACT INFORMATION

14.1. Helpdesk

The Helpdesk will answer queries submitted via email within 1 business day. Helpdesk support is available for questions regarding user registration, online submission of applications as well as page limitations, formatting, and how to upload application components/subsections in the appropriate tabs of the CPRIT Application Receipt System. Helpdesk staff cannot answer scientific questions and/or Academic Research programs aspects of an application. Before contacting the Helpdesk, please refer to the *Instructions for Applicants* document, which provides a step-by-step guide on using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time.

Tel: 866-941-7146

Email: Help@CPRITGrants.org

14.2. Scientific and Programmatic Questions

Scientific and Programmatic Questions-should be directed to the CPRIT Director of Academic Research. **Before contacting CPRIT, please refer to the *Instructions for Applicants* document and contact the Helpdesk for any items related to the Application Receipt System (CARS), page limitations, formatting, etc.**

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Research Peer Review C/TCR-2

(25.1 ACR C/TCR-2)

Observation Report

Report No. 2024-10-16 25.1_ACR_C/TCR-2
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Peer Review_C/TCR-2 (25.1_ACR_C/TCR-2)
Panel Date: October 16, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Peer Review_C/TCR-2 (25.1_ACR_C/TCR-2) meeting. The meeting was chaired by Richard O'Reilly and conducted via videoconference on October 16, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and seven (7) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Peer Review CB (25.1 ACR CB)
Observation Report

Report No. 2024-10-17 25.1_ACR_CB
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Peer Review_CB (25.1 _ACR_CB)
Panel Date: October 17, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Peer Review_CB (25.1_ACR_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on October 17, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, seventeen (17) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Research Imaging Technology and Informatics (ITI) (25.1 ACR-ITI)

Observation Report

Report No. 2024-10-18 25.1_ACR-ITI
Program Name: Academic Research
Panel Name: 25.1 Academic Research- Imaging Technology and Informatics (ITI) (25.1_ACR-ITI)
Panel Date: October 18, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research- Imaging Technology and Informatics (ITI) (25.1_ACR-ITI) meeting. The meeting was chaired by Jason Lewis and conducted via videoconference on October 18, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed and five (5) applications were not discussed
- Panelists: One (1) panel chair, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Seven (7)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Research Cancer Prevention Research

(25.1 ACR CPR)

Observation Report

Report No. 2024-10-22 25.1_ACR_CPR
Program Name: Academic Research
Panel Name: 25.1 Academic Research Cancer Prevention Research
(25.1_ACR_CPR)
Panel Date: October 22, 2024
Report Date: October 23, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Cancer Prevention Research (25.1_ACR_CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 22, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and eight (8) applications were not discussed
- Panelists: One (1) panel chair, ten (10) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict(s) of Interest (COIs) identified prior to and/or during the meeting. The COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Basic Cancer Research-1 (BCR-1)
Observation Report

Report No. 2024-10-23 25.1_ACR_BCR-1
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Basic Cancer Research-1 (BCR-1)
Panel Date: October 23, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Basic Cancer Research-1 (BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on October 23, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: One (15) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewer
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Basic Cancer Research-2 (BCR-2)
Observation Report

Report No. 2024-10-24 25.1_ACR_BCR-2
Program Name: Academic Research
Panel Name: 25.1 Academic Research Basic Cancer Research-2 (BCR-2)
Panel Date: October 24, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Basic Cancer Research-2 (BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 24, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Ten (10) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Clinical and Translational Cancer
Research-1 (CTCR-1) Observation Report

Report No. 2024-10-25 25.1_ACR_CTCR-1
Program Name: Academic Research
Panel Name: 25.1 Academic Research Clinical and Translational Cancer
Research-1 (CTCR-1)
Panel Date: October 25, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Clinical and Translational Cancer Research-1 (CTCR-1) meeting. The meeting was chaired by Margaret Tempero and conducted via videoconference on October 25, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed and twenty-nine (29) applications were not discussed
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Scientific Review Council (25.1 SRC)

Observation Report

Report No. 2024-12-12 25.1_SRC
Program Name: Academic Research
Panel Name: 25.1 Academic Scientific Review Council (25.1_SRC)
Panel Date: December 12, 2024
Report Date: December 18, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Scientific Review Council (25.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 12, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Forty-seven (47) applications were discussed
- Panelists: One (1) panel chair, six (6) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting; however, they are waived pursuant to the Section 102.1062 Conflict of Interest Waiver for FY 2025 approved by the CPRIT Oversight Committee.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 25.1

Awards Announced at the February 19, 2025, Oversight Committee Meeting

The following table lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research cycle 25.1 include *Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center; Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual; Investigator Research Awards for Computational and Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; and Individual Investigator Research Awards for Prevention and Early Detection.*

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP250156	Jia Wu	The University of Texas M.D. Anderson Cancer Center	Issam El Naqa
RP250247	James Yao	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250118	Masahiro Morita	The University of Texas Health Science Center at San Antonio	Sanja Vicković
RP250399	Natalie Vokes	The University of Texas M.D. Anderson Cancer Center	Walter Stadler
RP250355	Hashem El-Serag	Baylor College of Medicine	Christopher Haiman

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250069	Georgios Karras	The University of Texas M.D. Anderson Cancer Center	Jason Lewis ¹
RP250438	Stephen Chung	The University of Texas M.D. Anderson Cancer Center	Jason Lewis ²
RP250278	Samuel McBrayer	The University of Texas Southwestern Medical Center	Craig Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP250124	Payal Kapur	The University of Texas Southwestern Medical Center	Anna Wu
RP250007	Debananda Pati	Baylor College of Medicine	Steffi Oesterreich
RP250230	Anirban Maitra	The University of Texas M.D. Anderson Cancer Center	Michael Hollingsworth
RP250014	Alexander Pertsemlidis	The University of Texas Health Science Center at San Antonio	Jose Conejo-Garcia
RP250088	Christopher Rylander	The University of Texas at Austin	Jose Conejo-Garcia
RP250187	Fredrik Thege	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250216	Khalid Mohamedali	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250265	Nabil Ahmed	Baylor College of Medicine	Ying Lu
RP250173	Katsumi Kitagawa	The University of Texas Health Science Center at San Antonio	Alan Tomkinson
RP250229	Kunal Rai	The University of Texas M.D. Anderson Cancer Center	Vijaya B. Kolachalama

¹ This conflict was waived pursuant to an approved Texas Health and Safety Code § 102.1062 waiver applicable to CPRIT review councils. A copy of the FY2025 waiver is available on [CPRIT's website](#).

² Same as footnote 1.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250153	Ronald DePinho	The University of Texas M.D. Anderson Cancer Center	Kornelia Polyak
RP250307	Sandeep Burma	The University of Texas Health Science Center at San Antonio	Bart Williams
RP250046	Surendranath Shastri	The University of Texas M.D. Anderson Cancer Center	Karen Emmons
RP250063	Aaron Thrift	Baylor College of Medicine	Christopher Haiman
RP250163	Robert Bast	The University of Texas M.D. Anderson Cancer Center	Karen Emmons
RP250231	Weiva Sieh	The University of Texas M.D. Anderson Cancer Center	Christopher Haiman; Lawrence Kushi; Melissa Troester
RP250053	Dae Kim	The University of Texas Rio Grande Valley	Alan Tomkinson
RP250334	Linghua Wang	The University of Texas M.D. Anderson Cancer Center	Benjamin Greenbaum
RP250371	John Tainer	The University of Texas M.D. Anderson Cancer Center	Alan Tomkinson; John Petrini; Walter Chazin
RP250411	Salma Kaochar	Baylor College of Medicine	John Petrini
RP250121	Dan Nguyen	The University of Texas Southwestern Medical Center	Jun Deng
RP250219	Marites Melancon	The University of Texas M.D. Anderson Cancer Center	David Mankoff; James Babilion
RP250251	Hao Peng	The University of Texas Southwestern Medical Center	Jun Deng
RP250375	Alexander Bishop	The University of Texas Health Science Center at San Antonio	Patrick Grohar
RP250026	Eduardo Vilar-Sanchez	The University of Texas M.D. Anderson Cancer Center	Gregory Lesinski

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250135	Bouthaina Dabaja	The University of Texas M.D. Anderson Cancer Center	Charles Mullighan
RP250217	Ehsan Irajizad	The University of Texas M.D. Anderson Cancer Center	Lawrence Kushi

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards for Computational and Systems Biology of Cancer

Academic Research Cycle 25.1

Final Scores for Fully Reviewed Applications

Application ID	Final Overall Evaluation Score
RP250044*	2.0
RP250399*	2.9
RP250090*	2.9
Ea	3.2
Eb	3.3
Ec	3.7
Ed	3.8
Ee	4.0
Ef	5.7

* Recommended for funding.

Individual Investigator Research Awards for Computational and Systems Biology of Cancer

Academic Research Cycle 25.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

Application ID	Final Overall Evaluation Score
Ma	3.7
Mb	3.7
Mc	3.7
Md	3.7
Me	3.7
Mf	4.3
Mg	4.3
Mh	4.3
Mi	4.3
Mj	4.7
Mk	4.7
Ml	4.7
Mm	4.7
Mn	5.0
Mo	5.3
Mp	5.3
Mq	5.3
Mr	5.3
Ms	5.7
Mt	6.0

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 5, 2025

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Ms. Kristen Doyle
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to kdoyle@cprit.texas.gov

Dear Dr. Cummings and Ms. Doyle,


The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for the Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal); Core Facility Support Award (FY2024); Individual Investigator Research Awards; Individual Investigator Research Awards for Childhood and Adolescent Cancers; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; Investigator Research Awards for Early-Onset Cancers; Individual Investigator Research Awards for Prevention and Early Detection; Recruitment of Established Investigators; Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 12, 2024 to consider the FY25.1 applications recommended by the peer review panels following their meetings held October 16, 2024 to October 24, 2024 and one FY24.2 Core Facility application recommended by a peer review panel on April 24, 2024. The SRC met on November 14, 2024 to review recruitment applications submitted for Cycle FY25.2 and then on December 12, 2024 to review recruitment applications submitted for Cycle FY25.3.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the 53 recommended applications is \$67,753,626.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Chair, CPRIT Scientific Review Council

Rank	Grant ID	RFA	Score	Title	PI	Institution	Recommended Budget
1	RP250118	IIRA	1.0	Ribosome Localization at Mitochondria-ER Contacts in Obesity-Associated Liver Cancer	Morita, Masahiro	The University of Texas Health Science Center at San Antonio	\$900,000
2	RP250061	IIRA	1.0	Imaging of cranial radiotherapy neuroinflammatory sequelae by Positron Emission Tomography	Pisaneschi, Federica	The University of Texas Health Science Center at Houston	\$900,000
3	RR250077	RFTFM	1.0	Developing next generation of genome editing tools to study and engineer genetic variants for effective precision cancer treatment	Gao, Xin "Daniel"	Baylor College of Medicine	\$2,000,000
4	RR250070	RFTFM	1.0	Unlocking the Potential of Clonal Hematopoiesis in Early Detection and Interception of Lymphoid Malignancies	Griffin, Rosalie	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
5	RR250063	RFTFM	1.1	Co-opting antiviral innate immune pathways to target non-small cell lung cancer	Zou, Tao	The University of Texas Southwestern Medical Center	\$2,000,000
6	RR250071	RFTFM	1.1	CRISPR screening to uncover tumor intrinsic modulators of DNA repair and immune effects of radiation therapy	Verma, Nipun	Baylor College of Medicine	\$2,000,000
7	RP250278	IIRACCA	1.2	Developmental origins of IDH-mutant glioma in adolescents	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,198,416
8	RP250293	IIRAP	1.2	Development of a shared decision tool to facilitate uptake of the levonorgestrel-releasing intrauterine system for the primary prevention of endometrial cancer	Meyer, Larissa	The University of Texas M. D. Anderson Cancer Center	\$1,199,542
9	RP250208	IIRA	1.4	RPS23 is a new drug target to activate the integrated stress response and treat leukemia	Ready, Joseph	The University of Texas Southwestern Medical Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

10	RP250201	IIRA	1.4	Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in oral cavity squamous cell carcinoma	Gillison, Maura	The University of Texas M. D. Anderson Cancer Center	\$899,998
11	RP250028	IIRA	1.5	MALAT1 protects against osteoporosis and bone metastasis	Ma, Li	The University of Texas M. D. Anderson Cancer Center	\$900,000
12	RP250247	IIRA	1.5	Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETs	Yao, James	The University of Texas M. D. Anderson Cancer Center	\$900,000
13	RP250144	IIRACCA	1.5	Decoding how neuronal activity remodels the epigenome in ependymoma	Deneen, Benjamin	Baylor College of Medicine	\$1,200,000
14	RP250220	IIRA	1.8	Decellularized tissue matrices to study the “bad soil” in cancer metastasis	Wang, Andrew	The University of Texas Southwestern Medical Center	\$900,000
15	RP250269	IIRAP	1.8	Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules.	Ostrin, Edwin	The University of Texas M. D. Anderson Cancer Center	\$1,169,776
16	RP250222	IIRA	1.9	KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC	Gibbons, Don	The University of Texas M. D. Anderson Cancer Center	\$899,997
17	RP250043	IIRA	1.9	An integrated imaging informatics platform for HCC surveillance	Zhou, Xiaobo	The University of Texas Health Science Center at Houston	\$899,991
18	RP250374	IIRACCA	1.9	Dissecting TFE3 Mediated tRCC Tumorigenesis	Brugarolas, James	The University of Texas Southwestern Medical Center	\$1,196,812
19	RP240537	CFSA	2.0	Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core	Wu, Erxi	Baylor Research Institute	\$2,999,989
20	RP250213	IIRA	2.0	KRAS spatiotemporal dynamics: lipid glycosylation as a novel therapeutic target	Hancock, John	The University of Texas Health Science Center at Houston	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

21	RP250428	IIRA	2.0	Studying Hematopoietic Stem Cells to Predict and Understand Mechanisms of Post-transplant Relapse in the Myelodysplastic Syndromes	Chung, Stephen	The University of Texas Southwestern Medical Center	\$899,025
22	RP250143	IIRA	2.0	Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy	Lissanu, Yonathan	The University of Texas M. D. Anderson Cancer Center	\$899,991
23	RP250044	IIRACSBC	2.0	Heterogeneity of resistance to endocrine therapy and Cdk inhibition: An integrated systems biology approach to biologically informed treatment regimens	Brock, Amy	The University of Texas at Austin	\$763,596
24	RR250072	REI	2.0	Mechanisms behind copper dependence of cancer cells	Wittung Stafshede, Pernilla	Rice University	\$6,000,000
25	RR250061	RFTFM	2.0	Engineered antibody tools for targeted regulation of cancer-associated proteins and organelles through redirected autophagy process	Jiang, Ziwen	The University of Texas at Dallas	\$2,000,000
26	RP250398	IIRA	2.1	Synthetic lethality of TRIP13 and Aurora A in Rb-deficient cancer	Johnson, Faye	The University of Texas M. D. Anderson Cancer Center	\$899,994
27	RP250402	IIRA	2.1	Exploiting Tryptophan Metabolite Addiction to identify and Inhibit HCC	Conacci Sorrell, Maralice	The University of Texas Southwestern Medical Center	\$900,000
28	RP250131	IIRACT2	2.1	Randomized Clinical Trial Evaluating Fecal Microbiota Transplant in Chimeric Antigen Receptor Therapy for Reversing Antimicrobial-Associated Dysbiosis	Saini, Neeraj	The University of Texas M. D. Anderson Cancer Center	\$1,598,410
29	RP250282	IIRA	2.2	Harnessing BACH2 to enhance anti-tumor T cell immunity	Yao, Chen	The University of Texas Southwestern Medical Center	\$900,000
30	RP250280	IIRA	2.2	The role of glutathione in leukemia development	Agathocleous, Michalis	The University of Texas	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

						Southwestern Medical Center	
31	RP250062	IIRA	2.3	Clonal hematopoiesis and toxicity from radiation therapy	Nead, Kevin	The University of Texas M. D. Anderson Cancer Center	\$899,885
32	RP250407	IIRA	2.3	Protecting the GI tract with a C60 fullerene derivative to facilitate dose-escalated abdominopelvic radiotherapy	Mackeyev, Yuri	The University of Texas Health Science Center at Houston	\$900,000
33	RP250055	IIRA	2.4	TET2 mutations promote myeloid malignancies by dysregulating m5C oxidation of chromatin-associated RNAs	Xu, Mingjiang	The University of Texas Health Science Center at San Antonio	\$900,000
34	RP250391	IIRA	2.5	Novel PCDH7 monoclonal antibodies that direct immune surveillance and combat drug resistance in lung cancer	O'Donnell, Kathryn	The University of Texas Southwestern Medical Center	\$900,000
35	RP250321	IIRACT2	2.5	Leveraging synthetic and collateral lethality in MTAP loss tumors	Rodon Ahnert, Jordi	The University of Texas M. D. Anderson Cancer Center	\$1,599,783
36	RP250069	IIRA	2.6	HSP90 Capacitance: Discovery of a New Mechanism Driving Evolution of Drug Resistance in Head and Neck Squamous Cell Carcinoma	Karras, Georgios	The University of Texas M. D. Anderson Cancer Center	\$890,201
37	RP250305	IIRA	2.6	Exploiting synthetic lethality between HNRNPK loss and ribosomal dysfunction in del9q AML	Post, Sean	The University of Texas M. D. Anderson Cancer Center	\$896,322
38	RP250091	IIRA	2.6	Dissecting the Survival Mechanisms of Latent Brain-Tropic Cancer Cells for Therapeutic Interventions	Malladi, Srinivas	The University of Texas Southwestern Medical Center	\$900,000
39	RP250322	IIRA	2.6	Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2-mutant non-small cell lung cancer (NSCLC)	Heymach, John	The University of Texas M. D. Anderson Cancer Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

40	RP250154	IIRA	2.6	Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients	Fuentes, David	The University of Texas M. D. Anderson Cancer Center	\$899,808
41	RP250156	IIRAP	2.6	Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer	Wu, Jia	The University of Texas M. D. Anderson Cancer Center	\$1,200,000
42	RP250094	IIRACT2	2.7	A phase 2 clinical trial with Avasopasem, with anti-estrogen therapy (ET) and a CDK4/6 inhibitor in metastatic breast cancer progressing on ET/CDK4/6 therapy.	Gius, David	The University of Texas Health Science Center at San Antonio	\$1,390,420
43	RP250418	IIRAP	2.7	Approach Bias Retraining to Augment Long-Term Smoking Cessation Among a Diverse Sample	Garey, Lorra	University of Houston	\$1,200,000
44	RP250355	CAP-CAC-CR	2.8	The Texas Collaborative Center for Hepatocellular Cancer (TeCH)	El-Serag, Hashem	Baylor College of Medicine	\$3,000,000
45	RP250119	IIRACCA	2.8	Comparison of Symptom Burden, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients treated with Surgery vs. Surgery and Chemotherapy	Kahalley, Lisa	Baylor College of Medicine	\$1,200,000
46	RP250190	IIRACCA	2.8	Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-Exercise Intervention	Swartz, Maria	The University of Texas M. D. Anderson Cancer Center	\$1,199,756
47	RP250182	IIRAP	2.8	Implementing Newborn Screening for Pediatric Cancer Predisposition Syndromes in Texas: The INSPECT Study	Parsons, Donald	Baylor College of Medicine	\$1,187,187
48	RP250097	IIRA	2.9	Deciphering and targeting age-related metastatic	Naora, Honami	The University of Texas M. D.	\$899,984

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				competence of the omentum		Anderson Cancer Center	
49	RP250099	IIRA	2.9	Targeting lethal prostate cancers with a clinical-stage inverse agonist for G protein-coupled receptor 6	Li, Wenliang	The University of Texas Health Science Center at Houston	\$900,000
50	RP250399	IIRACSBC	2.9	Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture	Vokes, Natalie	The University of Texas M. D. Anderson Cancer Center	\$1,049,033
51	RP250090	IIRACSBC	2.9	Artificial Intelligence for Early Identification of Androgen-Indifferent, Lethal Prostate Cancer and Therapy Selection	Merényi, Erzsébet	Rice University	\$1,049,434
52	RP250191	IIRA	3.1	Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$898,263
53	RP250164	IIRACCA	3.1	Prediction of CAR-T Cell Immunotherapy Outcomes in Neuroblastoma using FE-MRI Nano-radiomics	Ghaghada, Ketan	Baylor College of Medicine	\$1,168,013

Core Facility Support Award (CFSA)

Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal)

Individual Investigator Research Awards (IIRA)

Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)

Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)

Individual Investigator Research Awards for Clinical Trials (IIRACT)

Individual Investigator Research Awards for Early Onset Cancers (IIRAEOC)

Individual Investigator Research Awards for Prevention and Early Detection (IIRAP)

Recruitment of Established Investigators (REI)

Recruitment of Rising Stars (RRS)

Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2025—Cycle 1**

***Individual Investigator Research Awards for
Clinical Trials***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS

RFA R-25.1-IIRACT

Individual Investigator Research Awards for Clinical Trials

Please also refer to the Instructions for Applicants document, which will be posted on February 22, 2024.

Due to the highly competitive nature of this RFA mechanism and available funds for FY25, CPRIT projects that only 10% of submitted applications will be funded

Application Receipt Opening Date: March 19, 2024

Application Receipt Closing Date: June 11, 2024

FY 2025

Fiscal Year Award Period

September 1, 2024-August 31, 2025

TABLE OF CONTENTS

1. BRIEF DESCRIPTION OF RFA	5
2. ABOUT CPRIT	5
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES.....	6
3. RATIONALE	7
4. RESEARCH OBJECTIVES	7
5. FUNDING INFORMATION	8
6. ELIGIBILITY	9
7. RESUBMISSION POLICY	11
8. RENEWAL POLICY	12
9. RESPONDING TO THIS RFA	12
9.1. APPLICATION SUBMISSION GUIDELINES.....	12
9.1.1. <i>Submission Deadline Extension</i>	12
9.2. APPLICATION COMPONENTS.....	13
9.2.1. <i>Abstract and Significance (5,000 characters)</i>	13
9.2.2. <i>Layperson’s Summary (2,000 characters)</i>	13
9.2.3. <i>Specific Aims and Sub-aims</i>	14
9.2.4. <i>Timeline (1 page)</i>	14
9.2.5. <i>Specific Aims (1 page)</i>	14
9.2.6. <i>Resubmission Summary (2 pages)</i>	15
9.2.7. <i>Renewal Summary (2 Pages)</i>	15
9.2.8. <i>Summary Checklist (1 Page)</i>	15
9.2.9. <i>Research Plan (11 pages)</i>	15
9.2.10. <i>Vertebrate Animals (1 page)</i>	16
9.2.11. <i>Human Subjects (2 pages)</i>	16
9.2.12. <i>Protocol Documentation</i>	16
9.2.13. <i>Investigational New Drug Application (IND)/Investigational Device Exemption (IDE)</i>	16
9.2.14. <i>Publications/References</i>	16
9.2.15. <i>Budget and Justification</i>	16
9.2.16. <i>Biographical Sketches (5 pages each)</i>	18
9.2.17. <i>Current and Pending Support</i>	18
9.2.18. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i>	18
9.2.19. <i>Previous Summary Statement</i>	19
9.3. FORMATTING INSTRUCTIONS.....	19
10. APPLICATION REVIEW	20
10.1. PRELIMINARY EVALUATION.....	20
10.2. FULL PEER REVIEW.....	20
10.3. CONFIDENTIALITY OF REVIEW.....	21
10.4. REVIEW CRITERIA.....	22
10.4.1. <i>Primary Criteria</i>	22
10.4.2. <i>Secondary Criteria</i>	23
11. KEY DATES	24
12. AWARD ADMINISTRATION	24
13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	25

14. CONTACT INFORMATION26
14.1. HELPDESK.....26
14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS26

RFA VERSION HISTORY

2/22/24 RFA released

1. BRIEF DESCRIPTION OF RFA

- Supports applications that propose innovative cancer clinical studies that are hypothesis driven and involve patients enrolled prospectively on a clinical trial. Applications must provide documentation that the proposed trial will be ready to commence immediately upon award of the CPRIT contract and the trial goals are feasible within the project timeline.
- Applicants are required to complete a checklist (required template provided in CARS under [Current Funding Opportunities](#))
- Applicants may request a maximum of \$400,000 per year for a period of up to 4 years.
- **Multi-Principal Investigators (MIs)** are allowed under this Request for Applications (RFA). See the Information for Applicants (IFA) document for definition and eligibility of MIs.
- See application limitations for **Principal Investigators (PIs)/MIs**, regardless of whether the MI is from the prime institution or a subcontracted institution.
- **Note that CPRIT does not allow the use of the term Co-PI.**
- Minimum effort for the PI and/or MIs throughout the project period is required.
- A PI and/or MI may not submit more than **one application** for this RFA (defined as either a new application, resubmission application or competitive renewal application).
- *Renewal applications are limited to one competitive renewal under this RFA, regardless of the year of the funded parent IIRACT award.
- The FY25 salary cap is \$225,000 per year.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state
- Reducing cancer disparities.

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer

- Expanding access to innovative clinical trials

3. RATIONALE

This Individual Investigator Research Awards for Clinical Trials (IIRACT) mechanism supports applications that propose innovative cancer clinical studies that are hypothesis driven and involve patients enrolled prospectively on a clinical trial. Areas of interest include clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices. Such clinical trials offer important opportunities to incorporate biomarkers, pharmacokinetic and pharmacodynamic monitoring, and/or imaging studies to provide more precise knowledge about what works, in whom, and in which types of cancer, and to guide subsequent clinical development of a novel cancer therapy.

The research supported by this mechanism is important because current clinical development of novel cancer therapeutics remains slow and expensive with many late-stage failures. Only 5% of cancer therapeutics that enter clinical evaluation will be approved, and the approval process is often measured in decades. There is an urgent need to accelerate and enhance the efficiency of this process by improving the clinical evaluation of novel cancer therapeutics through adoption of modern trial designs that incorporate biomarkers. Such trials will build on advances in basic discovery that have identified the critical targets involved in the hallmarks of cancer and have led to mechanism-based therapeutics. Trials that are designed to determine if predictors of response and efficacy identified in preclinical models also occur in patients have the potential to accelerate therapeutic development and approvals. They also guide the development of diagnostic tests to identify those patients most likely to benefit from these new treatments. Well-conducted early-phase studies will also inform reasons for treatment failure and feed back to preclinical studies designed to overcome barriers to success identified in patients.

4. RESEARCH OBJECTIVES

The goal of the IIRACT is to promote clinical research that will lead to a better understanding of the clinical efficacy of a cancer therapy or diagnostic device. Applications submitted under

this mechanism should propose innovative clinical studies that are hypothesis driven and involve patients enrolled prospectively on a clinical trial.

Clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices are all responsive to this RFA.

Applications that propose the development and validation of a biomarker prior to use of that biomarker in a prospective clinical trial are not responsive to this RFA and should be directed to the CPRIT Individual Investigator Research Award mechanism RFA R-25.1-IIRA. Applications that propose only correlative or biomarker studies in the context of a clinical trial conducted under other funding mechanisms are not responsive to this RFA.

Early-phase clinical trials of agents or combinations of agents for which there are robust nonclinical data that suggest there may be clinical activity are responsive to the RFA, even if there is no biomarker, as long as the early-phase clinical trial will lead to determining if the activity observed in the laboratory can be replicated in patients.

Additional examples of the types of studies appropriate for the IIRACT include, but are not limited to, phase 1 or small phase 2 trials of new agents, repurposed agents, radiation therapy, surgery, or combinations of interventions where the trial design incorporates biomarker and/or imaging strategies to determine one or more of the following: presence of the drug target, target inhibition, biological pathway inhibition, or pathophysiological alteration by the investigational drug or device. CPRIT recognizes the value of supporting trials sponsored by pharmaceutical companies. In this situation, the applicant should provide documentation from the industry partner as to what is being provided by the industry partner, ie, drug(s) only versus drug and funds for study conduct (may be partial funding) versus drugs and funds for study conduct and funds for correlative or translational studies or other resources.

5. FUNDING INFORMATION

Applicants may request a maximum of \$400,000 per year for a period of up to 4 years. Exceptions to these limits may be requested if extremely well justified (see [section 9.2.15](#)). Funds may be used for salary and fringe benefits, research supplies, equipment, subject

participation costs including diagnostic or interventional procedures associated with participation in a clinical trial and not considered routine patient care, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of indirect costs to no more than 5% of the total award amount.

The budget justification must include a timeline for the clinical trial initiation and accrual targets. Applications must provide documentation that the proposed trial will be ready to commence immediately upon award of the CPRIT contract and the trial goals are feasible within the project timeline. For example, drug access through an industry or CTEP arrangement should be documented. When indicated, an approved investigational new drug application (IND) or investigational device exemption (IDE) for devices from the Food and Drug Administration (FDA) should be cited, or if no IND is yet available for the agent(s), then a pre-IND meeting would have been held with the FDA, and the summary letter from that pre-IND meeting would be included as an attachment (see [section 9.2.13](#)).

Please see [section 9.2.15](#) and the IFA for additional information.

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.
- This award mechanism allows MIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for MI awards).
- For applications that include 1 PI, the PI is required to maintain a minimum of 15% level of effort through the duration of the entire award period. For applications that include MIs,

each PI is required to maintain a minimum of 10% effort through the duration of the entire award period.

- A PI may not submit applications to this RFA and to RFA R-25.1-IIRA, RFA R-25.1-IIRACSBC, RFA R-25.1-IIRACCA, RFA R-25.1-IIRAP, or RFA R25.1- IIRAEOC.
- A PI may not submit more than 1 application, either a new, resubmission, or renewal application under this RFA during this funding cycle.
- A PI may be a part of only one application, whether as a single applicant or as an MI on an application, under this RFA and RFA R-25.1-IIRA, RFA R-25.1-IIRACCA, RFA R-25.1-IIRACSBC, RFA R-25.1-IIRAP, or RFA R-25.1-IIRAEOC.
- **An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants.** Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project MIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2025).
- Applications that address prevention and early detection, cancers in children and adolescents, or computational systems biology of cancer should be submitted under the appropriate targeted RFA. As noted in [section 4](#), applications that propose the development and validation of a biomarker prior to use of that biomarker in a prospective clinical trial are not responsive to this RFA and should be directed to the CPRIT Individual Investigator Research Award mechanism RFA R-25.1-IIRA.
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.

- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, regardless of whether those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 12](#) and [section 13](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** and must follow all resubmission guidelines and be eligible for this mechanism under the criteria in [section 4](#). If a previously submitted application does not meet the new criteria for this mechanism outlined in [section 4](#) it must be resubmitted under the IIRA mechanism. **More than 1 resubmission is not permitted.** An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PI for a project, a change in the project title that was previously submitted to CPRIT, or omission or modification of an aim does not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 9.2.6](#).

8. RENEWAL POLICY

An application originally funded by CPRIT as an IIRA, IIRACCA, IIRACSBC, or IIRAP that is appropriate for the IIRACT mechanism may be submitted under this RFA for a competitive renewal. See [section 9.2.7](#). If an application originally funded as an IIRACT no longer meets the new criteria for this mechanism, it must be resubmitted under another mechanism, e.g., the IIRA mechanism. Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 10.2](#).

9. RESPONDING TO THIS RFA

9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 19, 2024, and must be submitted by 4 PM central time on June 11, 2024. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grant applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details. The IFA will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

9.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and significance of the research alone. Therefore, applicants are advised to prepare this section wisely. **Based on the Abstract and Significance statement (and the Specific Aims, Budget and Justification and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from peer review (see [section 10.1](#)).** Applicants should not waste this valuable space by stating obvious facts (e.g., that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. Provide the hypothesis to be tested, the specific aims, and the overall experimental approaches. Indicate whether this proposed clinical research addresses cancers with disparities and/or whether the trial will enroll patients from underserved populations.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Summarize how the proposed research creates new paradigms or challenges existing ones or may lead to changes in practice. Indicate whether this research plan represents a new direction for the PI.

9.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detections, prevention, or treatment. The information provided in this summary will be made

publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary will also be used by advocate reviewers ([section 10.2](#)) to evaluate the significance and impact of the proposed work.

9.2.3. Specific Aims and Sub-aims

Please provide a description of the aims and sub-aims and milestones to be achieved for each year of the project. Provide 2 to 3 sentences describing activities to be performed and anticipated milestones. These aims will also be used during the submission and evaluation of progress reports and assessment of project success.

9.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

Since a clinical trial is proposed as a component of this application, the timeline must include clearly defined patient accrual milestones.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

9.2.5. Specific Aims (1 page)

Please provide a 1-page summary of the aims of the proposal. The Specific Aims page should identify the problem or gap in our current knowledge. It should present a hypothesis and briefly describe the aims, subaims, and approaches. Address the proposal's innovation, novel approaches and significance and impact on the field and cancer research. Please also refer to the template located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.6. Resubmission Summary (2 pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a new research plan or modify the original research plan and mark the changes. However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with only editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

9.2.7. Renewal Summary (2 Pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

9.2.8. Summary Checklist (1 Page)

Applicants are required to complete a summary checklist. The required template is provided in CARS under [Current Funding Opportunities](#).

9.2.9. Research Plan (11 pages)

Background: Provide the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed. Describe the innovation and potential impact of the research.

Hypothesis and Specific Aims: Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required. This section has been lengthened to allow

the applicant to present the statistical considerations used to determine a trial design, accrual milestones, and biomarker validation. Describe the population of eligible patients and plans to enroll unique populations, e.g., underserved populations.

9.2.10. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

9.2.11. Human Subjects (2 pages)

For the use of human subjects or human biological samples, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional review board (IRB) will be required before funding.

9.2.12. Protocol Documentation

Provide a full protocol of the clinical trial; a PDF copy of the full protocol can be attached.

9.2.13. Investigational New Drug Application (IND)/Investigational Device Exemption (IDE)

If a clinical trial is proposed that requires an IND or IDE, provide evidence of an approved IND or IDE for devices from the FDA. If no IND is yet available for the agent(s), then provide a summary letter from a pre-IND meeting held with the FDA. If the drug or device is to be provided through an industry or CTEP mechanism, provide documentation that the drug or device will be available.

9.2.14. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

9.2.15. Budget and Justification

Provide a detailed justification of the budget for the entire proposed period of support, including salaries and fringe benefits, supplies, equipment, costs associated with the conduct of a clinical

trial, animal care costs, subject participation costs including diagnostic or interventional procedures associated with participation in a clinical trial and not considered routine patient care, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. While there will be 1 budget for the entire project, an individual budget and budget justification for the conduct of a clinical trial must be included. The justification should include the statistical considerations that led to the clinical trial design, accrual milestones, and validation of biomarkers. CPRIT recognizes that industry partners may provide various levels of support, e.g., (a) the provision of drug only versus (b) drug and funds for study conduct versus (c) drug, funds for study conduct, and funds for translational studies. The applicant must provide documentation from the industry partner, delineating their contribution to the study, and must provide a clear justification for funds requested from CPRIT for trials of industry-sponsored agents. Applicants are advised not to interpret the maximum allowable request under this award as a suggestion that they should expand their anticipated budget to this level. However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2025 is \$225,000; CPRIT FY 2025 is from September 1, 2024, through August 31, 2025. Salary does not include fringe

benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

- Funds can be used to pay for costs that a cancer clinical trial participant may have associated with their participation in a clinical trial, including (1) transportation, including car mileage, parking, bus fare, taxi or ride hailing fare exclusive of tips, and commercial economy class airfare within the borders of the State of Texas, and (2) lodging.

9.2.16. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. A biographical sketch must be provided for the PI and, if applicable, any additional MIs (for an MI application), as required by the online application receipt system. Up to **5 additional** biographical sketches for key personnel may be provided, these should be concatenated into a single PDF with a 25-page limit. **Each biographical sketch must not exceed 5 pages.** The NIH biosketch format is appropriate.

9.2.17. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, any additional MIs (if an MI application), must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.18. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

9.2.19. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively rejected without review.

9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations may be submitted as part of the submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. URLs of publications referenced in the application may be included.
Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants must not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see **Page Numbering** section below).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be printed, signed, scanned, and then uploaded in PDF format.

10. APPLICATION REVIEW

10.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may undergo a preliminary evaluation by CPRIT Scientific Research Program panel members for scientific merit and potential impact.

The preliminary evaluation is based on a subset of material presented in the application—namely, the Abstract and Significance, Specific Aims page, Budget and Justification, and Biographical Sketches. Applications that do not sufficiently capture the reviewers’ interest at this stage will not be considered for further peer review. Such applications will have been judged to offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

10.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent

peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 10.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

10.3. Confidentiality of Review

Each stage of the application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in [Texas Administrative Code RULE §703.9](#)

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an

Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

10.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Peer review committees will evaluate and score each primary criterion and subsequently assign an overall score that reflects a complete assessment of the application. **The overall score will not be an average of the individual criteria scores; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

10.4.1. Primary Criteria

The Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention, diagnosis, or treatment for patients? Is the application innovative? Does the applicant propose new paradigms or challenge existing ones? Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be

considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required creativity and expertise to make a significant contribution to the research? Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant(s) devoted a sufficient amount of his or her time (percent effort) to this project?

Relevance: Does the proposed research have a high degree of relevance to cancer research? This is a critical criterion for evaluation of applications for CPRIT support.

10.4.2. Secondary Criteria

Secondary criteria contribute to the global overall assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

11. KEY DATES

RFA

RFA release February 22, 2024

Application

Online application opens March 19, 2024, 7 AM central time

Application due June 11, 2024, 4 PM central time

Application review June 2024-February 2025

Award

Award notification February 2025

Anticipated start date March 1, 2025

12. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

14. CONTACT INFORMATION

14.1. Helpdesk

The Helpdesk will answer queries submitted via email within 1 business day. Helpdesk support is available for questions regarding user registration, online submission of applications as well as page limitations, formatting, and how to upload application components/subsections in the appropriate tabs of the CPRIT Application Receipt System. Helpdesk staff cannot answer scientific questions and/or Academic Research programs aspects of an application. Before contacting the Helpdesk, please refer to the *Instructions for Applicants* document, which provides a step-by-step guide on using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

14.2. Scientific and Programmatic Questions

Scientific and Programmatic Questions-should be directed to the CPRIT Director of Academic Research. **Before contacting CPRIT, please refer to the *Instructions for Applicants* document and contact the Helpdesk for any items related to the Application Receipt System (CARS), page limitations, formatting, etc.**

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Research Peer Review C/TCR-2

(25.1 ACR C/TCR-2)

Observation Report

Report No. 2024-10-16 25.1_ACR_C/TCR-2
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Peer Review_C/TCR-2 (25.1_ACR_C/TCR-2)
Panel Date: October 16, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Peer Review_C/TCR-2 (25.1_ACR_C/TCR-2) meeting. The meeting was chaired by Richard O'Reilly and conducted via videoconference on October 16, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and seven (7) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Peer Review CB (25.1 ACR CB)
Observation Report

Report No. 2024-10-17 25.1_ACR_CB
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Peer Review_CB (25.1 _ACR_CB)
Panel Date: October 17, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Peer Review_CB (25.1_ACR_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on October 17, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, seventeen (17) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Research Imaging Technology and

Informatics (ITI) (25.1 ACR-ITI)

Observation Report

Report No. 2024-10-18 25.1_ACR-ITI
Program Name: Academic Research
Panel Name: 25.1 Academic Research- Imaging Technology and Informatics (ITI)
(25.1_ACR-ITI)
Panel Date: October 18, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research- Imaging Technology and Informatics (ITI) (25.1_ACR-ITI) meeting. The meeting was chaired by Jason Lewis and conducted via videoconference on October 18, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed and five (5) applications were not discussed
- Panelists: One (1) panel chair, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Seven (7)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Research Cancer Prevention Research

(25.1 ACR CPR)

Observation Report

Report No. 2024-10-22 25.1_ACR_CPR
Program Name: Academic Research
Panel Name: 25.1 Academic Research Cancer Prevention Research
(25.1_ACR_CPR)
Panel Date: October 22, 2024
Report Date: October 23, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Cancer Prevention Research (25.1_ACR_CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 22, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and eight (8) applications were not discussed
- Panelists: One (1) panel chair, ten (10) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict(s) of Interest (COIs) identified prior to and/or during the meeting. The COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Basic Cancer Research-1 (BCR-1)
Observation Report

Report No. 2024-10-23 25.1_ACR_BCR-1
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Basic Cancer Research-1 (BCR-1)
Panel Date: October 23, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Basic Cancer Research-1 (BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on October 23, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: One (15) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewer
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Basic Cancer Research-2 (BCR-2)
Observation Report

Report No. 2024-10-24 25.1_ACR_BCR-2
Program Name: Academic Research
Panel Name: 25.1 Academic Research Basic Cancer Research-2 (BCR-2)
Panel Date: October 24, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Basic Cancer Research-2 (BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 24, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Ten (10) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Clinical and Translational Cancer
Research-1 (CTCR-1) Observation Report

Report No. 2024-10-25 25.1_ACR_CTCR-1
Program Name: Academic Research
Panel Name: 25.1 Academic Research Clinical and Translational Cancer
Research-1 (CTCR-1)
Panel Date: October 25, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Clinical and Translational Cancer Research-1 (CTCR-1) meeting. The meeting was chaired by Margaret Tempero and conducted via videoconference on October 25, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed and twenty-nine (29) applications were not discussed
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Scientific Review Council (25.1 SRC)

Observation Report

Report No. 2024-12-12 25.1_SRC
Program Name: Academic Research
Panel Name: 25.1 Academic Scientific Review Council (25.1_SRC)
Panel Date: December 12, 2024
Report Date: December 18, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Scientific Review Council (25.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 12, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Forty-seven (47) applications were discussed
- Panelists: One (1) panel chair, six (6) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting; however, they are waived pursuant to the Section 102.1062 Conflict of Interest Waiver for FY 2025 approved by the CPRIT Oversight Committee.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 25.1

Awards Announced at the February 19, 2025, Oversight Committee Meeting

The following table lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research cycle 25.1 include *Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center; Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual; Investigator Research Awards for Computational and Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; and Individual Investigator Research Awards for Prevention and Early Detection.*

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP250156	Jia Wu	The University of Texas M.D. Anderson Cancer Center	Issam El Naqa
RP250247	James Yao	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250118	Masahiro Morita	The University of Texas Health Science Center at San Antonio	Sanja Vicković
RP250399	Natalie Vokes	The University of Texas M.D. Anderson Cancer Center	Walter Stadler
RP250355	Hashem El-Serag	Baylor College of Medicine	Christopher Haiman

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250069	Georgios Karras	The University of Texas M.D. Anderson Cancer Center	Jason Lewis ¹
RP250438	Stephen Chung	The University of Texas M.D. Anderson Cancer Center	Jason Lewis ²
RP250278	Samuel McBrayer	The University of Texas Southwestern Medical Center	Craig Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP250124	Payal Kapur	The University of Texas Southwestern Medical Center	Anna Wu
RP250007	Debananda Pati	Baylor College of Medicine	Steffi Oesterreich
RP250230	Anirban Maitra	The University of Texas M.D. Anderson Cancer Center	Michael Hollingsworth
RP250014	Alexander Pertsemliadis	The University of Texas Health Science Center at San Antonio	Jose Conejo-Garcia
RP250088	Christopher Rylander	The University of Texas at Austin	Jose Conejo-Garcia
RP250187	Fredrik Thege	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250216	Khalid Mohamedali	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250265	Nabil Ahmed	Baylor College of Medicine	Ying Lu
RP250173	Katsumi Kitagawa	The University of Texas Health Science Center at San Antonio	Alan Tomkinson
RP250229	Kunal Rai	The University of Texas M.D. Anderson Cancer Center	Vijaya B. Kolachalama

¹ This conflict was waived pursuant to an approved Texas Health and Safety Code § 102.1062 waiver applicable to CPRIT review councils. A copy of the FY2025 waiver is available on [CPRIT's website](#).

² Same as footnote 1.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250153	Ronald DePinho	The University of Texas M.D. Anderson Cancer Center	Kornelia Polyak
RP250307	Sandeep Burma	The University of Texas Health Science Center at San Antonio	Bart Williams
RP250046	Surendranath Shastri	The University of Texas M.D. Anderson Cancer Center	Karen Emmons
RP250063	Aaron Thrift	Baylor College of Medicine	Christopher Haiman
RP250163	Robert Bast	The University of Texas M.D. Anderson Cancer Center	Karen Emmons
RP250231	Weiva Sieh	The University of Texas M.D. Anderson Cancer Center	Christopher Haiman; Lawrence Kushi; Melissa Troester
RP250053	Dae Kim	The University of Texas Rio Grande Valley	Alan Tomkinson
RP250334	Linghua Wang	The University of Texas M.D. Anderson Cancer Center	Benjamin Greenbaum
RP250371	John Tainer	The University of Texas M.D. Anderson Cancer Center	Alan Tomkinson; John Petrini; Walter Chazin
RP250411	Salma Kaochar	Baylor College of Medicine	John Petrini
RP250121	Dan Nguyen	The University of Texas Southwestern Medical Center	Jun Deng
RP250219	Marites Melancon	The University of Texas M.D. Anderson Cancer Center	David Mankoff; James Babilion
RP250251	Hao Peng	The University of Texas Southwestern Medical Center	Jun Deng
RP250375	Alexander Bishop	The University of Texas Health Science Center at San Antonio	Patrick Grohar
RP250026	Eduardo Vilar-Sanchez	The University of Texas M.D. Anderson Cancer Center	Gregory Lesinski

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250135	Bouthaina Dabaja	The University of Texas M.D. Anderson Cancer Center	Charles Mullighan
RP250217	Ehsan Irajizad	The University of Texas M.D. Anderson Cancer Center	Lawrence Kushi

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards for Clinical Trials

Academic Research Cycle 25.1

Final Evaluation Scores for Fully Reviewed Applications

Application ID	Final Overall Evaluation Score
RP250131*	2.1
RP250321*	2.5
RP250094*	2.7
Fa	3.0
Fb	3.0
Fc	3.3
Fd	3.3
Fe	3.3
Ff	3.6
Fg	3.7
Fh	3.7
Fi	3.8
Fj	4.0
Fk	5.3

* Recommended for funding.

Individual Investigator Research Awards for Clinical Trials

Academic Research Cycle 25.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

Application ID	Final Overall Evaluation Score
Na	3.7
Nb	3.7
Nc	4.0
Nd	4.0
Ne	4.3
Nf	4.3
Ng	4.7
Nh	5.0
Ni	5.3
Nj	5.7
Nk	6.3

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 5, 2025

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Ms. Kristen Doyle
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to kdoyle@cprit.texas.gov

Dear Dr. Cummings and Ms. Doyle,


The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for the Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal); Core Facility Support Award (FY2024); Individual Investigator Research Awards; Individual Investigator Research Awards for Childhood and Adolescent Cancers; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; Investigator Research Awards for Early-Onset Cancers; Individual Investigator Research Awards for Prevention and Early Detection; Recruitment of Established Investigators; Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 12, 2024 to consider the FY25.1 applications recommended by the peer review panels following their meetings held October 16, 2024 to October 24, 2024 and one FY24.2 Core Facility application recommended by a peer review panel on April 24, 2024. The SRC met on November 14, 2024 to review recruitment applications submitted for Cycle FY25.2 and then on December 12, 2024 to review recruitment applications submitted for Cycle FY25.3.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the 53 recommended applications is \$67,753,626.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Chair, CPRIT Scientific Review Council

Rank	Grant ID	RFA	Score	Title	PI	Institution	Recommended Budget
1	RP250118	IIRA	1.0	Ribosome Localization at Mitochondria-ER Contacts in Obesity-Associated Liver Cancer	Morita, Masahiro	The University of Texas Health Science Center at San Antonio	\$900,000
2	RP250061	IIRA	1.0	Imaging of cranial radiotherapy neuroinflammatory sequelae by Positron Emission Tomography	Pisaneschi, Federica	The University of Texas Health Science Center at Houston	\$900,000
3	RR250077	RFTFM	1.0	Developing next generation of genome editing tools to study and engineer genetic variants for effective precision cancer treatment	Gao, Xin "Daniel"	Baylor College of Medicine	\$2,000,000
4	RR250070	RFTFM	1.0	Unlocking the Potential of Clonal Hematopoiesis in Early Detection and Interception of Lymphoid Malignancies	Griffin, Rosalie	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
5	RR250063	RFTFM	1.1	Co-opting antiviral innate immune pathways to target non-small cell lung cancer	Zou, Tao	The University of Texas Southwestern Medical Center	\$2,000,000
6	RR250071	RFTFM	1.1	CRISPR screening to uncover tumor intrinsic modulators of DNA repair and immune effects of radiation therapy	Verma, Nipun	Baylor College of Medicine	\$2,000,000
7	RP250278	IIRACCA	1.2	Developmental origins of IDH-mutant glioma in adolescents	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,198,416
8	RP250293	IIRAP	1.2	Development of a shared decision tool to facilitate uptake of the levonorgestrel-releasing intrauterine system for the primary prevention of endometrial cancer	Meyer, Larissa	The University of Texas M. D. Anderson Cancer Center	\$1,199,542
9	RP250208	IIRA	1.4	RPS23 is a new drug target to activate the integrated stress response and treat leukemia	Ready, Joseph	The University of Texas Southwestern Medical Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

10	RP250201	IIRA	1.4	Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in oral cavity squamous cell carcinoma	Gillison, Maura	The University of Texas M. D. Anderson Cancer Center	\$899,998
11	RP250028	IIRA	1.5	MALAT1 protects against osteoporosis and bone metastasis	Ma, Li	The University of Texas M. D. Anderson Cancer Center	\$900,000
12	RP250247	IIRA	1.5	Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETS	Yao, James	The University of Texas M. D. Anderson Cancer Center	\$900,000
13	RP250144	IIRACCA	1.5	Decoding how neuronal activity remodels the epigenome in ependymoma	Deneen, Benjamin	Baylor College of Medicine	\$1,200,000
14	RP250220	IIRA	1.8	Decellularized tissue matrices to study the “bad soil” in cancer metastasis	Wang, Andrew	The University of Texas Southwestern Medical Center	\$900,000
15	RP250269	IIRAP	1.8	Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules.	Ostrin, Edwin	The University of Texas M. D. Anderson Cancer Center	\$1,169,776
16	RP250222	IIRA	1.9	KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC	Gibbons, Don	The University of Texas M. D. Anderson Cancer Center	\$899,997
17	RP250043	IIRA	1.9	An integrated imaging informatics platform for HCC surveillance	Zhou, Xiaobo	The University of Texas Health Science Center at Houston	\$899,991
18	RP250374	IIRACCA	1.9	Dissecting TFE3 Mediated tRCC Tumorigenesis	Brugarolas, James	The University of Texas Southwestern Medical Center	\$1,196,812
19	RP240537	CFSA	2.0	Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core	Wu, Erxi	Baylor Research Institute	\$2,999,989
20	RP250213	IIRA	2.0	KRAS spatiotemporal dynamics: lipid glycosylation as a novel therapeutic target	Hancock, John	The University of Texas Health Science Center at Houston	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

21	RP250428	IIRA	2.0	Studying Hematopoietic Stem Cells to Predict and Understand Mechanisms of Post-transplant Relapse in the Myelodysplastic Syndromes	Chung, Stephen	The University of Texas Southwestern Medical Center	\$899,025
22	RP250143	IIRA	2.0	Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy	Lissanu, Yonathan	The University of Texas M. D. Anderson Cancer Center	\$899,991
23	RP250044	IIRACSBC	2.0	Heterogeneity of resistance to endocrine therapy and Cdk inhibition: An integrated systems biology approach to biologically informed treatment regimens	Brock, Amy	The University of Texas at Austin	\$763,596
24	RR250072	REI	2.0	Mechanisms behind copper dependence of cancer cells	Wittung Stafshede, Pernilla	Rice University	\$6,000,000
25	RR250061	RFTFM	2.0	Engineered antibody tools for targeted regulation of cancer-associated proteins and organelles through redirected autophagy process	Jiang, Ziwen	The University of Texas at Dallas	\$2,000,000
26	RP250398	IIRA	2.1	Synthetic lethality of TRIP13 and Aurora A in Rb-deficient cancer	Johnson, Faye	The University of Texas M. D. Anderson Cancer Center	\$899,994
27	RP250402	IIRA	2.1	Exploiting Tryptophan Metabolite Addiction to identify and Inhibit HCC	Conacci Sorrell, Maralice	The University of Texas Southwestern Medical Center	\$900,000
28	RP250131	IIRACT2	2.1	Randomized Clinical Trial Evaluating Fecal Microbiota Transplant in Chimeric Antigen Receptor Therapy for Reversing Antimicrobial-Associated Dysbiosis	Saini, Neeraj	The University of Texas M. D. Anderson Cancer Center	\$1,598,410
29	RP250282	IIRA	2.2	Harnessing BACH2 to enhance anti-tumor T cell immunity	Yao, Chen	The University of Texas Southwestern Medical Center	\$900,000
30	RP250280	IIRA	2.2	The role of glutathione in leukemia development	Agathocleous, Michalis	The University of Texas	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

						Southwestern Medical Center	
31	RP250062	IIRA	2.3	Clonal hematopoiesis and toxicity from radiation therapy	Nead, Kevin	The University of Texas M. D. Anderson Cancer Center	\$899,885
32	RP250407	IIRA	2.3	Protecting the GI tract with a C60 fullerene derivative to facilitate dose-escalated abdominopelvic radiotherapy	Mackeyev, Yuri	The University of Texas Health Science Center at Houston	\$900,000
33	RP250055	IIRA	2.4	TET2 mutations promote myeloid malignancies by dysregulating m5C oxidation of chromatin-associated RNAs	Xu, Mingjiang	The University of Texas Health Science Center at San Antonio	\$900,000
34	RP250391	IIRA	2.5	Novel PCDH7 monoclonal antibodies that direct immune surveillance and combat drug resistance in lung cancer	O'Donnell, Kathryn	The University of Texas Southwestern Medical Center	\$900,000
35	RP250321	IIRACT2	2.5	Leveraging synthetic and collateral lethality in MTAP loss tumors	Rodon Ahnert, Jordi	The University of Texas M. D. Anderson Cancer Center	\$1,599,783
36	RP250069	IIRA	2.6	HSP90 Capacitance: Discovery of a New Mechanism Driving Evolution of Drug Resistance in Head and Neck Squamous Cell Carcinoma	Karras, Georgios	The University of Texas M. D. Anderson Cancer Center	\$890,201
37	RP250305	IIRA	2.6	Exploiting synthetic lethality between HNRNPK loss and ribosomal dysfunction in del9q AML	Post, Sean	The University of Texas M. D. Anderson Cancer Center	\$896,322
38	RP250091	IIRA	2.6	Dissecting the Survival Mechanisms of Latent Brain-Tropic Cancer Cells for Therapeutic Interventions	Malladi, Srinivas	The University of Texas Southwestern Medical Center	\$900,000
39	RP250322	IIRA	2.6	Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2-mutant non-small cell lung cancer (NSCLC)	Heymach, John	The University of Texas M. D. Anderson Cancer Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

40	RP250154	IIRA	2.6	Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients	Fuentes, David	The University of Texas M. D. Anderson Cancer Center	\$899,808
41	RP250156	IIRAP	2.6	Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer	Wu, Jia	The University of Texas M. D. Anderson Cancer Center	\$1,200,000
42	RP250094	IIRACT2	2.7	A phase 2 clinical trial with Avasopasem, with anti-estrogen therapy (ET) and a CDK4/6 inhibitor in metastatic breast cancer progressing on ET/CDK4/6 therapy.	Gius, David	The University of Texas Health Science Center at San Antonio	\$1,390,420
43	RP250418	IIRAP	2.7	Approach Bias Retraining to Augment Long-Term Smoking Cessation Among a Diverse Sample	Garey, Lorra	University of Houston	\$1,200,000
44	RP250355	CAP-CAC-CR	2.8	The Texas Collaborative Center for Hepatocellular Cancer (TeCH)	El-Serag, Hashem	Baylor College of Medicine	\$3,000,000
45	RP250119	IIRACCA	2.8	Comparison of Symptom Burden, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients treated with Surgery vs. Surgery and Chemotherapy	Kahalley, Lisa	Baylor College of Medicine	\$1,200,000
46	RP250190	IIRACCA	2.8	Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-Exercise Intervention	Swartz, Maria	The University of Texas M. D. Anderson Cancer Center	\$1,199,756
47	RP250182	IIRAP	2.8	Implementing Newborn Screening for Pediatric Cancer Predisposition Syndromes in Texas: The INSPECT Study	Parsons, Donald	Baylor College of Medicine	\$1,187,187
48	RP250097	IIRA	2.9	Deciphering and targeting age-related metastatic	Naora, Honami	The University of Texas M. D.	\$899,984

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				competence of the omentum		Anderson Cancer Center	
49	RP250099	IIRA	2.9	Targeting lethal prostate cancers with a clinical-stage inverse agonist for G protein-coupled receptor 6	Li, Wenliang	The University of Texas Health Science Center at Houston	\$900,000
50	RP250399	IIRACSBC	2.9	Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture	Vokes, Natalie	The University of Texas M. D. Anderson Cancer Center	\$1,049,033
51	RP250090	IIRACSBC	2.9	Artificial Intelligence for Early Identification of Androgen-Indifferent, Lethal Prostate Cancer and Therapy Selection	Merényi, Erzsébet	Rice University	\$1,049,434
52	RP250191	IIRA	3.1	Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$898,263
53	RP250164	IIRACCA	3.1	Prediction of CAR-T Cell Immunotherapy Outcomes in Neuroblastoma using FE-MRI Nano-radiomics	Ghaghada, Ketan	Baylor College of Medicine	\$1,168,013

Core Facility Support Award (CFSA)

Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal)

Individual Investigator Research Awards (IIRA)

Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)

Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)

Individual Investigator Research Awards for Clinical Trials (IIRACT)

Individual Investigator Research Awards for Early Onset Cancers (IIRAEOC)

Individual Investigator Research Awards for Prevention and Early Detection (IIRAP)

Recruitment of Established Investigators (REI)

Recruitment of Rising Stars (RRS)

Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit

Supporting Information

Academic Research
FY 2025—Cycle 1

***Individual Investigator Research Awards for
Prevention and Early Detection***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS

RFA R-25.1-IIRAP

**Individual Investigator Research Awards
for Prevention and Early Detection**

**Please also refer to the Instructions for Applicants document, which will be posted on
February 22, 2024.**

**Due to the highly competitive nature of this RFA mechanism and available funds for FY25,
CPRIT projects that only 10% of submitted applications will be funded.**

Application Receipt Opening Date: March 19, 2024

Application Receipt Closing Date: June 11, 2024

FY 2025

Fiscal Year Award Period

September 1, 2024-August 31, 2025

TABLE OF CONTENTS

1. BRIEF DESCRIPTION OF RFA.....	4
2. KEY POINTS.....	4
3. ABOUT CPRIT.....	5
3.1. ACADEMIC RESEARCH PROGRAM PRIORITIES.....	6
4. RATIONALE.....	6
5. RESEARCH OBJECTIVES.....	7
6. FUNDING INFORMATION.....	9
7. ELIGIBILITY.....	9
8. RESUBMISSION POLICY.....	11
9. RENEWAL POLICY.....	11
10. RESPONDING TO THIS RFA.....	12
10.1. APPLICATION SUBMISSION GUIDELINES.....	12
10.1.1. <i>Submission Deadline Extension</i>	12
10.2. APPLICATION COMPONENTS.....	12
10.2.1. <i>Abstract and Significance (5,000 characters)</i>	13
10.2.2. <i>Layperson’s Summary (2,000 characters)</i>	13
10.2.3. <i>Aims and Sub-aims</i>	13
10.2.4. <i>Timeline (1 page)</i>	14
10.2.5. <i>Specific Aims (1 page)</i>	14
10.2.6. <i>Resubmission Summary (2 pages)</i>	14
10.2.7. <i>Renewal Summary (2 pages)</i>	15
10.2.8. <i>Research Plan (10 pages)</i>	15
10.2.9. <i>Vertebrate Animals (1 page)</i>	15
10.2.10. <i>Human Subjects (2 pages)</i>	15
10.2.11. <i>Publications/References</i>	15
10.2.12. <i>Budget and Justification</i>	16
10.2.13. <i>Biographical Sketches (5 pages each)</i>	17
10.2.14. <i>Current and Pending Support</i>	17
10.2.15. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i>	18
10.2.16. <i>Previous Summary Statement</i>	18
10.3. FORMATTING INSTRUCTIONS.....	18
11. APPLICATION REVIEW.....	19
11.1. PRELIMINARY EVALUATION.....	19
11.2. FULL PEER REVIEW.....	20
11.3. CONFIDENTIALITY OF REVIEW.....	20
11.4. REVIEW CRITERIA.....	21
11.4.1. <i>Primary Criteria</i>	21
11.4.2. <i>Secondary Criteria</i>	22
12. KEY DATES.....	23
13. AWARD ADMINISTRATION.....	23
14. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS.....	24
15. CONTACT INFORMATION.....	25
15.1. HELPDESK.....	25
15.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS.....	25

RFA VERSION HISTORY

2/22/24 RFA released

1. BRIEF DESCRIPTION OF RFA

- Supports applications which propose clinical and population-based projects designed to develop effective prevention and early detection interventions to reduce cancer risk, mortality, and morbidity among Texans.
- Applicants may request up to a maximum of \$300,000 per year for a period of up to 4 years.
- **Multi-Principal Investigators (MIs)** are allowed under this Request for Applications (RFA). See the Information for Applicants (IFA) document for applicants for definition and eligibility of MIs.
- See application limitations for **Principal Investigators (PIs)/MIs**, regardless of whether the MI is from the primary institution or a subcontracted institution.
- **Note that CPRIT does not allow the use of the term Co-PI.**
- Minimum effort for the PI and/or MIs throughout the project period is required.
- A PI and/or MI may only submit **one application** for this RFA (defined as either a new application, resubmission application, *or competitive renewal application).
- *Renewal applications are limited to one competitive renewal under this RFA, regardless of the year of the funded parent IIRAP award.
- The FY25 salary cap is \$225,000 per year.

2. KEY POINTS

This new version of the Individual Investigator Research Award for Prevention and Early Detection invites clinical and population-based projects designed to develop effective prevention, early detection, or behavioral interventions to reduce cancer risk, mortality, and morbidity among Texans. Examples of projects responsive to this RFA include those planning clinical or population-based projects that will do the following:

- (1) Identify risk factors for cancers affecting Texans including social, environmental, and behavioral factors, genetic markers, and health disparities.
- (2) Validate biomarkers, genomic technologies, or imaging methods in Texas populations at high risk for cancer that will lead to detection of cancers at an early stage.

- (3) Develop and validate innovative interventions for the prevention or early detection of cancers with particular emphasis on Texans at highest risk for cancer.
- (4) Increase implementation and/or dissemination of evidence-based interventions for the prevention and/or early detection of cancers among all Texans as well as Texas populations at high risk for cancer.
- (5) Conduct health services research in Texas populations at highest risk for cancer to identify the most effective ways to address the disparities (eg, through systems change, outreach, access) and delivery of early detection and preventive care.

Basic research using laboratory and/or animal models designed to identify underlying mechanisms causing cancer ***is not responsive*** to this RFA and should be directed to other CPRIT mechanisms supporting basic discovery research. Please contact research@cprit.texas.gov before initiating an application should you have questions regarding this statement of no responsiveness.

Basic and clinical research to discover or to evaluate chemoprevention strategies ***is not responsive*** to this RFA and should be directed to other CPRIT mechanisms supporting basic discovery research or clinical translational research. Please contact research@cprit.texas.gov before initiating an application should you have questions regarding this statement of no responsiveness.

Applicants may request up to \$300,000 per year in CPRIT funds over 4 years.

3. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer;

- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

3.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency’s funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state
- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

4. RATIONALE

Nowhere is there greater potential to reduce the burden of cancer than by reducing its incidence. It is estimated that more than half of all cancer deaths could be prevented. It is also well established that early detection of cancer improves cancer mortality. The goal of this RFA is to

promote research to develop effective cancer prevention and early detection approaches for Texans.

Many opportunities exist to make greater progress in reducing cancer mortality in Texas through cancer prevention and early detection. Large numbers of Texans at average risk for cancers for which there are proven prevention and early detection strategies fail to take advantage of these strategies. This is particularly true among the medically underserved and hard-to-reach populations where numerous barriers inhibit the adoption and implementation of proven strategies for prevention or early detection. Early detection and prevention can improve mortality in individuals with an inherited predisposition to cancer, yet testing for inherited cancer syndromes in appropriate populations is vastly underused. Novel technologies and noninvasive approaches (e.g., liquid biopsies, novel imaging strategies) to detect cancer biomarkers are undergoing rapid advances that offer opportunities to improve surveillance of individuals at average or high risk for cancer. Behavioral sciences research informs the development and uptake of cancer-reducing strategies, e.g., tobacco cessation strategies and obesity control. Greater attention to implementation of evidence-based identification of at-risk individuals may empower them to make and act upon informed, cancer-preventing health decisions.

5. RESEARCH OBJECTIVES

This RFA solicits clinical and population-based projects designed to improve current methods and develop new strategies for the prevention and early detection of cancer among Texans. Examples of projects responsive to this RFA include those planning clinical or population-based novel projects to do the following:

- (1) To identify social, environmental, and behavioral factors, genetic markers, and health disparities that underlie cancer risk and predisposition among Texans at high risk for cancer.
- (2) To validate biomarkers, genomic technologies, or imaging methods in populations at risk for cancer that will lead to detection of cancers at an early stage.
- (3) To develop and validate innovative interventions for the prevention or early detection of cancers with particular emphasis on Texans at highest risk for cancer.

- (4) To conduct behavioral science studies that inform the development of interventions to reduce cancer risk, e.g., conducting obesity research, increasing uptake of screening or cancer vaccinations, or reducing use of combustible tobacco and vaping products, particularly in populations with cancer disparities.
- (5) To increase implementation and/or dissemination of evidence-based interventions for the prevention and/or early detection of cancers among all Texans as well as those populations at high risk.
- (6) To conduct health services research in populations at highest risk to identify the most effective ways to address the disparities (e.g., through systems change, outreach, access) and delivery of early detection and preventive care.

Basic research using laboratory and/or animal models designed to identify underlying mechanisms causing cancer ***is not responsive*** to this RFA and should be directed to other CPRIT mechanisms supporting basic discovery research.

Basic and clinical research to discover or to evaluate chemoprevention strategies ***is not responsive*** to this RFA and should be directed to other CPRIT mechanisms supporting basic discovery research or clinical translational research.

Basic and clinical research to predict outcomes, to identify children and adolescents at risk of developing late effects of treatment or to improve quality of life for survivors of childhood and adolescent cancers ***is not responsive*** to this RFA and should be directed to other CPRIT mechanisms supporting research on cancer in children and adolescents.

The *degree of relevance* to reducing the burden of cancer in Texas is a critical criterion for evaluation of projects for funding by CPRIT ([section 11.4.1](#)). Although CPRIT is required to spend 10% of its budget on cancer prevention, CPRIT's Cancer Prevention Program focuses exclusively on the delivery of evidence-based interventions to underserved populations and does not fund prevention research. **Thus, there is a unique opportunity for respondents to this RFA in CPRIT's Academic Research Program to develop collaborations with CPRIT Prevention Program grantees who have developed community-based partnerships and can provide access to Texas populations for research designed to improve current practices. Projects that propose such research collaborations with existing CPRIT Prevention**

Program awardees including the CPRIT funded *Texas Collaborative Center for Hepatocellular Cancer* (<https://www.bcm.edu/research/labs-and-centers/research-centers/texas-collaborative-center-for-hepatocellular-cancer>) are strongly encouraged.

6. FUNDING INFORMATION

Applicants may request a maximum up to \$300,000 in total costs per year for up to 4 years for clinical or population-based research, including implementation or dissemination research designed to accelerate the adoption and deployment of sustainable, evidence-based cancer prevention and screening interventions at multiple levels and in different clinical and community settings. Exceptions to these limits may be requested if extremely well justified (see [section 10.2.12](#)). Funds may be used for salary and fringe benefits, research supplies, equipment, subject participation costs, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of indirect costs to no more than 5% of the total award amount.

7. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.
- This award mechanism allows MIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for MI awards).
- For applications that include 1 PI, the PI is required to maintain a minimum of 15% level of effort through the duration of the entire award period. For applications that include MIs, each PI is required to maintain a minimum of 10% effort through the entire duration of the award period.

- A PI may not submit applications to this RFA and to RFA R-25.1-IIRA, RFA R-25.1-IIRACCA, RFA R-25.1-IIRACSBC, RFA R-25.1-IIRACT, or RFA R-25.1-IIRAEOC.
- A PI/MI may not submit more than 1 application, either a new, resubmission, **or** renewal application under this RFA during this funding cycle
- A PI may not be a part of more than one application, whether as a single applicant or as part of an MI on an application, under this RFA and RFA R-25.1-IIRA, RFA R-25.1-IIRACCA, RFA R-25.1-IIRACSBC, RFA R-25.1-IIRACT, or RFA R-25.1-IIRAEOC.
- An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants. Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project MIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2025).
- Applications that address basic or animal-based projects, cancers in children and adolescents, computational systems biology of cancer, or innovative clinical trials should be submitted under the appropriate targeted RFA.
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member, or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive,

measurable way, regardless of whether those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 13](#) and [section 14](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

8. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** and must follow all resubmission guidelines and be eligible for this mechanism under the criteria in Section 5. If a previously submitted application does not meet the new criteria for this mechanism outlined in [Section 5](#), it must be resubmitted under the IIRA mechanism. **More than 1 resubmission is not permitted.** An application is considered a resubmission if the proposed project is the same project presented in the original submission. A change in the identity of the PI for a project or a change in the project title that was previously submitted to CPRIT, or omission or modification of an aim do not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 10.2.6](#).

9. RENEWAL POLICY

An application funded by CPRIT under this mechanism may be submitted for **one** competitive renewal. An application originally funded by CPRIT as an IIRA that is now appropriate for the IIRAP mechanism may be submitted under this RFA for a competitive renewal. See [section 10.2.7](#). An application originally funded by CPRIT under this mechanism that does not meet the new criteria outlined in [Section 5](#) must be submitted under the IIRA mechanism. Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 11.2](#).

10. RESPONDING TO THIS RFA

10.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 19, 2024, and must be submitted by 4 PM central time on June 11, 2024. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

10.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

10.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details. The IFA will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 7](#) will be administratively withdrawn without review.

10.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and significance of the research alone. Therefore, applicants are advised to prepare this section wisely. **Based on the Abstract and Significance statement (and the Specific Aims, Budget and Justification and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from peer review (see [section 11.1](#)).** Applicants should not waste this valuable space by stating obvious facts (e.g., that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. Provide the hypothesis to be tested, the specific aims, and the overall experimental approaches.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Indicate whether this research addresses the identification, or mitigation, of cancer disparities. Summarize how the proposed research creates new paradigms or challenges existing ones. Indicate whether this research plan represents a new direction for the PI.

10.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, or treatment. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary will also be used by advocate reviewers ([section 11.2](#)) to evaluate the significance and impact of the proposed work.

10.2.3. Aims and Sub-aims

Please provide a description of the aims and sub aims and milestones to be achieved for each year of the project. Provide 2 to 3 sentences describing activities to be performed and anticipated

milestones. These aims will also be used during the submission and evaluation of progress reports and assessment of project success.

10.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

10.2.5. Specific Aims (1 page)

Please provide a 1-page summary of the aims of the proposal. The Specific Aims page should identify the problem or gap in our current knowledge. It should present a hypothesis and briefly describe the aims, subaims, and approaches. Address the proposal's innovation, novel approaches and significance and impact on the field and cancer research. Please also refer to the template located in [Current Funding Opportunities](#) for Academic Research in CARS.

10.2.6. Resubmission Summary (2 pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a new research plan or modify the original research plan and mark the changes.

However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with only editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

10.2.7. Renewal Summary (2 pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

10.2.8. Research Plan (10 pages)

Background: Provide the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed.

Hypothesis and Specific Aims: Concisely state the hypothesis to be tested, and specific aims to be addressed by the research described in the application. Describe the significance, innovation, and potential impact of the research.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required.

10.2.9. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

10.2.10. Human Subjects (2 pages)

If human subjects or human biological samples will be used, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional review board (IRB) will be required before funding can occur.

10.2.11. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

10.2.12. Budget and Justification

Provide a detailed justification of the budget for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses, subject participation costs, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. Do not exceed \$300,000 per year for studies, including implementation research designed to accelerate the adoption and deployment of sustainable, evidence-based cancer prevention and screening interventions at multiple levels and in different clinical and community settings. Applicants are advised not to interpret the maximum allowable request under this award as a suggestion that they should expand their anticipated budget to this level. Reasonable budgets clearly work in favor of the applicant.

However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2025 is \$225,000; CPRIT FY 2025 is from September 1, 2024, through August 31, 2025. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs.

An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

- Funds can be used to pay for costs that a cancer clinical trial participant may have associated with their participation in a clinical trial, including (1) transportation, including car mileage, parking, bus fare, taxi or ride hailing fare exclusive of tips, and commercial economy class airfare within the borders of the State of Texas and (2) lodging.

10.2.13. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. A biographical sketch must be provided for the PI and, if applicable, any additional MIs (for an MI application), as required by the online application receipt system. Up to **5 additional** biographical sketches for key personnel may be provided; these should be concatenated into a single PDF with a 25-page limit. **Each biographical sketch must not exceed 5 pages.** The NIH biosketch format is appropriate.

10.2.14. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, any additional MIs (for an MI application), must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

10.2.15. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

10.2.16. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively rejected without review.

10.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations may be submitted as part of the submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters

are also acceptable if the journal information is stated. URLs of publications referenced in the application may be included.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants must not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see **Page Numbering section** below).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be , printed, signed, scanned, and then uploaded in PDF format.

11. APPLICATION REVIEW

11.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may undergo a preliminary evaluation by CPRIT Scientific Research Program panel members for scientific merit and potential impact.

The preliminary evaluation is based on a subset of material presented in the application—namely, the Abstract and Significance, Specific Aims page, Budget and Justification, and Biographical Sketches. Applications that do not sufficiently capture the reviewers' interest at this stage will not be considered for further peer review. Such applications will have been judged to offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

11.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 11.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all the peer review panels and programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

11.3. Confidentiality of Review

Each stage of the application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules (Texas Administrative Code [RULE §703.9](#)).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

11.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Peer review committees will evaluate and score each primary criterion and subsequently assign an overall score that reflects a complete assessment of the application. **The overall score will not be an average of the individual criteria scores; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

11.4.1. Primary Criteria

The primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention or early detection? Is the application innovative? Does the applicant propose new paradigms or challenge existing ones?

Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required creativity and expertise to make a significant contribution to the research? Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant(s) devoted a sufficient amount of their time (percent effort) to this project?

Relevance: Does the proposed research have a high degree of relevance to cancer prevention research or early detection for Texans? This is a critical criterion for evaluation of applications for CPRIT support.

11.4.2. Secondary Criteria

Secondary criteria contribute to the overall score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

12. KEY DATES

RFA

RFA release February 22, 2024

Application

Online application opens March 19, 2024, 7 AM central time

Application due June 11, 2024, 4 PM central time

Application review June 2024-February 2025

Award

Award notification February 2025

Anticipated start date March 1, 2025

13. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

14. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

15. CONTACT INFORMATION

15.1. Helpdesk

The Helpdesk will answer queries submitted via email within 1 business day. Helpdesk support is available for questions regarding user registration, online submission of applications as well as page limitations, formatting and correct folders to place content in the CPRIT Application Receipt System. Helpdesk staff cannot answer scientific questions and/or Academic Research programs aspects of an application. Before contacting the Helpdesk, please refer to the *Instructions for Applicants* document, which provides a step-by-step guide on using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

15.2. Scientific and Programmatic Questions

Scientific and Programmatic Questions-should be directed to the CPRIT Director of Academic Research. **Before contacting CPRIT, please refer to the *Instructions for Applicants* document and contact the Helpdesk for any items related to the Application Receipt System (CARS), page limitations, formatting, etc.**

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Research Peer Review C/TCR-2

(25.1 ACR C/TCR-2)

Observation Report

Report No. 2024-10-16 25.1_ACR_C/TCR-2
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Peer Review_C/TCR-2 (25.1_ACR_C/TCR-2)
Panel Date: October 16, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Peer Review_C/TCR-2 (25.1_ACR_C/TCR-2) meeting. The meeting was chaired by Richard O'Reilly and conducted via videoconference on October 16, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and seven (7) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Peer Review CB (25.1 ACR CB)
Observation Report

Report No. 2024-10-17 25.1_ACR_CB
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Peer Review_CB (25.1 _ACR_CB)
Panel Date: October 17, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Peer Review_CB (25.1_ACR_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on October 17, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, seventeen (17) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a series of connected loops and a long horizontal tail.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Research Imaging Technology and Informatics (ITI) (25.1 ACR-ITI)

Observation Report

Report No. 2024-10-18 25.1_ACR-ITI
Program Name: Academic Research
Panel Name: 25.1 Academic Research- Imaging Technology and Informatics (ITI) (25.1_ACR-ITI)
Panel Date: October 18, 2024
Report Date: October 22, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research- Imaging Technology and Informatics (ITI) (25.1_ACR-ITI) meeting. The meeting was chaired by Jason Lewis and conducted via videoconference on October 18, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Nine (9) applications were discussed and five (5) applications were not discussed
- Panelists: One (1) panel chair, thirteen (13) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Seven (7)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)**25.1 Academic Research Cancer Prevention Research****(25.1 ACR CPR)****Observation Report**

Report No. 2024-10-22 25.1_ACR_CPR
Program Name: Academic Research
Panel Name: 25.1 Academic Research Cancer Prevention Research
(25.1_ACR_CPR)
Panel Date: October 22, 2024
Report Date: October 23, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Cancer Prevention Research (25.1_ACR_CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 22, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and eight (8) applications were not discussed
- Panelists: One (1) panel chair, ten (10) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were four (4) Conflict(s) of Interest (COIs) identified prior to and/or during the meeting. The COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Basic Cancer Research-1 (BCR-1)
Observation Report

Report No. 2024-10-23 25.1_ACR_BCR-1
Program Name: Academic Research
Panel Name: 25.1 Academic Research_Basic Cancer Research-1 (BCR-1)
Panel Date: October 23, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research_Basic Cancer Research-1 (BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on October 23, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: One (15) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewer
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COI(s) were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Basic Cancer Research-2 (BCR-2)
Observation Report

Report No. 2024-10-24 25.1_ACR_BCR-2
Program Name: Academic Research
Panel Name: 25.1 Academic Research Basic Cancer Research-2 (BCR-2)
Panel Date: October 24, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Basic Cancer Research-2 (BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 24, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Ten (10) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
25.1 Academic Research Clinical and Translational Cancer
Research-1 (CTCR-1) Observation Report

Report No. 2024-10-25 25.1_ACR_CTCR-1
Program Name: Academic Research
Panel Name: 25.1 Academic Research Clinical and Translational Cancer
Research-1 (CTCR-1)
Panel Date: October 25, 2024
Report Date: October 31, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Research Clinical and Translational Cancer Research-1 (CTCR-1) meeting. The meeting was chaired by Margaret Tempero and conducted via videoconference on October 25, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed and twenty-nine (29) applications were not discussed
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Scientific Review Council (25.1 SRC)

Observation Report

Report No. 2024-12-12 25.1_SRC
Program Name: Academic Research
Panel Name: 25.1 Academic Scientific Review Council (25.1_SRC)
Panel Date: December 12, 2024
Report Date: December 18, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Scientific Review Council (25.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 12, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Forty-seven (47) applications were discussed
- Panelists: One (1) panel chair, six (6) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting; however, they are waived pursuant to the Section 102.1062 Conflict of Interest Waiver for FY 2025 approved by the CPRIT Oversight Committee.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a horizontal line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 25.1

Awards Announced at the February 19, 2025, Oversight Committee Meeting

The following table lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research cycle 25.1 include *Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center; Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual; Investigator Research Awards for Computational and Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; and Individual Investigator Research Awards for Prevention and Early Detection.*

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP250156	Jia Wu	The University of Texas M.D. Anderson Cancer Center	Issam El Naqa
RP250247	James Yao	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250118	Masahiro Morita	The University of Texas Health Science Center at San Antonio	Sanja Vicković
RP250399	Natalie Vokes	The University of Texas M.D. Anderson Cancer Center	Walter Stadler
RP250355	Hashem El-Serag	Baylor College of Medicine	Christopher Haiman

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250069	Georgios Karras	The University of Texas M.D. Anderson Cancer Center	Jason Lewis ¹
RP250438	Stephen Chung	The University of Texas M.D. Anderson Cancer Center	Jason Lewis ²
RP250278	Samuel McBrayer	The University of Texas Southwestern Medical Center	Craig Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP250124	Payal Kapur	The University of Texas Southwestern Medical Center	Anna Wu
RP250007	Debananda Pati	Baylor College of Medicine	Steffi Oesterreich
RP250230	Anirban Maitra	The University of Texas M.D. Anderson Cancer Center	Michael Hollingsworth
RP250014	Alexander Pertsemliadis	The University of Texas Health Science Center at San Antonio	Jose Conejo-Garcia
RP250088	Christopher Rylander	The University of Texas at Austin	Jose Conejo-Garcia
RP250187	Fredrik Thege	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250216	Khalid Mohamedali	The University of Texas M.D. Anderson Cancer Center	Howard Hochster
RP250265	Nabil Ahmed	Baylor College of Medicine	Ying Lu
RP250173	Katsumi Kitagawa	The University of Texas Health Science Center at San Antonio	Alan Tomkinson
RP250229	Kunal Rai	The University of Texas M.D. Anderson Cancer Center	Vijaya B. Kolachalama

¹ This conflict was waived pursuant to an approved Texas Health and Safety Code § 102.1062 waiver applicable to CPRIT review councils. A copy of the FY2025 waiver is available on [CPRIT's website](#).

² Same as footnote 1.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250153	Ronald DePinho	The University of Texas M.D. Anderson Cancer Center	Kornelia Polyak
RP250307	Sandeep Burma	The University of Texas Health Science Center at San Antonio	Bart Williams
RP250046	Surendranath Shastri	The University of Texas M.D. Anderson Cancer Center	Karen Emmons
RP250063	Aaron Thrift	Baylor College of Medicine	Christopher Haiman
RP250163	Robert Bast	The University of Texas M.D. Anderson Cancer Center	Karen Emmons
RP250231	Weiva Sieh	The University of Texas M.D. Anderson Cancer Center	Christopher Haiman; Lawrence Kushi; Melissa Troester
RP250053	Dae Kim	The University of Texas Rio Grande Valley	Alan Tomkinson
RP250334	Linghua Wang	The University of Texas M.D. Anderson Cancer Center	Benjamin Greenbaum
RP250371	John Tainer	The University of Texas M.D. Anderson Cancer Center	Alan Tomkinson; John Petrini; Walter Chazin
RP250411	Salma Kaochar	Baylor College of Medicine	John Petrini
RP250121	Dan Nguyen	The University of Texas Southwestern Medical Center	Jun Deng
RP250219	Marites Melancon	The University of Texas M.D. Anderson Cancer Center	David Mankoff; James Babilion
RP250251	Hao Peng	The University of Texas Southwestern Medical Center	Jun Deng
RP250375	Alexander Bishop	The University of Texas Health Science Center at San Antonio	Patrick Grohar
RP250026	Eduardo Vilar-Sanchez	The University of Texas M.D. Anderson Cancer Center	Gregory Lesinski

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP250135	Bouthaina Dabaja	The University of Texas M.D. Anderson Cancer Center	Charles Mullighan
RP250217	Ehsan Irajizad	The University of Texas M.D. Anderson Cancer Center	Lawrence Kushi

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards for Prevention and Early Detection

Academic Research Cycle 25.1

Final Evaluation Scores for Fully Reviewed Applications

Application ID	Final Overall Evaluation Score
RP250293*	1.2
RP250269*	1.8
RP250156*	2.6
RP250418*	2.7
RP250182*	2.8
Ga	3.1
Gb	3.4
Gc	3.5
Gd	3.7
Ge	3.7
Gf	4.0
Gg	4.2
Gh	5.7
Gi	6.0

* Recommended for funding.

Individual Investigator Research Awards for Prevention and Early Detection

Academic Research Cycle 25.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

Application ID	Final Overall Evaluation Score
Oa	4.0
Ob	4.0
Oc	4.3
Od	4.7
Oe	4.7
Of	4.7
Og	5.0

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 5, 2025

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Ms. Kristen Doyle
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to kdoyle@cprit.texas.gov

Dear Dr. Cummings and Ms. Doyle,


The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for the Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal); Core Facility Support Award (FY2024); Individual Investigator Research Awards; Individual Investigator Research Awards for Childhood and Adolescent Cancers; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; Investigator Research Awards for Early-Onset Cancers; Individual Investigator Research Awards for Prevention and Early Detection; Recruitment of Established Investigators; Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 12, 2024 to consider the FY25.1 applications recommended by the peer review panels following their meetings held October 16, 2024 to October 24, 2024 and one FY24.2 Core Facility application recommended by a peer review panel on April 24, 2024. The SRC met on November 14, 2024 to review recruitment applications submitted for Cycle FY25.2 and then on December 12, 2024 to review recruitment applications submitted for Cycle FY25.3.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the 53 recommended applications is \$67,753,626.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Chair, CPRIT Scientific Review Council

Rank	Grant ID	RFA	Score	Title	PI	Institution	Recommended Budget
1	RP250118	IIRA	1.0	Ribosome Localization at Mitochondria-ER Contacts in Obesity-Associated Liver Cancer	Morita, Masahiro	The University of Texas Health Science Center at San Antonio	\$900,000
2	RP250061	IIRA	1.0	Imaging of cranial radiotherapy neuroinflammatory sequelae by Positron Emission Tomography	Pisaneschi, Federica	The University of Texas Health Science Center at Houston	\$900,000
3	RR250077	RFTFM	1.0	Developing next generation of genome editing tools to study and engineer genetic variants for effective precision cancer treatment	Gao, Xin "Daniel"	Baylor College of Medicine	\$2,000,000
4	RR250070	RFTFM	1.0	Unlocking the Potential of Clonal Hematopoiesis in Early Detection and Interception of Lymphoid Malignancies	Griffin, Rosalie	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
5	RR250063	RFTFM	1.1	Co-opting antiviral innate immune pathways to target non-small cell lung cancer	Zou, Tao	The University of Texas Southwestern Medical Center	\$2,000,000
6	RR250071	RFTFM	1.1	CRISPR screening to uncover tumor intrinsic modulators of DNA repair and immune effects of radiation therapy	Verma, Nipun	Baylor College of Medicine	\$2,000,000
7	RP250278	IIRACCA	1.2	Developmental origins of IDH-mutant glioma in adolescents	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,198,416
8	RP250293	IIRAP	1.2	Development of a shared decision tool to facilitate uptake of the levonorgestrel-releasing intrauterine system for the primary prevention of endometrial cancer	Meyer, Larissa	The University of Texas M. D. Anderson Cancer Center	\$1,199,542
9	RP250208	IIRA	1.4	RPS23 is a new drug target to activate the integrated stress response and treat leukemia	Ready, Joseph	The University of Texas Southwestern Medical Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

10	RP250201	IIRA	1.4	Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in oral cavity squamous cell carcinoma	Gillison, Maura	The University of Texas M. D. Anderson Cancer Center	\$899,998
11	RP250028	IIRA	1.5	MALAT1 protects against osteoporosis and bone metastasis	Ma, Li	The University of Texas M. D. Anderson Cancer Center	\$900,000
12	RP250247	IIRA	1.5	Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETs	Yao, James	The University of Texas M. D. Anderson Cancer Center	\$900,000
13	RP250144	IIRACCA	1.5	Decoding how neuronal activity remodels the epigenome in ependymoma	Deneen, Benjamin	Baylor College of Medicine	\$1,200,000
14	RP250220	IIRA	1.8	Decellularized tissue matrices to study the “bad soil” in cancer metastasis	Wang, Andrew	The University of Texas Southwestern Medical Center	\$900,000
15	RP250269	IIRAP	1.8	Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules.	Ostrin, Edwin	The University of Texas M. D. Anderson Cancer Center	\$1,169,776
16	RP250222	IIRA	1.9	KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC	Gibbons, Don	The University of Texas M. D. Anderson Cancer Center	\$899,997
17	RP250043	IIRA	1.9	An integrated imaging informatics platform for HCC surveillance	Zhou, Xiaobo	The University of Texas Health Science Center at Houston	\$899,991
18	RP250374	IIRACCA	1.9	Dissecting TFE3 Mediated tRCC Tumorigenesis	Brugarolas, James	The University of Texas Southwestern Medical Center	\$1,196,812
19	RP240537	CFSA	2.0	Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core	Wu, Erxi	Baylor Research Institute	\$2,999,989
20	RP250213	IIRA	2.0	KRAS spatiotemporal dynamics: lipid glycosylation as a novel therapeutic target	Hancock, John	The University of Texas Health Science Center at Houston	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

21	RP250428	IIRA	2.0	Studying Hematopoietic Stem Cells to Predict and Understand Mechanisms of Post-transplant Relapse in the Myelodysplastic Syndromes	Chung, Stephen	The University of Texas Southwestern Medical Center	\$899,025
22	RP250143	IIRA	2.0	Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy	Lissanu, Yonathan	The University of Texas M. D. Anderson Cancer Center	\$899,991
23	RP250044	IIRACSBC	2.0	Heterogeneity of resistance to endocrine therapy and Cdk inhibition: An integrated systems biology approach to biologically informed treatment regimens	Brock, Amy	The University of Texas at Austin	\$763,596
24	RR250072	REI	2.0	Mechanisms behind copper dependence of cancer cells	Wittung Stafshede, Pernilla	Rice University	\$6,000,000
25	RR250061	RFTFM	2.0	Engineered antibody tools for targeted regulation of cancer-associated proteins and organelles through redirected autophagy process	Jiang, Ziwen	The University of Texas at Dallas	\$2,000,000
26	RP250398	IIRA	2.1	Synthetic lethality of TRIP13 and Aurora A in Rb-deficient cancer	Johnson, Faye	The University of Texas M. D. Anderson Cancer Center	\$899,994
27	RP250402	IIRA	2.1	Exploiting Tryptophan Metabolite Addiction to identify and Inhibit HCC	Conacci Sorrell, Maralice	The University of Texas Southwestern Medical Center	\$900,000
28	RP250131	IIRACT2	2.1	Randomized Clinical Trial Evaluating Fecal Microbiota Transplant in Chimeric Antigen Receptor Therapy for Reversing Antimicrobial-Associated Dysbiosis	Saini, Neeraj	The University of Texas M. D. Anderson Cancer Center	\$1,598,410
29	RP250282	IIRA	2.2	Harnessing BACH2 to enhance anti-tumor T cell immunity	Yao, Chen	The University of Texas Southwestern Medical Center	\$900,000
30	RP250280	IIRA	2.2	The role of glutathione in leukemia development	Agathocleous, Michalis	The University of Texas	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

						Southwestern Medical Center	
31	RP250062	IIRA	2.3	Clonal hematopoiesis and toxicity from radiation therapy	Nead, Kevin	The University of Texas M. D. Anderson Cancer Center	\$899,885
32	RP250407	IIRA	2.3	Protecting the GI tract with a C60 fullerene derivative to facilitate dose-escalated abdominopelvic radiotherapy	Mackeyev, Yuri	The University of Texas Health Science Center at Houston	\$900,000
33	RP250055	IIRA	2.4	TET2 mutations promote myeloid malignancies by dysregulating m5C oxidation of chromatin-associated RNAs	Xu, Mingjiang	The University of Texas Health Science Center at San Antonio	\$900,000
34	RP250391	IIRA	2.5	Novel PCDH7 monoclonal antibodies that direct immune surveillance and combat drug resistance in lung cancer	O'Donnell, Kathryn	The University of Texas Southwestern Medical Center	\$900,000
35	RP250321	IIRACT2	2.5	Leveraging synthetic and collateral lethality in MTAP loss tumors	Rodon Ahnert, Jordi	The University of Texas M. D. Anderson Cancer Center	\$1,599,783
36	RP250069	IIRA	2.6	HSP90 Capacitance: Discovery of a New Mechanism Driving Evolution of Drug Resistance in Head and Neck Squamous Cell Carcinoma	Karras, Georgios	The University of Texas M. D. Anderson Cancer Center	\$890,201
37	RP250305	IIRA	2.6	Exploiting synthetic lethality between HNRNPK loss and ribosomal dysfunction in del9q AML	Post, Sean	The University of Texas M. D. Anderson Cancer Center	\$896,322
38	RP250091	IIRA	2.6	Dissecting the Survival Mechanisms of Latent Brain-Tropic Cancer Cells for Therapeutic Interventions	Malladi, Srinivas	The University of Texas Southwestern Medical Center	\$900,000
39	RP250322	IIRA	2.6	Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2-mutant non-small cell lung cancer (NSCLC)	Heymach, John	The University of Texas M. D. Anderson Cancer Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

40	RP250154	IIRA	2.6	Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients	Fuentes, David	The University of Texas M. D. Anderson Cancer Center	\$899,808
41	RP250156	IIRAP	2.6	Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer	Wu, Jia	The University of Texas M. D. Anderson Cancer Center	\$1,200,000
42	RP250094	IIRACT2	2.7	A phase 2 clinical trial with Avasopasem, with anti-estrogen therapy (ET) and a CDK4/6 inhibitor in metastatic breast cancer progressing on ET/CDK4/6 therapy.	Gius, David	The University of Texas Health Science Center at San Antonio	\$1,390,420
43	RP250418	IIRAP	2.7	Approach Bias Retraining to Augment Long-Term Smoking Cessation Among a Diverse Sample	Garey, Lorra	University of Houston	\$1,200,000
44	RP250355	CAP-CAC-CR	2.8	The Texas Collaborative Center for Hepatocellular Cancer (TeCH)	El-Serag, Hashem	Baylor College of Medicine	\$3,000,000
45	RP250119	IIRACCA	2.8	Comparison of Symptom Burden, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients treated with Surgery vs. Surgery and Chemotherapy	Kahalley, Lisa	Baylor College of Medicine	\$1,200,000
46	RP250190	IIRACCA	2.8	Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-Exercise Intervention	Swartz, Maria	The University of Texas M. D. Anderson Cancer Center	\$1,199,756
47	RP250182	IIRAP	2.8	Implementing Newborn Screening for Pediatric Cancer Predisposition Syndromes in Texas: The INSPECT Study	Parsons, Donald	Baylor College of Medicine	\$1,187,187
48	RP250097	IIRA	2.9	Deciphering and targeting age-related metastatic	Naora, Honami	The University of Texas M. D.	\$899,984

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				competence of the omentum		Anderson Cancer Center	
49	RP250099	IIRA	2.9	Targeting lethal prostate cancers with a clinical-stage inverse agonist for G protein-coupled receptor 6	Li, Wenliang	The University of Texas Health Science Center at Houston	\$900,000
50	RP250399	IIRACSBC	2.9	Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture	Vokes, Natalie	The University of Texas M. D. Anderson Cancer Center	\$1,049,033
51	RP250090	IIRACSBC	2.9	Artificial Intelligence for Early Identification of Androgen-Indifferent, Lethal Prostate Cancer and Therapy Selection	Merényi, Erzsébet	Rice University	\$1,049,434
52	RP250191	IIRA	3.1	Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$898,263
53	RP250164	IIRACCA	3.1	Prediction of CAR-T Cell Immunotherapy Outcomes in Neuroblastoma using FE-MRI Nano-radiomics	Ghaghada, Ketan	Baylor College of Medicine	\$1,168,013

Core Facility Support Award (CFSA)

Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal)

Individual Investigator Research Awards (IIRA)

Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)

Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)

Individual Investigator Research Awards for Clinical Trials (IIRACT)

Individual Investigator Research Awards for Early Onset Cancers (IIRAEOC)

Individual Investigator Research Awards for Prevention and Early Detection (IIRAP)

Recruitment of Established Investigators (REI)

Recruitment of Rising Stars (RRS)

Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research Recruitment
FY 2025—Cycles 2-3**

Recruitment of Established Investigators

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-25.1-REI

Recruitment of Established Investigators

**Please also refer to the Instructions for Applicants document, which will be
posted on June 21, 2024**

Application Receipt Dates:

June 21, 2024-June 20, 2025

FY 2025

Fiscal Year Award Period

September 1, 2024-August 31, 2025

TABLE OF CONTENTS

1. ABOUT CPRIT	4
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	4
2. RATIONALE	5
3. RECRUITMENT OBJECTIVES	6
4. INSTITUTIONAL COMMITMENT	7
5. FUNDING INFORMATION	8
6. ELIGIBILITY	9
7. RESUBMISSION POLICY	11
8. RESPONDING TO THIS RFA	11
8.1. APPLICATION SUBMISSION GUIDELINES	11
8.2. APPLICATION COMPONENTS	12
8.2.1. Summary of Nomination (2,500 characters)	12
8.2.2. Layperson's Summary (2,000 characters)	12
8.2.3. Summary of Specific Aims and Sub-Aims (2,000 characters)	12
8.2.4. Specific Aims and Sub-Aims	13
8.2.5. Institutional Commitment (3 pages)	13
8.2.6. Letter of Support from Department Chair (up to 2 pages)	15
8.2.7. Curriculum Vitae (CV)	16
8.2.8. Research (4 pages)	16
8.2.9. Publications/References (1 Page)	17
8.2.10. Research Collaboration/Synergy Plan (2 pages)	17
8.2.11. Publications	17
8.2.12. Timeline (1 page)	17
8.2.13. Current and Pending Support	17
8.2.14. Research Environment (1 page)	18
8.2.15. Descriptive Biography (Up to 2 pages)	18
9. APPLICATION REVIEW	18
9.1. REVIEW PROCESS	18
9.1.1. Confidentiality of Review	19
9.2. REVIEW CRITERIA	19
10. KEY DATES	21
11. AWARD ADMINISTRATION	21
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	23
13. CONTACT INFORMATION	23
13.1. HELPDESK	23
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	23

RFA VERSION HISTORY

6/21/24	RFA release
8/2/24	Modified language under Section 8.2.6: Letter of Support from Department Chair

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas
- Develop and implement the Texas Cancer Plan

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

To accomplish CPRIT's long-term vision, the Oversight Committee has identified these 2025 priorities:

- Investing in the cancer research capacity of Texas institutions through recruitment of cancer scholars, investment in core facilities, and investment in individual investigator awards in all regions of the state;
- Building the Texas cancer life science ecosystem across Texas by bridging discovery and translational research into early-stage company products with high impact on cancer patient care and creating economic development for the State of Texas; and
- Increasing the capacity for Texas to have a significant impact on cancer prevention and early detection, ultimately decreasing cancer incidence and mortality.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state

- Reducing disparities in cancer incidence and mortality

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access

2. RATIONALE

The aim of this award mechanism is to bolster cancer research in Texas by providing financial support to attract world-class research scientists with distinguished professional careers to Texas universities and cancer research institutes to establish research programs that add research talent to the state. This award will support established academic leaders whose body of work has made an outstanding contribution to cancer research. Awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research, thereby advancing cancer research and prevention efforts, and promoting economic development in the State of Texas.

The recruitment of outstanding scientists will greatly enhance programs of scientific excellence in cancer research and will position Texas as a leader in the fight against cancer. Applications may address any research topic related to cancer biology, causation, prevention, detection or screening, treatment, or survivorship. Principal Investigators (PIs) with research programs addressing CPRIT's priority areas for research are encouraged. These areas include implementation research to accelerate the adoption and deployment of evidence-based

prevention and screening interventions, research including population-based research addressing cancer disparities, computational oncology and analytic methods, childhood and adolescent cancers, hepatocellular cancer, and expansion of access to innovative clinical trials.

3. RECRUITMENT OBJECTIVES

The goal of this award mechanism is to recruit exceptional faculty to universities and/or cancer research institutions in the State of Texas. This award honors outstanding senior investigators with proven track records of research accomplishments combined with excellence in leadership and teaching. All PIs should be recognized as research or clinical investigators, held in the highest esteem by professional colleagues nationally and internationally, whose contributions have had a significant influence on their discipline and, likely, beyond. They must have clearly established themselves as exemplary faculty members with exceptional accomplishments in teaching and advising and/or basic, translational, population-based, or clinical cancer research activities. It is expected that the PI will contribute significantly to and have a major impact on the institution's overall cancer research initiative. PIs will be leaders capable of initiating and developing creative ideas leading to novel solutions related to cancer prevention and control, detection, diagnosis, treatment, and/or survivorship. They are also expected to maintain and lead a strong research group and have a stellar, high-impact publication portfolio, as well as continue to secure external funding. Furthermore, recipients will lead and inspire undergraduate and graduate students interested in pursuing research careers and will engage in collegial and collaborative relationships with others within and beyond their traditional discipline to expand the boundaries of cancer research.

Funding will be given for exceptional PIs who will continue to develop new research methods and techniques in the life, population-based, physical, engineering, or computational sciences and apply them to solving outstanding problems in cancer research that have been inadequately addressed or for which there may be an absence of an established paradigm or technical framework.

Ideal PIs will have specific expertise in cancer-related areas needed to address an institutional priority. PIs should be at the career level of a full professor or equivalent. This funding mechanism considers expertise, accomplishments, and breadth of experience as vital metrics for

guiding CPRIT's investment in that person's originality, insight, and potential for continued contribution. Relevance to cancer research and to CPRIT's priority areas are important evaluation criteria for CPRIT funding.

Applications nominating individuals who carry out patient-oriented research and who have demonstrated exceptional ability to lead innovative discovery campaigns through conduct of clinical trials are appropriate for this mechanism and encouraged.

Additionally, prevention and population health research that addresses the burden of cancer in Texas is a priority for CPRIT. Applications nominating individuals who have demonstrated exceptional ability to lead innovative research programs involving any component across the continuum of cancer prevention and control research are appropriate for this mechanism and are highly encouraged.

Applications that include purposeful collaborations with institutions eligible for a CPRIT Texas Regional Excellence in Cancer Award are highly encouraged.

Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

4. INSTITUTIONAL COMMITMENT

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the Recruitment of an Established Investigator (REI) Award must be complemented by a strong financial institutional commitment to the recruitment. The institutional commitment should be clearly documented in the application (see [section 8.2.5](#)) and include the amount and sources of salary support and all additional financial support that will be available to the PI's research program through the course of the CPRIT award. The financial commitments made to the PI by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

5. FUNDING INFORMATION

This award is up to 5 years and is not renewable. Grant support will be awarded based upon the breadth and nature of the research program proposed. Grant funds of up to \$6,000,000 (total costs) for the 5-year period may be requested. Applicants are encouraged to tailor the budget as appropriate to the exigencies of the project; grant funds totaling less than \$6,000,000 for the term of the award are acceptable if warranted by the scope of the research. Exceptions exceeding this limit will be entertained only if there is compelling written justification. The award request may include indirect costs of up to 5% of the total award amount (5.263% of the direct costs). CPRIT will make every effort to be flexible in the timing for disbursement of funds; recipients will be asked at the beginning of each year for an estimate of their needs for the year. Funds may not be carried over beyond 5 years except under extraordinary circumstances with strong justification for a no-cost extension. In addition, funds for extraordinary equipment needs may be awarded in the first year of the grant if very well justified and a detailed justification is provided along with an institutional plan should the additional funds not be approved. Scholars may request funds for travel for 2 project staff to attend CPRIT's conference.

Funds from this award mechanism may be used for salary support of this PI but may not be used to construct or renovate laboratory space.

No annual limit on the number of grant application submissions per institution has been set.

Note that the annual salary (also referred to as direct salary or institutional base salary) that an individual may be reimbursed from a CPRIT award for FY 2025 is limited to a maximum of \$225,000. In other words, an individual may request salary proportional to the percent of effort up to a maximum of \$225,000. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

Note: In the event of insufficient funds, specific recruitment categories may be eliminated (example: REI/RRS/RFTTFM) and nominations for specific categories may be closed for the remaining cycles of the fiscal year. Additionally, depending on the availability of funds, review

cycles may be reduced, and/or the number of applications per institution may be capped, and recommended nominations submitted in response to this Request for Applications (RFA) during the current receipt period may be announced and awarded either in the current fiscal year (prior to August 31, 2025) or in the first quarter of the next fiscal year (starting September 1, 2025).

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism.
- PIs must be nominated by the president, provost, vice president for research, or appropriate dean of a Texas-based public or private institution of higher education, including academic health institutions. The application must be submitted on behalf of a specific PI.
- A PI may be nominated by only 1 institution. If more than 1 institution is interested in a given PI, negotiations as to which institution will nominate him or her must be concluded before the nomination is made.
- No annual limit on the number of grant submissions per institution has been set.
- A PI who has already accepted a position at the recruiting institution prior to the time that the Scientific Review Council reviews the PI for a recruitment award is not eligible for a recruitment award, as an investment by CPRIT is obviously not necessary. No award is final until approved by the Oversight Committee at a public meeting. However, in recognition of the timeline involved with recruiting highly sought-after PIs who are often considering multiple offers, CPRIT's Academic Research program staff will notify the nominating institution of the Scientific Review Council's review decision following the Scientific Review Council meeting. If a position is offered to the PI during the period following the Scientific Review Council's review decision but prior to the Oversight Committee's final approval, the institution does so at its own risk. There is no guarantee that the recruitment award will be approved by the Oversight Committee.
- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, **and reside in Texas for the duration of the appointment**. The PI must

devote at least 70% effort to research activities. PIs whose major responsibilities are clinical care, teaching, or administration are not eligible.

- At the time of the application, the PI should hold an appointment at the rank of professor (or equivalent) at an accredited academic institution, research institution, industry, government agency, or private foundation. The PI must not reside in Texas at the time the application is submitted.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the nominator, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not the individuals will receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

Resubmissions will not be accepted for the REI award mechanism. Any nomination for the REI that was previously submitted to CPRIT and reviewed but was not recommended for funding may not be resubmitted. A nomination for the REI that was previously submitted to CPRIT for any of the recruitment RFA mechanisms and reviewed and recommended for funding but declined by the PI may be submitted in response to this RFA if the PI meets the eligibility criteria described in [section 6](#) and the application is not in the same fiscal year as the previous application. If a nomination was administratively rejected prior to review, it can be resubmitted in the following cycles. Applications being resubmitted according to the criteria permitted by this section should be submitted as a new application (refer to the *Instructions for Applicants* [IFA] document for more details).

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted. PIs must be nominated by the institution's president, provost, vice president for research, or appropriate dean. The individual submitting the application (nominator) must create a user account in the system (which includes the nominator's credentials and email address) to start and submit an application. Furthermore, the Application Signing Official, who is the person authorized to sign and submit the application for the organization, and the Grants Contract/Office of Sponsored Projects Official, who is the individual who will manage the grant contract if an award is made, also must create a user account in CARS.

Dependent upon available funding, applications will be accepted on a revised schedule for FY25 (See [section 10](#) for RFA schedule).

For an application to be considered for review during the review cycle, that application must be submitted on or before 11:59 PM central time on the 20th day of that cycle. In the event that the

closing date falls on Saturday or Sunday, applications may be submitted on or before 11:59 PM central time the following Monday. CPRIT will not extend the submission deadline. During periods when CPRIT does not receive an adequate number of applications, the review may be extended into the following cycle. Nominators will be notified if this occurs. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. For details, please refer to the *IFA* document that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

8.2.1. Summary of Nomination (2,500 characters)

Provide a brief summary of the nomination. Include the PI's name, organization from which the PI is being recruited, and the department and/or entity within the nominator's organization where the PI will hold the faculty position.

8.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. **This section must be completed by the PI.** Describe, in simple, nontechnical terms, the overall aims of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. Do not include any proprietary information in the layperson's summary.

8.2.3. Summary of Specific Aims and Sub Aims (2,000 characters)

Please provide a summary of the aims of the proposal. **This section must be completed by the PI.** The Specific Aims Summary should identify the problem or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches and address the

proposal's innovation, novel approaches, and significance and impact on the field and cancer research.

8.2.4. Specific Aims and Sub Aims

List Specific Aims and Sub Aims to be achieved during this award. **This section must be completed by the PI.** These Aims/Sub Aims will also be used during the submission and evaluation of progress reports and assessment of project success. Refer to the template for Specific Aims and Sub Aims document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.5. Institutional Commitment (3 pages)

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the REI faculty should be complemented by a strongly documented institutional commitment to the recruitment. The financial commitments made to the PI by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

The following guidelines should be followed when documenting the institutional commitment to the PI:

- The institutional commitment should be clearly documented in the form of a letter signed by the applicant institution's president, provost, or appropriate dean and include the amount and sources of salary support and all additional financial support that will be available to the PI's research program through the course of the CPRIT award. The financial commitments made to the PI by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.
- **The institutional commitment letter must include the following statement** regarding the institution's financial commitment required to meet the 50% match.
 - This institutional financial commitment will not be offset by funds from an investigator-initiated award received by the PI. If an award dictates that such funds

must be used for salary, the corresponding amount of institutional funds committed to pay the PI's salary will be redirected to allow the PI to use them for program support.

- Institutional commitment as described above must be presented in a table (example below), that clearly identifies the salary amount, sources of salary, and any additional research support from institutional sources over the course of the CPRIT award. Sources of support for the PI's full salary, including summer salary, for the duration of the award must be documented. If the PI is expected to provide salary support from grants during the award period, the institutional commitment must identify the source for salary support in the event grant support is not available. Note that a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the PI.
- Include a brief job description for the PI should recruitment be successful.
- Describe the institutional environment and any professional commitments to the PI including, but not limited to, dedicated personnel, access to students, space assignment, and access to shared equipment, and discuss all other agreements between the institution and the PI.
- Institutions may provide additional information in support of a PI's research plan to demonstrate how the institutional commitment, through development of strategic collaborations, will foster a PI's cancer research. This additional information is highly encouraged when proposing a PI with exceptional expertise and/or talent that can be directed to cancer research such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research.
- Note that Texas law allows an institution of higher learning to use its federal indirect cost rate credit to comply with the requirement to demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award (see [section 12](#)). However, a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the PI.

Example of an acceptable Institutional Commitment table:

PI's Name, Institutional Commitments

	Year 1	Year 2	Year 3	Year 4	Year 5
Salary/Benefits*					
Research Support					
Administrative Support					
Moving Expenses					

Total =

*** Sources of support for the PI's full salary, including summer salary, for the duration of the award must be documented.**

Note: CPRIT acknowledges that the institutional commitments by category may change during the course of the award; however, the total financial commitment to the PI must remain equal to or greater than 50% of the CPRIT award.

8.2.6. Letter of Support from Department Chair (up to 2 pages)

Provide the letter of support from and signed by the chair of the department to which the PI is being recruited. The following information should be included in the letter:

Recruitment Activities: CPRIT is committed to increasing the life sciences infrastructure in Texas via the recruitment of exceptional cancer researchers, as well as expanding research resources. The letter should provide a description of the recruitment activities, strategies, and priorities that have led to the nomination of this PI. Provide the necessary context by describing the institution's vision for the cancer programs, how the work of the nominee contributes to achieving these goals and the expected impact of the recruitment on the institution (or department) and the burden of cancer in Texas (if applicable).

Caliber of PI: The letter should include a description of the caliber of the PI and justification of nomination of the PI by the institution. CPRIT recognizes that there is variability in the metrics of impact applicable across the continuum of cancer research. For example, in some disciplines, research findings—although highly impactful on the field—are less likely to be published in the highest ranked journals, ie, *Science*, *Cell*, or *Nature* series. Thus, it is incumbent on the

institution to describe the impact of a nominee’s work, including paradigm-shifting, practice-changing, or influence on public policy, population health behavior, or cancer disparities.

Description of PI Duties and Certification of 70% Effort to Research: While scholars may engage in direct patient care activities and/or have some administrative or teaching duties, at least 70% of the PI’s effort must be committed to research. Breach of this requirement will constitute grounds for discontinuation of funding. The certification that 70% level of effort will be dedicated to research must be included.

8.2.7. Curriculum Vitae (CV)

Provide a complete CV and list of publications for the PI.

8.2.8. Research (4 pages)

Summarize the key elements of the PI’s research accomplishments and provide an overview of the proposed research by outlining the background and rationale, hypotheses and aims, strategies, specific aims, and projected impact of the focus of the research program. Highlight the innovative aspects of this effort and place it into context with regard to what pressing problem in cancer will be addressed. **This section of the application must be prepared by the PI.**

References cited in this section should be listed in the Publications/References section (see [section 8.2.9](#)).

PIs for CPRIT Scholar Awards must include the following signed statement at the end of this section. **Applications that do not contain this signed statement will be returned without review.**

“I understand that I do not need to have made a commitment to *<nominating institution>* before this application has been submitted. However, I also understand that only 1 Texas institution may nominate me for a CPRIT Recruitment Award, and this is the nomination that I have endorsed. I understand that requests to change the recruiting institution during the recruitment process are not allowed after the application is submitted to CPRIT.”

8.2.9. Publications/References (1 Page)

Provide a concise and relevant list of publications/references cited in the Research section of the application. Any appropriate citation format is acceptable; official journal abbreviations should be used.

8.2.10. Research Collaboration/Synergy Plan (2 pages)

Institutions may provide additional information in support of a PI's research plan to demonstrate how the institutional' commitment through development of strategic collaborations will foster a PI's cancer research. This additional information is highly encouraged when proposing a PI with exceptional expertise and/or talent that can be directed to cancer research, such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research. Biographical sketches of collaborators established in the research collaborative plan must be uploaded as part of the application. This will be in addition to the 2-page synergy plan (see IFA).

8.2.11. Publications

Provide the 5 most significant publications that have resulted from the PI's research efforts. Publications should be uploaded as PDFs of full-text articles. Only articles that have been published or that have been accepted for publication ("in press") should be submitted.

8.2.12. Timeline (1 page)

Provide a general outline of anticipated major award outcomes to be tracked. Timelines will be reviewed during the evaluation of annual progress reports. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.13. Current and Pending Support

State the funding source, duration, and title of all current and pending research support held by the PI. If the PI has no current or pending funding, a document stating this must be submitted. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.14. Research Environment (1 page)

Briefly describe the research environment available to support the PI's research program, including core facilities, training programs, and collaborative opportunities.

8.2.15. Descriptive Biography (Up to 2 pages)

Provide a brief descriptive biography of the PI, including his or her accomplishments, education and training, professional experience, awards and honors, publications relevant to cancer research, and a brief overview of the PI's specific aims, if selected, to receive the award. **This section of the application must be prepared by the PI.** If the application is approved for funding, this section will be made publicly available on CPRIT's website. PIs are advised not to include information that they consider confidential or proprietary when preparing this section.

Applications that are missing 1 or more of these components, exceed the specified page, word, or budget limits, or do not meet the eligibility requirements listed above will be administratively withdrawn without review.

9. APPLICATION REVIEW

9.1. Review Process

All eligible applications will be evaluated and scored by the CPRIT Scientific Review Council using the criteria listed in this RFA. Applications may be submitted continuously in response to this RFA but will be reviewed by the CPRIT Scientific Review Council according to the revised schedule (see [section 10](#)). Council members may seek additional ad hoc evaluations of PIs. Scientific Review Council members will review applications and provide an individual Overall Evaluation Score that conveys the members' recommendation related to the proposed recruitment. Applications recommended by the Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review, prioritization, and recommendation to the CPRIT Oversight Committee for approval and funding. Approval is based on an application receiving a positive vote from at least two-thirds of the members of the Oversight Committee. The review process is described more fully in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

The decision of the Scientific Review Council not to recommend an application is final, and such applications may not be resubmitted for a recruitment award. Notification of review decisions is sent to the nominator.

9.1.1. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, or a Scientific Review Council member.

Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of the Department of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

9.2. Review Criteria

Applications will be assessed based on evaluation of the quality of the PI and his or her potential for continued superb performance as a cancer researcher. **Also, of critical importance is the strength of the institutional commitment to the PI. Recruitment efforts are not likely to be**

successful unless there is a strong commitment from both CPRIT and the host institution. It is not necessary that a PI agrees to accept the recruitment offer at the time an application is submitted. However, applicant institutions should have an expectation that the recruitment will be successful if an award is granted by CPRIT. It is the expectation that the nominating institution provides CPRIT with a status of the award acceptance as soon as status is known.

Review criteria will focus on the overall impression of the PI, his/her proposed research program, and his/her long-term contribution to, and impact on, the field of cancer research.

Questions to be considered by the reviewers are as follows:

Quality of the PI: Has the PI made significant, transformative, and sustained contributions to basic, translational, clinical, or population-based cancer research? Is the PI an established and nationally and/or internationally recognized leader in the field? Has the PI demonstrated excellence in leadership and teaching? Has the PI provided mentorship, inspiration, and/or professional training opportunities to junior scientists and students? Does the PI have a strong record of research funding? Does the PI have a publication history in high-impact journals within cancer research broadly, or within their specialty field, if applicable? Does the PI show evidence of collaborative interaction with others?

Scientific Merit of Proposed Research: Is the research plan comprehensive and well thought out? Does the proposed research program demonstrate innovation, creativity, and feasibility? Will it expand the boundaries of cancer research beyond traditional methodology by incorporating novel and interdisciplinary techniques? Does the research program integrate with and/or increase collaborative research efforts and relationships at the nominating institution?

Relevance of PI's Research: Is the proposed research likely to have a significant impact on reducing the burden of cancer in the near term, or address unique aspects of the burden of cancer in Texas? Does the research contribute to basic, translational, clinical, or population-based cancer research?

Research Environment: Does the institution have the necessary facilities, expertise, and resources to support the PI's research program? Is there evidence of strong institutional support? Will the PI be free of major administrative/clinical responsibilities so that he or she can focus on maintaining and enhancing his or her research program?

10. KEY DATES

RFA Schedule

RFA Release June 21, 2024

Review Cycle Dates

Review Cycle	Cycle Opens	Cycle Closes	Oversight Committee Review	Potential Award Date
25.1	6/21/24	8/20/24	11/20/24	12/1/24
25.2	8/21/24	10/21/24*	2/19/25	3/1/25
25.3	10/22/24	11/20/24	2/19/25	3/1/25
25.4	11/21/24	1/20/25	5/21/25	6/1/25
25.5	1/21/25	2/20/25	5/21/25	6/1/25
25.6	2/21/25	3/20/25	5/21/25	6/1/25
25.7	3/21/25	4/21/25*	8/20/25	8/31/25
25.8	4/22/25	5/20/25	8/20/25	8/31/25
25.9	5/21/25	6/20/25	8/20/25	8/31/25

*Cycle close extended due to the 20th falling on a Sunday

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Awards made under this RFA are not transferable to another institution. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract

provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov.

Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research specific aims and address plans for the upcoming year. **Continuation of funding is contingent upon the timely receipt of these reports.** Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. CPRIT requires funding acknowledgement to include the award grant ID on all print and visual materials that are funded in whole or in part by CPRIT grants. Examples of print and visual materials include, but are not limited to, publications, brochures, pamphlets, project websites, videos, and media materials. Grantees must have written approval from CPRIT prior to the purchase of any equipment. If the equipment is clearly defined in the grantee's budget submitted with the initiating award requirements, then approval of the grant award constitutes "prior approval" for the purchase. Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#), for specific requirements regarding the demonstration of available funding.

13. CONTACT INFORMATION

13.1. Helpdesk

The Helpdesk will answer queries submitted via email within 1 business day. Helpdesk support is available for questions regarding user registration and online submission of applications as well as page limitations, formatting, and how to upload application components/subsections in the appropriate tabs of CARS. Helpdesk staff cannot answer scientific or programmatic questions. Before contacting the Helpdesk, please refer to the *Instructions for Applicants* document, which provides a step-by-step guide on using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Scientific and programmatic questions should be directed to the CPRIT Director of Academic Research. **Before contacting CPRIT, please refer to the *Instructions for Applicants* document and contact the Helpdesk for any items related to CARS, page limitations, formatting, etc.**

Email: Research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports

Cancer Prevention and Research Institute of Texas (CPRIT)
25.2 Academic Research Recruitment Review Panel
(25.2 REC)
Observation Report

Report No. 2024-11-14 25.2_REC
Program Name: Academic Research
Panel Name: 25.2 Academic Research Recruitment Review Panel (25.2_REC)
Panel Date: November 14, 2024
Report Date: November 18, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.2 Academic Research Recruitment Review Panel (25.2_REC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on November 14, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seven (7) applications were discussed
- Panelists: One (1) panel chair, eight (8) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning the application(s) for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)**25.3 Academic Research Recruitment Review Panel-25.3****(REC 25.3)****Observation Report**

Report No. 2024-12-12 25.3_REC
Program Name: Academic Research
Panel Name: 25.3 Academic Research Recruitment Review Panel - 25.3
(REC_25.3)
Panel Date: December 12, 2024
Report Date: December 18, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.3 Academic Research Recruitment Review Panel-25.3 (REC_25.3) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 12, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Five (5) applications were discussed
- Panelists: One (1) panel chair, eight (8) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Recruitment Cycles 25.2-25.3

Awards Announced at the February 19, 2025, Oversight Committee Meeting

The following table lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Recruitment cycles 25.2-25.3 include *Recruitment of Established Investigators*; *Recruitment of Rising Stars*; and *Recruitment of First-Time, Tenure-Track Faculty Members*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RR250072	Pernilla Wittung Stafshede	Rice University	Carol Prives
Applications not considered by the PIC or Oversight Committee:			
RR250065	Neil Bhowmick	Baylor College of Medicine	Peter Jones

De-Identified Overall Evaluation Scores

Recruitment of Established Investigators

Academic Research Recruitment Cycles 25.2-25.3

Application ID	Final Overall Evaluation Score
RR250072*	2.0
a	4.0

* Recommended for funding.

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 5, 2025

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Ms. Kristen Doyle
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to kdoyle@cprit.texas.gov

Dear Dr. Cummings and Ms. Doyle,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for the Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal); Core Facility Support Award (FY2024); Individual Investigator Research Awards; Individual Investigator Research Awards for Childhood and Adolescent Cancers; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; Investigator Research Awards for Early-Onset Cancers; Individual Investigator Research Awards for Prevention and Early Detection; Recruitment of Established Investigators; Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 12, 2024 to consider the FY25.1 applications recommended by the peer review panels following their meetings held October 16, 2024 to October 24, 2024 and one FY24.2 Core Facility application recommended by a peer review panel on April 24, 2024. The SRC met on November 14, 2024 to review recruitment applications submitted for Cycle FY25.2 and then on December 12, 2024 to review recruitment applications submitted for Cycle FY25.3.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the 53 recommended applications is \$67,753,626.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Chair, CPRIT Scientific Review Council

Rank	Grant ID	RFA	Score	Title	PI	Institution	Recommended Budget
1	RP250118	IIRA	1.0	Ribosome Localization at Mitochondria-ER Contacts in Obesity-Associated Liver Cancer	Morita, Masahiro	The University of Texas Health Science Center at San Antonio	\$900,000
2	RP250061	IIRA	1.0	Imaging of cranial radiotherapy neuroinflammatory sequelae by Positron Emission Tomography	Pisaneschi, Federica	The University of Texas Health Science Center at Houston	\$900,000
3	RR250077	RFTFM	1.0	Developing next generation of genome editing tools to study and engineer genetic variants for effective precision cancer treatment	Gao, Xin "Daniel"	Baylor College of Medicine	\$2,000,000
4	RR250070	RFTFM	1.0	Unlocking the Potential of Clonal Hematopoiesis in Early Detection and Interception of Lymphoid Malignancies	Griffin, Rosalie	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
5	RR250063	RFTFM	1.1	Co-opting antiviral innate immune pathways to target non-small cell lung cancer	Zou, Tao	The University of Texas Southwestern Medical Center	\$2,000,000
6	RR250071	RFTFM	1.1	CRISPR screening to uncover tumor intrinsic modulators of DNA repair and immune effects of radiation therapy	Verma, Nipun	Baylor College of Medicine	\$2,000,000
7	RP250278	IIRACCA	1.2	Developmental origins of IDH-mutant glioma in adolescents	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,198,416
8	RP250293	IIRAP	1.2	Development of a shared decision tool to facilitate uptake of the levonorgestrel-releasing intrauterine system for the primary prevention of endometrial cancer	Meyer, Larissa	The University of Texas M. D. Anderson Cancer Center	\$1,199,542
9	RP250208	IIRA	1.4	RPS23 is a new drug target to activate the integrated stress response and treat leukemia	Ready, Joseph	The University of Texas Southwestern Medical Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

10	RP250201	IIRA	1.4	Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in oral cavity squamous cell carcinoma	Gillison, Maura	The University of Texas M. D. Anderson Cancer Center	\$899,998
11	RP250028	IIRA	1.5	MALAT1 protects against osteoporosis and bone metastasis	Ma, Li	The University of Texas M. D. Anderson Cancer Center	\$900,000
12	RP250247	IIRA	1.5	Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETS	Yao, James	The University of Texas M. D. Anderson Cancer Center	\$900,000
13	RP250144	IIRACCA	1.5	Decoding how neuronal activity remodels the epigenome in ependymoma	Deneen, Benjamin	Baylor College of Medicine	\$1,200,000
14	RP250220	IIRA	1.8	Decellularized tissue matrices to study the “bad soil” in cancer metastasis	Wang, Andrew	The University of Texas Southwestern Medical Center	\$900,000
15	RP250269	IIRAP	1.8	Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules.	Ostrin, Edwin	The University of Texas M. D. Anderson Cancer Center	\$1,169,776
16	RP250222	IIRA	1.9	KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC	Gibbons, Don	The University of Texas M. D. Anderson Cancer Center	\$899,997
17	RP250043	IIRA	1.9	An integrated imaging informatics platform for HCC surveillance	Zhou, Xiaobo	The University of Texas Health Science Center at Houston	\$899,991
18	RP250374	IIRACCA	1.9	Dissecting TFE3 Mediated tRCC Tumorigenesis	Brugarolas, James	The University of Texas Southwestern Medical Center	\$1,196,812
19	RP240537	CFSA	2.0	Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core	Wu, Erxi	Baylor Research Institute	\$2,999,989
20	RP250213	IIRA	2.0	KRAS spatiotemporal dynamics: lipid glycosylation as a novel therapeutic target	Hancock, John	The University of Texas Health Science Center at Houston	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

21	RP250428	IIRA	2.0	Studying Hematopoietic Stem Cells to Predict and Understand Mechanisms of Post-transplant Relapse in the Myelodysplastic Syndromes	Chung, Stephen	The University of Texas Southwestern Medical Center	\$899,025
22	RP250143	IIRA	2.0	Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy	Lissanu, Yonathan	The University of Texas M. D. Anderson Cancer Center	\$899,991
23	RP250044	IIRACSBC	2.0	Heterogeneity of resistance to endocrine therapy and Cdk inhibition: An integrated systems biology approach to biologically informed treatment regimens	Brock, Amy	The University of Texas at Austin	\$763,596
24	RR250072	REI	2.0	Mechanisms behind copper dependence of cancer cells	Wittung Stafshede, Pernilla	Rice University	\$6,000,000
25	RR250061	RFTFM	2.0	Engineered antibody tools for targeted regulation of cancer-associated proteins and organelles through redirected autophagy process	Jiang, Ziwen	The University of Texas at Dallas	\$2,000,000
26	RP250398	IIRA	2.1	Synthetic lethality of TRIP13 and Aurora A in Rb-deficient cancer	Johnson, Faye	The University of Texas M. D. Anderson Cancer Center	\$899,994
27	RP250402	IIRA	2.1	Exploiting Tryptophan Metabolite Addiction to identify and Inhibit HCC	Conacci Sorrell, Maralice	The University of Texas Southwestern Medical Center	\$900,000
28	RP250131	IIRACT2	2.1	Randomized Clinical Trial Evaluating Fecal Microbiota Transplant in Chimeric Antigen Receptor Therapy for Reversing Antimicrobial-Associated Dysbiosis	Saini, Neeraj	The University of Texas M. D. Anderson Cancer Center	\$1,598,410
29	RP250282	IIRA	2.2	Harnessing BACH2 to enhance anti-tumor T cell immunity	Yao, Chen	The University of Texas Southwestern Medical Center	\$900,000
30	RP250280	IIRA	2.2	The role of glutathione in leukemia development	Agathocleous, Michalis	The University of Texas	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

						Southwestern Medical Center	
31	RP250062	IIRA	2.3	Clonal hematopoiesis and toxicity from radiation therapy	Nead, Kevin	The University of Texas M. D. Anderson Cancer Center	\$899,885
32	RP250407	IIRA	2.3	Protecting the GI tract with a C60 fullerene derivative to facilitate dose-escalated abdominopelvic radiotherapy	Mackeyev, Yuri	The University of Texas Health Science Center at Houston	\$900,000
33	RP250055	IIRA	2.4	TET2 mutations promote myeloid malignancies by dysregulating m5C oxidation of chromatin-associated RNAs	Xu, Mingjiang	The University of Texas Health Science Center at San Antonio	\$900,000
34	RP250391	IIRA	2.5	Novel PCDH7 monoclonal antibodies that direct immune surveillance and combat drug resistance in lung cancer	O'Donnell, Kathryn	The University of Texas Southwestern Medical Center	\$900,000
35	RP250321	IIRACT2	2.5	Leveraging synthetic and collateral lethality in MTAP loss tumors	Rodon Ahnert, Jordi	The University of Texas M. D. Anderson Cancer Center	\$1,599,783
36	RP250069	IIRA	2.6	HSP90 Capacitance: Discovery of a New Mechanism Driving Evolution of Drug Resistance in Head and Neck Squamous Cell Carcinoma	Karras, Georgios	The University of Texas M. D. Anderson Cancer Center	\$890,201
37	RP250305	IIRA	2.6	Exploiting synthetic lethality between HNRNPK loss and ribosomal dysfunction in del9q AML	Post, Sean	The University of Texas M. D. Anderson Cancer Center	\$896,322
38	RP250091	IIRA	2.6	Dissecting the Survival Mechanisms of Latent Brain-Tropic Cancer Cells for Therapeutic Interventions	Malladi, Srinivas	The University of Texas Southwestern Medical Center	\$900,000
39	RP250322	IIRA	2.6	Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2-mutant non-small cell lung cancer (NSCLC)	Heymach, John	The University of Texas M. D. Anderson Cancer Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

40	RP250154	IIRA	2.6	Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients	Fuentes, David	The University of Texas M. D. Anderson Cancer Center	\$899,808
41	RP250156	IIRAP	2.6	Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer	Wu, Jia	The University of Texas M. D. Anderson Cancer Center	\$1,200,000
42	RP250094	IIRACT2	2.7	A phase 2 clinical trial with Avasopasem, with anti-estrogen therapy (ET) and a CDK4/6 inhibitor in metastatic breast cancer progressing on ET/CDK4/6 therapy.	Gius, David	The University of Texas Health Science Center at San Antonio	\$1,390,420
43	RP250418	IIRAP	2.7	Approach Bias Retraining to Augment Long-Term Smoking Cessation Among a Diverse Sample	Garey, Lorra	University of Houston	\$1,200,000
44	RP250355	CAP-CAC-CR	2.8	The Texas Collaborative Center for Hepatocellular Cancer (TeCH)	El-Serag, Hashem	Baylor College of Medicine	\$3,000,000
45	RP250119	IIRACCA	2.8	Comparison of Symptom Burden, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients treated with Surgery vs. Surgery and Chemotherapy	Kahalley, Lisa	Baylor College of Medicine	\$1,200,000
46	RP250190	IIRACCA	2.8	Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-Exercise Intervention	Swartz, Maria	The University of Texas M. D. Anderson Cancer Center	\$1,199,756
47	RP250182	IIRAP	2.8	Implementing Newborn Screening for Pediatric Cancer Predisposition Syndromes in Texas: The INSPECT Study	Parsons, Donald	Baylor College of Medicine	\$1,187,187
48	RP250097	IIRA	2.9	Deciphering and targeting age-related metastatic	Naora, Honami	The University of Texas M. D.	\$899,984

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				competence of the omentum		Anderson Cancer Center	
49	RP250099	IIRA	2.9	Targeting lethal prostate cancers with a clinical-stage inverse agonist for G protein-coupled receptor 6	Li, Wenliang	The University of Texas Health Science Center at Houston	\$900,000
50	RP250399	IIRACSBC	2.9	Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture	Vokes, Natalie	The University of Texas M. D. Anderson Cancer Center	\$1,049,033
51	RP250090	IIRACSBC	2.9	Artificial Intelligence for Early Identification of Androgen-Indifferent, Lethal Prostate Cancer and Therapy Selection	Merényi, Erzsébet	Rice University	\$1,049,434
52	RP250191	IIRA	3.1	Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$898,263
53	RP250164	IIRACCA	3.1	Prediction of CAR-T Cell Immunotherapy Outcomes in Neuroblastoma using FE-MRI Nano-radiomics	Ghaghada, Ketan	Baylor College of Medicine	\$1,168,013

Core Facility Support Award (CFSA)

Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal)

Individual Investigator Research Awards (IIRA)

Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)

Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)

Individual Investigator Research Awards for Clinical Trials (IIRACT)

Individual Investigator Research Awards for Early Onset Cancers (IIRAEOC)

Individual Investigator Research Awards for Prevention and Early Detection (IIRAP)

Recruitment of Established Investigators (REI)

Recruitment of Rising Stars (RRS)

Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research Recruitment
FY 2025—Cycles 2-3**

***Recruitment of First-Time, Tenure-Track
Faculty Members***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-25.1-RFT

**Recruitment of First-Time, Tenure-Track
Faculty Members**

**Please also refer to the Instructions for Applicants document,
which will be posted on June 21, 2024**

**Application Receipt Dates:
June 21, 2024-June 20, 2025**

FY 2025

Fiscal Year Award Period
September 1, 2024-August 31, 2025

TABLE OF CONTENTS

1. ABOUT CPRIT	4
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	4
2. RATIONALE	5
3. RECRUITMENT OBJECTIVES	6
4. INSTITUTIONAL COMMITMENT	7
5. FUNDING INFORMATION	7
6. ELIGIBILITY	8
7. RESUBMISSION POLICY	10
8. RESPONDING TO THIS RFA	10
8.1. APPLICATION SUBMISSION GUIDELINES	10
8.2. APPLICATION COMPONENTS	11
8.2.1. <i>Summary of Nomination (2,000 characters)</i>	11
8.2.2. <i>Layperson’s Summary (2,000 characters)</i>	11
8.2.3. <i>Summary of Specific Aims and Sub Aims (2,000 characters)</i>	12
8.2.4. <i>Specific Aims and Sub Aims</i>	12
8.2.5. <i>Institutional Commitment (3 pages)</i>	12
8.2.6. <i>Letter of Support from Department Chair (up to 2 pages)</i>	14
8.2.7. <i>Curriculum Vitae (CV)</i>	15
8.2.8. <i>Research (4 pages)</i>	15
8.2.9. <i>Publications/References (1 page)</i>	16
8.2.10. <i>Research Collaboration/Synergy Plan (2 pages)</i>	16
8.2.11. <i>Publications</i>	16
8.2.12. <i>Timeline (1 page)</i>	16
8.2.13. <i>Current and Pending Support</i>	17
8.2.14. <i>Letters of Recommendation</i>	17
8.2.15. <i>Research Environment (1 page)</i>	17
8.2.16. <i>Descriptive Biography (Up to 2 pages)</i>	17
9. APPLICATION REVIEW	18
9.1. REVIEW PROCESS.....	18
9.1.1. <i>Confidentiality of Review</i>	18
9.2. REVIEW CRITERIA.....	19
10. KEY DATES	20
11. AWARD ADMINISTRATION	21
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	22
13. CONTACT INFORMATION	23
13.1. HELPDESK.....	23
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	23

RFA VERSION HISTORY

6/21/24	RFA release
8/2/24	Modified language under Section 8.2.6: Letter of Support from Department Chair

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas
- Develop and implement the Texas Cancer Plan

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

To accomplish CPRIT's long-term vision, the Oversight Committee has identified these 2025 priorities:

- Investing in the cancer research capacity of Texas institutions through recruitment of cancer scholars, investment in core facilities, and investment in individual investigator awards in all regions of the state;
- Building the Texas cancer life science ecosystem across Texas by bridging discovery and translational research into early-stage company products with high impact on cancer patient care and creating economic development for the State of Texas; and
- Increasing the capacity for Texas to have a significant impact on cancer prevention and early detection, ultimately decreasing cancer incidence and mortality.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state

- Reducing disparities in cancer incidence and mortality

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access

2. RATIONALE

The aim of this award mechanism is to bolster cancer research in Texas by providing financial support to attract very promising investigators who are pursuing their first faculty appointment at the level of assistant professor (first-time, tenure-track faculty members). These individuals must have demonstrated academic excellence, innovation during predoctoral and/or postdoctoral research training, commitment to pursuing cancer research, and exceptional potential for achieving future impact in basic, translational, population-based, or clinical research. Awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research, thereby advancing cancer research and prevention efforts, and promoting economic development in the State of Texas.

The recruitment of outstanding scientists will greatly enhance programs of scientific excellence in cancer research and will position Texas as a leader in the fight against cancer. Applications may address any research topic related to cancer biology, causation, prevention, detection or screening, treatment, or survivorship. Principal Investigators (PIs) with research programs addressing CPRIT's priority areas for research are encouraged. These include implementation

research to accelerate the adoption and deployment of evidence-based prevention and screening interventions, computational oncology and analytic methods, research including population-based research addressing cancer disparities, childhood and adolescent cancers, hepatocellular cancer, and expansion of access to innovative clinical trials.

3. RECRUITMENT OBJECTIVES

The goal of this award mechanism is to recruit exceptional faculty to universities and/or cancer research institutions in the State of Texas. All PIs are expected to have completed their doctoral and fellowship training and to have clearly demonstrated truly superior ability as evidenced by their accomplishments during training, proposed research plan, publication record, and letters of recommendation. This CPRIT-supported initiative is designed to enhance innovative programs of excellence by providing research support for promising, early-stage investigators **seeking their first tenure-track position.**

CPRIT will provide start-up funding for newly independent investigators, with the goal of augmenting and expanding the institution's efforts in cancer research. PIs will be expected to develop research projects within the sponsoring institution. Projects should be appropriate for a newly independent investigator and should foster the development of preliminary data that can be used to prepare applications for future independent research project grants to further both the investigator's research career and the CPRIT mission. The institution will be expected to work with each newly recruited research faculty member to design and execute a faculty career development plan consistent with his or her research emphasis. Relevance to cancer research and to CPRIT's priority areas are important evaluation criteria for CPRIT funding.

Applications nominating individuals who are well prepared to pursue careers in patient-oriented research and who have demonstrated exceptional potential to lead innovative discovery campaigns through conduct of clinical trials are appropriate for this mechanism and are encouraged.

Additionally, population research that addresses the burden of cancer in Texas is a priority for CPRIT. Applications nominating individuals who have demonstrated exceptional ability to lead innovative research programs involving any component across the continuum of cancer prevention and control research are appropriate for this mechanism and are highly encouraged.

Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of “CPRIT Scholar in Cancer Research,” and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

4. INSTITUTIONAL COMMITMENT

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world’s best talent in cancer research to Texas. The funds provided by CPRIT for the Recruitment of a First-Time, Tenure-Track Faculty Member (RFTTFM) Award must therefore be complemented by a strong institutional commitment to the PI’s career development that includes financial commitments that are in addition to the CPRIT award. The institutional commitment should be clearly documented in the application (see [section 8.2.5](#)) and include the amount and sources of salary support and all additional financial support that will be available to the PI’s research program through the course of the CPRIT award. The financial commitments made to the PI for his or her research program by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

5. FUNDING INFORMATION

This award is up to 5 years and is not renewable, although individuals may apply for other future CPRIT funding as appropriate. Grant funds of up to \$2,000,000 (total costs) for the 5-year period may be requested. Applicants are encouraged to tailor the budget as appropriate to the exigencies of the project; grant funds totaling less than \$2,000,000 for the term of the award are acceptable if warranted by the scope of the research. Funding is to be used by the PI to support his or her research program. The award request may include indirect costs of up to 5% of the total award amount (5.263% of the direct costs). CPRIT will make every effort to be flexible in the timing for disbursement of funds; recipients will be asked at the beginning of each year for an estimate of their needs for the year. Funds may not be carried over beyond 5 years except under extraordinary circumstances with strong justification for a no-cost extension. In addition, funds for extraordinary equipment needs may be awarded in the first year of the grant if very well justified and a detailed justification is provided along with an institutional plan should the

additional funds not be approved. Scholars may request funds for travel for 2 project staff to attend CPRIT's conference.

Funds from this CPRIT award may not be used for salary support of this PI or to construct or renovate laboratory space.

No annual limit on the number of grant application submissions for institutions has been set.

Note: In the event of insufficient funds, specific recruitment categories may be eliminated (example REI/RRS/RFTTFM) and nominations for specific categories may be closed for the remaining cycles of the fiscal year. Additionally, depending on the availability of funds, review cycles may be reduced, and/or the number of applications per institution may be capped, and recommended nominations submitted in response to this Request for Applications (RFA) during the current receipt period may be announced and awarded either in the current fiscal year (prior to August 31, 2025) or in the first quarter of the next fiscal year (starting September 1, 2025).

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism.
- PIs must be nominated by the president, provost, vice president for research, or appropriate dean of a Texas-based public or private institution of higher education, including academic health institutions. The application must be submitted on behalf of a specific PI.
- A PI may be nominated by only 1 institution. If more than 1 institution is interested in a given PI, negotiations as to which institution will nominate him or her must be concluded before the nomination is made.
- No annual limit on the number of grant submissions per institutions has been set.
- A PI who has already accepted a position as a tenure-track assistant professor at the recruiting institution prior to the time that the Scientific Review Council reviews the PI for a recruitment award is not eligible for a recruitment award, as an investment by CPRIT is obviously not necessary. No award is final until approved by the Oversight Committee at a public meeting. However, in recognition of the timeline involved with

recruiting highly sought-after PIs who are often considering multiple offers, CPRIT's Academic Research program staff will notify the nominating institution of the Scientific Review Council's review decision following the Scientific Review Council meeting. If a position is offered to the PI during the period following the Scientific Review Council's review decision but prior to the Oversight Committee's final approval, the institution does so at its own risk. There is no guarantee that the recruitment award will be approved by the Oversight Committee.

- The PI must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, **and reside in Texas for the duration of the appointment.** The PI must devote at least 70% effort to research activities. PIs whose major responsibilities are clinical care, teaching, or administration are not eligible.
- At the time of the application, the PI must **not** hold an appointment at the rank of assistant professor or above (or equivalent) at an accredited academic institution, research institution, industry, government agency, or private foundation. PIs holding non-tenure-track appointments at the rank of assistant professor are **not** eligible for this award. Examples of such appointments include research assistant professor, adjunct research assistant professor, assistant professor (non-tenure track).
- The PI **may or may not** reside in Texas at the time the application is submitted and may be nominated for a faculty position at the Texas institution where he or she is completing postdoctoral training or at another Texas institution.
- Applications nominating a PI for a faculty position at the Texas institution where he or she is completing postdoctoral training that do not clearly demonstrate a subsequent career pathway to independence for the PI will not be looked upon with favor.
- Successful PIs will be offered tenure-track academic positions at the rank of assistant professor.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.

- An applicant is not eligible to receive a CPRIT grant award if the applicant nominator, any senior member, or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the nominator, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not the individuals will receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

Resubmissions will not be accepted for the RFTTFM Award mechanism. Any nomination for the RFTTFM Award that was previously submitted to CPRIT and reviewed but was not recommended for funding may not be resubmitted. If a nomination was administratively rejected prior to review, it can be resubmitted in the following cycles.

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted. PIs must be nominated by

the institution's president, provost, vice president for research, or appropriate dean. The individual submitting the application (nominator) must create a user account in the system (which includes the nominator's credentials and email address) to start and submit an application. Furthermore, the Application Signing Official, who is the person authorized to sign and submit the application for the organization, and the Grants Contract/Office of Sponsored Projects Official, who is the individual who will manage the grant contract if an award is made, also must create a user account in CARS.

Dependent upon available funding, applications will be accepted on a revised schedule for FY25 (See [section 10](#) for RFA schedule).

For an application to be considered for review during the cycle, that application must be submitted on or before 11:59 PM central time on the 20th day of that cycle. In the event that the closing date falls on Saturday or Sunday, applications may be submitted on or before 11:59 PM central time the following Monday. CPRIT will not extend the submission deadline. During periods when CPRIT does not receive an adequate number of applications, the review may be extended into the following month. Nominators will be notified if this occurs. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. For details, please refer to the Instructions for Applicants (IFA) document that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

8.2.1. Summary of Nomination (2,000 characters)

Provide a brief summary of the nomination. Include the PI's name, organization from which the PI is being recruited, and also the department and/or entity within the nominator's organization where the PI will hold the faculty position.

8.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. **This section must be completed by the PI.** Describe, in simple, nontechnical terms, the overall aims of the proposed work, the type(s) of

cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. Do not include any proprietary information in the layperson's summary.

8.2.3. Summary of Specific Aims and Sub Aims (2,000 characters)

Please provide a summary of the aims of the proposal. **This section must be completed by the PI.** The specific aims summary should identify the problem or gap in our current knowledge. It should present a hypothesis and briefly describe the aims and approaches and address the proposal's innovation, novel approaches, and significance and impact on the field and cancer research.

8.2.4. Specific Aims and Sub Aims

List specific aims and sub aims to be achieved during this award. **This section must be completed by the PI.** These aims/sub aims will also be used during the submission and evaluation of progress reports and assessment of project success. Refer to the template specific aims and sub aims document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.5. Institutional Commitment (3 pages)

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the RFTTFM Award must therefore be complemented by a strongly documented institutional commitment to the PI's career development that includes financial commitments that are in addition to the CPRIT award.

The following guidelines should be followed when documenting the institutional commitment to the PI:

- The institutional commitment should be clearly documented in the form of a letter signed by the applicant institution's president, provost, or appropriate dean and include the amount and sources of salary support and all additional financial support that will be available to the PI's research program through the course of the CPRIT award. The

financial commitments made to the PI by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

- **The institutional commitment letter must include the following statement** regarding the institution's financial commitment required to meet the 50% match.
 - This institutional financial commitment will not be offset by funds from a career transition award (K99/R00) or an investigator-initiated award received by the PI. If an award dictates that such funds must be used for salary, the corresponding amount of institutional funds committed to pay the PI's salary will be redirected to allow the PI to use them for program support.
- Institutional commitment as described above must be presented in a table (example below) that clearly identifies the salary amount, sources of salary, and any additional research support from institutional sources over the course of the CPRIT award. Sources of support for the PI's full salary, including summer salary, for the duration of the award must be documented. If the PI is expected to provide salary support from grants during the award period, the institutional commitment must identify the source for salary support in the event grant support is not available. Note that a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the PI.
- Include a brief job description for the PI should recruitment be successful.
- Describe the institutional environment and any professional commitments to the PI including, but not limited to, dedicated personnel, access to students, space assignment, and access to shared equipment, and discuss all other agreements between the institution and the PI.
- Institutions may provide additional information in support of a PI's research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a PI's cancer research. This additional information is highly encouraged when proposing a PI with exceptional expertise and/or talent that can be directed to cancer research such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research.
- Note that Texas law allows an institution of higher learning to use its federal indirect cost rate credit to comply with the requirement to demonstrate that it has an amount of funds

equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award (see [section 12](#)). However, a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the PI.

Example of an acceptable Institutional Commitment table:

PI's Name, Institutional Commitments

	Year 1	Year 2	Year 3	Year 4	Year 5
*Salary/Benefits					
Research Support					
Administrative Support					
Moving Expenses					

Total =

***Sources of support for the PI's full salary, including summer salary, for the duration of the award must be documented.**

Note: CPRIT acknowledges that the institutional commitments by category may change during the course of the award; however, the total financial commitment to the PI must remain equal to or greater than 50% of the CPRIT award.

8.2.6. Letter of Support from Department Chair (up to 2 pages)

Provide the letter of support from and signed by the chair of the department to which the PI is being recruited. The following information should be included in the letter:

Recruitment Activities: CPRIT is committed to increasing the life sciences infrastructure in Texas via the recruitment of exceptional cancer researchers, as well as expanding research resources. The letter should provide a description of the recruitment activities, strategies, and priorities that have led to the nomination of this PI. Provide the necessary context by describing the institution's vision for the cancer programs, how the work of the nominee contributes to achieving these goals and the expected impact of the recruitment on the institution (or department) and the burden of cancer in Texas (if applicable).

Caliber of PI: The letter should include a description of the caliber of the PI and justification of the nomination of the PI by the institution. CPRIT recognizes that there is variability in the

metrics of impact applicable across the continuum of cancer research. For example, in some disciplines, research findings—although highly impactful on the field—are less likely to be published in the highest ranked journals, ie, *Science*, *Cell*, or *Nature* series. Thus, it is incumbent upon the institution to describe the impact of a nominee’s work, including paradigm-shifting, practice-changing, or influence on public policy, population health behavior, or cancer disparities.

Description of PI Duties and Certification of 70% Effort to Research: While scholars may engage in direct patient care activities and/or have some administrative or teaching duties, at least 70% of the PI’s effort must be committed to research. Breach of this requirement will constitute grounds for discontinuation of funding. The certification that 70% level of effort will be dedicated to research must be included.

The letter of support from the department chair must also do the following:

1. Describe how the PI will be independent and autonomous in developing his or her research program at the institution.
2. Present a plan for mentoring that includes the design and execution of a faculty career development plan for the PI.

8.2.7. Curriculum Vitae (CV)

Provide a complete CV and list of publications for the PI. Only articles that have been published or that have been accepted for publication (“in press”) should be cited.

8.2.8. Research (4 pages)

Summarize the key elements of the PI’s research accomplishments and provide an overview of the proposed research by outlining the background and rationale, hypotheses and aims, strategies, specific aims, and projected impact of the focus of the research program. Highlight the innovative aspects of this effort and place it into context with regard to what pressing problem in cancer will be addressed. **This section of the application must be prepared by the PI.**

References cited in this section should be included in the Publications/References section ([see 8.2.9](#)).

PIs for CPRIT Scholar Awards must include the following signed statement at the end of this section. **Applications that do not contain this signed statement will be returned without review.**

“I understand that I do not need to have made a commitment to <nominating institution> before this application has been submitted. However, I also understand that only 1 Texas institution may nominate me for a CPRIT Recruitment Award, and this is the nomination that I have endorsed. I understand that requests to change the recruiting institution during the recruitment process are not allowed after the application is submitted to CPRIT.”

8.2.9. Publications/References (1 page)

Provide a concise and relevant list of publications/references cited in the Research section of the application. Any appropriate citation format is acceptable; official journal abbreviations should be used.

8.2.10. Research Collaboration/Synergy Plan (2 pages)

Institutions may provide additional information in support of a PI’s research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a PI’s cancer research. This additional information is highly encouraged when proposing a PI with exceptional expertise and/or talent that can be directed to cancer research, such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research. Biographical sketches of collaborators established in the research collaborative plan must be uploaded as part of the application. This will be in addition to the 2-page synergy plan (see IFA).

8.2.11. Publications

Provide the 3 most significant publications that have resulted from the PI’s research efforts. Publications should be uploaded as PDFs of full-text articles. Only articles that have been published or that have been accepted for publication (“in press”) should be submitted.

8.2.12. Timeline (1 page)

Provide a general outline of anticipated major award outcomes to be tracked. Timelines will be reviewed during the evaluation of annual progress reports. If the application is approved for

funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.13. Current and Pending Support

State the funding source, duration, and title of all current and pending research support held by the PI. If the PI has no current or pending funding, a document stating this must be submitted. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.14. Letters of Recommendation

Provide 3 letters of recommendation from individuals who are in a position to detail the PI's academic and scientific research accomplishments, potential for high-impact research, and ability to make a significant contribution to the field of cancer research.

8.2.15. Research Environment (1 page)

Clearly and concisely describe the research environment available to support the PI's research program, including core facilities, training programs, and collaborative opportunities.

8.2.16. Descriptive Biography (Up to 2 pages)

Provide a brief descriptive biography of the PI, including his or her accomplishments, education and training, professional experience, awards and honors, publications relevant to cancer research, and a brief overview of the PI's specific aims, if selected, to receive the award. **This section of the application must be prepared by the PI.** If the application is approved for funding, this section will be made publicly available on CPRIT's website. PIs are advised not to include information that they consider confidential or proprietary when preparing this section.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or do not meet the eligibility requirements listed above will be administratively withdrawn without review.

9. APPLICATION REVIEW

9.1. Review Process

All eligible applications will be evaluated and scored by the CPRIT Scientific Review Council using the criteria listed in this RFA. Applications may be submitted continuously in response to this RFA but will be reviewed by the CPRIT Scientific Review Council according to the revised schedule (see [section 10](#) for RFA schedule). Council members may seek additional ad hoc evaluations of PIs. Scientific Review Council members will review applications and provide an individual Overall Evaluation Score that conveys the members' recommendation related to the proposed recruitment. Applications recommended by the Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review, prioritization, and recommendation to the CPRIT Oversight Committee for approval and funding. Approval is based on an application receiving a positive vote from at least two-thirds of the members of the Oversight Committee. The review process is described more fully in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

The decision of the Scientific Review Council not to recommend an application is final, and such applications may not be resubmitted for a recruitment award. Notification of review decisions is sent to the nominator.

9.1.1. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, or a Scientific Review Council member.

Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of the Department of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

9.2. Review Criteria

Applications will be assessed based on evaluation of the quality of the PI and his or her potential for continued superb performance as a cancer researcher. **Also, of critical importance is the strength of the institutional commitment to the PI. Recruitment efforts are not likely to be successful unless there is a strong commitment from both CPRIT and the host institution.** It is not necessary that a PI agrees to accept the recruitment offer at the time an application is submitted. However, applicant institutions should have an expectation that the recruitment will be successful if an award is granted by CPRIT. It is the expectation that the nominating institution provides CPRIT with a status of the award acceptance as soon as status is known.

Review criteria will focus on the overall impression of the PI, his or her proposed research program, and his or her long-term potential for contributions to, and impact on, the field of cancer research. Questions to be considered by the reviewers are as follows:

Quality of the PI: Has the PI demonstrated academic excellence? Has the PI received excellent predoctoral and postdoctoral training? Does the PI show exceptional potential for achieving future impact on basic, translational, clinical, or population-based cancer research in the future? Has the PI demonstrated a commitment to cancer research? Has the PI demonstrated independence or the potential for independence?

Scientific Merit of Proposed Research: Is the research plan comprehensive and well thought out? Does the proposed research program demonstrate innovation, creativity, and feasibility? Will it have a significant impact on the field of cancer research? Will the proposed research

generate preliminary data that can be used for the preparation of applications for future independent research project grants?

Relevance of PI’s Research: Is the proposed research likely to have a significant impact on reducing the burden of cancer in the near term or address unique aspects of the burden of cancer in Texas? Does the research contribute to basic, translational, clinical, or population-based cancer research?

Letters of Recommendation: Do the letters of recommendation detail the PI’s academic and clinical research accomplishments, potential for high-impact research, and ability to make a significant contribution to the field of cancer research?

Research Environment: Does the institution have the necessary facilities, expertise, and resources to support the PI’s research? Is there evidence of strong institutional support? Will the PI be free of major administrative/clinical responsibilities so that he or she can focus on growing his or her research? Has the institution identified a mentor who will design and execute a faculty career development plan for the PI?

10. KEY DATES

RFA Schedule

RFA Release June 21, 2024

Review Cycle Dates

Review Cycle	Cycle Opens	Cycle Closes	Oversight Committee Review	Potential Award Date
25.1	6/21/24	8/20/24	11/20/24	12/1/24
25.2	8/21/24	10/21/24*	2/19/25	3/1/25
25.3	10/22/24	11/20/24	2/19/25	3/1/25
25.4	11/21/24	1/20/25	5/21/25	6/1/25
25.5	1/21/25	2/20/25	5/21/25	6/1/25
25.6	2/21/25	3/20/25	5/21/25	6/1/25
25.7	3/21/25	4/21/25*	8/20/25	8/31/25
25.8	4/22/25	5/20/25	8/20/25	8/31/25
25.9	5/21/25	6/20/25	8/20/25	8/31/25

*Cycle close extended due to the 20th falling on a Sunday

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Awards made under this RFA are not transferable to another institution. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov.

Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the specific aims and address plans for the upcoming year.

Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. CPRIT requires funding acknowledgement to include the award grant ID

on all print and visual materials that are funded in whole or in part by CPRIT grants. Examples of print and visual materials include, but are not limited to, publications, brochures, pamphlets, project websites, videos, and media materials. Grantees must have written approval from CPRIT prior to the purchase of any equipment. If the equipment is clearly defined in the grantee's budget submitted with the initiating award requirements, then approval of the grant award constitutes "prior approval" for the purchase. Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#), for specific requirements regarding the demonstration of available funding.

13. CONTACT INFORMATION

13.1. Helpdesk

The Helpdesk will answer queries submitted via email within 1 business day. Helpdesk support is available for questions regarding user registration, online submission of applications as well as page limitations, formatting, and how to upload application components/subsections in the appropriate tabs of CARS. Helpdesk staff cannot answer scientific or programmatic questions. Before contacting the Helpdesk, please refer to the *Instructions for Applicants* document, which provides a step-by-step guide on using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Scientific and programmatic questions should be directed to the CPRIT Director of Academic Research. **Before contacting CPRIT, please refer to the *Instructions for Applicants* document and contact the Helpdesk for any items related to CARS, page limitations, formatting, etc.**

Email: Research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports

Cancer Prevention and Research Institute of Texas (CPRIT)**25.2 Academic Research Recruitment Review Panel****(25.2 REC)****Observation Report**

Report No. 2024-11-14 25.2_REC
Program Name: Academic Research
Panel Name: 25.2 Academic Research Recruitment Review Panel (25.2_REC)
Panel Date: November 14, 2024
Report Date: November 18, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.2 Academic Research Recruitment Review Panel (25.2_REC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on November 14, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seven (7) applications were discussed
- Panelists: One (1) panel chair, eight (8) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning the application(s) for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over a light blue horizontal line.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)**25.3 Academic Research Recruitment Review Panel-25.3****(REC 25.3)****Observation Report**

Report No. 2024-12-12 25.3_REC
Program Name: Academic Research
Panel Name: 25.3 Academic Research Recruitment Review Panel - 25.3
(REC_25.3)
Panel Date: December 12, 2024
Report Date: December 18, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.3 Academic Research Recruitment Review Panel-25.3 (REC_25.3) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 12, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Five (5) applications were discussed
- Panelists: One (1) panel chair, eight (8) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Recruitment Cycles 25.2-25.3

Awards Announced at the February 19, 2025, Oversight Committee Meeting

The following table lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Recruitment cycles 25.2-25.3 include *Recruitment of Established Investigators*; *Recruitment of Rising Stars*; and *Recruitment of First-Time, Tenure-Track Faculty Members*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RR250072	Pernilla Wittung Stafshede	Rice University	Carol Prives
Applications not considered by the PIC or Oversight Committee:			
RR250065	Neil Bhowmick	Baylor College of Medicine	Peter Jones

De-Identified Overall Evaluation Scores

Recruitment of First-Time, Tenure-Track Faculty Members

Academic Research Recruitment Cycles 25.2-25.3

Application ID	Final Overall Evaluation Score
RR250077*	1.0
RR250070*	1.0
RR250063*	1.1
RR250071*	1.1
RR250061*	2.0
b	5.0

* Recommended for funding.

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

January 5, 2025

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Ms. Kristen Doyle
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to kdoyle@cprit.texas.gov

Dear Dr. Cummings and Ms. Doyle,


The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for the Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal); Core Facility Support Award (FY2024); Individual Investigator Research Awards; Individual Investigator Research Awards for Childhood and Adolescent Cancers; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; Investigator Research Awards for Early-Onset Cancers; Individual Investigator Research Awards for Prevention and Early Detection; Recruitment of Established Investigators; Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 12, 2024 to consider the FY25.1 applications recommended by the peer review panels following their meetings held October 16, 2024 to October 24, 2024 and one FY24.2 Core Facility application recommended by a peer review panel on April 24, 2024. The SRC met on November 14, 2024 to review recruitment applications submitted for Cycle FY25.2 and then on December 12, 2024 to review recruitment applications submitted for Cycle FY25.3.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the 53 recommended applications is \$67,753,626.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Chair, CPRIT Scientific Review Council

Rank	Grant ID	RFA	Score	Title	PI	Institution	Recommended Budget
1	RP250118	IIRA	1.0	Ribosome Localization at Mitochondria-ER Contacts in Obesity-Associated Liver Cancer	Morita, Masahiro	The University of Texas Health Science Center at San Antonio	\$900,000
2	RP250061	IIRA	1.0	Imaging of cranial radiotherapy neuroinflammatory sequelae by Positron Emission Tomography	Pisaneschi, Federica	The University of Texas Health Science Center at Houston	\$900,000
3	RR250077	RFTFM	1.0	Developing next generation of genome editing tools to study and engineer genetic variants for effective precision cancer treatment	Gao, Xin "Daniel"	Baylor College of Medicine	\$2,000,000
4	RR250070	RFTFM	1.0	Unlocking the Potential of Clonal Hematopoiesis in Early Detection and Interception of Lymphoid Malignancies	Griffin, Rosalie	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
5	RR250063	RFTFM	1.1	Co-opting antiviral innate immune pathways to target non-small cell lung cancer	Zou, Tao	The University of Texas Southwestern Medical Center	\$2,000,000
6	RR250071	RFTFM	1.1	CRISPR screening to uncover tumor intrinsic modulators of DNA repair and immune effects of radiation therapy	Verma, Nipun	Baylor College of Medicine	\$2,000,000
7	RP250278	IIRACCA	1.2	Developmental origins of IDH-mutant glioma in adolescents	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,198,416
8	RP250293	IIRAP	1.2	Development of a shared decision tool to facilitate uptake of the levonorgestrel-releasing intrauterine system for the primary prevention of endometrial cancer	Meyer, Larissa	The University of Texas M. D. Anderson Cancer Center	\$1,199,542
9	RP250208	IIRA	1.4	RPS23 is a new drug target to activate the integrated stress response and treat leukemia	Ready, Joseph	The University of Texas Southwestern Medical Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

10	RP250201	IIRA	1.4	Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in oral cavity squamous cell carcinoma	Gillison, Maura	The University of Texas M. D. Anderson Cancer Center	\$899,998
11	RP250028	IIRA	1.5	MALAT1 protects against osteoporosis and bone metastasis	Ma, Li	The University of Texas M. D. Anderson Cancer Center	\$900,000
12	RP250247	IIRA	1.5	Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETS	Yao, James	The University of Texas M. D. Anderson Cancer Center	\$900,000
13	RP250144	IIRACCA	1.5	Decoding how neuronal activity remodels the epigenome in ependymoma	Deneen, Benjamin	Baylor College of Medicine	\$1,200,000
14	RP250220	IIRA	1.8	Decellularized tissue matrices to study the “bad soil” in cancer metastasis	Wang, Andrew	The University of Texas Southwestern Medical Center	\$900,000
15	RP250269	IIRAP	1.8	Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules.	Ostrin, Edwin	The University of Texas M. D. Anderson Cancer Center	\$1,169,776
16	RP250222	IIRA	1.9	KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC	Gibbons, Don	The University of Texas M. D. Anderson Cancer Center	\$899,997
17	RP250043	IIRA	1.9	An integrated imaging informatics platform for HCC surveillance	Zhou, Xiaobo	The University of Texas Health Science Center at Houston	\$899,991
18	RP250374	IIRACCA	1.9	Dissecting TFE3 Mediated tRCC Tumorigenesis	Brugarolas, James	The University of Texas Southwestern Medical Center	\$1,196,812
19	RP240537	CFSA	2.0	Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core	Wu, Erxi	Baylor Research Institute	\$2,999,989
20	RP250213	IIRA	2.0	KRAS spatiotemporal dynamics: lipid glycosylation as a novel therapeutic target	Hancock, John	The University of Texas Health Science Center at Houston	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

21	RP250428	IIRA	2.0	Studying Hematopoietic Stem Cells to Predict and Understand Mechanisms of Post-transplant Relapse in the Myelodysplastic Syndromes	Chung, Stephen	The University of Texas Southwestern Medical Center	\$899,025
22	RP250143	IIRA	2.0	Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy	Lissanu, Yonathan	The University of Texas M. D. Anderson Cancer Center	\$899,991
23	RP250044	IIRACSBC	2.0	Heterogeneity of resistance to endocrine therapy and Cdk inhibition: An integrated systems biology approach to biologically informed treatment regimens	Brock, Amy	The University of Texas at Austin	\$763,596
24	RR250072	REI	2.0	Mechanisms behind copper dependence of cancer cells	Wittung Stafshede, Pernilla	Rice University	\$6,000,000
25	RR250061	RFTFM	2.0	Engineered antibody tools for targeted regulation of cancer-associated proteins and organelles through redirected autophagy process	Jiang, Ziwen	The University of Texas at Dallas	\$2,000,000
26	RP250398	IIRA	2.1	Synthetic lethality of TRIP13 and Aurora A in Rb-deficient cancer	Johnson, Faye	The University of Texas M. D. Anderson Cancer Center	\$899,994
27	RP250402	IIRA	2.1	Exploiting Tryptophan Metabolite Addiction to identify and Inhibit HCC	Conacci Sorrell, Maralice	The University of Texas Southwestern Medical Center	\$900,000
28	RP250131	IIRACT2	2.1	Randomized Clinical Trial Evaluating Fecal Microbiota Transplant in Chimeric Antigen Receptor Therapy for Reversing Antimicrobial-Associated Dysbiosis	Saini, Neeraj	The University of Texas M. D. Anderson Cancer Center	\$1,598,410
29	RP250282	IIRA	2.2	Harnessing BACH2 to enhance anti-tumor T cell immunity	Yao, Chen	The University of Texas Southwestern Medical Center	\$900,000
30	RP250280	IIRA	2.2	The role of glutathione in leukemia development	Agathocleous, Michalis	The University of Texas	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

						Southwestern Medical Center	
31	RP250062	IIRA	2.3	Clonal hematopoiesis and toxicity from radiation therapy	Nead, Kevin	The University of Texas M. D. Anderson Cancer Center	\$899,885
32	RP250407	IIRA	2.3	Protecting the GI tract with a C60 fullerene derivative to facilitate dose-escalated abdominopelvic radiotherapy	Mackeyev, Yuri	The University of Texas Health Science Center at Houston	\$900,000
33	RP250055	IIRA	2.4	TET2 mutations promote myeloid malignancies by dysregulating m5C oxidation of chromatin-associated RNAs	Xu, Mingjiang	The University of Texas Health Science Center at San Antonio	\$900,000
34	RP250391	IIRA	2.5	Novel PCDH7 monoclonal antibodies that direct immune surveillance and combat drug resistance in lung cancer	O'Donnell, Kathryn	The University of Texas Southwestern Medical Center	\$900,000
35	RP250321	IIRACT2	2.5	Leveraging synthetic and collateral lethality in MTAP loss tumors	Rodon Ahnert, Jordi	The University of Texas M. D. Anderson Cancer Center	\$1,599,783
36	RP250069	IIRA	2.6	HSP90 Capacitance: Discovery of a New Mechanism Driving Evolution of Drug Resistance in Head and Neck Squamous Cell Carcinoma	Karras, Georgios	The University of Texas M. D. Anderson Cancer Center	\$890,201
37	RP250305	IIRA	2.6	Exploiting synthetic lethality between HNRNPK loss and ribosomal dysfunction in del9q AML	Post, Sean	The University of Texas M. D. Anderson Cancer Center	\$896,322
38	RP250091	IIRA	2.6	Dissecting the Survival Mechanisms of Latent Brain-Tropic Cancer Cells for Therapeutic Interventions	Malladi, Srinivas	The University of Texas Southwestern Medical Center	\$900,000
39	RP250322	IIRA	2.6	Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2-mutant non-small cell lung cancer (NSCLC)	Heymach, John	The University of Texas M. D. Anderson Cancer Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

40	RP250154	IIRA	2.6	Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients	Fuentes, David	The University of Texas M. D. Anderson Cancer Center	\$899,808
41	RP250156	IIRAP	2.6	Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer	Wu, Jia	The University of Texas M. D. Anderson Cancer Center	\$1,200,000
42	RP250094	IIRACT2	2.7	A phase 2 clinical trial with Avasopasem, with anti-estrogen therapy (ET) and a CDK4/6 inhibitor in metastatic breast cancer progressing on ET/CDK4/6 therapy.	Gius, David	The University of Texas Health Science Center at San Antonio	\$1,390,420
43	RP250418	IIRAP	2.7	Approach Bias Retraining to Augment Long-Term Smoking Cessation Among a Diverse Sample	Garey, Lorra	University of Houston	\$1,200,000
44	RP250355	CAP-CAC-CR	2.8	The Texas Collaborative Center for Hepatocellular Cancer (TeCH)	El-Serag, Hashem	Baylor College of Medicine	\$3,000,000
45	RP250119	IIRACCA	2.8	Comparison of Symptom Burden, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients treated with Surgery vs. Surgery and Chemotherapy	Kahalley, Lisa	Baylor College of Medicine	\$1,200,000
46	RP250190	IIRACCA	2.8	Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-Exercise Intervention	Swartz, Maria	The University of Texas M. D. Anderson Cancer Center	\$1,199,756
47	RP250182	IIRAP	2.8	Implementing Newborn Screening for Pediatric Cancer Predisposition Syndromes in Texas: The INSPECT Study	Parsons, Donald	Baylor College of Medicine	\$1,187,187
48	RP250097	IIRA	2.9	Deciphering and targeting age-related metastatic	Naora, Honami	The University of Texas M. D.	\$899,984

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				competence of the omentum		Anderson Cancer Center	
49	RP250099	IIRA	2.9	Targeting lethal prostate cancers with a clinical-stage inverse agonist for G protein-coupled receptor 6	Li, Wenliang	The University of Texas Health Science Center at Houston	\$900,000
50	RP250399	IIRACSBC	2.9	Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture	Vokes, Natalie	The University of Texas M. D. Anderson Cancer Center	\$1,049,033
51	RP250090	IIRACSBC	2.9	Artificial Intelligence for Early Identification of Androgen-Indifferent, Lethal Prostate Cancer and Therapy Selection	Merényi, Erzsébet	Rice University	\$1,049,434
52	RP250191	IIRA	3.1	Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$898,263
53	RP250164	IIRACCA	3.1	Prediction of CAR-T Cell Immunotherapy Outcomes in Neuroblastoma using FE-MRI Nano-radiomics	Ghaghada, Ketan	Baylor College of Medicine	\$1,168,013

Core Facility Support Award (CFSA)

Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal)

Individual Investigator Research Awards (IIRA)

Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)

Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)

Individual Investigator Research Awards for Clinical Trials (IIRACT)

Individual Investigator Research Awards for Early Onset Cancers (IIRAEOC)

Individual Investigator Research Awards for Prevention and Early Detection (IIRAP)

Recruitment of Established Investigators (REI)

Recruitment of Rising Stars (RRS)

Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2024—Cycle 2
*Core Facility Support Awards***

Updated February 2025

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS

RFA R-24.2-CFSA

Core Facility Support Awards

**Please also refer to the Instructions for Applicants document,
which will be posted on September 14, 2023**

Applications for this award mechanism are subject to institutional limits.
Applicants are advised to consult with their institution's
Office of Research and Sponsored Programs (or equivalent).

Application Receipt Opening Date: October 17, 2023

Application Receipt Closing Date: January 18, 2024

FY2024

Fiscal Year Award Period

September 1, 2023-August 31, 2024

TABLE OF CONTENTS

1. BRIEF DESCRIPTION OF RFA	4
2. ABOUT CPRIT	5
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES.....	5
3. RATIONALE	6
4. RESEARCH OBJECTIVES	6
5. FUNDING INFORMATION	7
6. ELIGIBILITY	8
7. RESUBMISSION POLICY	10
8. RENEWAL POLICY -NEW	10
9. RESPONDING TO THIS RFA	11
9.1. APPLICATION SUBMISSION GUIDELINES.....	11
9.1.1. <i>Submission Deadline Extension</i>	11
9.2. APPLICATION COMPONENTS.....	12
9.2.1. <i>Abstract and Significance (5,000 characters)</i>	12
9.2.2. <i>Layperson’s Summary (2,000 characters)</i>	12
9.2.3. <i>Specific Aims and Sub Aims</i>	13
9.2.4. <i>Timeline (1 page)</i>	13
9.2.5. <i>Institutional Support (2 pages)</i>	13
9.2.6. <i>Resubmission Summary (1 page)</i>	13
9.2.7. <i>Renewal Summary (2 pages not including facility impact forms)</i>	14
9.2.8. <i>Core Facility Plan (5 pages)</i>	15
9.2.9. <i>Documentation That the Proposed Core Facility Does Not Duplicate Existing Services (2 pages)</i> 16	
9.2.10. <i>Vertebrate Animals and/or Human Subjects (2 pages)</i>	17
9.2.11. <i>Publications/References</i>	17
9.2.12. <i>Budget and Justification</i>	17
9.2.13. <i>User Group (8 pages)</i>	18
9.2.14. <i>Biographical Sketches (5 pages each)</i>	18
9.2.15. <i>Current and Pending Support</i>	19
9.2.16. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i>	19
9.2.17. <i>Previous Summary Statement</i>	19
9.3. FORMATTING INSTRUCTIONS.....	19
10. APPLICATION REVIEW	20
10.1. REVIEW PROCESS OVERVIEW.....	20
10.2. CONFIDENTIALITY OF REVIEW	21
10.3. REVIEW CRITERIA	22
10.3.1. <i>Primary Criteria</i>	22
10.3.2. <i>Secondary Criteria</i>	23
11. KEY DATES	24
12. AWARD ADMINISTRATION	24
13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	25
14. CONTACT INFORMATION	26
14.1. HELPDESK.....	26
14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	26

RFA VERSION HISTORY

09/14/23 RFA release

1/16/24 Revised to extend the submission deadline to 4 PM central time on January 18, 2024

1. BRIEF DESCRIPTION OF RFA

CPRIT limits the number of applications that a single institution may submit under this RFA. For purposes of this RFA, an institution is defined as that component of a university system that has a geographically distinct campus. Academic institutions and health science centers that are components of the same university system and share contiguous or near-contiguous campuses are eligible to submit a single application.

- Due to limited funding allocated to the Academic Research Program, an institution may submit only 1 application (1 new, 1 renewal, or 1 resubmission) under the CFSA RFA during this funding cycle. **An exception will be made for institutions submitting applications for core facilities that support research directed toward childhood and adolescent cancer or population science; in this case, institutions may submit 1 childhood and adolescent cancer application or 1 population science and 1 additional application in another aspect of cancer research (new, renewal, or resubmission).**
- CPRIT's maximum total funding under this RFA is \$3,000,000 for a period of 5 years.
- CPRIT only allows 1 opportunity to submit an active award renewal application in response to this RFA.
- For a Renewal CFSA, an applicant may request a maximum of \$2,000,000 in total costs for a period of 5 years.
- The CFSA must be led by one PI, multi-PIs are not allowed.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer.
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas.
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

To accomplish CPRIT's long-term vision, the Oversight Committee has identified these 2024 priorities:

- Investing in the cancer research capacity of Texas institutions through recruitment of cancer scholars, investment in core facilities, and investment in individual investigator awards in all regions of the state;
- Building the Texas cancer life science ecosystem across Texas by bridging discovery and translational research into early-stage company products with high impact on cancer patient care and creating economic development for the State of Texas; and
- Increasing the capacity for Texas to have a significant impact on cancer prevention and early detection, ultimately decreasing cancer incidence and mortality.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure in all regions of the state
- Reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities
- Computational oncology and analytic methods
- Childhood cancer and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials, particularly to regions of the state currently with limited access

3. RATIONALE

Core Facility Support Awards seek to facilitate the development or improvement of core facilities that will provide valuable services to support and enhance scientifically meritorious cancer research projects. A user group of Texas-based investigators must be identified, each of whom should have supported cancer research projects that will make use of the requested facility. This requirement is not intended to exclude early-career-stage investigators who have not yet secured peer-reviewed grant support. Successful applicants should be working in a research environment capable of supporting potentially high-impact cancer studies.

CPRIT is particularly interested in supporting core facilities that provide services to cancer investigators from multiple Texas institutions, in particular TREC-eligible institutions (see IFA for list of institutions) and that address CPRIT Program Priorities.

4. RESEARCH OBJECTIVES

CPRIT will foster cancer research in Texas by providing financial support for a wide variety of projects relevant to cancer research. This RFA solicits applications from institutions to establish or enhance core facilities (laboratory, clinical, population-based, or computer-based) that will

directly support cancer research programs to advance knowledge of the causes, prevention, and/or treatment of cancer or improve quality of life for patients with, and survivors of, cancer.

CPRIT expects outcomes of supported activities to directly and indirectly benefit subsequent cancer research efforts, cancer public health policy, or the continuum of cancer care—from prevention to survivorship. To fulfill this vision, applications may address any topic or issue related to cancer biology, causation, prevention, detection or screening, treatment, cure, quality of life, or survivorship. This award provides cancer researchers access to appropriate research infrastructure, instrumentation, and technical expertise necessary to achieve their research objectives.

Funds may be requested to develop a new facility or to enhance the capabilities of an existing facility that will directly support and impact cancer research programs at the institution and in the region. **CPRIT will look with special favor on applications that propose a facility that will serve cancer researchers at multiple Texas research institutions, in particular, TREC-eligible institutions (see IFA for list of institutions).**

5. FUNDING INFORMATION

The maximum duration for this award mechanism is 5 years. Applicants may request up to a maximum of \$3,000,000 in total costs.

Allowable expenses include the cost of instruments (must be expended in the first 2 years), installation and/or necessary renovation expenses in the first year (installation/renovation expenses not to exceed 10% of the total first-year request), and maintenance/service contracts. Note that maintenance/service agreements must not extend past the award period, if seeking reimbursement from CPRIT.

Installation/renovation expenses can be requested in the first year only. **Equipment must be purchased within the first 2 years. Note this will be monitored by CPRIT.** Applicants may request salary support and fringe benefits for the facility director, data analysts, and technical staff. Travel to scientific/technical meetings or collaborating institutions is also an allowable expense for these individuals. Note all international travel must receive prior approval by CPRIT. All of these costs and expenses must be prorated for direct use in cancer research efforts if the core facility also serves non-cancer-related researchers. Also allowable are funds to

support the use of the facility by qualified cancer research investigators for relevant projects (research supplies and services, clinical research costs, etc). Institutions must describe and justify the process to be used to disburse funds to support use of the facility by cancer investigators. Finally, some fraction of available funds may be used by the facility director for development of new or improved approaches to technical challenges.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism.
- A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The Principal Investigator (PI) must be the director of the facility and must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must reside in Texas during the time the research that is the subject of the grant is conducted. The PI should also hold a faculty position, preferably at the level of associate or full professor or the equivalent.
- The PI must commit a minimum 10% level of effort throughout the entire award period.
- This award and core facility must be directed by the PI. Multi-PIs are not permitted.
- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Collaborators should have specific and well-defined roles. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds. In no event shall equipment purchased under this award leave the State of Texas.
- **An institution may submit only 1 application (1 new, 1 renewal, or 1 resubmission) under this RFA during this funding cycle. An exception will be made for institutions submitting applications for core facilities that support research totally directed**

toward childhood and adolescent cancer or population science; in this case, institutions may submit 1 childhood and adolescent cancer application or 1 population science application and 1 additional application in another aspect of cancer research (new, renewal, or resubmission).

- For purposes of this RFA, an institution is defined as that component of a university system that has a geographically distinct campus.
- Academic institutions and health science centers that are components of the same university system and share a contiguous or near-contiguous campus are eligible to submit a single application.
- An institution may only resubmit an application that was previously not funded once (see [section 6](#)).
- Support for only 1 facility may be requested per application. Applications that propose to provide services to researchers at multiple institutions are permitted and encouraged.
- The coherence of the facility and the ability of the PI to oversee all of the facility's operations will be critical components of the review process. If support is requested for an existing facility, applicants must provide details on how CPRIT support will enhance its capabilities and improve access for cancer investigators rather than simply replace ongoing institutional support.
- An individual may serve as a PI or Multi-PI on no more than 3 active Academic Research grants. Recruitment grants and research training awards do not count toward the 3-grant maximum; however, CPRIT considers project leaders on a MIRA award equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be 8/31/2024).
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.

- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** and must follow all resubmission guidelines. More than 1 resubmission per application is not permitted.

8. RENEWAL POLICY -NEW

CPRIT only allows one opportunity to submit an active award renewal application in response to this RFA. Funding for renewal applications is capped at \$2,000,000 as the Core Facility has matured over the initial 5 years and is expected to be partially funded by substantial charge backs and institutional commitment.

Renewal applications must demonstrate a compelling justification for continued CPRIT support of the facility that is based upon the scientific impact of current and continued CPRIT support, as well as a strong plan delineating how the services provided will be developed further to advance cancer research. Quality and cost efficiency of the services alone are not sufficient justifications

for continued CPRIT support. Renewal applications will be expected to demonstrate an exceptional record of impact on cancer research as measured by:

- Utilization (number of PIs utilizing facility; number of institutions served);
- Publications that cite CPRIT support;
- New peer-reviewed grant awards supported;
- Clinical trials supported;
- Patents supported.

The applicant should time the submission of the renewal application so that the new contract execution date for the grant award comes after the contract expiration date of the initial CPRIT award; any overlap in funding should be avoided. In the event that a renewal application is funded prior to the expiration date of the current CPRIT award, an early termination of the current award is required.

9. RESPONDING TO THIS RFA

9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Authorized Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS.

Applications will be accepted beginning on October 17, 2023 at 7 AM central time and must be submitted by 4 PM central time on January 18, 2024. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be

submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the *IFA* document for details. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 5](#) will be administratively rejected without review.

9.2.1. Abstract and Significance (5,000 characters)

Clearly explain the proposed program, including a summary of the facility to be developed, an outline of the overall goals of the research projects that will be supported, and an overview of institutional infrastructure and commitment. The specific aims of the application must be obvious from the abstract. Clearly address how the proposed project, if successful, will have a major impact on cancer.

If the application is a renewal of an existing CPRIT-funded resource, the abstract must state the impact of the resource and document why continued CPRIT support is justified and how the resource will be developed further to advance cancer research.

Note: It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section wisely. Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem, that better diagnostic and therapeutic approaches are needed urgently, or that the type of cancer of interest to the PI is important, vexing, or deadly).

9.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early diagnosis, prevention, or treatment. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding.

Do not include any proprietary information in the layperson's summary. The layperson's summary will also be used by advocate reviewers ([section 9.1](#)) in evaluating the significance and impact of the proposed work.

9.2.3. Specific Aims and Sub Aims

List specific aims and sub aims for each year of the project. These aims and sub aims will also be used during the submission and evaluation of progress reports and assessment of the project's success if the award is made.

9.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

9.2.5. Institutional Support (2 pages)

Each application must be accompanied by a strong letter of institutional support from the president or provost or equivalent indicating and detailing the commitment to the program and certifying that this is the sole application submitted by this institution in response to this RFA. Furthermore, the letter should indicate any support of the facility for activities not related to cancer research. The letter should address the institutional oversight ensuring that the facility will be operated in a superior fashion and discuss how this will be ascertained. If the application is a renewal of an existing CPRIT-funded resource, a compelling justification for continued CPRIT support of the resource must be provided.

9.2.6. Resubmission Summary (1 page)

An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

9.2.7. Renewal Summary (2 pages not including facility impact forms)

Note that CPRIT only allows one opportunity to submit an active award renewal application in response to this RFA. Funding for renewal applications is capped at \$2,000,000 as the Core Facility has matured over the initial 5 years and it is expected that the Core will be partially funded by substantial charge backs and institutional commitment.

Applicants preparing a renewal of a CPRIT-funded core facility must describe and demonstrate that exceptional progress has been made on the current funded award and demonstrate a compelling justification for continued CPRIT support of the facility that is based upon the scientific impact of continued CPRIT support and the innovation and impact of the proposed evolution of the facility. Quality and cost efficiency of the services alone are not sufficient justifications for continued CPRIT support.

Using facility impact forms provided, list the number of PIs utilizing the facility and the institutions served (Table 1), the peer-reviewed grants resulting from facility support (Table 2), publications (published and in press) citing utilization of the facility (Table 3), clinical trials utilizing the facility (Table 4), and patents filed or granted that have resulted from work supported by the facility (Table 5) for the prior grant funding period.

The following 5 tables displayed below are required. **Note that the utilization parameters and table formats should follow the instructions for completing the CPRIT annual progress report.** Refer to the Table templates in the document located in [Current Funding Opportunities](#) for Academic Research in CARS.

Table 1: Utilization of the facility by PIs. (Provide the total number of PIs that have utilized the facility by PI's institution).

Table 2: Additional/Follow-On Funding. (Provide information in Table 2 about the funding source, type of funder, grant ID, title of grant, total amount received (direct plus indirect costs over the entire performance period), total project period of investment/award, a description of the subject of the funding, PI of the grant, and PI's organization).

Funding Source	Type of Funder	Award ID	Title of Grant	Total Amount Received (Direct and Indirect Costs for All Years)	Total Project Period of Investment/Award	Investment/Award Description	PI	PI Organization
----------------	----------------	----------	----------------	--	--	------------------------------	----	-----------------

Table 3: Publications citing the facility. Enter information about each publication in the table. Information includes PubMed ID, author, title, journal, and publication date.

Table 4: Clinical trials supported by the facility. Enter trial name, clinicaltrials.gov identifier, clinical research categories (interventional and observational), primary purpose, primary anatomic cancer site, phase, clinical trial focus, clinical trial site, and number of patients enrolled.

Table 5: Filed/granted patents resulting from research supported by the facility. Enter patent number, inventors, patent title, description, date of publication or issue, and date the patent application was filed and/or granted.

9.2.8. Core Facility Plan (5 pages)

Background: Present the rationale and need for the facility, emphasizing the pressing problems in cancer research that will be addressed. Address the research community served and if researchers at other institutions will have access. Address how the proposed facility does not duplicate services provided by existing facilities. Address how the proposed facility addresses CPRIT priorities.

Instrument Details: Provide details of the equipment/instruments, if any, that will be acquired.

Technical Expertise: Describe the qualifications of the facility director and other key personnel that make them suitable to oversee the establishment and operations of the facility.

Administrative Plan:

1. Clearly describe the plan under which the operation, sharing, time allocation, and maintenance of the facility will be administered.

2. Discuss in detail the plan for cost recovery and charge backs for core services. If a cost recovery plan is not included in the administrative plan, provide strong justification for its absence.
3. Discuss whether cancer researchers from other Texas academic institutions or industry scientists have access to the facility and the terms for such access.
4. Discuss if funds will be allocated to support the use of the facility by qualified cancer research investigators, and describe the process to be used to disburse funds to support use of the facility by these cancer investigators. If some fraction of available funds is to be used by the facility director for development of new or improved approaches to technical challenges, discuss the process to identify and evaluate such development projects.
5. Discuss plans including the creation of a website link for disseminating information on the resource services, fees, and operations, particularly to external institutions and investigators.

Training Plan: Describe the plan to train users to use the facility, to educate users on applications and advances in the technology, and to evaluate the results obtained. If applicable, describe the plan to contribute to the preparation of research grant proposals.

Evaluation Plan: Describe an evaluation plan for the facility.

Sustainability: Describe in detail the plans for continuation of the core facility service at the conclusion of the CPRIT award, such as documentation of institutional support and additional award mechanisms and/or user fees.

9.2.9. Documentation That the Proposed Core Facility Does Not Duplicate Existing Services (2 pages)

In this section, provide a comprehensive list of existing cores or facilities in Texas that offer researchers access to technology and services similar to that proposed in this application. Explain why the proposed core is not duplicative of these and is required to support the research of the users of the new core proposed in this application.

9.2.10. Vertebrate Animals and/or Human Subjects (2 pages)

If vertebrate animals will be used, provide an outline of the appropriate protocols that will be followed. If human subjects or human biological samples will be used, provide a plan for recruitment of subjects or acquisition of samples that will meet the time constraints of this award mechanism.

9.2.11. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

9.2.12. Budget and Justification

Provide a compelling and clear justification of the budget, demonstrating need for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses. Applicants are advised not to interpret the maximum allowable request under this award as a suggestion that they should expand their anticipated budget to this level. However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit **must be specifically approved by CPRIT**. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cpriti.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be administratively withdrawn.

- The annual salary (also referred to as direct salary or institutional base salary) that an individual may be reimbursed from a CPRIT award is limited to a maximum of \$200,000. In other words, an individual may request salary proportional to the percent of effort up to a maximum of \$200,000. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization. The PI must commit a minimum 10% level of effort throughout the entire award period.
- The PI is expected to attend CPRIT's Conference. CPRIT funds may be used to send up to 2 people to the conference.

9.2.13. User Group (8 pages)

Provide concise descriptions of the research projects of major users of the facility. Provide a tabular summary of all users of the requested facility. List the names of all researchers, their academic appointment and affiliation, include user grant-funded award data (project title(s)/number(s), award grant ID, award duration), a brief description of the project(s), and approximate percentage use of the facility for direct use in cancer research efforts. Discuss whether cancer researchers from other Texas academic institutions or industry scientists have access to the facility and the terms for such access. CPRIT will look with special favor on the development of core facilities that serve multi-institutions, including TREC-eligible institutions.

9.2.14. Biographical Sketches (5 pages each)

The PI should provide a biographical sketch that describes his/her education and training, professional experience, awards and honors, and publications relevant to cancer research.

A biographical sketch must be provided for the PI (as required by the online application receipt system). Up to 5 additional biographical sketches for key personnel from the user group may be provided. Each biographical sketch must not exceed 5 pages.

9.2.15. Current and Pending Support

State the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. All current and pending support of the PI must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.16. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants are required to provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

9.2.17. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively withdrawn.

9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should

include text to explain illustrations that may be difficult to interpret when printed in black and white.

- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.
Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45–67.
- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

10. APPLICATION REVIEW

10.1. Review Process Overview

All eligible applications will be evaluated using a 2-stage peer review process: (1) Peer review and (2) prioritization of grant applications by the CPRIT Scientific Review Council (SRC). In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts, as well as advocate reviewers, using the criteria listed below. In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT SRC based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the SRC will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider

factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

10.2. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, SRC members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and SRC members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#)

Communication, regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Scientific Review Panel member, or an SRC member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism

are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period prior to the opening of CARS. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

10.3. Review Criteria

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

10.3.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the request for the instrument/equipment. Primary criteria include the following:

Justification of Need/Value: Is the uniqueness of the facility addressed? Is the need for the facility justified? Is it necessary and appropriate for the research projects? Will the state-of-the-art facility directly support and impact cancer research programs at the institution and in the region? How will the availability of the facility offer incipient research projects by investigators at various career stages the opportunity to develop? Will the facility make the user group more competitive for external funding? Will the facility provide cancer researchers from other Texas academic institutions or industry scientists access to the facility? Does the facility address CPRIT priorities?

If this is a renewal application, is there evidence that the facility has had an exceptional impact on the cancer research and that the renewal will provide further innovation and impact.

Quality and Significance of research projects supported: Does the facility support a significant number of different, independently funded users? Are the projects at the forefront of cancer research? Are the projects of significance in reducing cancer incidence, morbidity, or mortality?

Technical Expertise: Is there sufficient technical expertise for optimal use of the facility? How well qualified is the user group to take optimal advantage of the facility and evaluate the research results for the proposed projects? How will the facility be maintained? Is there a satisfactory training plan for new users?

Administration: Is there assurance that the facility will be managed and operated in a superior fashion? To whom does the facility director report? Is that person committed to appropriate oversight (a letter of commitment should be submitted)? Is there an adequate plan for the management of the facility, including an appropriate system for charging for services and subsidy of user fees for specific cancer-related projects and individuals (especially early-career-stage investigators)? How will facility time be allocated among the projects? Have biosafety issues been addressed? Are there criteria and is there a mechanism for prioritization of user requests? Are there appropriate advisory committees?

Institutional Commitment: Is there clear institutional commitment for support and sustainability of the facility for cancer research? Has the host institution provided an appropriate site for the facility? For renewal applications, is there evidence of a significant institutional commitment and/or financial plan for sustainability of the facility beyond the period of this award.

10.3.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed project.

Secondary criteria include the following:

Research Environment: Does the team have the needed expertise and resources to accomplish all aspects of the project? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support for the project?

Vertebrate Animals and/or Human Subjects: If vertebrate animals and/or human biological samples are included in the proposed research, is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed? Note that certification of approval by the institutional IACUC and/or IRB, as appropriate, will be required before funding can occur.

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

11. KEY DATES

RFA

RFA release September 14, 2023

Application

Online application opens October 17, 2023, 7 AM central time

Application due January 18, 2024, 4 PM central time

Application review February 2024 to August 2024

Award

Award notification August 2024

Anticipated start date August 31, 2024

12. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [Texas Administrative Code, Title 25, chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [Texas Administrative Code, Title 25, chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals documented in the grant award contract and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate.

CPRIT will review annual progress reports and continuation of funding is contingent upon the timely receipt of these reports and documentation of sufficient progress toward completing project goals. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of award contract. Forms and instructions will be made available at www.cprit.texas.gov.

13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, chapters 701 to 703](#), for specific requirements regarding demonstration of available funding.

14. CONTACT INFORMATION

14.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

14.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director for Academic Research.

Tel: 512-305-8491

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports

Cancer Prevention and Research Institute of Texas (CPRIT)**24.2 Academic Research - Basic Cancer Research-1****(24.2 ACR BCR-1)****Observation Report**

Report No. 2024-04-16 24.2_ACR_BCR-1
Program Name: Academic Research
Panel Name: 24.2 Academic Research - Basic Cancer Research-1 (24.2_ACR_BCR-1)
Panel Date: April 16, 2024
Report Date: April 23, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.2 Academic Research - Basic Cancer Research-1 (24.2_ACR_BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on April 16, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed and thirteen (13) applications were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)**24.2 Academic Research Basic Cancer Research – 2****(24.2 ACR BCR-2)****Observation Report**

Report No. 2024-04-17 24.2_ACR_BCR-2
Program Name: Academic Research
Panel Name: 24.2 Academic Research Basic Cancer Research – 2 (24.2_ACR_BCR-2)
Panel Date: April 17, 2024
Report Date: April 23, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.2 Academic Research Basic Cancer Research – 2 (24.2_ACR_BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on April 17, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and Thirty (30) were not discussed.
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were thirteen (13) Conflicts of Interest (COIs) identified prior to and/or during the meeting. No (0) applications with COIs were discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)**24.2 Academic Research Cancer Biology (CB)****(24.2 ACR CB)****Observation Report**

Report No. 2024-04-24 24.2_ACR_CB
Program Name: Academic Research
Panel Name: 24.2 Academic Research Cancer Biology (CB) (24.2 _ACR_CB)
Panel Date: April 24, 2024
Report Date: April 29, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.2 Academic Research Cancer Biology (CB) (24.2_ACR_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on April 24, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and thirty-six (36) applications were not discussed
- Panelists: One (1) panel chair, nineteen (19) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were eight (8) Conflicts of Interest (COIs) identified prior to and/or during the meeting. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)**24.2 Academic Research - Imaging Technology and****Informatics (24.2 ACR ITI)****Observation Report**

Report No. 2024-04-23 24.2_ACR_ITI
Program Name: Academic Research
Panel Name: 24.2 Academic Research - Imaging Technology and Informatics
(24.2_ACR_ITI)
Panel Date: April 23, 2024
Report Date: April 29, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.2 Academic Research - Imaging Technology and Informatics (24.2_ACR_ITI) meeting. The meeting was chaired by Henry VanBrocklin and conducted via videoconference on April 23, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twelve (12) applications were discussed and fourteen (14) were not discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
24.2 Academic Research Clinical and Translational Cancer
Research-1 (24.2 ACR CTCR-1)
Observation Report

Report No. 2024-04-18 24.2_ACR_CTCR-1
Program Name: Academic Research
Panel Name: 24.2 Academic Research Clinical and Translational Cancer
Research-1 (24.2_ACR_CTCR-1)
Panel Date: April 18, 2024
Report Date: April 23, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.2 Academic Research Clinical and Translational Cancer Research-1 (24.2_ACR_CTCR-1) meeting. The meeting was chaired by Margaret Tempero and conducted via videoconference on April 18, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eighteen (18) applications were discussed and twenty-four (24) were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. No (0) applications with COIs were discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
24.2 Academic Research Clinical and Translational Cancer
Research-2 (24.2 ACR C/TCR-2)
Observation Report

Report No. 2024-04-25 24.2_ACR_C/TCR-2
Program Name: Academic Research
Panel Name: 24.2 Academic Research Clinical and Translational Cancer
Research-2 (24.2_ACR_C/TCR-2)
Panel Date: April 25, 2024
Report Date: April 29, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 24.2 Academic Research Clinical and Translational Cancer Research-2 (24.2_ACR_C/TCR-2) meeting. The meeting was chaired by Richard O'Reilly and conducted via videoconference on April 25, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-eight (28) applications were discussed and eleven (11) were not discussed
- Panelists: One (1) panel chair, fourteen (14) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were fourteen (14) Conflicts of Interest (COIs) identified prior to and/or during the meeting. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written in a cursive style.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)
FY24.2 Scientific Review Council (24.2 SRC)
Observation Report

Report No. 2024-07-11 24.2 SRC
Program Name: Academic Research
Panel Name: FY24.2 Scientific Review Council (24.2 SRC)
Panel Date: July 11, 2024
Report Date: July 17, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the FY24.2 Scientific Review Council (24.2 SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on July 11, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirty one (31) applications were discussed and one (1) application was withdrawn
- Panelists: One (1) discussion lead, and five (5) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Cancer Prevention and Research Institute of Texas (CPRIT)

25.1 Academic Scientific Review Council (25.1 SRC)

Observation Report

Report No. 2024-12-12 25.1_SRC
Program Name: Academic Research
Panel Name: 25.1 Academic Scientific Review Council (25.1_SRC)
Panel Date: December 12, 2024
Report Date: December 18, 2024

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 25.1 Academic Scientific Review Council (25.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 12, 2024.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Forty-seven (47) applications were discussed
- Panelists: One (1) panel chair, six (6) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting; however, they are waived pursuant to the Section 102.1062 Conflict of Interest Waiver for FY 2025 approved by the CPRIT Oversight Committee.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 24.2

Awards Announced at the August 21, 2024, and February 19, 2025, Oversight Committee Meetings

The following table lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research cycle 24.2 include *Core Facility Support Awards*; *Clinical Investigator Award*; *High-Impact/High-Risk Research Awards*; and *Multi-Investigator Research Awards*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP240440	Richard Gorlick	The University of Texas M. D. Anderson Cancer Center	Patrick Grohar
RP240439	Sattva Neelapu	The University of Texas M. D. Anderson Cancer Center	Joshua Campbell
RP240454	Everett Stone	The University of Texas at Austin	Weiping Zou
RP240474	Leonid Metelitsa	Baylor College of Medicine	W. Martin Kast
Applications not considered by the PIC or Oversight Committee:			
RP240428	Neelam Mukherjee	The University of Texas Health Science Center at San Antonio	Jose Conejo-Garcia
RP240564	Kevin Pinney	Baylor University	Jose Conejo-Garcia
RP240591	Ming You	The Methodist Hospital Research Institute	Steven Belinsky

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP240448	Kevin Dalby	The University of Texas at Austin	Joseph Mancias
RP240459	Abhishek Jain	Texas A&M Engineering Experiment Station	Benjamin Greenbaum

De-Identified Overall Evaluation Scores

Core Facility Support Awards

Academic Research Cycle 24.2

Application ID	Final Overall Evaluation Score
RP240545^	1.0
RP240610^	1.4
RP240494^	1.7
RP240497^	1.7
RP240432^	1.8
RP240430^	1.9
RP240537*	2.0
RP240508^	2.1
RP240559^	2.1
RP240521^	2.3
Db	3.0
Dc	3.0
Dd	3.3
De	3.4
Df	3.7
Dg	3.7
Dh	4.0
Di	4.3
Dj	4.7
Dk	4.8
Dl	5.7

* Recommended for funding.

^ Approved for grant award by the Oversight Committee at their meeting on August 21, 2024.

Final Overall Evaluation Scores and Rank Order Scores

UC San Diego

SCHOOL OF MEDICINE

July 29, 2024

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Ms. Kristen Doyle
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to kdoyle@cprit.texas.gov

Dear Dr. Cummings and Ms. Doyle,

The Scientific Review Council (SRC) is pleased to submit this list of 36 research grant recommendations for the Clinical Investigator Award, Core Facility Support Awards, High-Impact/High Risk Awards, Multi-Investigator Research Awards and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on July 11, 2024 to review First-Time Tenure-Track Faculty Members recruitment applications submitted for Cycle FY24.12 and to consider the applications recommended by the peer review panels following their meetings held April 16, 2024 to April 25, 2024. On July 29, 2024 the SRC met to discuss application RP240474, which was peer reviewed on April 25, 2024 but not recommended. The application received a favorable score but just missed the cut off line made by the peer review panel. The SRC chose to consider and recommend RP240474 because of how it addresses program priorities of childhood and adolescent cancers. With available funds the SRC recommended RP240474 to the Program Integration Committee (PIC), bringing the total number of recommended academic research awards to 36.

Recommended funding amounts and the overall evaluation score are stated for each grant application in the following table. The total amount for the applications recommended to the PIC is \$60,577,922.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	RFA	Score	Application Title	PI	PI Org.	Rec. Budget
1	RP240545	CFSA	1.0	Renewal of CPRIT GMP Core	Lapteva, Natalia	Baylor College of Medicine	\$2,000,000
2	RR240070	RFTFM	1.0	Expanding the Accessibility and Efficacy of CAR-T Cells Through In Vivo Engineering	Labanieh, Louai	Baylor College of Medicine	\$2,000,000
3	RR240076	RFTFM	1.0	Discovery of Molecular Glue Degraders Targeting the Undruggable Cancer Proteome	Yoon, Hojong	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
4	RR240082	RFTFM	1.2	Identification of Neural Mechanisms Contributing to Chemotherapy-Associated Cognitive Impairments	Sun, Yanjun	The University of Texas Health Science Center at Houston	\$2,000,000
5	RP240610	CFSA	1.4	UTHealth Cancer Genomics Core (UTHealth CGC)	Zhao, Zhongming	The University of Texas Health Science Center at Houston	\$2,000,000
6	RP240478	CIA	1.4	Advancing immunotherapy for high-risk cancers in children and adolescents	Hegde, Meenakshi	Baylor College of Medicine	\$1,030,892
7	RP240473	CIA	1.6	Signal-Augmented Cancer Cell Therapies: Integrating Advanced	Omer, Bilal	Baylor College of Medicine	\$1,046,414

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

				Correlatory Studies and Mentorship			
8	RP240494	CFSA	1.7	Children's Research Institute Metabolomics Core: Advanced Methodologies in Cancer Metabolism	DeBerardinis, Ralph	The University of Texas Southwestern Medical Center	\$2,601,616
9	RP240497	CFSA	1.7	Advanced Spatial Genomics Core Facility	Navin, Nicholas	The University of Texas M. D. Anderson Cancer Center	\$2,999,993
10	RR240079	RFTFM	1.7	Immune surveillance and elimination of aneuploid cells in vivo	Trakala, Marianna	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
11	RP240432	CFSA	1.8	Advanced Multiparameter Cytometry and Cell Sorting Core	Beeton, Christine	Baylor College of Medicine	\$1,999,882
12	RP240440	MIRA2	1.8	Novel Therapies for Osteosarcoma	Gorlick, Richard	The University of Texas M. D. Anderson Cancer Center	\$4,498,684
13	RP240557	CIA	1.8	Dietary intervention to modulate the microbiome and immune response	McQuade, Jennifer	The University of Texas M. D. Anderson Cancer Center	\$1,074,727
14	RP240430	CFSA	1.9	GCC Center for Comprehensive PK/PD & Formulation	Liang, Dong	Texas Southern University	\$2,000,000
15	RP240590	HIHRA	2.0	Bidentate ERK Traps: Revolutionizing Combination Cancer Therapy Strategies	Dalby, Kevin	The University of Texas at Austin	\$249,996
16	RP240539	HIHRA	2.0	Spectroscopy for quantitative real-time imaging of radical formation	Gustavsson, Anna-Karin	Rice University	\$250,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				in ultra-high dose rate radiation therapy			
17	RP240508	CFSA	2.1	The Texas Decision Science Core Facility: A CPRIT Population Science Core	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$2,995,778
18	RP240446	HIHRA	2.1	Regulation of Transcription Factor Function by Local Chromatin Context	Soshnev, Alexey	The University of Texas at San Antonio	\$249,561
19	RP240442	CIA	2.1	Identifying and exploiting novel metabolic vulnerabilities in the treatment of kidney cancer	Courtney, Kevin	The University of Texas Southwestern Medical Center	\$913,682
20	RP240559	CFSA	2.1	High Performance Mass Spectrometry Imaging Core Facility	Brodbelt, Jennifer	The University of Texas at Austin	\$1,998,763
21	RP240441	CIA	2.2	Precision Lung Cancer Interception by Targeting High-Risk Lung Nodules	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,098,945
22	RP240438	MIRA2	2.2	Overcoming major barriers to the delivery of successful T-cell immunotherapies	Rooney, Cliona	Baylor College of Medicine	\$4,500,000
23	RP240579	HIHRA	2.3	Renal Clearable Nano Delivery Systems for Maximizing Anti-tumor Immunity in Breast Cancer Brain Metastasis Treatment	Zheng, Jie	The University of Texas at Dallas	\$250,000
24	RP240521	CFSA	2.3	Pediatric Cancer Data Core	Xie, Yang	The University of Texas Southwestern Medical Center	\$1,999,760

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

25	RP240518	CIA	2.4	Adapting radiotherapy clinical trials to treatment response and artificial intelligence innovations	Desai, Neil	The University of Texas Southwestern Medical Center	\$1,460,229
26	RP240462	HIHRA	2.5	Development of an Endoscopic Nuclear Imaging Capsule for Radio-Guided Cancer Surgery	Zannoni, Elena Maria	The University of Texas at Austin	\$250,000
27	RP240501	HIHRA	2.6	Delivering Immunotherapy more effectively to glioblastoma with a “magnetic switch”	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
28	RP240542	HIHRA	2.6	Digital Twin Augmented Reality for Prostate Laparoscopic Surgery	Fei, Baowei	The University of Texas at Dallas	\$250,000
29	RP240454	HIHRA	2.7	Reversing Tumor Immune Exclusion with Sphingosine-1-Phosphate Depleting Therapeutics	Stone, Everett	The University of Texas at Austin	\$249,998
30	RP240498	HIHRA	2.7	Improving the management of gastric peritoneal carcinomatosis with Photo-Betabody Immunotherapy	Obaid, Girgis	The University of Texas at Dallas	\$248,991
31	RP240493	HIHRA	2.8	Engineering in vivo chimeric antigen receptor (CAR) macrophages for diffuse midline glioma	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$250,000
32	RP240516	HIHRA	2.9	Mapping multivalent chromatin	Mani, Ram	The University of Texas	\$250,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

				interactions to define the 3D genome of Clear cell renal cell carcinoma		Southwestern Medical Center	
33	RP240605	HIHRA	3.1	Stimulate Mucosal-associated Invariant T cells to Kill Cancer Cells	Huang, Shouxiong	Texas Biomedical Research Institute	\$249,484
34	RP240439	MIRA2	3.1	Innovative cell therapy approaches for hematological and solid malignancies	Neelapu, Sattva	The University of Texas M. D. Anderson Cancer Center	\$4,500,000
35	RP240489	MIRA2	3.2	Neural Regulation of Childhood Cancers	Morrison, Sean	The University of Texas Southwestern Medical Center	\$4,362,563
36	RP240474	MIRA2	3.6	Cellular Immunotherapies for Pediatric Solid Tumors	Metelitsa, Leonid	Baylor College of Medicine	\$4,497,964

Clinical Investigator Award (CIA)
Core Facility Support Awards (CFSA)
High-Impact/High Risk Awards (HIHR)
Multi-Investigator Research Awards (MIRA2)
Recruitment of First-Time, Tenure Track Faculty Members (RFTTFM)

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego

SCHOOL OF MEDICINE

January 5, 2025

Dr. David A. Cummings, M.D.
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dcummingsmd@yahoo.com

Ms. Kristen Doyle
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to kdoyle@cprit.texas.gov

Dear Dr. Cummings and Ms. Doyle,


The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for the Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal); Core Facility Support Award (FY2024); Individual Investigator Research Awards; Individual Investigator Research Awards for Childhood and Adolescent Cancers; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Trials; Investigator Research Awards for Early-Onset Cancers; Individual Investigator Research Awards for Prevention and Early Detection; Recruitment of Established Investigators; Recruitment of Rising Stars and Recruitment of First-Time, Tenure-Track Faculty Members.

The SRC met on December 12, 2024 to consider the FY25.1 applications recommended by the peer review panels following their meetings held October 16, 2024 to October 24, 2024 and one FY24.2 Core Facility application recommended by a peer review panel on April 24, 2024. The SRC met on November 14, 2024 to review recruitment applications submitted for Cycle FY25.2 and then on December 12, 2024 to review recruitment applications submitted for Cycle FY25.3.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the 53 recommended applications is \$67,753,626.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Chair, CPRIT Scientific Review Council

Rank	Grant ID	RFA	Score	Title	PI	Institution	Recommended Budget
1	RP250118	IIRA	1.0	Ribosome Localization at Mitochondria-ER Contacts in Obesity-Associated Liver Cancer	Morita, Masahiro	The University of Texas Health Science Center at San Antonio	\$900,000
2	RP250061	IIRA	1.0	Imaging of cranial radiotherapy neuroinflammatory sequelae by Positron Emission Tomography	Pisaneschi, Federica	The University of Texas Health Science Center at Houston	\$900,000
3	RR250077	RFTFM	1.0	Developing next generation of genome editing tools to study and engineer genetic variants for effective precision cancer treatment	Gao, Xin "Daniel"	Baylor College of Medicine	\$2,000,000
4	RR250070	RFTFM	1.0	Unlocking the Potential of Clonal Hematopoiesis in Early Detection and Interception of Lymphoid Malignancies	Griffin, Rosalie	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
5	RR250063	RFTFM	1.1	Co-opting antiviral innate immune pathways to target non-small cell lung cancer	Zou, Tao	The University of Texas Southwestern Medical Center	\$2,000,000
6	RR250071	RFTFM	1.1	CRISPR screening to uncover tumor intrinsic modulators of DNA repair and immune effects of radiation therapy	Verma, Nipun	Baylor College of Medicine	\$2,000,000
7	RP250278	IIRACCA	1.2	Developmental origins of IDH-mutant glioma in adolescents	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,198,416
8	RP250293	IIRAP	1.2	Development of a shared decision tool to facilitate uptake of the levonorgestrel-releasing intrauterine system for the primary prevention of endometrial cancer	Meyer, Larissa	The University of Texas M. D. Anderson Cancer Center	\$1,199,542
9	RP250208	IIRA	1.4	RPS23 is a new drug target to activate the integrated stress response and treat leukemia	Ready, Joseph	The University of Texas Southwestern Medical Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

10	RP250201	IIRA	1.4	Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in oral cavity squamous cell carcinoma	Gillison, Maura	The University of Texas M. D. Anderson Cancer Center	\$899,998
11	RP250028	IIRA	1.5	MALAT1 protects against osteoporosis and bone metastasis	Ma, Li	The University of Texas M. D. Anderson Cancer Center	\$900,000
12	RP250247	IIRA	1.5	Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETS	Yao, James	The University of Texas M. D. Anderson Cancer Center	\$900,000
13	RP250144	IIRACCA	1.5	Decoding how neuronal activity remodels the epigenome in ependymoma	Deneen, Benjamin	Baylor College of Medicine	\$1,200,000
14	RP250220	IIRA	1.8	Decellularized tissue matrices to study the “bad soil” in cancer metastasis	Wang, Andrew	The University of Texas Southwestern Medical Center	\$900,000
15	RP250269	IIRAP	1.8	Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules.	Ostrin, Edwin	The University of Texas M. D. Anderson Cancer Center	\$1,169,776
16	RP250222	IIRA	1.9	KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC	Gibbons, Don	The University of Texas M. D. Anderson Cancer Center	\$899,997
17	RP250043	IIRA	1.9	An integrated imaging informatics platform for HCC surveillance	Zhou, Xiaobo	The University of Texas Health Science Center at Houston	\$899,991
18	RP250374	IIRACCA	1.9	Dissecting TFE3 Mediated tRCC Tumorigenesis	Brugarolas, James	The University of Texas Southwestern Medical Center	\$1,196,812
19	RP240537	CFSA	2.0	Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core	Wu, Erxi	Baylor Research Institute	\$2,999,989
20	RP250213	IIRA	2.0	KRAS spatiotemporal dynamics: lipid glycosylation as a novel therapeutic target	Hancock, John	The University of Texas Health Science Center at Houston	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

21	RP250428	IIRA	2.0	Studying Hematopoietic Stem Cells to Predict and Understand Mechanisms of Post-transplant Relapse in the Myelodysplastic Syndromes	Chung, Stephen	The University of Texas Southwestern Medical Center	\$899,025
22	RP250143	IIRA	2.0	Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy	Lissanu, Yonathan	The University of Texas M. D. Anderson Cancer Center	\$899,991
23	RP250044	IIRACSBC	2.0	Heterogeneity of resistance to endocrine therapy and Cdk inhibition: An integrated systems biology approach to biologically informed treatment regimens	Brock, Amy	The University of Texas at Austin	\$763,596
24	RR250072	REI	2.0	Mechanisms behind copper dependence of cancer cells	Wittung Stafshede, Pernilla	Rice University	\$6,000,000
25	RR250061	RFTFM	2.0	Engineered antibody tools for targeted regulation of cancer-associated proteins and organelles through redirected autophagy process	Jiang, Ziwen	The University of Texas at Dallas	\$2,000,000
26	RP250398	IIRA	2.1	Synthetic lethality of TRIP13 and Aurora A in Rb-deficient cancer	Johnson, Faye	The University of Texas M. D. Anderson Cancer Center	\$899,994
27	RP250402	IIRA	2.1	Exploiting Tryptophan Metabolite Addiction to identify and Inhibit HCC	Conacci Sorrell, Maralice	The University of Texas Southwestern Medical Center	\$900,000
28	RP250131	IIRACT2	2.1	Randomized Clinical Trial Evaluating Fecal Microbiota Transplant in Chimeric Antigen Receptor Therapy for Reversing Antimicrobial-Associated Dysbiosis	Saini, Neeraj	The University of Texas M. D. Anderson Cancer Center	\$1,598,410
29	RP250282	IIRA	2.2	Harnessing BACH2 to enhance anti-tumor T cell immunity	Yao, Chen	The University of Texas Southwestern Medical Center	\$900,000
30	RP250280	IIRA	2.2	The role of glutathione in leukemia development	Agathocleous, Michalis	The University of Texas	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

						Southwestern Medical Center	
31	RP250062	IIRA	2.3	Clonal hematopoiesis and toxicity from radiation therapy	Nead, Kevin	The University of Texas M. D. Anderson Cancer Center	\$899,885
32	RP250407	IIRA	2.3	Protecting the GI tract with a C60 fullerene derivative to facilitate dose-escalated abdominopelvic radiotherapy	Mackeyev, Yuri	The University of Texas Health Science Center at Houston	\$900,000
33	RP250055	IIRA	2.4	TET2 mutations promote myeloid malignancies by dysregulating m5C oxidation of chromatin-associated RNAs	Xu, Mingjiang	The University of Texas Health Science Center at San Antonio	\$900,000
34	RP250391	IIRA	2.5	Novel PCDH7 monoclonal antibodies that direct immune surveillance and combat drug resistance in lung cancer	O'Donnell, Kathryn	The University of Texas Southwestern Medical Center	\$900,000
35	RP250321	IIRACT2	2.5	Leveraging synthetic and collateral lethality in MTAP loss tumors	Rodon Ahnert, Jordi	The University of Texas M. D. Anderson Cancer Center	\$1,599,783
36	RP250069	IIRA	2.6	HSP90 Capacitance: Discovery of a New Mechanism Driving Evolution of Drug Resistance in Head and Neck Squamous Cell Carcinoma	Karras, Georgios	The University of Texas M. D. Anderson Cancer Center	\$890,201
37	RP250305	IIRA	2.6	Exploiting synthetic lethality between HNRNPK loss and ribosomal dysfunction in del9q AML	Post, Sean	The University of Texas M. D. Anderson Cancer Center	\$896,322
38	RP250091	IIRA	2.6	Dissecting the Survival Mechanisms of Latent Brain-Tropic Cancer Cells for Therapeutic Interventions	Malladi, Srinivas	The University of Texas Southwestern Medical Center	\$900,000
39	RP250322	IIRA	2.6	Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2-mutant non-small cell lung cancer (NSCLC)	Heymach, John	The University of Texas M. D. Anderson Cancer Center	\$900,000

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

UC San Diego
SCHOOL OF MEDICINE

40	RP250154	IIRA	2.6	Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients	Fuentes, David	The University of Texas M. D. Anderson Cancer Center	\$899,808
41	RP250156	IIRAP	2.6	Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer	Wu, Jia	The University of Texas M. D. Anderson Cancer Center	\$1,200,000
42	RP250094	IIRACT2	2.7	A phase 2 clinical trial with Avasopasem, with anti-estrogen therapy (ET) and a CDK4/6 inhibitor in metastatic breast cancer progressing on ET/CDK4/6 therapy.	Gius, David	The University of Texas Health Science Center at San Antonio	\$1,390,420
43	RP250418	IIRAP	2.7	Approach Bias Retraining to Augment Long-Term Smoking Cessation Among a Diverse Sample	Garey, Lorra	University of Houston	\$1,200,000
44	RP250355	CAP-CAC-CR	2.8	The Texas Collaborative Center for Hepatocellular Cancer (TeCH)	El-Serag, Hashem	Baylor College of Medicine	\$3,000,000
45	RP250119	IIRACCA	2.8	Comparison of Symptom Burden, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients treated with Surgery vs. Surgery and Chemotherapy	Kahalley, Lisa	Baylor College of Medicine	\$1,200,000
46	RP250190	IIRACCA	2.8	Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-Exercise Intervention	Swartz, Maria	The University of Texas M. D. Anderson Cancer Center	\$1,199,756
47	RP250182	IIRAP	2.8	Implementing Newborn Screening for Pediatric Cancer Predisposition Syndromes in Texas: The INSPECT Study	Parsons, Donald	Baylor College of Medicine	\$1,187,187
48	RP250097	IIRA	2.9	Deciphering and targeting age-related metastatic	Naora, Honami	The University of Texas M. D.	\$899,984

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

				competence of the omentum		Anderson Cancer Center	
49	RP250099	IIRA	2.9	Targeting lethal prostate cancers with a clinical-stage inverse agonist for G protein-coupled receptor 6	Li, Wenliang	The University of Texas Health Science Center at Houston	\$900,000
50	RP250399	IIRACSBC	2.9	Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture	Vokes, Natalie	The University of Texas M. D. Anderson Cancer Center	\$1,049,033
51	RP250090	IIRACSBC	2.9	Artificial Intelligence for Early Identification of Androgen-Indifferent, Lethal Prostate Cancer and Therapy Selection	Merényi, Erzsébet	Rice University	\$1,049,434
52	RP250191	IIRA	3.1	Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$898,263
53	RP250164	IIRACCA	3.1	Prediction of CAR-T Cell Immunotherapy Outcomes in Neuroblastoma using FE-MRI Nano-radiomics	Ghaghada, Ketan	Baylor College of Medicine	\$1,168,013

Core Facility Support Award (CFSA)

Collaborative Action Center (CAC) to Reduce Liver Cancer Mortality in Texas (competitive renewal)

Individual Investigator Research Awards (IIRA)

Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)

Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)

Individual Investigator Research Awards for Clinical Trials (IIRACT)

Individual Investigator Research Awards for Early Onset Cancers (IIRAEOC)

Individual Investigator Research Awards for Prevention and Early Detection (IIRAP)

Recruitment of Established Investigators (REI)

Recruitment of Rising Stars (RRS)

Recruitment of First-Time, Tenure Track Faculty Members (FTTFM)

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660

T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu

Department of Cellular and Molecular Medicine

UC San Diego School of Medicine • 9500 Gilman Drive, Mail Code 0660 • La Jolla, CA 92093-0660
T: 858-534-7804 • F: 858-534-7750 • rkolodner@health.ucsd.edu



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP240537
Core Facility Support Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Core Facility Support Awards* Request for Applications (RFA). CPRIT received 22 applications in response to this RFA, including one withdrawn application. CPRIT temporarily withdrew this application to undergo additional compliance verifications. After confirming that the application met compliance requirements, CPRIT allowed the application to resume peer review. This application was assigned to the 24.2 Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:10 PM CT

FY: 2024
 CYCLE: 2
 PROGRAM: Research
 MECHANISM: Core Facilities Support Awards
 APPLICATION ID: RP240537
 APPLICATION TITLE: Cancer Agent Target Discovery and Aptamer Development (CATDAD) Core
 APPLICANT NAME: Wu, Erxi
 ORGANIZATION: Baylor Research Institute
 PANEL NAME: 24.2 Cancer Biology

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	09/13/2023	07/09/2024
	RFA Approved by CSO (revised)	01/16/2024	07/09/2024
	RFA published in Texas.gov eGrants	09/14/2023	07/09/2024
	CPRIT Application Receipt System (CARS) opened	10/17/2023	07/09/2024
	CPRIT Application Receipt System (CARS) closed	01/18/2024	07/09/2024
	Date application submitted	01/16/2024	07/09/2024
	Method of submission	CARS	07/09/2024
	Within receipt period	YES	07/09/2024
	Request for extension to submit application after CARS closed	N/A	07/09/2024
	Request for extension for late application submission accepted	N/A	07/09/2024
Receipt, Referral, and Assignment	Administrative review notification	N/A	07/09/2024
	Donation(s) made to CPRIT / foundation	NO	07/09/2024
	Assigned to primary reviewers	03/11/2024	07/09/2024
	Applicant notified of review panel assignment	02/28/2024	07/09/2024
	Primary Reviewer 1 COI signed	03/04/2024	07/09/2024
	Primary Reviewer 2 COI signed	02/28/2024	07/09/2024
	Primary Reviewer 3 COI signed	03/14/2024	07/09/2024
	Primary (Advocate) Reviewer 4 COI signed	02/28/2024	07/09/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	07/09/2024
	Primary Reviewer 2 critique submitted	N/A	07/09/2024
	Primary Reviewer 3 critique submitted	N/A	07/09/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	07/09/2024
	COI indicated by non-primary reviewer	N/A	07/09/2024
	Preliminary Evaluation score summary sent to Chair	N/A	07/09/2024
	Recommended for full review	N/A	07/09/2024
	Applicant notified of outcome	N/A	07/09/2024
Peer Review Meeting	Assigned to primary reviewers	03/11/2024	07/09/2024
	Primary Reviewer 1 COI signed	03/04/2024	07/09/2024
	Primary Reviewer 2 COI signed	02/28/2024	07/09/2024
	Primary Reviewer 3 COI signed	03/14/2024	07/09/2024
	Primary (Advocate) Reviewer 4 COI signed	02/28/2024	07/09/2024
	Primary Reviewer 1 critique submitted	04/11/2024	07/09/2024
	Primary Reviewer 2 critique submitted	04/09/2024	07/09/2024
	Primary Reviewer 3 critique submitted	04/14/2024	07/09/2024
	Primary (Advocate) Reviewer 4 critique submitted	03/16/2024	07/09/2024
	COI indicated by non-primary reviewer	NONE	07/09/2024
	COI recused from participation	N/A	07/09/2024
	Discussed at Peer Review Meeting	YES	07/09/2024
	Peer Review Meeting	04/24/2024	07/09/2024
	Post review statements signed	04/29/2024	07/09/2024
	Third Party Observer Report	04/29/2024	07/09/2024
Score report delivered to CSO	05/09/2024	07/09/2024	
Recommended for SRC review	YES	07/09/2024	
Final SRC Recommendation	COI indicated by SRC member	N/A	07/16/2024
	COI recused from participation	N/A	07/16/2024
	SRC Meeting	07/11/2024	07/16/2024
	Third Party Observer Report	07/17/2024	07/30/2024
	Recommended for grant award	N/A	07/16/2024
	SRC Chair Notification to PIC and OC	07/29/2024	07/30/2024
	COI indicated by SRC member	NONE	01/14/2025
	COI recused from participation	N/A	01/14/2025
	25.1 SRC Meeting	12/12/2024	01/14/2025
	Third Party Observer Report	12/18/2024	01/30/2025
Recommended for grant award	YES	01/14/2025	
SRC Chair Notification to PIC and OC	01/10/2025	01/30/2025	
PIC Review	COI indicated by PIC member	None	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
	Recommended for grant award	YES	02/05/2025
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		

Comments:	Created Date
This application was recommended to the SRC at the 24.2 panel meeting. It was removed from consideration due to administrative issues, these issues were resolved and the application was reviewed and recommended at the 25.1 meeting to move forward to the PIC.	2025-01-07 15:44:46.237



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250355
Collaborative Action Program to Reduce Liver Cancer
Mortality in Texas: Collaborative Action Center

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center* Request for Applications (RFA). CPRIT received one application in response to this RFA. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Kristen P. Doyle

CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:14 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Collaborative Action Program (CAP) to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center (Competitive Renewal)
APPLICATION ID: RP250355
APPLICATION TITLE: The Texas Collaborative Center for Hepatocellular Cancer (TeCH)
APPLICANT NAME: El-Serag, Hashem B
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 25.1 Cancer Prevention Research Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/09/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		09/05/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/23/2024
Primary Reviewer 1 COI signed		09/11/2024	12/23/2024
Primary Reviewer 2 COI signed		09/06/2024	12/23/2024
Primary Reviewer 3 COI signed		08/29/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		08/29/2024	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	12/23/2024
	Primary Reviewer 2 critique submitted	N/A	12/23/2024
	Primary Reviewer 3 critique submitted	N/A	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	N/A	12/23/2024
	Preliminary Evaluation score summary sent to Chair	N/A	12/23/2024
	Recommended for full review	N/A	12/23/2024
	Applicant notified of outcome	N/A	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	09/11/2024	12/23/2024
	Primary Reviewer 2 COI signed	09/06/2024	12/23/2024
	Primary Reviewer 3 COI signed	08/29/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	08/29/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/13/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/09/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/14/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/04/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/22/2024	12/23/2024
	Post review statements signed	10/22/2024	12/23/2024
	Third Party Observer Report	10/23/2024	12/23/2024
Score report delivered to CSO	11/08/2024	12/23/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/23/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	None	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250028
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or


affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 7th day of February, 2025, by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:10 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250028
APPLICATION TITLE: MALAT1 protects against osteoporosis and bone metastasis
APPLICANT NAME: Ma, Li
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Cancer Biology Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/04/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/01/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/20/2024
Primary Reviewer 1 COI signed		07/05/2024	12/23/2024
Primary Reviewer 2 COI signed		07/08/2024	12/23/2024
Primary Reviewer 3 COI signed		07/18/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/09/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/16/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/12/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	09/02/2024	12/23/2024
	Primary Reviewer 2 COI signed	09/20/2024	12/23/2024
	Primary Reviewer 3 COI signed	09/27/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	09/11/2024	12/23/2024
	Primary Reviewer 1 critique submitted	09/30/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/04/2024	12/23/2024
	Primary Reviewer 3 critique submitted	09/28/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/04/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/17/2024	12/23/2024
	Post review statements signed	10/18/2024	12/20/2024
	Third Party Observer Report	10/22/2024	12/20/2024
Score report delivered to CSO	11/08/2024	12/20/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/20/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250043
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or


affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 7th day of February, 2025, by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:10 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250043
APPLICATION TITLE: An integrated imaging informatics platform for HCC surveillance
APPLICANT NAME: Zhou, Xiaobo
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 25.1 Imaging Technology and Informatics Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/11/2024	12/24/2024
	Method of submission	CARS	12/24/2024
	Within receipt period	YES	12/24/2024
	Request for extension to submit application after CARS closed	N/A	12/24/2024
	Request for extension for late application submission accepted	N/A	12/24/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/24/2024
Assigned to primary reviewers		08/01/2024	12/24/2024
Applicant notified of review panel assignment		07/31/2024	12/24/2024
Primary Reviewer 1 COI signed		07/07/2024	12/24/2024
Primary Reviewer 2 COI signed		07/03/2024	12/24/2024
Primary Reviewer 3 COI signed		07/05/2024	12/24/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/24/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/24/2024
	Primary Reviewer 2 critique submitted	08/04/2024	12/24/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/24/2024
	Recommended for full review	YES	12/24/2024
	Applicant notified of outcome	10/01/2024	12/24/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/24/2024
	Primary Reviewer 1 COI signed	10/03/2024	12/24/2024
	Primary Reviewer 2 COI signed	08/28/2024	12/24/2024
	Primary Reviewer 3 COI signed	08/28/2024	12/24/2024
	Primary (Advocate) Reviewer 4 COI signed	08/29/2024	12/24/2024
	Primary Reviewer 1 critique submitted	10/04/2024	12/24/2024
	Primary Reviewer 2 critique submitted	09/29/2024	12/24/2024
	Primary Reviewer 3 critique submitted	10/02/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/03/2024	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	Discussed at Peer Review Meeting	YES	12/24/2024
	Peer Review Meeting	10/18/2024	12/24/2024
	Post review statements signed	10/18/2024	12/24/2024
	Third Party Observer Report	10/22/2024	12/24/2024
Score report delivered to CSO	11/08/2024	12/24/2024	
Recommended for SRC review	YES	12/24/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	SRC Meeting	12/12/2024	12/24/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/24/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250055
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:10 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250055
APPLICATION TITLE: TET2 mutations promote myeloid malignancies by dysregulating m5C oxidation of chromatin-associated RNAs
APPLICANT NAME: Xu, Mingjiang
ORGANIZATION: The University of Texas Health Science Center at San Antonio
PANEL NAME: 25.1 Basic Cancer Research 2 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	05/21/2024	12/19/2024
	Method of submission	CARS	12/19/2024
	Within receipt period	YES	12/19/2024
	Request for extension to submit application after CARS closed	N/A	12/19/2024
	Request for extension for late application submission accepted	N/A	12/19/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/19/2024
Assigned to primary reviewers		08/02/2024	12/19/2024
Applicant notified of review panel assignment		07/31/2024	12/19/2024
Primary Reviewer 1 COI signed		07/08/2024	12/19/2024
Primary Reviewer 2 COI signed		07/03/2024	12/19/2024
Primary Reviewer 3 COI signed		07/15/2024	12/19/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/19/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/11/2024	12/19/2024
	Primary Reviewer 2 critique submitted	08/14/2024	12/19/2024
	Primary Reviewer 3 critique submitted	08/13/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/19/2024
	Prelim Eval score summary sent to Chair (revised)	09/03/2024	12/19/2024
	Recommended for full review	YES	12/19/2024
	Applicant notified of outcome	10/01/2024	12/19/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/19/2024
	Primary Reviewer 1 COI signed	09/01/2024	12/19/2024
	Primary Reviewer 2 COI signed	08/30/2024	12/19/2024
	Primary Reviewer 3 COI signed	09/10/2024	12/19/2024
	Primary (Advocate) Reviewer 4 COI signed	08/30/2024	12/19/2024
	Primary Reviewer 1 critique submitted	10/11/2024	12/19/2024
	Primary Reviewer 2 critique submitted	10/12/2024	12/19/2024
	Primary Reviewer 3 critique submitted	10/06/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/10/2024	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	Discussed at Peer Review Meeting	YES	12/19/2024
	Peer Review Meeting	10/24/2024	12/19/2024
	Post review statements signed	10/26/2024	12/19/2024
	Third Party Observer Report	10/31/2024	12/19/2024
Score report delivered to CSO	11/08/2024	12/19/2024	
Recommended for SRC review	YES	12/19/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	SRC Meeting	12/12/2024	01/24/2025
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/19/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250061
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or


affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 7th day of February, 2025, by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:10 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250061
APPLICATION TITLE: Imaging of cranial radiotherapy neuroinflammatory sequelae by Positron Emission Tomography
APPLICANT NAME: Pisaneschi, Federica
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 25.1 Imaging Technology and Informatics Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/10/2024	12/24/2024
	Method of submission	CARS	12/24/2024
	Within receipt period	YES	12/24/2024
	Request for extension to submit application after CARS closed	N/A	12/24/2024
	Request for extension for late application submission accepted	N/A	12/24/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/24/2024
Assigned to primary reviewers		08/01/2024	12/24/2024
Applicant notified of review panel assignment		07/31/2024	12/24/2024
Primary Reviewer 1 COI signed		07/07/2024	12/24/2024
Primary Reviewer 2 COI signed		07/08/2024	12/24/2024
Primary Reviewer 3 COI signed		07/06/2024	12/24/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/24/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/04/2024	12/24/2024
	Primary Reviewer 2 critique submitted	08/15/2024	12/24/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/24/2024
	Recommended for full review	YES	12/24/2024
	Applicant notified of outcome	10/01/2024	12/24/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/24/2024
	Primary Reviewer 1 COI signed	08/28/2024	12/24/2024
	Primary Reviewer 2 COI signed	09/03/2024	12/24/2024
	Primary Reviewer 3 COI signed	08/29/2024	12/24/2024
	Primary (Advocate) Reviewer 4 COI signed	08/29/2024	12/24/2024
	Primary Reviewer 1 critique submitted	09/28/2024	12/24/2024
	Primary Reviewer 2 critique submitted	10/04/2024	12/24/2024
	Primary Reviewer 3 critique submitted	10/04/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/03/2024	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	Discussed at Peer Review Meeting	YES	12/24/2024
	Peer Review Meeting	10/18/2024	12/24/2024
	Post review statements signed	10/18/2024	12/24/2024
	Third Party Observer Report	10/22/2024	12/24/2024
Score report delivered to CSO	11/08/2024	12/24/2024	
Recommended for SRC review	YES	12/24/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	SRC Meeting	12/12/2024	12/24/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/24/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250062
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or


affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 7th day of February, 2025, by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:10 PM CT

FY: 2025
 CYCLE: 1
 PROGRAM: Research
 MECHANISM: Individual Investigator Research Awards
 APPLICATION ID: RP250062
 APPLICATION TITLE: Clonal hematopoiesis and toxicity from radiation therapy
 APPLICANT NAME: Nead, Kevin
 ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
 PANEL NAME: 25.1 Cancer Prevention Research Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/06/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/02/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/23/2024
Primary Reviewer 1 COI signed		07/14/2024	12/23/2024
Primary Reviewer 2 COI signed		07/03/2024	12/23/2024
Primary Reviewer 3 COI signed		07/08/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/13/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/13/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	09/05/2024	12/23/2024
	Primary Reviewer 2 COI signed	09/05/2024	12/23/2024
	Primary Reviewer 3 COI signed	09/03/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	08/29/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/15/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/11/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/09/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/25/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/22/2024	12/23/2024
	Post review statements signed	10/22/2024	12/23/2024
	Third Party Observer Report	10/23/2024	12/23/2024
Score report delivered to CSO	11/08/2024	12/23/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/23/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250069
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Basic Cancer Research Panel I for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted

The Scientific Review Council (SRC) recommended this application at their December 12, 2024, meeting. Dr. Jason Lewis, an SRC member who was not part of the peer review panel to which this application was assigned, identified a conflict of interest with this application. The conflict was waived pursuant to an approved Texas Health and Safety Code § 102.1062 waiver applicable to CPRIT review councils during FY2025.

- The third-party observer report(s) documenting that CPRIT's grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle.

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the SRC for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:11 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250069
APPLICATION TITLE: HSP90 Capacitance: Discovery of a New Mechanism Driving Evolution of Drug Resistance in Head and Neck Squamous Cell Carcinoma
APPLICANT NAME: Karras, Georgios
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Basic Cancer Research 1 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/07/2024	12/19/2024
	Method of submission	CARS	12/19/2024
	Within receipt period	YES	12/19/2024
	Request for extension to submit application after CARS closed	N/A	12/19/2024
	Request for extension for late application submission accepted	N/A	12/19/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/19/2024
Assigned to primary reviewers		08/02/2024	12/19/2024
Applicant notified of review panel assignment		07/31/2024	12/19/2024
Primary Reviewer 1 COI signed		07/08/2024	12/19/2024
Primary Reviewer 2 COI signed		07/06/2024	12/19/2024
Primary Reviewer 3 COI signed		07/09/2024	12/19/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/19/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/11/2024	12/19/2024
	Primary Reviewer 2 critique submitted	08/10/2024	12/19/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/19/2024
	Recommended for full review	YES	12/19/2024
Peer Review Meeting	Applicant notified of outcome	10/01/2024	12/19/2024
	Assigned to primary reviewers	09/05/2024	12/19/2024
	Primary Reviewer 1 COI signed	08/29/2024	12/19/2024
	Primary Reviewer 2 COI signed	08/29/2024	12/19/2024
	Primary Reviewer 3 COI signed	08/30/2024	12/19/2024
	Primary (Advocate) Reviewer 4 COI signed	08/28/2024	12/19/2024
	Primary Reviewer 1 critique submitted	10/11/2024	12/19/2024
	Primary Reviewer 2 critique submitted	10/06/2024	12/19/2024
	Primary Reviewer 3 critique submitted	10/12/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/12/2024	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	Discussed at Peer Review Meeting	YES	12/19/2024
	Peer Review Meeting	10/23/2024	12/19/2024
	Post review statements signed	10/24/2024	12/19/2024
	Third Party Observer Report	10/31/2024	12/19/2024
	Score report delivered to CSO	11/08/2024	12/19/2024
Recommended for SRC review	YES	12/19/2024	
Final SRC Recommendation	COI indicated by SRC member	Jason Lewis	12/19/2024
	COI recused from participation	Other: Present per FY25 waiver for RC members	12/19/2024
	SRC Meeting	12/12/2024	12/19/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/19/2024
	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
PIC Review	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
	Recommended for grant award	YES	02/05/2025
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250091
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:11 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250091
APPLICATION TITLE: Dissecting the Survival Mechanisms of Latent Brain-Tropic Cancer Cells for Therapeutic Interventions
APPLICANT NAME: Malladi, Srinivas
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 25.1 Cancer Biology Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/10/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/01/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/20/2024
Primary Reviewer 1 COI signed		07/03/2024	12/23/2024
Primary Reviewer 2 COI signed		07/08/2024	12/23/2024
Primary Reviewer 3 COI signed		07/23/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/12/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/16/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/16/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	08/28/2024	12/23/2024
	Primary Reviewer 2 COI signed	09/20/2024	12/23/2024
	Primary Reviewer 3 COI signed	10/01/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	09/11/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/01/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/04/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/07/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/04/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/17/2024	12/23/2024
	Post review statements signed	10/18/2024	12/20/2024
	Third Party Observer Report	10/22/2024	12/20/2024
Score report delivered to CSO	11/08/2024	12/20/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/20/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250097
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Basic Cancer Research Panel I for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.



This statement is true."



Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:11 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250097
APPLICATION TITLE: Deciphering and targeting age-related metastatic competence of the omentum
APPLICANT NAME: Naora, Honami
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Basic Cancer Research 1 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/05/2024	12/19/2024
	Method of submission	CARS	12/19/2024
	Within receipt period	YES	12/19/2024
	Request for extension to submit application after CARS closed	N/A	12/19/2024
	Request for extension for late application submission accepted	N/A	12/19/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/19/2024
Assigned to primary reviewers		08/02/2024	12/19/2024
Applicant notified of review panel assignment		07/31/2024	12/19/2024
Primary Reviewer 1 COI signed		07/09/2024	12/19/2024
Primary Reviewer 2 COI signed		07/04/2024	12/19/2024
Primary Reviewer 3 COI signed		07/03/2024	12/19/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/19/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/19/2024
	Primary Reviewer 2 critique submitted	08/08/2024	12/19/2024
	Primary Reviewer 3 critique submitted	08/13/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/19/2024
	Recommended for full review	YES	12/19/2024
	Applicant notified of outcome	10/01/2024	12/19/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/19/2024
	Primary Reviewer 1 COI signed	08/30/2024	12/19/2024
	Primary Reviewer 2 COI signed	08/31/2024	12/19/2024
	Primary Reviewer 3 COI signed	08/27/2024	12/19/2024
	Primary (Advocate) Reviewer 4 COI signed	08/28/2024	12/19/2024
	Primary Reviewer 1 critique submitted	10/13/2024	12/19/2024
	Primary Reviewer 2 critique submitted	10/10/2024	12/19/2024
	Primary Reviewer 3 critique submitted	10/03/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/12/2024	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	Discussed at Peer Review Meeting	YES	12/19/2024
	Peer Review Meeting	10/23/2024	12/19/2024
	Post review statements signed	10/24/2024	12/19/2024
	Third Party Observer Report	10/31/2024	12/19/2024
Score report delivered to CSO	11/08/2024	12/19/2024	
Recommended for SRC review	YES	12/19/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	SRC Meeting	12/12/2024	12/19/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/19/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250099
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Basic Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true.”



Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:11 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250099
APPLICATION TITLE: Targeting lethal prostate cancers with a clinical-stage inverse agonist for G protein-coupled receptor 6
APPLICANT NAME: Li, Wenliang
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 25.1 Basic Cancer Research 1 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/11/2024	12/19/2024
	Method of submission	CARS	12/19/2024
	Within receipt period	YES	12/19/2024
	Request for extension to submit application after CARS closed	N/A	12/19/2024
	Request for extension for late application submission accepted	N/A	12/19/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/19/2024
Assigned to primary reviewers		08/02/2024	12/19/2024
Applicant notified of review panel assignment		07/31/2024	12/19/2024
Primary Reviewer 1 COI signed		07/08/2024	12/19/2024
Primary Reviewer 2 COI signed		07/04/2024	12/19/2024
Primary Reviewer 3 COI signed		07/03/2024	12/19/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/19/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/13/2024	12/19/2024
	Primary Reviewer 2 critique submitted	08/11/2024	12/19/2024
	Primary Reviewer 3 critique submitted	08/13/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/19/2024
	Recommended for full review	YES	12/19/2024
	Applicant notified of outcome	10/01/2024	12/19/2024
	Peer Review Meeting	Assigned to primary reviewers	09/05/2024
Primary Reviewer 1 COI signed		09/05/2024	12/19/2024
Primary Reviewer 2 COI signed		08/31/2024	12/19/2024
Primary Reviewer 3 COI signed		08/27/2024	12/19/2024
Primary (Advocate) Reviewer 4 COI signed		08/28/2024	12/19/2024
Primary Reviewer 1 critique submitted		10/13/2024	12/19/2024
Primary Reviewer 2 critique submitted		10/14/2024	12/19/2024
Primary Reviewer 3 critique submitted		10/03/2024	12/19/2024
Primary (Advocate) Reviewer 4 critique submitted		10/12/2024	12/19/2024
COI indicated by non-primary reviewer		NONE	12/19/2024
COI recused from participation		N/A	12/19/2024
Discussed at Peer Review Meeting		YES	12/19/2024
Peer Review Meeting		10/23/2024	12/19/2024
Post review statements signed		10/24/2024	12/19/2024
Third Party Observer Report		10/31/2024	12/19/2024
Score report delivered to CSO		11/08/2024	12/19/2024
Recommended for SRC review	YES	12/19/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	SRC Meeting	12/12/2024	12/19/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/19/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250118
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Kristen P. Doyle,


CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:11 PM CT

FY: 2025
 CYCLE: 1
 PROGRAM: Research
 MECHANISM: Individual Investigator Research Awards
 APPLICATION ID: RP250118
 APPLICATION TITLE: Ribosome Localization at Mitochondria-ER Contacts in Obesity-Associated Liver Cancer
 APPLICANT NAME: Morita, Masahiro
 ORGANIZATION: The University of Texas Health Science Center at San Antonio
 PANEL NAME: 25.1 Basic Cancer Research 2 Full

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024	
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024	
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024	
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024	
	Date application submitted	06/11/2024	12/19/2024	
	Method of submission	CARS	12/19/2024	
	Within receipt period	YES	12/19/2024	
	Request for extension to submit application after CARS closed	N/A	12/19/2024	
	Request for extension for late application submission accepted	N/A	12/19/2024	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	12/19/2024
Donation(s) made to CPRIT / foundation		NO	12/19/2024	
Assigned to primary reviewers		08/02/2024	12/19/2024	
Applicant notified of review panel assignment		07/31/2024	12/19/2024	
Primary Reviewer 1 COI signed		07/08/2024	12/19/2024	
Primary Reviewer 2 COI signed		07/07/2024	12/19/2024	
Primary Reviewer 3 COI signed		07/03/2024	12/19/2024	
Primary (Advocate) Reviewer 4 COI signed		N/A	12/19/2024	
Preliminary Evaluation		Primary Reviewer 1 critique submitted	08/11/2024	12/19/2024
		Primary Reviewer 2 critique submitted	08/14/2024	12/19/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/19/2024	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/19/2024	
	COI indicated by non-primary reviewer	Sanja VickoviÄ	12/19/2024	
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/19/2024	
	Prelim Eval score summary sent to Chair (revised)	09/03/2024	12/19/2024	
	Recommended for full review	YES	12/19/2024	
	Applicant notified of outcome	10/01/2024	12/19/2024	
	Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/19/2024
Primary Reviewer 1 COI signed		09/01/2024	12/19/2024	
Primary Reviewer 2 COI signed		08/30/2024	12/19/2024	
Primary Reviewer 3 COI signed		08/30/2024	12/19/2024	
Primary (Advocate) Reviewer 4 COI signed		09/05/2024	12/19/2024	
Primary Reviewer 1 critique submitted		10/11/2024	12/19/2024	
Primary Reviewer 2 critique submitted		10/13/2024	12/19/2024	
Primary Reviewer 3 critique submitted		10/13/2024	12/19/2024	
Primary (Advocate) Reviewer 4 critique submitted		10/11/2024	12/19/2024	
COI indicated by non-primary reviewer		Sanja VickoviÄ	12/19/2024	
COI recused from participation		YES	12/19/2024	
Discussed at Peer Review Meeting		YES	12/19/2024	
Peer Review Meeting		10/24/2024	12/19/2024	
Post review statements signed		10/26/2024	12/19/2024	
Third Party Observer Report		10/31/2024	12/19/2024	
Score report delivered to CSO	11/08/2024	12/19/2024		
Recommended for SRC review	YES	12/19/2024		
Final SRC Recommendation	COI indicated by SRC member	NONE	12/19/2024	
	COI recused from participation	N/A	12/19/2024	
	SRC Meeting	12/12/2024	01/24/2025	
	Third Party Observer Report	12/18/2024	01/30/2025	
	Recommended for grant award	YES	12/19/2024	
	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025	
PIC Review	COI indicated by PIC member	none	02/05/2025	
	COI recused from participation	N/A	02/05/2025	
	PIC Review Meeting	02/05/2025	02/05/2025	
	Recommended for grant award	YES	02/05/2025	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		

Comments:	Created Date
Reviewer name rendered herein as VickoviÄ is actually Vicovi but does not appear as such due to the use of the special character.	2024-11-14 10:33:34.12



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250143
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true.”




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:11 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250143
APPLICATION TITLE: Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy
APPLICANT NAME: Lissanu, Yonathan
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Clinical and Translational Cancer Research 2 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/06/2024	12/24/2024
	Method of submission	CARS	12/24/2024
	Within receipt period	YES	12/24/2024
	Request for extension to submit application after CARS closed	N/A	12/24/2024
	Request for extension for late application submission accepted	N/A	12/24/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/24/2024
Assigned to primary reviewers		08/02/2024	12/24/2024
Applicant notified of review panel assignment		07/31/2024	12/24/2024
Primary Reviewer 1 COI signed		07/16/2024	12/24/2024
Primary Reviewer 2 COI signed		07/25/2024	12/24/2024
Primary Reviewer 3 COI signed		07/10/2024	12/24/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/24/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/10/2024	12/24/2024
	Primary Reviewer 2 critique submitted	08/13/2024	12/24/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/24/2024
	Recommended for full review	YES	12/24/2024
	Applicant notified of outcome	10/01/2024	12/24/2024
	Peer Review Meeting	Assigned to primary reviewers	09/05/2024
Primary Reviewer 1 COI signed		08/30/2024	12/24/2024
Primary Reviewer 2 COI signed		09/16/2024	12/24/2024
Primary Reviewer 3 COI signed		08/29/2024	12/24/2024
Primary (Advocate) Reviewer 4 COI signed		08/28/2024	12/24/2024
Primary Reviewer 1 critique submitted		10/02/2024	12/24/2024
Primary Reviewer 2 critique submitted		10/05/2024	12/24/2024
Primary Reviewer 3 critique submitted		09/28/2024	12/24/2024
Primary (Advocate) Reviewer 4 critique submitted		09/13/2024	12/24/2024
COI indicated by non-primary reviewer		NONE	12/24/2024
COI recused from participation		N/A	12/24/2024
Discussed at Peer Review Meeting		YES	12/24/2024
Peer Review Meeting		10/16/2024	12/24/2024
Post review statements signed		10/16/2024	12/24/2024
Third Party Observer Report		10/22/2024	12/24/2024
Score report delivered to CSO		11/08/2024	12/24/2024
Recommended for SRC review		YES	12/24/2024
Final SRC Recommendation	COI indicated by SRC member	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	SRC Meeting	12/12/2024	12/24/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/24/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250154
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:11 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250154
APPLICATION TITLE: Improving Detection of Hepatocellular Carcinoma in Non-Cirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASLD) Patients
APPLICANT NAME: Fuentes, David
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Imaging Technology and Informatics Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/06/2024	12/24/2024
	Method of submission	CARS	12/24/2024
	Within receipt period	YES	12/24/2024
	Request for extension to submit application after CARS closed	N/A	12/24/2024
	Request for extension for late application submission accepted	N/A	12/24/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/24/2024
Assigned to primary reviewers		08/01/2024	12/24/2024
Applicant notified of review panel assignment		07/31/2024	12/24/2024
Primary Reviewer 1 COI signed		07/14/2024	12/24/2024
Primary Reviewer 2 COI signed		07/03/2024	12/24/2024
Primary Reviewer 3 COI signed		07/05/2024	12/24/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/24/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/15/2024	12/24/2024
	Primary Reviewer 2 critique submitted	08/11/2024	12/24/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/24/2024
	Recommended for full review	YES	12/24/2024
	Applicant notified of outcome	10/01/2024	12/24/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/24/2024
	Primary Reviewer 1 COI signed	10/01/2024	12/24/2024
	Primary Reviewer 2 COI signed	08/28/2024	12/24/2024
	Primary Reviewer 3 COI signed	08/28/2024	12/24/2024
	Primary (Advocate) Reviewer 4 COI signed	08/29/2024	12/24/2024
	Primary Reviewer 1 critique submitted	10/03/2024	12/24/2024
	Primary Reviewer 2 critique submitted	09/30/2024	12/24/2024
	Primary Reviewer 3 critique submitted	10/04/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/03/2024	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	Discussed at Peer Review Meeting	YES	12/24/2024
	Peer Review Meeting	10/18/2024	12/24/2024
	Post review statements signed	10/18/2024	12/24/2024
	Third Party Observer Report	10/22/2024	12/24/2024
Score report delivered to CSO	11/08/2024	12/24/2024	
Recommended for SRC review	YES	12/24/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	SRC Meeting	12/12/2024	12/24/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/24/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250191
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true.”




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:11 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250191
APPLICATION TITLE: Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy
APPLICANT NAME: Jiang, Wen
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Clinical and Translational Cancer Research 2 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/06/2024	12/24/2024
	Method of submission	CARS	12/24/2024
	Within receipt period	YES	12/24/2024
	Request for extension to submit application after CARS closed	N/A	12/24/2024
	Request for extension for late application submission accepted	N/A	12/24/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/24/2024
Assigned to primary reviewers		08/02/2024	12/24/2024
Applicant notified of review panel assignment		07/31/2024	12/24/2024
Primary Reviewer 1 COI signed		07/18/2024	12/24/2024
Primary Reviewer 2 COI signed		07/25/2024	12/24/2024
Primary Reviewer 3 COI signed		07/07/2024	12/24/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/24/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/24/2024
	Primary Reviewer 2 critique submitted	08/13/2024	12/24/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/24/2024
	Recommended for full review	YES	12/24/2024
	Applicant notified of outcome	10/01/2024	12/24/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/24/2024
	Primary Reviewer 1 COI signed	08/30/2024	12/24/2024
	Primary Reviewer 2 COI signed	08/30/2024	12/24/2024
	Primary Reviewer 3 COI signed	09/08/2024	12/24/2024
	Primary (Advocate) Reviewer 4 COI signed	09/11/2024	12/24/2024
	Primary Reviewer 1 critique submitted	10/01/2024	12/24/2024
	Primary Reviewer 2 critique submitted	10/02/2024	12/24/2024
	Primary Reviewer 3 critique submitted	10/02/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/24/2024	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	Discussed at Peer Review Meeting	YES	12/24/2024
	Peer Review Meeting	10/16/2024	12/24/2024
	Post review statements signed	10/16/2024	12/24/2024
	Third Party Observer Report	10/22/2024	12/24/2024
Score report delivered to CSO	11/08/2024	12/24/2024	
Recommended for SRC review	YES	12/24/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	SRC Meeting	12/12/2024	12/24/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/24/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250201
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.



This statement is true.”



Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7^m day of February, 2025,
by KRISTEN P. DOYLE.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:11 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250201
APPLICATION TITLE: Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in oral cavity squamous cell carcinoma
APPLICANT NAME: Gillison, Maura L
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Clinical and Translational Cancer Research 2 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/07/2024	12/24/2024
	Method of submission	CARS	12/24/2024
	Within receipt period	YES	12/24/2024
	Request for extension to submit application after CARS closed	N/A	12/24/2024
	Request for extension for late application submission accepted	N/A	12/24/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/24/2024
Assigned to primary reviewers		08/02/2024	12/24/2024
Applicant notified of review panel assignment		07/31/2024	12/24/2024
Primary Reviewer 1 COI signed		07/03/2024	12/24/2024
Primary Reviewer 2 COI signed		07/10/2024	12/24/2024
Primary Reviewer 3 COI signed		07/24/2024	12/24/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/24/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/05/2024	12/24/2024
	Primary Reviewer 2 critique submitted	08/14/2024	12/24/2024
	Primary Reviewer 3 critique submitted	08/11/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/24/2024
	Recommended for full review	YES	12/24/2024
	Applicant notified of outcome	10/01/2024	12/24/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/24/2024
	Primary Reviewer 1 COI signed	08/26/2024	12/24/2024
	Primary Reviewer 2 COI signed	08/29/2024	12/24/2024
	Primary Reviewer 3 COI signed	08/30/2024	12/24/2024
	Primary (Advocate) Reviewer 4 COI signed	09/11/2024	12/24/2024
	Primary Reviewer 1 critique submitted	09/10/2024	12/24/2024
	Primary Reviewer 2 critique submitted	10/07/2024	12/24/2024
	Primary Reviewer 3 critique submitted	10/01/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/24/2024	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	Discussed at Peer Review Meeting	YES	12/24/2024
	Peer Review Meeting	10/16/2024	12/24/2024
	Post review statements signed	10/16/2024	12/24/2024
Third Party Observer Report	10/22/2024	12/24/2024	
Score report delivered to CSO	11/08/2024	12/24/2024	
Recommended for SRC review	YES	12/24/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	SRC Meeting	12/12/2024	12/24/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/24/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250208
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.



This statement is true."



Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:12 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250208
APPLICATION TITLE: RPS23 is a new drug target to activate the integrated stress response and treat leukemia
APPLICANT NAME: Ready, Joseph M
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 25.1 Cancer Biology Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/10/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/01/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/20/2024
Primary Reviewer 1 COI signed		07/14/2024	12/23/2024
Primary Reviewer 2 COI signed		07/03/2024	12/23/2024
Primary Reviewer 3 COI signed		07/18/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/13/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	09/13/2024	12/23/2024
	Primary Reviewer 2 COI signed	08/26/2024	12/23/2024
	Primary Reviewer 3 COI signed	09/30/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	09/05/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/07/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/05/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/06/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/26/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/17/2024	12/23/2024
	Post review statements signed	10/18/2024	12/20/2024
	Third Party Observer Report	10/22/2024	12/20/2024
Score report delivered to CSO	11/08/2024	12/20/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/20/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250213
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards Request for Applications (RFA)*. CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:12 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250213
APPLICATION TITLE: KRAS spatiotemporal dynamics: lipid glycosylation as a novel therapeutic target
APPLICANT NAME: Hancock, John F
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 25.1 Cancer Biology Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/10/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/01/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/20/2024
Primary Reviewer 1 COI signed		07/23/2024	12/23/2024
Primary Reviewer 2 COI signed		07/14/2024	12/23/2024
Primary Reviewer 3 COI signed		07/07/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/16/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/13/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	10/01/2024	12/23/2024
	Primary Reviewer 2 COI signed	09/13/2024	12/23/2024
	Primary Reviewer 3 COI signed	08/26/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	09/05/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/07/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/07/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/04/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/03/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/17/2024	12/23/2024
	Post review statements signed	10/18/2024	12/20/2024
	Third Party Observer Report	10/22/2024	12/20/2024
Score report delivered to CSO	11/08/2024	12/20/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/20/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250220
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:12 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250220
APPLICATION TITLE: Decellularized tissue matrices to study the “bad soil” in cancer metastasis
APPLICANT NAME: Wang, Andrew Z
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 25.1 Basic Cancer Research 2 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/10/2024	12/19/2024
	Method of submission	CARS	12/19/2024
	Within receipt period	YES	12/19/2024
	Request for extension to submit application after CARS closed	N/A	12/19/2024
	Request for extension for late application submission accepted	N/A	12/19/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/19/2024
Assigned to primary reviewers		08/02/2024	12/19/2024
Applicant notified of review panel assignment		07/31/2024	12/19/2024
Primary Reviewer 1 COI signed		07/05/2024	12/19/2024
Primary Reviewer 2 COI signed		07/06/2024	12/19/2024
Primary Reviewer 3 COI signed		07/08/2024	12/19/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/19/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/19/2024
	Primary Reviewer 2 critique submitted	08/13/2024	12/19/2024
	Primary Reviewer 3 critique submitted	08/11/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/19/2024
	Prelim Eval score summary sent to Chair (revised)	09/03/2024	12/19/2024
	Recommended for full review	YES	12/19/2024
Peer Review Meeting	Applicant notified of outcome	10/01/2024	12/19/2024
	Assigned to primary reviewers	09/05/2024	12/19/2024
	Primary Reviewer 1 COI signed	09/10/2024	12/19/2024
	Primary Reviewer 2 COI signed	08/29/2024	12/19/2024
	Primary Reviewer 3 COI signed	10/07/2024	12/19/2024
	Primary (Advocate) Reviewer 4 COI signed	08/30/2024	12/19/2024
	Primary Reviewer 1 critique submitted	10/03/2024	12/19/2024
	Primary Reviewer 2 critique submitted	10/10/2024	12/19/2024
	Primary Reviewer 3 critique submitted	10/14/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/26/2024	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	Discussed at Peer Review Meeting	YES	12/19/2024
	Peer Review Meeting	10/24/2024	12/19/2024
	Post review statements signed	10/26/2024	12/19/2024
	Third Party Observer Report	10/31/2024	12/19/2024
	Score report delivered to CSO	11/08/2024	12/19/2024
Recommended for SRC review	YES	12/19/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	SRC Meeting	12/12/2024	01/24/2025
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/19/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250222
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:12 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250222
APPLICATION TITLE: KRAS inhibitor-induced adaptive resistance mechanisms and immune suppression in NSCLC
APPLICANT NAME: Gibbons, Don L
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Clinical and Translational Cancer Research 2 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/06/2024	12/24/2024
	Method of submission	CARS	12/24/2024
	Within receipt period	YES	12/24/2024
	Request for extension to submit application after CARS closed	N/A	12/24/2024
	Request for extension for late application submission accepted	N/A	12/24/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/24/2024
Assigned to primary reviewers		08/02/2024	12/24/2024
Applicant notified of review panel assignment		07/31/2024	12/24/2024
Primary Reviewer 1 COI signed		07/08/2024	12/24/2024
Primary Reviewer 2 COI signed		07/24/2024	12/24/2024
Primary Reviewer 3 COI signed		07/08/2024	12/24/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/24/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/24/2024
	Primary Reviewer 2 critique submitted	08/11/2024	12/24/2024
	Primary Reviewer 3 critique submitted	08/15/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/24/2024
	Recommended for full review	YES	12/24/2024
	Applicant notified of outcome	10/01/2024	12/24/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/24/2024
	Primary Reviewer 1 COI signed	08/28/2024	12/24/2024
	Primary Reviewer 2 COI signed	08/30/2024	12/24/2024
	Primary Reviewer 3 COI signed	09/05/2024	12/24/2024
	Primary (Advocate) Reviewer 4 COI signed	08/28/2024	12/24/2024
	Primary Reviewer 1 critique submitted	10/03/2024	12/24/2024
	Primary Reviewer 2 critique submitted	10/01/2024	12/24/2024
	Primary Reviewer 3 critique submitted	10/01/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/14/2024	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	Discussed at Peer Review Meeting	YES	12/24/2024
	Peer Review Meeting	10/16/2024	12/24/2024
	Post review statements signed	10/16/2024	12/24/2024
Third Party Observer Report	10/22/2024	12/24/2024	
Score report delivered to CSO	11/08/2024	12/24/2024	
Recommended for SRC review	YES	12/24/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	SRC Meeting	12/12/2024	12/24/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/24/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250247
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 7th day of February, 2025, by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:12 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250247
APPLICATION TITLE: Innovative in vitro and in vivo patient-derived cancer models to advance precision medicine in G1/G2 GEP-NETs
APPLICANT NAME: Yao, James
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Clinical and Translational Cancer Research I Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/07/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/02/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/23/2024
Primary Reviewer 1 COI signed		07/09/2024	12/23/2024
Primary Reviewer 2 COI signed		07/08/2024	12/23/2024
Primary Reviewer 3 COI signed		07/04/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/13/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/13/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	Howard Hochster	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
	Peer Review Meeting	Assigned to primary reviewers	09/05/2024
Primary Reviewer 1 COI signed		08/28/2024	12/23/2024
Primary Reviewer 2 COI signed		08/29/2024	12/23/2024
Primary Reviewer 3 COI signed		08/31/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		08/28/2024	12/23/2024
Primary Reviewer 1 critique submitted		10/11/2024	12/23/2024
Primary Reviewer 2 critique submitted		10/09/2024	12/23/2024
Primary Reviewer 3 critique submitted		10/11/2024	12/23/2024
Primary (Advocate) Reviewer 4 critique submitted		09/15/2024	12/23/2024
COI indicated by non-primary reviewer		Howard Hochster	12/23/2024
COI recused from participation		YES	12/23/2024
Discussed at Peer Review Meeting		YES	12/23/2024
Peer Review Meeting		10/25/2024	12/23/2024
Post review statements signed		10/29/2024	12/23/2024
Third Party Observer Report		10/31/2024	12/23/2024
Score report delivered to CSO	11/08/2024	12/23/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/23/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250280
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:12 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250280
APPLICATION TITLE: The role of glutathione in leukemia development
APPLICANT NAME: Agathocleous, Michalis
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 25.1 Basic Cancer Research 2 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/10/2024	12/19/2024
	Method of submission	CARS	12/19/2024
	Within receipt period	YES	12/19/2024
	Request for extension to submit application after CARS closed	N/A	12/19/2024
	Request for extension for late application submission accepted	N/A	12/19/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/19/2024
Assigned to primary reviewers		08/02/2024	12/19/2024
Applicant notified of review panel assignment		07/31/2024	12/19/2024
Primary Reviewer 1 COI signed		07/15/2024	12/19/2024
Primary Reviewer 2 COI signed		07/07/2024	12/19/2024
Primary Reviewer 3 COI signed		07/08/2024	12/19/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/19/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/12/2024	12/19/2024
	Primary Reviewer 2 critique submitted	08/14/2024	12/19/2024
	Primary Reviewer 3 critique submitted	08/11/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/19/2024
	Prelim Eval score summary sent to Chair (revised)	09/03/2024	12/19/2024
	Recommended for full review	YES	12/19/2024
Peer Review Meeting	Applicant notified of outcome	10/01/2024	12/19/2024
	Assigned to primary reviewers	09/05/2024	12/19/2024
	Primary Reviewer 1 COI signed	08/30/2024	12/19/2024
	Primary Reviewer 2 COI signed	08/30/2024	12/19/2024
	Primary Reviewer 3 COI signed	09/01/2024	12/19/2024
	Primary (Advocate) Reviewer 4 COI signed	08/30/2024	12/19/2024
	Primary Reviewer 1 critique submitted	10/15/2024	12/19/2024
	Primary Reviewer 2 critique submitted	10/13/2024	12/19/2024
	Primary Reviewer 3 critique submitted	10/11/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/26/2024	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	Discussed at Peer Review Meeting	YES	12/19/2024
	Peer Review Meeting	10/24/2024	12/19/2024
	Post review statements signed	10/26/2024	12/19/2024
	Third Party Observer Report	10/31/2024	12/19/2024
	Score report delivered to CSO	11/08/2024	12/19/2024
Recommended for SRC review	YES	12/19/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	SRC Meeting	12/12/2024	01/24/2025
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/19/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
	Recommended for grant award	YES	02/05/2025
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250282
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Basic Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or


affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 7th day of February, 2025, by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:12 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250282
APPLICATION TITLE: Harnessing BACH2 to enhance anti-tumor T cell immunity
APPLICANT NAME: Yao, Chen
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 25.1 Basic Cancer Research 1 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/11/2024	12/19/2024
	Method of submission	CARS	12/19/2024
	Within receipt period	YES	12/19/2024
	Request for extension to submit application after CARS closed	N/A	12/19/2024
	Request for extension for late application submission accepted	N/A	12/19/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/19/2024
Assigned to primary reviewers		08/02/2024	12/19/2024
Applicant notified of review panel assignment		07/31/2024	12/19/2024
Primary Reviewer 1 COI signed		07/03/2024	12/19/2024
Primary Reviewer 2 COI signed		07/16/2024	12/19/2024
Primary Reviewer 3 COI signed		07/08/2024	12/19/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/19/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/09/2024	12/19/2024
	Primary Reviewer 2 critique submitted	08/14/2024	12/19/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/19/2024
	Recommended for full review	YES	12/19/2024
	Applicant notified of outcome	10/01/2024	12/19/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/19/2024
	Primary Reviewer 1 COI signed	08/29/2024	12/19/2024
	Primary Reviewer 2 COI signed	08/30/2024	12/19/2024
	Primary Reviewer 3 COI signed	08/29/2024	12/19/2024
	Primary (Advocate) Reviewer 4 COI signed	08/28/2024	12/19/2024
	Primary Reviewer 1 critique submitted	09/08/2024	12/19/2024
	Primary Reviewer 2 critique submitted	10/20/2024	12/19/2024
	Primary Reviewer 3 critique submitted	10/14/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/06/2024	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	Discussed at Peer Review Meeting	YES	12/19/2024
	Peer Review Meeting	10/23/2024	12/19/2024
	Post review statements signed	10/24/2024	12/19/2024
	Third Party Observer Report	10/31/2024	12/19/2024
Score report delivered to CSO	11/08/2024	12/19/2024	
Recommended for SRC review	YES	12/19/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	SRC Meeting	12/12/2024	12/19/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/19/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250305
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Basic Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:14 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250305
APPLICATION TITLE: Exploiting synthetic lethalties between HNRNPk loss and ribosomal dysfunction in del9q AML
APPLICANT NAME: Post, Sean M
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Basic Cancer Research 2 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/07/2024	12/19/2024
	Method of submission	CARS	12/19/2024
	Within receipt period	YES	12/19/2024
	Request for extension to submit application after CARS closed	N/A	12/19/2024
	Request for extension for late application submission accepted	N/A	12/19/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/19/2024
Assigned to primary reviewers		08/02/2024	12/19/2024
Applicant notified of review panel assignment		07/31/2024	12/19/2024
Primary Reviewer 1 COI signed		07/03/2024	12/19/2024
Primary Reviewer 2 COI signed		07/15/2024	12/19/2024
Primary Reviewer 3 COI signed		07/08/2024	12/19/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/19/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/08/2024	12/19/2024
	Primary Reviewer 2 critique submitted	08/13/2024	12/19/2024
	Primary Reviewer 3 critique submitted	08/07/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/19/2024
	Prelim Eval score summary sent to Chair (revised)	09/03/2024	12/19/2024
	Recommended for full review	YES	12/19/2024
	Applicant notified of outcome	10/01/2024	12/19/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/19/2024
	Primary Reviewer 1 COI signed	08/28/2024	12/19/2024
	Primary Reviewer 2 COI signed	08/29/2024	12/19/2024
	Primary Reviewer 3 COI signed	10/07/2024	12/19/2024
	Primary (Advocate) Reviewer 4 COI signed	08/30/2024	12/19/2024
	Primary Reviewer 1 critique submitted	10/09/2024	12/19/2024
	Primary Reviewer 2 critique submitted	10/10/2024	12/19/2024
	Primary Reviewer 3 critique submitted	10/14/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/09/2024	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	Discussed at Peer Review Meeting	YES	12/19/2024
	Peer Review Meeting	10/24/2024	12/19/2024
	Post review statements signed	10/26/2024	12/19/2024
	Third Party Observer Report	10/31/2024	12/19/2024
	Score report delivered to CSO	11/08/2024	12/19/2024
Recommended for SRC review	YES	12/19/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	SRC Meeting	12/12/2024	01/24/2025
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/19/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250322
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true.”





Kristen P. Doyle.

CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:14 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250322
APPLICATION TITLE: Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) in HER2-mutant non-small cell lung cancer (NSCLC)
APPLICANT NAME: Heymach, John V
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Clinical and Translational Cancer Research 2 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/07/2024	12/24/2024
	Method of submission	CARS	12/24/2024
	Within receipt period	YES	12/24/2024
	Request for extension to submit application after CARS closed	N/A	12/24/2024
	Request for extension for late application submission accepted	N/A	12/24/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/24/2024
Assigned to primary reviewers		08/02/2024	12/24/2024
Applicant notified of review panel assignment		07/31/2024	12/24/2024
Primary Reviewer 1 COI signed		07/10/2024	12/24/2024
Primary Reviewer 2 COI signed		07/08/2024	12/24/2024
Primary Reviewer 3 COI signed		07/04/2024	12/24/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/24/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/24/2024
	Primary Reviewer 2 critique submitted	08/14/2024	12/24/2024
	Primary Reviewer 3 critique submitted	08/10/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/24/2024
	Recommended for full review	YES	12/24/2024
	Applicant notified of outcome	10/01/2024	12/24/2024
	Peer Review Meeting	Assigned to primary reviewers	09/05/2024
Primary Reviewer 1 COI signed		08/29/2024	12/24/2024
Primary Reviewer 2 COI signed		08/28/2024	12/24/2024
Primary Reviewer 3 COI signed		08/29/2024	12/24/2024
Primary (Advocate) Reviewer 4 COI signed		08/28/2024	12/24/2024
Primary Reviewer 1 critique submitted		09/26/2024	12/24/2024
Primary Reviewer 2 critique submitted		10/03/2024	12/24/2024
Primary Reviewer 3 critique submitted		09/28/2024	12/24/2024
Primary (Advocate) Reviewer 4 critique submitted		10/09/2024	12/24/2024
COI indicated by non-primary reviewer		NONE	12/24/2024
COI recused from participation		N/A	12/24/2024
Discussed at Peer Review Meeting		YES	12/24/2024
Peer Review Meeting		10/16/2024	12/24/2024
Post review statements signed		10/16/2024	12/24/2024
Third Party Observer Report		10/22/2024	12/24/2024
Score report delivered to CSO	11/08/2024	12/24/2024	
Recommended for SRC review	YES	12/24/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	SRC Meeting	12/12/2024	12/24/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/24/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250391
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true.”




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:18 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250391
APPLICATION TITLE: Novel PCDH7 monoclonal antibodies that direct immune surveillance and combat drug resistance in lung cancer
APPLICANT NAME: O'Donnell, Kathryn A
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 25.1 Cancer Biology Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/10/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/01/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/20/2024
Primary Reviewer 1 COI signed		07/03/2024	12/23/2024
Primary Reviewer 2 COI signed		07/08/2024	12/23/2024
Primary Reviewer 3 COI signed		07/03/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/15/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/13/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
	Peer Review Meeting	Assigned to primary reviewers	09/05/2024
Primary Reviewer 1 COI signed		08/26/2024	12/23/2024
Primary Reviewer 2 COI signed		10/01/2024	12/23/2024
Primary Reviewer 3 COI signed		08/28/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		09/05/2024	12/23/2024
Primary Reviewer 1 critique submitted		10/04/2024	12/23/2024
Primary Reviewer 2 critique submitted		10/04/2024	12/23/2024
Primary Reviewer 3 critique submitted		10/01/2024	12/23/2024
Primary (Advocate) Reviewer 4 critique submitted		09/26/2024	12/23/2024
COI indicated by non-primary reviewer		NONE	12/23/2024
COI recused from participation		N/A	12/23/2024
Discussed at Peer Review Meeting		YES	12/23/2024
Peer Review Meeting		10/17/2024	12/23/2024
Post review statements signed		10/18/2024	12/20/2024
Third Party Observer Report		10/22/2024	12/20/2024
Score report delivered to CSO	11/08/2024	12/20/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/20/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250398
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Basic Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:18 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250398
APPLICATION TITLE: Synthetic lethality of TRIP13 and Aurora A in Rb-deficient cancer
APPLICANT NAME: Johnson, Faye M
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Basic Cancer Research 1 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/07/2024	12/19/2024
	Method of submission	CARS	12/19/2024
	Within receipt period	YES	12/19/2024
	Request for extension to submit application after CARS closed	N/A	12/19/2024
	Request for extension for late application submission accepted	N/A	12/19/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/19/2024
Assigned to primary reviewers		08/02/2024	12/19/2024
Applicant notified of review panel assignment		07/31/2024	12/19/2024
Primary Reviewer 1 COI signed		07/05/2024	12/19/2024
Primary Reviewer 2 COI signed		07/03/2024	12/19/2024
Primary Reviewer 3 COI signed		07/04/2024	12/19/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/19/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/13/2024	12/19/2024
	Primary Reviewer 2 critique submitted	08/10/2024	12/19/2024
	Primary Reviewer 3 critique submitted	08/09/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/19/2024
	Recommended for full review	YES	12/19/2024
	Applicant notified of outcome	10/01/2024	12/19/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/19/2024
	Primary Reviewer 1 COI signed	08/29/2024	12/19/2024
	Primary Reviewer 2 COI signed	08/29/2024	12/19/2024
	Primary Reviewer 3 COI signed	08/29/2024	12/19/2024
	Primary (Advocate) Reviewer 4 COI signed	08/28/2024	12/19/2024
	Primary Reviewer 1 critique submitted	10/10/2024	12/19/2024
	Primary Reviewer 2 critique submitted	10/05/2024	12/19/2024
	Primary Reviewer 3 critique submitted	10/14/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/06/2024	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	Discussed at Peer Review Meeting	YES	12/19/2024
	Peer Review Meeting	10/23/2024	12/19/2024
	Post review statements signed	10/24/2024	12/19/2024
Third Party Observer Report	10/31/2024	12/19/2024	
Score report delivered to CSO	11/08/2024	12/19/2024	
Recommended for SRC review	YES	12/19/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	SRC Meeting	12/12/2024	12/19/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/19/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250402
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true.”




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:19 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250402
APPLICATION TITLE: Exploiting Tryptophan Metabolite Addiction to identify and Inhibit HCC
APPLICANT NAME: Conacci Sorrell, Maralice
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 25.1 Cancer Biology Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/08/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		09/05/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/20/2024
Primary Reviewer 1 COI signed		08/26/2024	12/23/2024
Primary Reviewer 2 COI signed		08/30/2024	12/23/2024
Primary Reviewer 3 COI signed		09/25/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		09/05/2024	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	12/23/2024
	Primary Reviewer 2 critique submitted	N/A	12/23/2024
	Primary Reviewer 3 critique submitted	N/A	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	N/A	12/23/2024
	Preliminary Evaluation score summary sent to Chair	N/A	12/23/2024
	Recommended for full review	N/A	12/23/2024
	Applicant notified of outcome	N/A	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	08/26/2024	12/23/2024
	Primary Reviewer 2 COI signed	08/30/2024	12/23/2024
	Primary Reviewer 3 COI signed	09/25/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	09/05/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/04/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/02/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/04/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/26/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/17/2024	12/23/2024
	Post review statements signed	10/18/2024	12/20/2024
	Third Party Observer Report	10/22/2024	12/20/2024
Score report delivered to CSO	11/08/2024	12/20/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/20/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250407
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or

affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:14 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250407
APPLICATION TITLE: Protecting the GI tract with a C60 fullerene derivative to facilitate dose-escalated abdominopelvic radiotherapy
APPLICANT NAME: Mackeyev, Yuri
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 25.1 Clinical and Translational Cancer Research I Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/11/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/02/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/23/2024
Primary Reviewer 1 COI signed		07/03/2024	12/23/2024
Primary Reviewer 2 COI signed		07/11/2024	12/23/2024
Primary Reviewer 3 COI signed		07/17/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/08/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/05/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	08/29/2024	12/23/2024
	Primary Reviewer 2 COI signed	09/10/2024	12/23/2024
	Primary Reviewer 3 COI signed	10/01/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	08/28/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/07/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/01/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/15/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/28/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/25/2024	12/23/2024
	Post review statements signed	10/29/2024	12/23/2024
	Third Party Observer Report	10/31/2024	12/23/2024
Score report delivered to CSO	11/08/2024	12/23/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/23/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250428
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 220 applications in response to this RFA, including five withdrawn applications. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted

The Scientific Review Council (SRC) recommended this application at their December 12, 2024, meeting. Dr. Jason Lewis, an SRC member who was not part of the peer review panel to which this application was assigned, identified a conflict of interest with this application. The conflict was waived pursuant to an approved Texas Health and Safety Code § 102.1062 waiver applicable to CPRIT review councils during FY2025.

- The third-party observer report(s) documenting that CPRIT's grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the SRC for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the

conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."



Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/07/2025 01:14 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP250428
APPLICATION TITLE: Studying Hematopoietic Stem Cells to Predict and Understand Mechanisms of Post-transplant Relapse in the Myelodysplastic Syndromes
APPLICANT NAME: Chung, Stephen S
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 25.1 Clinical and Translational Cancer Research 1 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/10/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/02/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/23/2024
Primary Reviewer 1 COI signed		07/11/2024	12/23/2024
Primary Reviewer 2 COI signed		07/09/2024	12/23/2024
Primary Reviewer 3 COI signed		07/15/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/13/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/15/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	08/29/2024	12/23/2024
	Primary Reviewer 2 COI signed	08/28/2024	12/23/2024
	Primary Reviewer 3 COI signed	08/29/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	08/30/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/13/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/11/2024	12/23/2024
	Primary Reviewer 3 critique submitted	09/25/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/22/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/25/2024	12/23/2024
	Post review statements signed	10/29/2024	12/23/2024
	Third Party Observer Report	10/31/2024	12/23/2024
Score report delivered to CSO	11/08/2024	12/23/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	Jason Lewis	12/23/2024
	COI recused from participation	Other: Present per FY25 waiver for RC members	12/23/2024
	SRC Meeting	12/12/2024	12/23/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
PIC Review	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
	Recommended for grant award	YES	02/05/2025
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250119
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 36 applications in response to this RFA, including one withdrawn application. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true,"


Kristen P. Doyle

Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.

Sandra Reyes
Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:16 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP250119
APPLICATION TITLE: Comparison of Symptom Burden, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients treated with Surgery vs. Surgery and Chemotherapy
APPLICANT NAME: Kahalley, Lisa S
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 25.1 Cancer Prevention Research Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/09/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/02/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/23/2024
Primary Reviewer 1 COI signed		07/09/2024	12/23/2024
Primary Reviewer 2 COI signed		07/08/2024	12/23/2024
Primary Reviewer 3 COI signed		07/15/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/13/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/16/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	08/31/2024	12/23/2024
	Primary Reviewer 2 COI signed	09/05/2024	12/23/2024
	Primary Reviewer 3 COI signed	09/05/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	08/29/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/08/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/09/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/11/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/20/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/22/2024	12/23/2024
	Post review statements signed	10/22/2024	12/23/2024
	Third Party Observer Report	10/23/2024	12/23/2024
Score report delivered to CSO	11/08/2024	12/23/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/23/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250144
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 36 applications in response to this RFA, including one withdrawn application. This application was assigned to the Basic Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.



This statement is true."



Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:17 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP250144
APPLICATION TITLE: Decoding how neuronal activity remodels the epigenome in ependymoma
APPLICANT NAME: Deneen, Benjamin
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 25.1 Basic Cancer Research 1 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/03/2024	12/19/2024
	Method of submission	CARS	12/19/2024
	Within receipt period	YES	12/19/2024
	Request for extension to submit application after CARS closed	N/A	12/19/2024
	Request for extension for late application submission accepted	N/A	12/19/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/19/2024
Assigned to primary reviewers		08/02/2024	12/19/2024
Applicant notified of review panel assignment		07/31/2024	12/19/2024
Primary Reviewer 1 COI signed		07/03/2024	12/19/2024
Primary Reviewer 2 COI signed		07/03/2024	12/19/2024
Primary Reviewer 3 COI signed		07/06/2024	12/19/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/19/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/10/2024	12/19/2024
	Primary Reviewer 2 critique submitted	08/08/2024	12/19/2024
	Primary Reviewer 3 critique submitted	08/10/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/19/2024
	Recommended for full review	YES	12/19/2024
	Applicant notified of outcome	10/01/2024	12/19/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/19/2024
	Primary Reviewer 1 COI signed	08/29/2024	12/19/2024
	Primary Reviewer 2 COI signed	08/29/2024	12/19/2024
	Primary Reviewer 3 COI signed	08/29/2024	12/19/2024
	Primary (Advocate) Reviewer 4 COI signed	08/28/2024	12/19/2024
	Primary Reviewer 1 critique submitted	10/08/2024	12/19/2024
	Primary Reviewer 2 critique submitted	10/01/2024	12/19/2024
	Primary Reviewer 3 critique submitted	10/07/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/28/2024	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	Discussed at Peer Review Meeting	YES	12/19/2024
	Peer Review Meeting	10/23/2024	12/19/2024
	Post review statements signed	10/24/2024	12/19/2024
	Third Party Observer Report	10/31/2024	12/19/2024
Score report delivered to CSO	11/08/2024	12/19/2024	
Recommended for SRC review	YES	12/19/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	SRC Meeting	12/12/2024	12/19/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/19/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250164
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 36 applications in response to this RFA, including one withdrawn application. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:17 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP250164
APPLICATION TITLE: Prediction of CAR-T Cell Immunotherapy Outcomes in Neuroblastoma using FE-MRI Nano-radiomics
APPLICANT NAME: Ghaghada, Ketan
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 25.1 Imaging Technology and Informatics Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/09/2024	12/24/2024
	Method of submission	CARS	12/24/2024
	Within receipt period	YES	12/24/2024
	Request for extension to submit application after CARS closed	N/A	12/24/2024
	Request for extension for late application submission accepted	N/A	12/24/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/24/2024
Assigned to primary reviewers		08/01/2024	12/24/2024
Applicant notified of review panel assignment		07/31/2024	12/24/2024
Primary Reviewer 1 COI signed		07/17/2024	12/24/2024
Primary Reviewer 2 COI signed		07/14/2024	12/24/2024
Primary Reviewer 3 COI signed		07/16/2024	12/24/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/24/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/24/2024
	Primary Reviewer 2 critique submitted	08/15/2024	12/24/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/24/2024
	Recommended for full review	YES	12/24/2024
	Applicant notified of outcome	10/01/2024	12/24/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/24/2024
	Primary Reviewer 1 COI signed	09/04/2024	12/24/2024
	Primary Reviewer 2 COI signed	09/15/2024	12/24/2024
	Primary Reviewer 3 COI signed	09/03/2024	12/24/2024
	Primary (Advocate) Reviewer 4 COI signed	08/29/2024	12/24/2024
	Primary Reviewer 1 critique submitted	10/04/2024	12/24/2024
	Primary Reviewer 2 critique submitted	10/04/2024	12/24/2024
	Primary Reviewer 3 critique submitted	10/04/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/03/2024	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	Discussed at Peer Review Meeting	YES	12/24/2024
	Peer Review Meeting	10/18/2024	12/24/2024
	Post review statements signed	10/18/2024	12/24/2024
	Third Party Observer Report	10/22/2024	12/24/2024
Score report delivered to CSO	11/08/2024	12/24/2024	
Recommended for SRC review	YES	12/24/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	SRC Meeting	12/12/2024	12/24/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/24/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250190
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 36 applications in response to this RFA, including one withdrawn application. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.



This statement is true."



Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:17 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP250190
APPLICATION TITLE: Cancer-Related Fatigue and its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-Exercise Intervention
APPLICANT NAME: Swartz, Maria C
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Cancer Prevention Research Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/06/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/02/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/23/2024
Primary Reviewer 1 COI signed		07/09/2024	12/23/2024
Primary Reviewer 2 COI signed		07/09/2024	12/23/2024
Primary Reviewer 3 COI signed		07/15/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/13/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	08/31/2024	12/23/2024
	Primary Reviewer 2 COI signed	08/29/2024	12/23/2024
	Primary Reviewer 3 COI signed	09/05/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	08/28/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/07/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/09/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/11/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/30/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/22/2024	12/23/2024
	Post review statements signed	10/22/2024	12/23/2024
	Third Party Observer Report	10/23/2024	12/23/2024
Score report delivered to CSO	11/08/2024	12/23/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/23/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250278
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 36 applications in response to this RFA, including one withdrawn application. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.


The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."



Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:18 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP250278
APPLICATION TITLE: Developmental origins of IDH-mutant glioma in adolescents
APPLICANT NAME: McBrayer, Samuel K
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 25.1 Cancer Biology Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/10/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/01/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/20/2024
Primary Reviewer 1 COI signed		07/12/2024	12/23/2024
Primary Reviewer 2 COI signed		07/07/2024	12/23/2024
Primary Reviewer 3 COI signed		07/03/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/13/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	09/01/2024	12/23/2024
	Primary Reviewer 2 COI signed	08/29/2024	12/23/2024
	Primary Reviewer 3 COI signed	09/02/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	09/11/2024	12/23/2024
	Primary Reviewer 1 critique submitted	09/30/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/02/2024	12/23/2024
	Primary Reviewer 3 critique submitted	09/30/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/04/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/17/2024	12/23/2024
	Post review statements signed	10/18/2024	12/20/2024
	Third Party Observer Report	10/22/2024	12/20/2024
Score report delivered to CSO	11/08/2024	12/20/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/20/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250374
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 36 applications in response to this RFA, including one withdrawn application. This application was assigned to the Basic Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."



Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:18 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP250374
APPLICATION TITLE: Dissecting TFE3 Mediated tRCC Tumorigenesis
APPLICANT NAME: Brugarolas, James
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 25.1 Basic Cancer Research 1 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/06/2024	12/19/2024
	Method of submission	CARS	12/19/2024
	Within receipt period	YES	12/19/2024
	Request for extension to submit application after CARS closed	N/A	12/19/2024
	Request for extension for late application submission accepted	N/A	12/19/2024
	Receipt, Referral, and Assignment	Administrative review notification	07/17/2024
Donation(s) made to CPRIT / foundation		NO	12/19/2024
Assigned to primary reviewers		08/02/2024	12/19/2024
Applicant notified of review panel assignment		07/31/2024	12/19/2024
Primary Reviewer 1 COI signed		07/08/2024	12/19/2024
Primary Reviewer 2 COI signed		07/04/2024	12/19/2024
Primary Reviewer 3 COI signed		07/06/2024	12/19/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/19/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/04/2024	12/19/2024
	Primary Reviewer 2 critique submitted	08/10/2024	12/19/2024
	Primary Reviewer 3 critique submitted	08/10/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/19/2024
	Recommended for full review	YES	12/19/2024
	Applicant notified of outcome	10/01/2024	12/19/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/19/2024
	Primary Reviewer 1 COI signed	08/30/2024	12/19/2024
	Primary Reviewer 2 COI signed	09/05/2024	12/19/2024
	Primary Reviewer 3 COI signed	08/29/2024	12/19/2024
	Primary (Advocate) Reviewer 4 COI signed	08/28/2024	12/19/2024
	Primary Reviewer 1 critique submitted	09/25/2024	12/19/2024
	Primary Reviewer 2 critique submitted	10/05/2024	12/19/2024
	Primary Reviewer 3 critique submitted	10/08/2024	12/19/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/04/2024	12/19/2024
	COI indicated by non-primary reviewer	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	Discussed at Peer Review Meeting	YES	12/19/2024
	Peer Review Meeting	10/23/2024	12/19/2024
	Post review statements signed	10/24/2024	12/19/2024
	Third Party Observer Report	10/31/2024	12/19/2024
Score report delivered to CSO	11/08/2024	12/19/2024	
Recommended for SRC review	YES	12/19/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/19/2024
	COI recused from participation	N/A	12/19/2024
	SRC Meeting	12/12/2024	12/19/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/19/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250044
Individual Investigator Research Awards for
Computational and Systems Biology of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Computational and Systems Biology of Cancer* Request for Applications (RFA). CPRIT received 29 applications in response to this RFA. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.

Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:16 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Computational Systems Biology of Cancer
APPLICATION ID: RP250044
APPLICATION TITLE: Heterogeneity of resistance to endocrine therapy and Cdk inhibition: An integrated systems biology approach to biologically-informed treatment regimens
APPLICANT NAME: Brock, Amy
ORGANIZATION: The University of Texas at Austin
PANEL NAME: 25.1 Cancer Biology Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/11/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/01/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/20/2024
Primary Reviewer 1 COI signed		07/17/2024	12/23/2024
Primary Reviewer 2 COI signed		07/23/2024	12/23/2024
Primary Reviewer 3 COI signed		07/14/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/15/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	08/29/2024	12/23/2024
	Primary Reviewer 2 COI signed	08/29/2024	12/23/2024
	Primary Reviewer 3 COI signed	09/13/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	09/05/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/10/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/02/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/07/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/26/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/17/2024	12/23/2024
	Post review statements signed	10/18/2024	12/20/2024
Third Party Observer Report	10/22/2024	12/20/2024	
Score report delivered to CSO	11/08/2024	12/20/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/20/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250090
Individual Investigator Research Awards for
Computational and Systems Biology of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Computational and Systems Biology of Cancer* Request for Applications (RFA). CPRIT received 29 applications in response to this RFA. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:16 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Computational Systems Biology of Cancer
APPLICATION ID: RP250090
APPLICATION TITLE: Artificial Intelligence for Early Identification of Androgen-Indifferent, Lethal Prostate Cancer and Therapy Selection
APPLICANT NAME: Merényi, Erzsébet
ORGANIZATION: Rice University
PANEL NAME: 25.1 Imaging Technology and Informatics Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/10/2024	12/24/2024
	Method of submission	CARS	12/24/2024
	Within receipt period	YES	12/24/2024
	Request for extension to submit application after CARS closed	N/A	12/24/2024
	Request for extension for late application submission accepted	N/A	12/24/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/24/2024
Assigned to primary reviewers		08/01/2024	12/24/2024
Applicant notified of review panel assignment		07/31/2024	12/24/2024
Primary Reviewer 1 COI signed		07/03/2024	12/24/2024
Primary Reviewer 2 COI signed		07/04/2024	12/24/2024
Primary Reviewer 3 COI signed		07/12/2024	12/24/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/24/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/12/2024	12/24/2024
	Primary Reviewer 2 critique submitted	08/05/2024	12/24/2024
	Primary Reviewer 3 critique submitted	08/16/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/24/2024
	Recommended for full review	YES	12/24/2024
	Applicant notified of outcome	10/01/2024	12/24/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/24/2024
	Primary Reviewer 1 COI signed	08/28/2024	12/24/2024
	Primary Reviewer 2 COI signed	08/29/2024	12/24/2024
	Primary Reviewer 3 COI signed	08/29/2024	12/24/2024
	Primary (Advocate) Reviewer 4 COI signed	08/29/2024	12/24/2024
	Primary Reviewer 1 critique submitted	09/29/2024	12/24/2024
	Primary Reviewer 2 critique submitted	10/04/2024	12/24/2024
	Primary Reviewer 3 critique submitted	09/13/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/03/2024	12/24/2024
	COI indicated by non-primary reviewer	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	Discussed at Peer Review Meeting	YES	12/24/2024
	Peer Review Meeting	10/18/2024	12/24/2024
	Post review statements signed	10/18/2024	12/24/2024
	Third Party Observer Report	10/22/2024	12/24/2024
Score report delivered to CSO	11/08/2024	12/24/2024	
Recommended for SRC review	YES	12/24/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	SRC Meeting	12/12/2024	12/24/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/24/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250399
Individual Investigator Research Awards for
Computational and Systems Biology of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Computational and Systems Biology of Cancer* Request for Applications (RFA). CPRIT received 29 applications in response to this RFA. This application was assigned to the Clinical and Translational Cancer Research Panel 2 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.


The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:18 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Computational Systems Biology of Cancer
APPLICATION ID: RP250399
APPLICATION TITLE: Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture
APPLICANT NAME: Vokes, Natalie
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Clinical and Translational Cancer Research 2 Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/07/2024	12/24/2024
	Method of submission	CARS	12/24/2024
	Within receipt period	YES	12/24/2024
	Request for extension to submit application after CARS closed	N/A	12/24/2024
	Request for extension for late application submission accepted	N/A	12/24/2024
	Receipt, Referral, and Assignment	Administrative review notification	07/17/2024
Donation(s) made to CPRIT / foundation		NO	12/24/2024
Assigned to primary reviewers		08/02/2024	12/24/2024
Applicant notified of review panel assignment		07/31/2024	12/24/2024
Primary Reviewer 1 COI signed		07/10/2024	12/24/2024
Primary Reviewer 2 COI signed		07/25/2024	12/24/2024
Primary Reviewer 3 COI signed		07/24/2024	12/24/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/24/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/24/2024
	Primary Reviewer 2 critique submitted	08/14/2024	12/24/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/24/2024
	COI indicated by non-primary reviewer	Walter Stadler	12/24/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/24/2024
	Recommended for full review	YES	12/24/2024
	Applicant notified of outcome	10/01/2024	12/24/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/24/2024
	Primary Reviewer 1 COI signed	08/29/2024	12/24/2024
	Primary Reviewer 2 COI signed	09/16/2024	12/24/2024
	Primary Reviewer 3 COI signed	08/29/2024	12/24/2024
	Primary (Advocate) Reviewer 4 COI signed	08/28/2024	12/24/2024
	Primary Reviewer 1 critique submitted	09/26/2024	12/24/2024
	Primary Reviewer 2 critique submitted	10/05/2024	12/24/2024
	Primary Reviewer 3 critique submitted	09/29/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/13/2024	12/24/2024
	COI indicated by non-primary reviewer	Walter Stadler	12/24/2024
	COI recused from participation	YES	12/24/2024
	Discussed at Peer Review Meeting	YES	12/24/2024
	Peer Review Meeting	10/16/2024	12/24/2024
	Post review statements signed	10/16/2024	12/24/2024
Third Party Observer Report	10/22/2024	12/24/2024	
Score report delivered to CSO	11/08/2024	12/24/2024	
Recommended for SRC review	YES	12/24/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	SRC Meeting	12/12/2024	12/24/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/24/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250156
Individual Investigator Research Awards for
Prevention and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Prevention and Early Detection* Request for Applications (RFA). CPRIT received 21 applications in response to this RFA. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."

Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.

Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:17 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Prevention and Early Detection
APPLICATION ID: RP250156
APPLICATION TITLE: Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer
APPLICANT NAME: Wu, Jia
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Imaging Technology and Informatics Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/06/2024	12/24/2024
	Method of submission	CARS	12/24/2024
	Within receipt period	YES	12/24/2024
	Request for extension to submit application after CARS closed	N/A	12/24/2024
	Request for extension for late application submission accepted	N/A	12/24/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/24/2024
Assigned to primary reviewers		08/01/2024	12/24/2024
Applicant notified of review panel assignment		07/31/2024	12/24/2024
Primary Reviewer 1 COI signed		07/17/2024	12/24/2024
Primary Reviewer 2 COI signed		07/14/2024	12/24/2024
Primary Reviewer 3 COI signed		07/12/2024	12/24/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/24/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/24/2024
	Primary Reviewer 2 critique submitted	08/15/2024	12/24/2024
	Primary Reviewer 3 critique submitted	08/13/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/24/2024
	COI indicated by non-primary reviewer	Issam El Naqa	12/24/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/24/2024
	Recommended for full review	YES	12/24/2024
	Applicant notified of outcome	10/01/2024	12/24/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/24/2024
	Primary Reviewer 1 COI signed	09/04/2024	12/24/2024
	Primary Reviewer 2 COI signed	10/01/2024	12/24/2024
	Primary Reviewer 3 COI signed	08/29/2024	12/24/2024
	Primary (Advocate) Reviewer 4 COI signed	08/29/2024	12/24/2024
	Primary Reviewer 1 critique submitted	10/04/2024	12/24/2024
	Primary Reviewer 2 critique submitted	10/05/2024	12/24/2024
	Primary Reviewer 3 critique submitted	10/02/2024	12/24/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/03/2024	12/24/2024
	COI indicated by non-primary reviewer	Issam El Naqa	12/24/2024
	COI recused from participation	YES	12/24/2024
	Discussed at Peer Review Meeting	YES	12/24/2024
	Peer Review Meeting	10/18/2024	12/24/2024
	Post review statements signed	10/18/2024	12/24/2024
Third Party Observer Report	10/22/2024	12/24/2024	
Score report delivered to CSO	11/08/2024	12/24/2024	
Recommended for SRC review	YES	12/24/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/24/2024
	COI recused from participation	N/A	12/24/2024
	SRC Meeting	12/12/2024	12/24/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/24/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250182
Individual Investigator Research Awards for
Prevention and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Prevention and Early Detection* Request for Applications (RFA). CPRIT received 21 applications in response to this RFA. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:17 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Prevention and Early Detection
APPLICATION ID: RP250182
APPLICATION TITLE: Implementing Newborn Screening for Pediatric Cancer Predisposition Syndromes in Texas: The INSPECT Study
APPLICANT NAME: Parsons, Donald W
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 25.1 Cancer Prevention Research Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/10/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/02/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/23/2024
Primary Reviewer 1 COI signed		07/03/2024	12/23/2024
Primary Reviewer 2 COI signed		07/09/2024	12/23/2024
Primary Reviewer 3 COI signed		07/15/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	09/05/2024	12/23/2024
	Primary Reviewer 2 COI signed	09/06/2024	12/23/2024
	Primary Reviewer 3 COI signed	09/05/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	08/28/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/11/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/14/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/10/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/27/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/22/2024	12/23/2024
	Post review statements signed	10/22/2024	12/23/2024
	Third Party Observer Report	10/23/2024	12/23/2024
Score report delivered to CSO	11/08/2024	12/23/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/23/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250269
Individual Investigator Research Awards for
Prevention and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Prevention and Early Detection* Request for Applications (RFA). CPRIT received 21 applications in response to this RFA. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.


The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 7th day of February, 2025, by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:17 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Prevention and Early Detection
APPLICATION ID: RP250269
APPLICATION TITLE: Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules.
APPLICANT NAME: Ostrin, Edwin J
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Cancer Prevention Research Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/04/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/02/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/23/2024
Primary Reviewer 1 COI signed		07/15/2024	12/23/2024
Primary Reviewer 2 COI signed		07/09/2024	12/23/2024
Primary Reviewer 3 COI signed		07/23/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/13/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/15/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	09/05/2024	12/23/2024
	Primary Reviewer 2 COI signed	08/31/2024	12/23/2024
	Primary Reviewer 3 COI signed	09/05/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	08/29/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/10/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/06/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/09/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/19/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/22/2024	12/23/2024
	Post review statements signed	10/22/2024	12/23/2024
	Third Party Observer Report	10/23/2024	12/23/2024
Score report delivered to CSO	11/08/2024	12/23/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/23/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250293
Individual Investigator Research Awards for
Prevention and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Prevention and Early Detection* Request for Applications (RFA). CPRIT received 21 applications in response to this RFA. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."

Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 1th day of February, 2025, by KRISTEN P. DOYLE.

Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:18 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Prevention and Early Detection
APPLICATION ID: RP250293
APPLICATION TITLE: Development of a shared decision tool to facilitate uptake of the levonorgestrel-releasing intrauterine system for the primary prevention of endometrial cancer
APPLICANT NAME: Meyer, Larissa A
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Cancer Prevention Research Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/06/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/02/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/23/2024
Primary Reviewer 1 COI signed		07/08/2024	12/23/2024
Primary Reviewer 2 COI signed		07/09/2024	12/23/2024
Primary Reviewer 3 COI signed		07/09/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/07/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/12/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
	Peer Review Meeting	Assigned to primary reviewers	09/05/2024
Primary Reviewer 1 COI signed		08/29/2024	12/23/2024
Primary Reviewer 2 COI signed		08/31/2024	12/23/2024
Primary Reviewer 3 COI signed		08/29/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		08/28/2024	12/23/2024
Primary Reviewer 1 critique submitted		10/09/2024	12/23/2024
Primary Reviewer 2 critique submitted		10/08/2024	12/23/2024
Primary Reviewer 3 critique submitted		10/09/2024	12/23/2024
Primary (Advocate) Reviewer 4 critique submitted		09/26/2024	12/23/2024
COI indicated by non-primary reviewer		NONE	12/23/2024
COI recused from participation		N/A	12/23/2024
Discussed at Peer Review Meeting		YES	12/23/2024
Peer Review Meeting		10/22/2024	12/23/2024
Post review statements signed		10/22/2024	12/23/2024
Third Party Observer Report		10/23/2024	12/23/2024
Score report delivered to CSO		11/08/2024	12/23/2024
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/23/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250418
Individual Investigator Research Awards for
Prevention and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Prevention and Early Detection* Request for Applications (RFA). CPRIT received 21 applications in response to this RFA. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.


The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:19 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Prevention and Early Detection
APPLICATION ID: RP250418
APPLICATION TITLE: Approach Bias Retraining to Augment Long-Term Smoking Cessation Among a Diverse Sample
APPLICANT NAME: Garey, Lorra
ORGANIZATION: University of Houston
PANEL NAME: 25.1 Cancer Prevention Research Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/10/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/02/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/23/2024
Primary Reviewer 1 COI signed		07/23/2024	12/23/2024
Primary Reviewer 2 COI signed		07/08/2024	12/23/2024
Primary Reviewer 3 COI signed		07/09/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/15/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/08/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/14/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/17/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	09/05/2024	12/23/2024
	Primary Reviewer 2 COI signed	08/29/2024	12/23/2024
	Primary Reviewer 3 COI signed	08/29/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	08/28/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/09/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/09/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/09/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/09/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/22/2024	12/23/2024
	Post review statements signed	10/22/2024	12/23/2024
	Third Party Observer Report	10/23/2024	12/23/2024
Score report delivered to CSO	11/08/2024	12/23/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/23/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR250072
Recruitment of Established Investigators
Nomination of Dr. Pernilla Wittung Stafshede

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of Established Investigators* Request for Applications (RFA). CPRIT received two applications in response to this RFA during cycles 25.2 through 25.3. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."





Kristen P. Doyle,

CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/06/2025 03:14 PM CT

FY:	2025			
CYCLE:	1			
PROGRAM:	Recruitment			
MECHANISM:	Recruitment of Established Investigators			
APPLICATION ID:	RR250072			
APPLICATION TITLE:	Mechanisms behind copper dependence of cancer cells			
APPLICANT NAME:	Wittung Stafshede, Pernilla			
ORGANIZATION:	Rice University			
PANEL NAME:	Recruitment FY25_Cycle 3			
Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	06/17/2024	10/04/2024	
	RFA Approved by CSO (revised)	08/01/2024	10/04/2024	
	RFA published in Texas.gov eGrants	06/21/2024	10/04/2024	
	CPRIT Application Receipt Cycle opened	10/22/2024	01/10/2025	
	CPRIT Application Receipt Cycle closed	11/20/2024	01/10/2025	
	Date application submitted	11/18/2024	01/10/2025	
	Method of submission	CARS	01/10/2025	
	Within receipt period	YES	01/10/2025	
	Receipt, Referral, and Assignment	Administrative review notification	11/27/2024	01/10/2025
		Donation(s) made to CPRIT / foundation	NO	01/10/2025
Assigned to primary reviewers		11/30/2024	01/10/2025	
Applicant notified of review panel assignment		N/A	01/10/2025	
Primary Reviewer 1 COI signed		11/25/2024	01/10/2025	
Primary Reviewer 2 COI signed		11/22/2024	01/10/2025	
Peer Review Meeting		Primary Reviewer 1 critique submitted	12/09/2024	01/10/2025
		Primary Reviewer 2 critique submitted	12/07/2024	01/10/2025
		COI indicated by non-primary reviewer	Carol Prives	01/10/2025
		COI recused from participation	YES	01/10/2025
	Discussed at Peer Review Meeting	YES	01/10/2025	
	Peer Review Meeting	12/12/2024	01/10/2025	
	Post review statements signed	01/09/2025	01/10/2025	
	Third Party Observer Report	12/18/2024	01/10/2025	
Final SRC Recommendation	Score report delivered to CSO	12/16/2024	01/10/2025	
	Recommended for SRC review	YES	01/10/2025	
	COI indicated by SRC member	Carol Prives	01/10/2025	
	COI recused from participation	YES	01/10/2025	
	SRC Meeting	12/12/2024	01/10/2025	
	Third Party Observer Report	12/18/2024	01/10/2025	
	Recommended for grant award	YES	01/10/2025	
	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025	
PIC Review	Candidate not accepted position prior to SRC date	YES	02/06/2025	
	COI indicated by PIC member	none	02/06/2025	
	COI recused from participation	N/A	02/06/2025	
	PIC Review Meeting	02/05/2025	02/06/2025	
	Recommended for grant award	YES	02/06/2025	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		
Comments:				
Comment	Created Date	Created By		
No Comment				



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR250061
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Dr. Ziwen Jiang

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received six applications in response to this RFA during cycles 25.2 through 25.3. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 7th day of February, 2025, by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/06/2025 03:14 PM CT

FY:	2025			
CYCLE:	1			
PROGRAM:	Recruitment			
MECHANISM:	Recruitment of First-Time, Tenure-Track Faculty Members			
APPLICATION ID:	RR250061			
APPLICATION TITLE	Engineered antibody tools for targeted regulation of cancer-associated proteins and organelles through redirected autophagy process			
APPLICANT NAME:	Jiang, Ziwen			
ORGANIZATION:	The University of Texas at Dallas			
PANEL NAME:	Recruitment FY25_Cycle 2			
Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	06/17/2024	10/04/2024	
	RFA Approved by CSO (revised)	08/01/2024	10/04/2024	
	RFA published in Texas.gov eGrants	06/21/2024	10/04/2024	
	CPRIT Application Receipt Cycle opened	08/21/2024	12/17/2024	
	CPRIT Application Receipt Cycle closed	10/21/2024	12/17/2024	
	Date application submitted	10/18/2024	12/17/2024	
	Method of submission	CARS	12/17/2024	
	Within receipt period	YES	12/17/2024	
	Receipt, Referral, and Assignment	Administrative review notification	10/28/2024	12/17/2024
		Donation(s) made to CPRIT / foundation	NO	12/17/2024
Assigned to primary reviewers		11/01/2024	12/17/2024	
Applicant notified of review panel assignment		N/A	12/17/2024	
Primary Reviewer 1 COI signed		10/28/2024	12/17/2024	
Primary Reviewer 2 COI signed		11/01/2024	12/17/2024	
Peer Review Meeting		Primary Reviewer 1 critique submitted	11/11/2024	12/17/2024
		Primary Reviewer 2 critique submitted	11/11/2024	12/17/2024
		COI indicated by non-primary reviewer	NONE	12/17/2024
		COI recused from participation	N/A	12/17/2024
	Discussed at Peer Review Meeting	YES	12/17/2024	
	Peer Review Meeting	11/14/2024	12/17/2024	
	Post review statements signed	11/15/2024	12/17/2024	
	Third Party Observer Report	11/18/2024	12/17/2024	
	Score report delivered to CSO	11/18/2024	12/17/2024	
	Recommended for SRC review	YES	12/17/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/17/2024	
	COI recused from participation	N/A	12/17/2024	
	SRC Meeting	11/14/2024	12/17/2024	
	Third Party Observer Report	11/18/2024	12/17/2024	
	Recommended for grant award	YES	12/17/2024	
	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025	
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	02/06/2025	
	COI indicated by PIC member	none	02/06/2025	
	COI recused from participation	N/A	02/06/2025	
	PIC Review Meeting	02/05/2025	02/06/2025	
	Recommended for grant award	YES	02/06/2025	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		
Comments:				
Comment	Created Date	Created By		
No Comment				



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR250063
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Dr. Tao Zou

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received six applications in response to this RFA during cycles 25.2 through 25.3. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.



This statement is true."



Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/06/2025 03:14 PM CT

FY:	2025			
CYCLE:	1			
PROGRAM:	Recruitment			
MECHANISM:	Recruitment of First-Time, Tenure-Track Faculty Members			
APPLICATION ID:	RR250063			
APPLICATION TITLE	Co-opting antiviral innate immune pathways to target non-small cell lung cancer			
APPLICANT NAME:	Zou, Tao			
ORGANIZATION:	The University of Texas Southwestern Medical Center			
PANEL NAME:	Recruitment FY25_Cycle 2			
Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	06/17/2024	10/04/2024	
	RFA Approved by CSO (revised)	08/01/2024	10/04/2024	
	RFA published in Texas.gov eGrants	06/21/2024	10/04/2024	
	CPRIT Application Receipt Cycle opened	08/21/2024	12/17/2024	
	CPRIT Application Receipt Cycle closed	10/21/2024	12/17/2024	
	Date application submitted	10/21/2024	12/17/2024	
	Method of submission	CARS	12/17/2024	
	Within receipt period	YES	12/17/2024	
	Administrative review notification	11/04/2024	12/17/2024	
Receipt, Referral, and Assignment	Donation(s) made to CPRIT / foundation	NO	12/17/2024	
	Assigned to primary reviewers	11/01/2024	12/17/2024	
	Applicant notified of review panel assignment	N/A	12/17/2024	
	Primary Reviewer 1 COI signed	10/28/2024	12/17/2024	
	Primary Reviewer 2 COI signed	10/29/2024	12/17/2024	
	Primary Reviewer 1 critique submitted	11/12/2024	12/17/2024	
	Primary Reviewer 2 critique submitted	11/11/2024	12/17/2024	
	COI indicated by non-primary reviewer	NONE	12/17/2024	
	COI recused from participation	N/A	12/17/2024	
Peer Review Meeting	Discussed at Peer Review Meeting	YES	12/17/2024	
	Peer Review Meeting	11/14/2024	12/17/2024	
	Post review statements signed	11/15/2024	12/17/2024	
	Third Party Observer Report	11/18/2024	12/17/2024	
	Score report delivered to CSO	11/18/2024	12/17/2024	
	Recommended for SRC review	YES	12/17/2024	
	COI indicated by SRC member	NONE	12/17/2024	
	COI recused from participation	N/A	12/17/2024	
	SRC Meeting	11/14/2024	12/17/2024	
Final SRC Recommendation	Third Party Observer Report	11/18/2024	12/17/2024	
	Recommended for grant award	YES	12/17/2024	
	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025	
	PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	02/06/2025
		COI indicated by PIC member	none	02/06/2025
		COI recused from participation	N/A	02/06/2025
		PIC Review Meeting	02/05/2025	02/06/2025
		Recommended for grant award	YES	02/06/2025
	Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
COI Indicated by Oversight Committee member		N/A		
COI Recused from participation		N/A		
Donation(s) made to CPRIT / foundation		N/A		
Presented to CPRIT Oversight Committee		N/A		
Award approved by Oversight Committee		NO		
Authority to advance funds requested		N/A		
Advance authority approved by Oversight Committee		N/A		
Comments:				
Comment	Created Date	Created By		
No Comment				



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR250070
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Dr. Rosalie Griffin

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received six applications in response to this RFA during cycles 25.2 through 25.3. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/06/2025 03:14 PM CT

FY:	2025		
CYCLE:	1		
PROGRAM:	Recruitment		
MECHANISM:	Recruitment of First-Time, Tenure-Track Faculty Members		
APPLICATION ID:	RR250070		
APPLICATION TITLE	Unlocking the Potential of Clonal Hematopoiesis in Early Detection and Interception of Lymphoid Malignancies		
APPLICANT NAME:	Griffin, Rosalie		
ORGANIZATION:	The University of Texas M. D. Anderson Cancer Center		
PANEL NAME:	Recruitment FY25_Cycle 3		
Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/17/2024	10/04/2024
	RFA Approved by CSO (revised)	08/01/2024	10/04/2024
	RFA published in Texas.gov eGrants	06/21/2024	10/04/2024
	CPRIT Application Receipt Cycle opened	10/22/2024	01/10/2025
	CPRIT Application Receipt Cycle closed	11/20/2024	01/10/2025
	Date application submitted	11/15/2024	01/10/2025
	Method of submission	CARS	01/10/2025
	Within receipt period	YES	01/10/2025
	Administrative review notification	11/27/2024	01/10/2025
	Receipt, Referral, and Assignment	Donation(s) made to CPRIT / foundation	NO
Assigned to primary reviewers		11/30/2024	01/10/2025
Applicant notified of review panel assignment		N/A	01/10/2025
Primary Reviewer 1 COI signed		11/22/2024	01/10/2025
Primary Reviewer 2 COI signed		11/25/2024	01/10/2025
Primary Reviewer 1 critique submitted		12/09/2024	01/10/2025
Primary Reviewer 2 critique submitted		12/10/2024	01/10/2025
COI indicated by non-primary reviewer		NONE	01/10/2025
COI recused from participation		N/A	01/10/2025
Discussed at Peer Review Meeting		YES	01/10/2025
Peer Review Meeting	Peer Review Meeting	12/12/2024	01/10/2025
	Post review statements signed	01/09/2025	01/10/2025
	Third Party Observer Report	12/18/2024	01/10/2025
	Score report delivered to CSO	12/16/2024	01/10/2025
	Recommended for SRC review	YES	01/10/2025
	COI indicated by SRC member	NONE	01/10/2025
	COI recused from participation	N/A	01/10/2025
	SRC Meeting	12/12/2024	01/10/2025
	Third Party Observer Report	12/18/2024	01/10/2025
	Recommended for grant award	YES	01/10/2025
Final SRC Recommendation	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	02/06/2025
	COI indicated by PIC member	none	02/06/2025
	COI recused from participation	N/A	02/06/2025
	PIC Review Meeting	02/05/2025	02/06/2025
	Recommended for grant award	YES	02/06/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
Oversight Committee Approval	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	
	Comments:		
	Comment	Created Date	Created By
	No Comment		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR250071
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Dr. Nipun Verma

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received six applications in response to this RFA during cycles 25.2 through 25.3. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/06/2025 03:14 PM CT

FY:	2025			
CYCLE:	1			
PROGRAM:	Recruitment			
MECHANISM:	Recruitment of First-Time, Tenure-Track Faculty Members			
APPLICATION ID:	RR250071			
APPLICATION TITLE	CRISPR screening to uncover tumor intrinsic modulators of DNA repair and immune effects of radiation therapy.			
APPLICANT NAME:	Verma, Nipun			
ORGANIZATION:	Baylor College of Medicine			
PANEL NAME:	Recruitment FY25_Cycle 3			
Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	06/17/2024	10/04/2024	
	RFA Approved by CSO (revised)	08/01/2024	10/04/2024	
	RFA published in Texas.gov eGrants	06/21/2024	10/04/2024	
	CPRIT Application Receipt Cycle opened	10/22/2024	01/10/2025	
	CPRIT Application Receipt Cycle closed	11/20/2024	01/10/2025	
	Date application submitted	11/20/2024	01/10/2025	
	Method of submission	CARS	01/10/2025	
	Within receipt period	YES	01/10/2025	
	Receipt, Referral, and Assignment	Administrative review notification	11/27/2024	01/10/2025
		Donation(s) made to CPRIT / foundation	NO	01/10/2025
Assigned to primary reviewers		11/30/2024	01/10/2025	
Applicant notified of review panel assignment		N/A	01/10/2025	
Primary Reviewer 1 COI signed		11/22/2024	01/10/2025	
Primary Reviewer 2 COI signed		11/22/2024	01/10/2025	
Peer Review Meeting		Primary Reviewer 1 critique submitted	12/09/2024	01/10/2025
		Primary Reviewer 2 critique submitted	12/04/2024	01/10/2025
		COI indicated by non-primary reviewer	NONE	01/10/2025
		COI recused from participation	N/A	01/10/2025
	Discussed at Peer Review Meeting	YES	01/10/2025	
	Peer Review Meeting	12/12/2024	01/10/2025	
	Post review statements signed	01/09/2025	01/10/2025	
	Third Party Observer Report	12/18/2024	01/10/2025	
	Score report delivered to CSO	12/16/2024	01/10/2025	
	Recommended for SRC review	YES	01/10/2025	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/10/2025	
	COI recused from participation	N/A	01/10/2025	
	SRC Meeting	12/12/2024	01/10/2025	
	Third Party Observer Report	12/18/2024	01/10/2025	
	Recommended for grant award	YES	01/10/2025	
	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025	
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	02/06/2025	
	COI indicated by PIC member	none	02/06/2025	
	COI recused from participation	N/A	02/06/2025	
	PIC Review Meeting	02/05/2025	02/06/2025	
	Recommended for grant award	YES	02/06/2025	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		
Comments:				
Comment	Created Date	Created By		
No Comment				



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR250077
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Dr. Xin "Daniel" Gao

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle, who swore or affirmed to tell the truth, and stated as follows:

"My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received six applications in response to this RFA during cycles 25.2 through 25.3. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT's third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT's grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT's third-party grants management vendor in my capacity as CPRIT's CEO to prepare this affidavit. Some information ("CEO Affidavit-Supporting Information") is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT's grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE Date and time exported: 02/06/2025 03:14 PM CT

FY:	2025			
CYCLE:	1			
PROGRAM:	Recruitment			
MECHANISM:	Recruitment of First-Time, Tenure-Track Faculty Members			
APPLICATION ID:	RR250077			
APPLICATION TITLE	Developing next generation of genome editing tools to study and engineer genetic variants for effective precision cancer treatment			
APPLICANT NAME:	Gao, Xin "Daniel"			
ORGANIZATION:	Baylor College of Medicine			
PANEL NAME:	Recruitment FY25_Cycle 3			
Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	06/17/2024	10/04/2024	
	RFA Approved by CSO (revised)	08/01/2024	10/04/2024	
	RFA published in Texas.gov eGrants	06/21/2024	10/04/2024	
	CPRIT Application Receipt Cycle opened	10/22/2024	01/10/2025	
	CPRIT Application Receipt Cycle closed	11/20/2024	01/10/2025	
	Date application submitted	11/20/2024	01/10/2025	
	Method of submission	CARS	01/10/2025	
	Within receipt period	YES	01/10/2025	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/10/2025
		Donation(s) made to CPRIT / foundation	NO	01/10/2025
Assigned to primary reviewers		11/30/2024	01/10/2025	
Applicant notified of review panel assignment		N/A	01/10/2025	
Primary Reviewer 1 COI signed		11/25/2024	01/10/2025	
Primary Reviewer 2 COI signed		11/25/2024	01/10/2025	
Peer Review Meeting		Primary Reviewer 1 critique submitted	12/10/2024	01/10/2025
		Primary Reviewer 2 critique submitted	12/09/2024	01/10/2025
	COI indicated by non-primary reviewer	NONE	01/10/2025	
	COI recused from participation	N/A	01/10/2025	
	Discussed at Peer Review Meeting	YES	01/10/2025	
	Peer Review Meeting	12/12/2024	01/10/2025	
	Post review statements signed	01/09/2025	01/10/2025	
	Third Party Observer Report	12/18/2024	01/10/2025	
	Score report delivered to CSO	12/16/2024	01/10/2025	
	Recommended for SRC review	YES	01/10/2025	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/10/2025	
	COI recused from participation	N/A	01/10/2025	
	SRC Meeting	12/12/2024	01/10/2025	
	Third Party Observer Report	12/18/2024	01/10/2025	
	Recommended for grant award	YES	01/10/2025	
	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025	
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	02/06/2025	
	COI indicated by PIC member	none	02/06/2025	
	COI recused from participation	N/A	02/06/2025	
	PIC Review Meeting	02/05/2025	02/06/2025	
	Recommended for grant award	YES	02/06/2025	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		
Comments:				
Comment	Created Date	Created By		
No Comment				



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250094
Individual Investigator Research Awards for Clinical Trials

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Clinical Trials* Request for Applications (RFA). CPRIT received 26 applications in response to this RFA, including one withdrawn application. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."



Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.


Sandra Reyes
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:16 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Clinical Trials
APPLICATION ID: RP250094
APPLICATION TITLE: A phase 2 clinical trial with Avasopasem, with anti-estrogen therapy (ET) and a CDK4/6 inhibitor in metastatic breast cancer progressing on ET/CDK4/6 therapy.
APPLICANT NAME: Gius, David
ORGANIZATION: The University of Texas Health Science Center at San Antonio
PANEL NAME: 25.1 Clinical and Translational Cancer Research I Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/11/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/02/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/23/2024
Primary Reviewer 1 COI signed		07/07/2024	12/23/2024
Primary Reviewer 2 COI signed		07/15/2024	12/23/2024
Primary Reviewer 3 COI signed		07/09/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/14/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/16/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/21/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	08/30/2024	12/23/2024
	Primary Reviewer 2 COI signed	09/05/2024	12/23/2024
	Primary Reviewer 3 COI signed	09/05/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	09/11/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/01/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/11/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/12/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	10/11/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/25/2024	12/23/2024
	Post review statements signed	10/29/2024	12/23/2024
	Third Party Observer Report	10/31/2024	12/23/2024
Score report delivered to CSO	11/08/2024	12/23/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/23/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250131
Individual Investigator Research Awards for Clinical Trials

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Clinical Trials* Request for Applications (RFA). CPRIT received 26 applications in response to this RFA, including one withdrawn application. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.


The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:17 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Clinical Trials
APPLICATION ID: RP250131
APPLICATION TITLE: Randomized Clinical Trial Evaluating Fecal Microbiota Transplant in Chimeric Antigen Receptor Therapy for Reversing Antimicrobial-Associated Dysbiosis
APPLICANT NAME: Saini, Neeraj Y
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Clinical and Translational Cancer Research I Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/07/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/02/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/23/2024
Primary Reviewer 1 COI signed		07/11/2024	12/23/2024
Primary Reviewer 2 COI signed		07/12/2024	12/23/2024
Primary Reviewer 3 COI signed		07/03/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/12/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/12/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/06/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	08/30/2024	12/23/2024
	Primary Reviewer 2 COI signed	08/29/2024	12/23/2024
	Primary Reviewer 3 COI signed	08/30/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	08/30/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/09/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/10/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/04/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/28/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/25/2024	12/23/2024
	Post review statements signed	10/29/2024	12/23/2024
Third Party Observer Report	10/31/2024	12/23/2024	
Score report delivered to CSO	11/08/2024	12/23/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/23/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP250321
Individual Investigator Research Awards for Clinical Trials

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Kristen P. Doyle who swore or affirmed to tell the truth, and stated as follows:

“My name is Kristen P. Doyle, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Individual Investigator Research Awards for Clinical Trials* Request for Applications (RFA). CPRIT received 26 applications in response to this RFA, including one withdrawn application. This application was assigned to the Clinical and Translational Cancer Research Panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Kristen P. Doyle,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 7th day of February, 2025,
by KRISTEN P. DOYLE.



Sandra Reyes
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/06/2025 03:18 PM CT

FY: 2025
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Clinical Trials
APPLICATION ID: RP250321
APPLICATION TITLE: Leveraging synthetic and collateral lethality in MTAP loss tumors
APPLICANT NAME: Rodon Ahnert, Jordi
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 25.1 Clinical and Translational Cancer Research I Full

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	02/22/2024	11/27/2024
	RFA published in Texas.gov eGrants	02/23/2024	11/27/2024
	CPRIT Application Receipt System (CARS) opened	03/19/2024	11/27/2024
	CPRIT Application Receipt System (CARS) closed	06/11/2024	11/27/2024
	Date application submitted	06/07/2024	12/23/2024
	Method of submission	CARS	12/23/2024
	Within receipt period	YES	12/23/2024
	Request for extension to submit application after CARS closed	N/A	12/23/2024
	Request for extension for late application submission accepted	N/A	12/23/2024
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/23/2024
Assigned to primary reviewers		08/02/2024	12/23/2024
Applicant notified of review panel assignment		07/31/2024	12/23/2024
Primary Reviewer 1 COI signed		07/11/2024	12/23/2024
Primary Reviewer 2 COI signed		07/11/2024	12/23/2024
Primary Reviewer 3 COI signed		07/11/2024	12/23/2024
Primary (Advocate) Reviewer 4 COI signed		N/A	12/23/2024
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/13/2024	12/23/2024
	Primary Reviewer 2 critique submitted	08/04/2024	12/23/2024
	Primary Reviewer 3 critique submitted	08/12/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	N/A	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	Preliminary Evaluation score summary sent to Chair	08/16/2024	12/23/2024
	Recommended for full review	YES	12/23/2024
	Applicant notified of outcome	10/01/2024	12/23/2024
Peer Review Meeting	Assigned to primary reviewers	09/05/2024	12/23/2024
	Primary Reviewer 1 COI signed	08/29/2024	12/23/2024
	Primary Reviewer 2 COI signed	09/10/2024	12/23/2024
	Primary Reviewer 3 COI signed	08/30/2024	12/23/2024
	Primary (Advocate) Reviewer 4 COI signed	08/28/2024	12/23/2024
	Primary Reviewer 1 critique submitted	10/13/2024	12/23/2024
	Primary Reviewer 2 critique submitted	10/11/2024	12/23/2024
	Primary Reviewer 3 critique submitted	10/09/2024	12/23/2024
	Primary (Advocate) Reviewer 4 critique submitted	09/18/2024	12/23/2024
	COI indicated by non-primary reviewer	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	Discussed at Peer Review Meeting	YES	12/23/2024
	Peer Review Meeting	10/25/2024	12/23/2024
	Post review statements signed	10/29/2024	12/23/2024
	Third Party Observer Report	10/31/2024	12/23/2024
Score report delivered to CSO	11/08/2024	12/23/2024	
Recommended for SRC review	YES	12/23/2024	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/23/2024
	COI recused from participation	N/A	12/23/2024
	SRC Meeting	12/12/2024	12/23/2024
	Third Party Observer Report	12/18/2024	01/30/2025
	Recommended for grant award	YES	12/23/2024
PIC Review	SRC Chair Notification to PIC and OC	01/10/2025	01/24/2025
	COI indicated by PIC member	none	02/05/2025
	COI recused from participation	N/A	02/05/2025
	PIC Review Meeting	02/05/2025	02/05/2025
Oversight Committee Approval	Recommended for grant award	YES	02/05/2025
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		